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SUMMARY 
Human cardiac ryanodine receptors (hRyR2) are calcium (Ca2+) release channels central to 
excitation-contraction coupling. Mutations in hRyR2 are linked to catecholaminergic polymorphic 
ventricular tachycardia (CPVT), a genetic disorder characterized by arrhythmia, occurring under 
adrenergic drive. Recent studies suggest gain-of-function mutant channels may undergo 
different mechanisms of dysfunction, with some showing altered Ca2+ release under basal 
conditions and others requiring an additional trigger (possibly in the form of β-adrenergic 
phosphorylation). This study evaluated whether mutants from different domains of hRyR2 
(S2246L and N4104K) were functionally heterogeneous in a cellular setting and whether this 
was related to phosphorylation status. 
Cells (human embryonic kidney 293) expressing N4104K-hRyR2 displayed smaller, faster Ca2+ 
release events than those expressing the wild type (WT), while those of cells expressing 
S2246L-hRyR2 were similar to WT. However, a lower proportion of S2246L cells showed any 
kind of Ca2+ release functionality compared to those expressing WT or N4104K, reinforcing that 
these mutations cause different types of dysfunction. Assessment of phosphorylation status 
using site-specific antibodies for protein kinase A (PKA) target sites S2808 and S2031 showed 
that mutant phosphorylation levels were different to each other and to that of the WT, indicating 
a possible role of phosphorylation in this. Activation of PKA-mediated phosphorylation in cells 
using a cyclic AMP analogue resulted in changes to the kinetics of spontaneous Ca2+ release 
via WT hRyR2, but did not significantly affect that of mutants. Genetic phosphorylation at either 
PKA site (S2808D and S2031D) altered the Ca2+ release of mutants as well as WT hRyR2, but 
this was found to be due to changes in expression of sarco-endoplasmic reticulum Ca2+-ATPase 
(SERCa) pump, which also contributes to Ca2+ homeostasis.   
These findings reinforce the concept that phosphorylation is linked to dysfunction and 
contributes to our understanding of hRyR2 mutation in arrhythmia, highlighting that ‘gain-of-
function’ does not necessarily equate to dysfunction via the same mechanism.  
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1.1 Calcium signalling 
 
1.1.1 Versatility of Ca2+ signalling 
 
Calcium (Ca2+) is a ubiquitous secondary messenger responsible for controlling many 
cellular processes, including gene expression, energy metabolism, cell proliferation, 
fertilization and muscle contraction (Berridge et al. 2000). Increasing intracellular Ca2+ levels 
from resting levels of ~100 nM to ~1 mM activates a cell for many of these processes. While 
this action is relatively simple, control of this process via a network of Ca2+ signalling 
components allows for enormous versatility, whereby components can be mixed and 
matched to create a range of spatial and temporal Ca2+ signals (Berridge et al. 2000). 
Berridge et al. (2000) describe how this Ca2+ signalling network can be split into four 
functional units; Ca2+-mobilizing signals, triggered by a stimulus; ON mechanisms, activated 
by the former, that feed Ca2+ into the cytoplasm; messenger signals, where Ca2+ functions to 
stimulate many Ca2+-sensitive processes; and OFF mechanisms, composed of pumps and 
exchangers that remove Ca2+ from the cytoplasm to restore a cell to a resting state.  
 
An elevation of intracellular Ca2+ concentration is achieved during on reactions, whereby 
stimuli cause the entry of external Ca2+ and the release of internal Ca2+ from intracellular 
stores, the endoplasmic/sarcoplasmic reticulum (ER/SR) (Berridge et al. 2003). Off reactions 
terminate a cellular event and return intracellular Ca2+ concentrations to resting levels by 
extruding Ca2+ from the cell by exchangers and pumps. Ca2+ homeostasis is therefore 
dependent on fluxes of multiple Ca2+ channels and handling proteins during these off and on 
reactions. 
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1.1.2 Compartmentalization of Ca2+ signalling 
 
Versatility of Ca2+ signalling is achieved by variation of the localization, amplitude and 
duration of a signal. Propagation and termination of these events is dependent on 
cytoplasmic buffering, Ca2+ extrusion and internal store uptake by proteins and organelles 
within the cell. Ca2+ must therefore enter the cell near the target protein, or pass through the 
cell as a propagating signal (Berridge et al. 2000). Internal stores are held within the ER or 
equivalent organelle in muscle cells, the SR. The Ca2+ release from intracellular SR stores 
through ryanodine receptors (RyR) in a cardiomyocyte is an example of signal 
compartmentalization.  
 
Activation of a single RyR channel is termed a “nanoscopic Ca2+ release event” or “Ca2+ 
quark”, resulting in a small increase in localized cytoplasmic Ca2+ levels (~30 nM) that 
spreads no more than ~2 μm in the cell and last ~200 msec (Niggli and Shirokova 2007; 
Lipp and Niggli 1996). Activation of several neighbouring RyR channels in a cluster 
produces a Ca2+ release event termed a ‘Ca2+ spark’, the first discovered subcellular Ca2+ 
signal (H. Cheng et al. 1994).  Up to 20 RyR channels may open during each Ca2+ spark, 
resulting in a greater increase in localized Ca2+ levels (~100-300 nM) that spreads up to ~6 
μm, lasting ~500 msec (Niggli and Shirokova 2007). If many Ca2+ sparks occur in RyR 
clusters close together, this can result in the generation of a propagating ‘Ca2+ wave’ that 
spreads throughout the cell (H. Cheng et al. 1994). The amplitude of the whole-cell Ca2+ 
transient is therefore regulated by recruiting Ca2+ sparks, which then sum up to shape the 
cellular Ca2+ transient (Collier et al. 1999; Inoue and Bridge 2003).  
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1.2 Calcium signalling in the heart 
 
1.2.1 Structure of cardiac muscle and the mechanism of contraction 
 
The wall of the heart, the myocardium, predominantly consists of cardiomyocytes which are 
critical for muscle contraction (see Figure 1.1). A ventricular myocyte is typically rod like in 
shape, with a diameter 10-20 µm and a length of 50-100 μm. These cells are connected in a 
longitudinal direction and connect at intercalated discs. This gives cardiac muscle a 
characteristic striated patterning. (Shimada et al., 2004). 
 
The outside layer of the cardiomyocyte is bounded by a lipid bilayer containing various ion 
channels that allow transport in and out of the cell and is termed the sarcolemma. 
Invaginations of the sarcolemma form transverse tubule structures (t-tubules, TT) that 
protrude into the cell. These invaginations mean that L-type Ca2+ channels (LTCC) and 
cardiac RyR channels (RyR2), present on the intracellular SR, are in close proximity. TTs 
are 100-300 nm in diameter and occur every 1.8 μm along the axis of every cell in a highly-
ordered fashion, forming a branched and interconnected network (L.-S. Song et al. 2005). 
These ‘calcium release units’ formed at the junctional contact between TTs and the SR are 
critical for Ca2+ signalling (Franzini-Armstrong et al. 1998; Hong and Shaw 2016).  
   
Cardiomyocytes contain myofilaments, proteins that form the contractile apparatus (see 
Figure 1.1). An organized array of myofilament fibres makes up the sarcomere, comprised 
of titin filaments and repeating units of thick and thin filaments. Thin filaments consist of 
regulatory proteins tropomyosin and the troponin complex (troponin T, I and C), while thick 
filaments are composed of myosin and accessory proteins (Gautel and Djinović-Carugo 
2016). Cardiomyocyte contraction involves the interaction of these filaments and proteins.  
 
In diastole, a cardiomyocyte is relaxed, with tropomyosin wrapped around the actin filament, 
preventing interaction with the myosin filament. In systole, elevated levels of cytoplasmic 
Ca2+ causes a conformational switch in troponin C (TnC), exposing an active site between 
actin and myosin. Hydrolysis of adenosine triphosphate (ATP) by ATPase on myosin (which 
is no longer inhibited by troponin I, TnI) induces cross bridge formation between myosin 
heads and active sites on actin. This interaction causes the myosin head to ‘pull’ itself along 
the actin filament. Adenosine diphosphate (ADP) is released from myosin heads, which then 
binds to a new ATP molecule, releasing the actin filament. The cycle can then repeat, with 
myosin travelling along the actin molecules, progressively shortening the muscle sarcomere 
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while cytosolic Ca2+ concentrations remain high enough to inhibit TnI and there is enough 
ATP present for cross bridge formation. Extrusion of Ca2+ from the cardiomyocyte 
dissociates Ca2+ from TnC, TnI is no longer inhibited and myocytes return to their original 
conformation – myocyte relaxation occurs (Gautel and Djinović-Carugo 2016).  
 
The process linking action potential and cycling of Ca2+ throughout the cell to generate 
cardiomyocyte contraction and relaxation in this manner is termed excitation-contraction 
(EC) coupling (Bers 2002a).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Cardiac muscle structure. Cardiac myocytes form muscle fibres that are separated by 
intercalated disks, which allow for signal transduction across the muscle. Each myocyte consists of 
sarcomere structures; repeating thin (actin) and thick (myosin) filaments.  
Figure taken from Golob et al. (2014).  
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1.2.2 The cardiac action potential 
 
Excitability in the heart is generated by a delicate balance of polarizing and depolarizing 
ionic currents, mediated by channels and transporter proteins that move positively or 
negatively charged ions to enter or leave the cell. The electrical origin of cardiac contraction 
is called cardiac action potential (AP). There are four distinct phases of ventricular cardiac 
AP (Figure 1.2), outlined below (Bers 2008; Marbán 2002; Bers 2002b): 
 
Phase 4 – This phase represents a cardiomyocyte under diastolic (resting) 
conditions, at a resting membrane potential (Em) of -85 mV. This is maintained by the K+ 
gradient across the membrane.  
Phase 0 – Voltage-dependent activation of fast inward Na+ currents results in a rapid 
depolarization, a sharp increase in membrane potential, to +40 mV.   
Phase 1 – After depolarization, the inward Na+ current is inactivated. Efflux of K+ and 
Cl- ions from the cell causes slight repolarization, a downward shift in membrane potential.  
Phase 2 – A balance between efflux of K+ ions through delayed rectifier K+ channels 
and influx of Ca2+ through LTCCs causes a plateau in membrane potential. 
Phase 3 – Inward Ca2+ current stops as there is RyR2-mediated Ca2+ release from 
the SR, Ca2+ reuptake into the SR via cardiac sarcoplasmic reticulum Ca2+ ATPase 
(SERCa2a) and K+ ions continue to be extruded by outward K+ channels. This removes 
positive charge from the cell, which continues until a resting potential of -85 mV is once 
again reached. During this period the cell is refractory to any further activation, until the rapid 
depolarization and increase in membrane potential in Phase 0. The whole AP event lasts 
~300 msec.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The cardiac action potential. Distinct phases are numbered and discussed further in 
Section 1.2.2. Adapted from Marban (2002). 
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1.2.3 Excitation-contraction coupling  
 
In normal ventricular EC coupling, in response to inward Na+ current during AP, 
depolarization of the sarcolemma activates voltage-gated LTCCs in TTs. Ca2+ influx into the 
cytoplasm via LTCCs subsequently induces massive Ca2+ release from clusters of RyR2 
channels on the sarcoplasmic reticulum (SR) (Bers 2008). There is also a small amount of 
Ca2+ release from the SR via inositol 1,4,5-trisphosphate receptors (IP3R). This is a 
mechanism termed Ca2+-induced Ca2+ release (CICR) and the close physical association of 
sarcolemmal LTCCs and junctional SR membrane RyR2 channels (~15 nm) is necessary for 
optimal CICR and efficient EC coupling (Fabiato 1985b; Bers 2002b; Hong and Shaw 2016). 
CICR is also highly sensitive to both the speed and amplitude of the Ca2+ trigger (Fabiato 
1985a; Fabiato 1985b). The global increase in intracellular Ca2+ levels activates contractile 
machinery and leads to muscle contraction. For relaxation to occur, there must be a 
decrease in intracellular Ca2+ levels. Ca2+ is extruded from the cell via Na+/Ca2+ exchanger 
(NXC) and plasmalemmal ATPase, while Ca2+ is returned to mitochondria by a/the 
mitochondrial Ca2+ uniporter, and sequestered to the SR via SERCa2a (Bers 2002b). 
SERCa2a activity is modulated by phospholamban (PLB), whose inhibitory association to 
SERCa2a is relieved by phosphorylation. Figure 1.3 outlines EC coupling within a 
ventricular cardiomyocyte.  
 
The events that occur in EC coupling are tightly regulated to ensure a Ca2+ flux balance, 
whereby during the steady state, the amount of Ca2+ entering the cell is equal to that which 
is removed from the cell (Negretti et al. 1995; Eisner et al. 1998). In response to imbalances 
between Ca2+ influx and efflux, Ca2+ transient amplitude changes. The amplitude of a Ca2+ 
transient is controlled by both Ca2+ current and SR Ca2+ content. Increased Ca2+ current 
through activated LTCCs will increase the number of RyR2 channels that open, thus (albeit 
briefly) increasing the Ca2+ current through RyR2. This explains the observation of an 
increased amplitude of systolic Ca2+ transient amplitude in cardiomyocytes upon the addition 
of submicromolar levels of caffeine, concentrations which enhance the opening of RyR2 
(O’Neill et al. 1990; Trafford et al. 2000). This increase in Ca2+ transient is brief however, as 
to restore a Ca2+ flux balance, the SR Ca2+ content decreases until a new steady state is 
achieved, thus Ca2+ transient amplitude declines. The amplitude of a Ca2+ transient is 
therefore a steep function of SR Ca2+ content (Bassani et al. 1987; Trafford et al. 1997). The 
content of the SR is determined by balance of Ca2+ uptake into SR by SERCa and efflux 
through RyR2 (Eisner et al. 2017). This therefore depends of biophysical properties of these 
proteins as well as the concentration of Ca2+ in the cytoplasm.  
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Although SR content is tightly controlled, Ca2+ will leak out of the SR through RyR2s due to 
stochastic channel openings and some spark activity (Bridge 1986; Sitsapesan and Williams 
1994; Zima et al. 2010). Decreased SR Ca2+ content and decreased Ca2+ transient 
amplitude occurs because of Ca2+ leak, even in a physiological setting, but is compensated 
for by fine tuning of the flux balance to restore a steady state. However, increased Ca2+ leak 
can be arrhythmogenic, as a result of intracellular Ca2+ waves. Waves occur when Ca2+ 
spark frequency in flux through RyR2 increases, activating other RyR2 channel clusters in a 
propagating and untimely manner (Cheng H. et al. 1996). This can activate NCX, driving an 
arrhythmogenic inward depolarization (Ferrier et al. 1973). This is discussed further in 
Section 1.6.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Excitation-contraction coupling within a ventricular cardiomyocyte. Illustrated are the 
major proteins involved in EC coupling. Depolarization of the ventricular cardiomyocyte initiates Ca2+ 
influx through LTCCs, triggering Ca2+ release from the SR store through RyR2 channels. There is also 
Ca2+ release via inositol 1,4,5-trisphosphate receptors (IP3R). An overall increase in cytosolic Ca2+ 
level initiates the contraction of myofilaments. During relaxation, there is Ca2+ reuptake via SERCa 
(SERCa2a) back into the SR (modulated by PLB), as well as Ca2+ uptake into mitochondria via 
uniporters and removal of Ca2+ from the cell via NCX. Associated proteins of RyR2 include FK-506 
binding protein 12.6 (FKBP), junctin (JUN), triadin (TRDN) and calsequestrin (CSQ2). These proteins 
are discussed in Section 1.3.4. Figure adapted from Bers (2002).  
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1.2.4 The β-adrenergic pathway 
 
The force and rate of the heartbeat increases to pump more blood around the body in 
response to increased metabolic demand and there are many mechanisms to regulate this, 
both intrinsic and extrinsic to the heart. In situations of physical and emotional stress, the 
‘fight or flight response’ is critical to maintain Ca2+ homeostasis (Marx, Reiken, et al. 2001; 
Marks et al. 2002).  Stimulation of β-adrenergic receptors by catecholamines such as 
adrenaline (epinephrine) leads to increased production of secondary messenger cyclic AMP 
(cAMP, see Figure 1.4). When intracellular levels of cAMP rise, cells that generate AP to 
trigger cardiac contraction (sinoatrial node cells) depolarize faster. This leads to an increase 
in chronotropy (an acceleration in heart rate).  
 
Increased levels of cAMP also activate protein kinase A (PKA) that phosphorylates many 
proteins involved in EC coupling, upregulating their activity (Reiken et al. 2003; Bers 2002b). 
PKA-mediated phosphorylation of LTCCs increases Ca2+ influx into the cell, whereas that of 
RyR2 and IP3R increases Ca2+ release from the SR. This increased concentration of 
cytosolic Ca2+ results in a positive inotropic effect i.e. with more Ca2+ ions being available to 
bind to the contractile machinery, increasing actin-myosin cross bridge formation and 
therefore contractile force (as described in Section 1.2.1). 
 
Phospholemman (PLM) is also phosphorylated, relieving its inhibitory effect on 
plasmalemmal Na+/K+ ATPase (ATP in Figure 1.4), therefore increasing Na+ extrusion and 
K+ influx (Q. Song et al. 2011; Tulloch et al. 2011). Enhanced Ca2+ efflux therefore 
upregulates lusitropic effects (faster relaxation). PKA-mediated phosphorylation of NCX is 
suggested to increase NCX activity, although this is disputed (Reppel et al. 2007; Bers et al. 
2006). Overall, these actions result in increased cardiac output (G. D. Thomas 2011; Bers 
2008; Bers 2001).  
 
The roles of Ca2+/Calmodulin-dependent protein kinase II (CaMKII) and exchange factor 
directly activated by cAMP (Epac) in this process are discussed in Section 1.4.  
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Figure 1.4 β-adrenergic stimulation and phosphorylation of EC coupling proteins. Sympathetic 
beta-adrenergic receptor (β-AR) activation by catecholamines such as adrenaline (Epi) triggers 
downstream signalling cascades leading to increased inotropy and lusitropy in EC coupling. 
Stimulatory G protein (Gs) activates adenylate cyclase (AC) to produce the secondary messenger 
cAMP from ATP. This in turn stimulates the catalytic unit of PKA (PKAc) and Epac. PKAr, the 
regulatory subunit, is anchored to the sarcolemma by muscle anchoring protein kinase A (mAKAP, 
(Newlon et al. 1999; L. J. Huang et al. 1997; Scott and McCartney 1994)). When PKAc is dissociated 
from PKAr by cAMP, it phosphorylates proteins LTCC, RyR2, IP3R, TnC and PLB. The stimulation of 
Epac is thought to activate CaMKII, which also leads to phosphorylation of proteins RyR2, PLB and 
TnC. Proteins which feature in this figure that are not mentioned here are discussed in more detail in 
Section 1.4. Also indicated on the diagram are proteins activated by parasympathetic stimulation, the 
muscarinic receptor (M2R). Stimulation via acetylcholine (ACh) and activation of inhibitory G protein 
(Gi) decreases inotropic and lusitropic effects. Adapted from Bers (2002) Ruiz-Hurtado et al. (2013) 
and Pereira et al. (2007).
TnI 
Gi 
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1.3 RyR2 as an ion channel 
 
RyR channels are the largest ion channels known, functional as a ~2.2 MDa homotetramer 
consisting of four 565 kDa subunits (Tunwell et al. 1996). They reside on the ER/SR as Ca2+ 
release channels and are so named after their interaction with alkaloid ryanodine, extracted 
from the Ryania speciosa plant (Jenden and Fairhurst 1969; Pessah et al. 1986). Although 
ryanodine was first isolated as an insecticide, paralytic action on both skeletal and cardiac 
muscle was quickly evident (Fabiato 1985a; Sutko and Kenyon 1983; Nayler et al. 1970; 
Fairhurst 1973; Elison and Jenden 1967). The alkaloid was shown to inhibit Ca2+ release 
from the SR by binding to a high molecular weight protein present in the membrane (Fabiato 
1985a; Sutko and Kenyon 1983; Cannell and Vaughan 1985). This protein was 
subsequently purified and revealed as a homotetrameric ion channel (Inui et al. 1987; 
Holmberg and Williams 1989; Lai et al. 1988; Campbell et al. 1987; Tunwell et al. 1996; 
Hymel et al. 1988; Sitsapesan and Williams 1994a; Pessah et al. 1986). 
 
RyR channels are expressed in many cell types in a variety of tissues, but are at highest 
density in striated muscle (Fill and Copello 2002). Molecular cloning studies have identified 
three different mammalian isoforms, encoded by three different genes found on different 
chromosomes (Zorzato et al. 1990; Marks et al. 1989; Takeshima et al. 1989). RyR1 is 
predominately expressed in skeletal muscle (Otsu et al. 1990; Zorzato et al. 1990; Ogawa 
1994); RyR2 predominately in cardiac muscle, although also in the brain (Lai et al. 1988; 
Tunwell et al. 1996; Sorrentino and Volpe 1993; Otsu et al. 1990); and RyR3 more 
ubiquitously throughout the body, including the brain, diaphragm and smooth muscle tissue 
(Sutko 1991; Froemming et al. 2000; Nakai et al. 1990). At the amino acid level, these 
isoforms share ~70% homology (Nakai et al. 1990; Hakamata et al. 1992). While each 
isoform is tissue specific, similar characteristics include that they function as a poorly 
selective Ca2+ channels with high conductance, regulated by Ca2+, magnesium (Mg2+), ATP 
and caffeine (Fill and Copello 2002). 
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1.3.1 Structure of RyR 
 
The structure of solubilized RyR channels can be assessed by three-dimensional (3D) 
reconstruction techniques whereby electron microscopy images of the protein at different 
angles are merged (Y. Cheng et al. 2015; Frank 2009). In combination with cryo-electron 
microscopy (cryo-EM) the specimen can be imaged without staining and under frozen-
hydrated conditions, allowing access to the structure of the protein fully hydrated within 
physiological buffer (Skiniotis and Southworth 2015; Samsó 2016).  
 
Three single particle cryo-EM studies have recently described the architecture of the closed 
state of rabbit RyR1, with a near-atomic model described for ~70 % of the channel at a 
resolution of 3.8 Å (Efremov et al. 2014; Zalk et al. 2014; Yan et al. 2014). The open state 
structure has been resolved to ~4 Å (Georges et al. 2016; Wei et al. 2016). The elucidation 
of RyR2 channels in this manner is hindered by difficulties in isolating large quantities of 
purified functional channels from cardiac muscle, but with ~70 % sequence homology 
between isoforms, much can be gleaned from the structure of RyR1 (Z. Liu et al. 2001; 
Nakai et al. 1990; Hakamata et al. 1992).  
 
Originally described as ‘foot-like structures’ observed at the junction between cisternae of 
the SR and the TT network, RyR channels have a mushroom-shaped architecture with a 
large N-terminal domain that protrudes into the cytosol (Franzini-Armstrong et al. 1998). The 
C-terminal domain of the protein consists of a pore-forming region and ~6 transmembrane 
(TM) helices. Regulatory proteins that associate to the channel make the structure overall a 
large macromolecular complex (see Section 1.3.4, (Yano et al. 2009)). 
 
RyR1 can be divided into a ‘cytosolic shell’, consisting of the N-terminal domains through to 
the end of the bridging solenoid for each subunit, and a ‘channel and activation core’ from 
the C-terminal remainders, including the core solenoid and associations with cytosolic 
extensions from the tetrameric pore ((Georges et al. 2016), see Figure 1.5 A).  
 
The cytosolic shell has a flat square prism shape formed by multiple domains of each of the 
four identical subunits. N-terminal domains A, B and C (NTD-A, -B and -C)  
SPRY domains are protein-protein interaction molecules that consist of a β-sandwich of two 
β-sheets, named after their discovery in sp1A kinase and RyR channels (D'Cruz et al. 2013; 
Efremov et al. 2014; Ponting et al. 1997). There are three SPRY domains per RyR1 subunit 
(SPRY1, 2 and 3); SPRY 1 protrudes into the cytoplasmic assembly and forms part of the 
binding site for FKBP12 (see Section 1.4.1.5), SPRY2 interacts with subunits of LTCCs 
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(although the equivalent peptide of RyR2 does not), and SPRY3 sits on the surface of RyR1 
facing TTs (Yuchi et al. 2015; Ponting et al. 1997; Leong and MacLennan 1998; Samsó 
2016). RyR repeats 1&2 (also referred to as P1) is a sequence that continues from the 
SPRY cluster, with two β-sheets forming an L-shaped attachment (Yuchi et al. 2015).  
 
Following RyR repeats is the junctional solenoid (JSol, also known as the Handle domain) 
and the bridging solenoid (BSol, also known as HD1 and HD2). JSol is formed by 16 α-
helices and contains the binding sites for FKBP12 and CaM, while BSol forms an extended 
α-solenoid that includes a crevice and a 200 Å-long ribbon that loops out and connects JSol 
to SPRY2 of the neighbouring subunit (Georges et al. 2016). Both JSol and SPRY1 bind 
FKBP12.6. The flexibility and architecture of these domains confer elasticity to the structure 
and are likely to have a role in long range allosteric communication (Samsó 2016). They also 
lie close to the phosphorylation P domain, predicted at residues 2735-2938 (Yuchi et al. 
2013). The analogous region in RyR2 contains phosphorylation sites Serine 2808 and 
Serine 2814.  
 
The channel and activation core are linked to the cytosolic shell by a shell-core linker 
peptide (SCLP) that contains CaM and JSol binding sites. The core solenoid (CSol, or 
central domain) is the only cytoplasmic domain that interacts with the transmembrane 
domain, and is thought to regulate conformational changes necessary to control channel 
opening and closing (Georges et al. 2016; Yan et al. 2014). This domain contains two EF 
hands that are suggested to confer Ca2+-sensing ability to the channel by a large 
conformational change upon binding Ca2+ in the pore of the protein (Y. Chen et al. 2014). It 
also contains a ‘thumb and forefinger’ domain (TaF) and two auxiliary transmembrane 
domains (TMx2) that are located between pVSD and pore domains of adjacent protomers 
(Georges et al. 2016).  
 
The secondary structure of the pore is predicted to have six helical transmembrane regions 
per subunit (S1-S6, see Figure 1.5 B), which collectively form the pseudo voltage sensor 
domain (pVSD (Georges et al. 2016; Yan et al. 2014)). pVSD is named as such as RyR 
does not exhibit voltage dependence but this fold is characteristic of voltage-gated ion 
channels. The fold is formed by the sequences in between S2 and S3 transmembrane 
regions and links to the C-terminal domain (CTD), four of which contact each other in the 
closed state of the channel, forming the ‘cytoplasmic restriction’ (Samsó et al. 2009). CTD 
resides close to S1-S4 regions and forms a ‘column-like’ structure with CSol. A luminal 
hairpin loop between S5 and the pore helix projects into the lumen of the SR and resides 
above the selectivity filter, and together with S6 transmembrane region forms the channel 
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pore. The selectivity filter (SF) and S6, rich in aspartic and glutamic acid residues, form a 
long pathway of ~90 Å for ion conduction that allows Ca2+ transport across the SR 
membrane (Yan et al. 2014).  
 
Channel gating is thought to involve global conformational changes in both the cytosolic 
shell and channel and activation core, including bending of the S6 transmembrane segment 
(Georges et al. 2016). Subsequent pore dilation, displacement and deformation of the S4-S5 
linker leads to conformational changes in the pVSD allowing for Ca2+ ion transport.  
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Figure 1.5 An Illustration of the structure of RyR channels. Schematic displaying the domains with residue spans of RyR1. Image and table modified from 
des Georges et al. (2016).   
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Figure 1.5 B Illustrations of the structure of RyR channels. A. Illustration of the RyR1 channel, domain organization and it’s positioning in the SR lumen 
(left). The domains are colour-coded per the labelled schematic (right). B. Transmembrane regions (S1-S6), pore helix, luminal loops etc. are shown in one 
RyR1 protomer (left). Also shown is the ion-conducting pathway of the channel, predicted to consist of a selectivity filter (SF) and S6 segments (right). Image 
modified from Yan et al. (2015). 
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1.3.2 RyR2 organization and coupled channel gating 
 
RyR2 channels do not normally act independently of one another. Activation of other RyR2 
channels within a cluster is a critical component of CICR. RyR2 channels in cardiac muscle 
therefore are suggested to form regular arrays within the native environment (see Figure 
1.6) - two dimensional (2D) crystals often described as a ‘checkerboard’ (Franzini-Armstrong 
2016; Cabra et al. 2016; Franzini-Armstrong et al. 1998; Ferguson et al. 1984). Adjacent 
RyR2 channels within a cluster can be as close as 30nm apart, allowing Ca2+ released by 
one RyR2 channel to travel and activate neighbouring channels (Kunitomo and Terentyev 
2011). Coordinated Ca2+ release through RyR2 channels within a cluster constitutes a Ca2+ 
spark (H. Cheng et al. 1994). During pathological conditions of aberrant Ca2+ release, Ca2+ 
sparks ignite neighbouring clusters by a fire-diffuse-fire mechanism, triggering regenerative 
CICR-driven Ca2+ waves that are proarrhythmic (Bovo et al. 2011; Kunitomo and Terentyev 
2011). 
 
This supports the notion that allosteric movements of one RyR2 channel can be transmitted 
mechanically to neighbouring channels. In single channel studies of both RyR1 and RyR2, it 
has been observed that RyR2s can undergo ‘coupled gating’, whereby two or more channels 
open simultaneously (Mojzisova 2002; J. Gaburjakova and M. Gaburjakova 2016; Porta et 
al. 2012; Marx et al. 1998; J. Gaburjakova and M. Gaburjakova 2014; Marx, Gaburjakova, et 
al. 2001). The Marks group proposed that a coupled interaction of RyR2 channels is 
mediated by FKBP12.6 and that dissociation from RyR2 disrupts gating, without causing a 
physical uncoupling (Marx et al. 1998; Marx, Gaburjakova, et al. 2001). However, the role of 
FKBP12.6 dissociation on RyR2 channel function remains heavily debated (see Section 
1.4.2.1).  
 
In single channel studies, where authors report to observe coupled RyR2 channels, there is 
a change in the kinetics of channel gating (J. Gaburjakova and M. Gaburjakova 2014; Porta 
et al. 2012; J. Gaburjakova and M. Gaburjakova 2008; J. Gaburjakova and M. Gaburjakova 
2010). Where channels are coupled they exhibit much longer closed times and less 
openings, as well as much longer open times under activating conditions. Coupled gating of 
individual RyR2 channels recruited into a functional complex is suggested to ensure the 
correlation of Ca2+ fluxes during Ca2+ release. 
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Figure 1.6 Illustration of possible RyR arrays. A. The checkerboard array of RyR1 in skeletal 
muscle is well established. B. A filtered and two-dimensional reconstructed image from the RyR array 
of scorpion tail muscle shows two alternate orientations of RyRs. C. Profiles of RyR2 oriented as 
predicted by the “oblique interaction” whereby two partially overlapped RyR2s form an angle of 12 º, 
fit well over the scorpion array, suggesting this may be a possible disposition of RyR2 in cardiac 
muscle. Image modified from Cabra et al. (2016) and Franzini-Armstrong (2016).  
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1.3.3 Regulation by endogenous modulators 
 
A variety of physiological ligands can modulate RyR2 activity, with Ca2+ by far the most 
important effector of channel function. There remains debate as to the specific contributions 
of cytosolic and luminal Ca2+ to channel activation and the termination of CICR by RyR2 
channels during EC coupling. However, four Ca2+-sensing/binding sites per RyR2 monomer 
have been proposed by Laver (2007, Figure 1.7). Contribution of each of these sites and 
related physiological ligands is discussed below.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Schematic of location of proposed RyR2 binding sites. Image from Laver (2007).  
Exact locations of these binding sites remain to be identified.  
 
1.3.3.1  RyR2 activation by cytosolic and luminal Ca2+ 
 
Single channel analysis of RyR2 from explanted hearts of patients with end-stage heart 
failure (HF) revealed that raising the cytosolic Ca2+ concentration from 1 to 100 µM, when 
luminal Ca2+ concentration was maintained at 67 mM, increased the number of channel 
opening events significantly (Holmberg and Williams 1989). Cytosolic Ca2+ also increases 
the number of opening events of RyR2 channels isolated from healthy human hearts (that 
were not required for transplant) and of WT recombinant human RyR2 (Mukherjee et al. 
Site Proposed effect Ligand Dissociation 
constant 
A-site Cytoplasmic activation Ca2+ 1-10 μM 
I1-site Cytoplasmic inhibition Ca2+ and Mg2+ 10 mM 
I2-site Cytoplasmic inactivation Ca2+ 1 µM 
L-site Luminal activation Ca2+ 60 μM 
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2012; Walweel et al. 2014). In the work of Mukherjee et al. (2012), the greatest increase in 
recombinant hRyR2 open probability (Po) was observed at cytoplasmic Ca2+ concentrations 
between 100 nM -1 µM at 5 nM luminal Ca2+ concentration, while increases in concentration 
about 10 µM caused Po to reach saturation.  
 
Luminal Ca2+ has been implicated in regulating RyR2 channel function since the early works 
of Fabiato (Fabiato 1985a; Fabiato 1985b) and demonstration of luminal regulation of single 
RyR channels in the early 1990s {Sitsapesan:1994vs, Sitsapesan:1995tw}. As spontaneous 
Ca2+ release and waves occurs when SR Ca2+ content reaches a critical threshold 
(Venetucci et al. 2008), it would logically follow that luminal Ca2+ concentration is causative 
of this release event. The feed-through hypothesis proposes that luminal Ca2+ can activate 
the channel by flowing through the open channel and activating cytosolic activation sites, 
(Tripathy and Meissner 1996)(L. Xu and Meissner 1998). However, single channels have 
been shown to activate under conditions where luminal-to-cytosolic Ca2+ flux is prevented 
(Gyorke 1998; Ching et al. 2000). Ca2+ release also increases in a nonlinear fashion with 
increased SR Ca2+ content (Shannon et al. 2000), suggesting the process is regulated by 
more than one mechanism (Rovetti et al. 2010). In the luminal-triggered feed through 
mechanism, luminal Ca2+ is thought to be sensed by a luminal Ca2+ activation site (L-site, 
Figure 1.7), which is distinct from the cytosolic A-site (Laver 2007), but the identity of this 
site remains to be defined (Priori and S. R. W. Chen 2011). This luminal activation has also 
been suggested as CSQ2-dependent (Terentyev 2008), the accessory protein acting as a 
luminal Ca2+ sensor, exerting an inhibitory effect on RyR2 (see Section 1.3.4.1).  
 
1.3.3.2   Termination of CICR by cytosolic and luminal Ca2+ 
 
CICR by nature is a positive feedback mechanism, whereby the increase of cytosolic Ca2+ 
concentrations lead to RyR2 Ca2+ release from intracellular stores. In turn this increases 
cytosolic Ca2+, so should be a self-regenerating and inherently unstable process (Fill and 
Copello 2002; Kunitomo and Terentyev 2011). However, this is not observed in 
cardiomyocytes and regulation by either cytosolic Ca2+, luminal Ca2+, both or other RyR2 
channel modulators must be key to terminating SR Ca2+ release. Several mechanisms have 
been proposed that involve RyR2 Ca2+ binding sites (Zima et al. 2014; Stern and H. Cheng 
2004). 
 
Fabiato originally proposed that an increase in intracellular cytosolic Ca2+ levels during CICR 
stops RyR2 Ca2+ release via binding of Ca2+ to cytosolic low affinity sites, suggested by 
Laver (2007) as the I1-site (Figure 1.7) on the channel at concentrations of 1-10 mM. 
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Evidence has accumulated that inactivation of RyR2 by cytosolic Ca2+ plays a limited role in 
the termination of CICR, with single channel experiments showing no evidence of Ca2+-
dependence at these low Ca2+ concentrations (Percival et al. 1994; 1995).  
 
It was demonstrated that RyR2 responds to change in luminal Ca2+ concentration within the 
SR, and this luminal-Ca2+ dependent deactivation has been proposed as an underlying 
cause of the termination of Ca2+ sparks (Terentyev, Kubalova, et al. 2008; Gyorke 1998; 
Brochet et al. 2005; Sitsapesan and Williams 1994b; Zima et al. 2008). This is supported by 
further evidence that Ca2+ sparks cease when the SR Ca2+ concentration falls to a critical 
threshold level (Terentyev, Kubalova, et al. 2008; Brochet et al. 2005; Zima et al. 2008). 
Termination in this instance may occur by two different mechanisms. Firstly, the depletion 
Ca2+ from the SR may drive unbinding of Ca2+ from the RyR2 luminal activation site (L-site) 
and promote channel closing via direct regulation (Terentyev, Kubalova, et al. 2008; D. Jiang 
et al. 2007). Secondly, a local SR Ca2+ depletion could reduce the unitary current via RyR2, 
decreasing local intracellular Ca2+ levels and breaking the feedback of local CICR within a 
cluster (Laver et al. 2012; T. Guo et al. 2012; Sato and Bers 2011). 
 
Adaptation was proposed by Györke and Fill, who found that the application of fast trigger 
Ca2+ signals to single RyR2 channels led to an initial burst of single-channel activity with high 
Po values, which spontaneously decayed with no evidence of Ca2+-dependent inactivation 
(Györke and Fill 1993a). On application of a second Ca2+ stimulus, the ‘inactivated’ channels 
were reactivated (exhibiting a short-lived Ca2+ transient termed the ‘fast Ca2+ overshoot’), 
suggesting spontaneous decay of Po after the initial stimulus was not due to a Ca2+-
dependent inactivation, but mediated by a process termed adaptation (Valdivia et al. 1995; 
Györke and Fill 1993a). This spurred debate, with not all groups reporting ‘adaptive 
behaviour’ and that flash photolysis application of Ca2+ in this experiment simply leads to 
deactivation following the fast Ca2+ overshoot (Lamb et al. 2000; Lamb and Stephenson 
1995). It has since been suggested that adaption is due to a time and Ca2+-dependent shift 
in gating behaviour of single channels and that it is not a mutually exclusive mechanism from 
Ca2+-dependent inactivation (Zahradník et al. 2005; Györke and Fill 1993b; Györke 1999).  
 
Stochastic attrition refers to random spontaneous closing of an individual RyR2 channel. 
Stern (1992) hypothesized from mathematical modelling that this process was sufficient to 
terminate local Ca2+ release from the SR if there were <10 RyR2 channels within a cluster, 
but likelihood of termination in clusters of 10-30 channels was low (Stern 1992; Sham et al. 
1998). However, the rate of Ca2+ release termination is proportional to the magnitude of the 
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release event (Lukyanenko and Wiesner 1998), so stochastic attrition is unlikely to play a 
major role in CICR (Fill and Copello 2002) 
 
1.3.3.3  Role of ATP and Mg2+ 
 
The cytosol of a cardiomyocyte contains approximately ~5 mM total ATP, with most in a 
Mg2+-bound form (Fill and Copello 2002). Free ATP (~300 μM) binds to and activates RyR2 
and has been shown to increase RyR2 Po, but only when cytoplasmic Ca2+ is present (Laver 
2007; Witcher et al. 1991). ATP may sensitize the channel to activation by Ca2+, rather than 
direct activation, although earlier studies suggest that ATP can in fact have a Ca2+-
independent action {Kermode:1998ga}. 
 
Mg2+ is a potent channel inhibitor, but its action is more complicated. Firstly, it inhibits RyR2 
activity in the millimolar concentration range, most prominently at low cytoplasmic Ca2+ 
concentrations, suggestive that Mg2+ exhibits physiological effects during diastole (Rousseau 
and Meissner 1989; Rousseau et al. 1987; Holmberg and Williams 1989). This action is 
likely by competition with Ca2+ at the non-specific Ca2+ inhibition I1-site (Figure 1.7, (Laver 
2007)).  Secondly, Mg2+ has been shown to increase RyR2 activation at higher cytoplasmic 
Ca2+ concentrations (~10-100 μM) in one instance and may compete with luminal Ca2+ at the 
luminal activation L-site (Laver 2007; Chugun et al. 2006).  
 
23 
 
1.3.4 Accessory and associated proteins  
 
Accessory and associated proteins of the macromolecular RyR2 complex are illustrated in 
Figure 1.8 and are described below.  
 
The termination of SR Ca2+ release through RyR2 remains incompletely understood, yet it 
appears to involve luminal Ca2+ regulation of channel activity (Terentyev et al. 2002; 
Radwański et al. 2012). A luminal Ca2+ sensor is formed within the RyR2 quaternary 
complex (see Figure 1.8), consisting of cardiac calsequestrin (CSQ2) and SR membrane 
proteins triadin and junctin (G. Liu and Pessah 1994; W. Guo and Campbell 1995; L. Zhang 
et al. 1997). The presence of all these accessory proteins is thought to be required for CSQ2 
to regulate RyR2 activity in response to changes in luminal Ca2+ concentrations (Gyorke et 
al., 2004; Gyorke et al., 2009). Luminal Ca2+ has been shown to directly affect RyR2, and 
indirectly affect the channel through CSQ2, a Ca2+ buffering protein that traps Ca2+ within the 
SR store (Terentyev 2008; Wenqian Chen et al. 2014; Beard et al. 2009; M. Gaburjakova et 
al. 2012). CSQ2 exists as organized aggregates; monomers and dimers at low 
concentrations and polymers at high concentrations of luminal Ca2+ (E. Kim et al. 2007; 
Beard et al. 2005). The C-terminal of CSQ2 is negatively charged which allows high capacity 
binding of Ca2+ ions, ensuring Ca2+ is available at the pore of the RyR2 channel, ready for 
Ca2+ release during CICR (E. Kim et al. 2007). Functional association of RyR2 and CSQ2 
has been well established, but only recently has a direct interaction been shown to exist 
(Handhle et al. 2016). 
 
Junctin (JUN), a 26 kDa anchoring protein component of the luminal Ca2+ sensor, is a non-
catalytic splice variant encoded by the aspartate-β-hydroxylase (Asph) gene (Dulhunty et al. 
2009; Dulhunty et al. 2012). Junctin contains binding sites for both CSQ2 and RyR2 in a 
long luminal C-terminal domain containing several charged sequence repeats known as 
‘KEKE’ motifs (L. R. Jones et al. 1995; Altschafl et al. 2011; Y. M. Kobayashi et al. 2000). 
JUN is suggested to act as a direct regulator of RyR2 activity, or transduce signals from 
CSQ2 to the channel in a Ca2+-dependent manner, or both (Beard et al. 2009; Hester et al. 
2004)). Interaction between the cytoplasmic domain of JUN and the cytoplasmic, not luminal 
domain of RyR2 has been evidenced, with binding enhancing RyR2 channel activity (L. Li et 
al. 2015). Knockout of the protein (KO) or knockdown in mouse models leads to an 
enhancement of Ca2+ release, suggestive that JUN or JUN-CSQ2 inhibit RyR2 at low 
concentrations of luminal Ca2+, anchoring and positioning CSQ2 near the channel (L. Zhang 
et al. 1997; Fan et al. 2008; Hester et al. 2004). 
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Triadin (TRDN) can exist as three different isoforms produced by alternative splicing of the 
single TRDN gene (Marty 2014; Thevenon et al. 2003). Trisk 32 (32 kDa, also known as 
TRDN1) is the major cardiac isoform (Y. M. Kobayashi and L. R. Jones 1999). Much like 
JUN, TRDN is thought to anchor CSQ2 in the vicinity of RyR2, facilitating Ca2+ release 
indirectly by permitting CSQ2 to buffer luminal Ca2+ near the Ca2+ release site of RyR2 (L. 
Zhang et al. 1997; Y. M. Kobayashi et al. 2000). While functional studies have shown that 
TRDN itself is able to inhibit the activity of the RyR calcium channel in vitro (studies in 
RyR1), in vivo investigations suggest this RyR2 regulation is only via interaction with CSQ2 
(Terentyev et al. 2007; Ohkura et al. 1998; Kučerová et al. 2012).  
 
Calmodulin (CaM) is a 16.7kDa Ca2+ binding protein that directly associates with and 
regulates RyR2 channels, as well as other proteins and ion channels (Samsó and 
Wagenknecht 2001; Bers 2004). Structurally it consists of two pairs of Ca2+ binding EF hand 
domains separated by a flexible peptide linker, and binds to one site on each RyR2 
monomer (Fruen et al. 2000). After binding to Ca2+, CaM undergoes a conformational 
change and is known as Ca2+-calmodulin or CaCaM, while the Ca2+-free state is known as 
apoCaM (Samsó and Wagenknecht 2001; Chin and Means 2000). CaM is predicted to 
regulate RyR2 channel activity in both states. It has been proposed to inhibit RyR2 opening 
at the single channel level (S. L. Hamilton et al. 2001; Tripathy et al. 1995) and prevention of 
CaM binding to RyR2 in a knock-in mouse model harbouring a central domain CPVT 
mutation resulted in an arrhythmogenic phenotype (Xu et al., 2010), suggestive that CaM 
has a critical role in regulating RyR2 function. CaM is also critical in regulating the activity of 
CaMKII, a protein kinase involved in RyR2 phosphorylation (see Section 1.4.1). CaM 
binding to RyR2 has also been suggested as required for the activity of the drug dantrolene 
(Nishimura et al. 2015; Oo et al. 2015). See Section 1.7.4 for further discussion.  
 
Sharing structural features with CaM, sorcin is also an EF hand-containing Ca2+ binding 
protein of 22 kDa which directly interacts with RyR2 channels (Farrell and Antaramian 2003; 
Meyers et al. 1998; Bers 2004; Balshaw et al. 2002). The precise role of sorcin is yet to be 
established, but it has been shown to bind to Ca2+ with high affinity and is thought to cause 
RyR2 inhibition in a similar way to CaM (Farrell and Antaramian 2003; Zamparelli et al. 
2000; Lokuta et al. 1997). S100A (also known as S100A1) is another EF hand-containing 
protein predicted to regulate RyR2 activity, reported to increase the likelihood of RyR2 
opening (Prosser et al. 2011). It has also been shown to interact with CaMKII, inhibiting 
kinase activity, while CaMKII has been shown to phosphorylate sorcin, suggesting a joint 
regulatory effect on RyR2 channels (Anthony et al. 2007). Recent work suggests that CaM 
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and S100A can concurrently bind to RyR2 and modulate its activity, but this does not involve 
direct competition at the RyR2 CaM binding site (Rebbeck et al. 2016). 
 
FK506 binding proteins are accessory proteins of RyR2 found in the macromolecular 
complex, also implicated in phosphorylation of the channel. They are described as 
immunophilins, based on their interactions with immunosuppressant drugs FK506 and 
rapamycin (Timerman et al. 1996; Zissimopoulos and Lai 2004). Two FKBP isoforms are 
detected in the cardiomyocyte, FKBP12 (or calstabin) and FKBP12.6 (or calstabin2), named 
as such by molecular weight (12 vs. 12.6 kDa). FKBP12.6 however has ~600-1000 fold 
increased affinity for RyR2 and it has been shown to directly interact with the cytoplasmic 
assembly of the protein (T. Guo et al. 2010; Timerman et al. 1996). There is a single 
FKBP12.6 binding site on each RyR2 monomer and therefore RyR2 associates with 
FKBP12.6 in a 1:4 stoichiometry (Jeyakumar et al. 2001; Timerman et al. 1996).  
 
FKBP12 does not alter Ca2+ spark frequency of RyR2 as opposed to FKBP12.6 (T. Guo et 
al. 2010), or modulate recombinant RyR2 in heterologous expression systems 
(Goonasekera et al. 2005; George, SORATHIA, et al. 2003), indicating that FKBP12 may be 
functionally irrelevant to the channel. FKBP12 was shown as the predominant isoform in 
cardiac SR of many mammals and it has been reasoned that FKBP12 may undergo post-
translational modifications that induce structural changes so that is resembles FKBP12.6 
and confers the high-affinity binding observed with FKBP12.6 (Zissimopoulos et al. 2012).  
 
FKBP12.6 interaction with RyR2 has been proposed to stabilize the channel, preventing 
spontaneous Ca2+ release and SR Ca2+ leak observed in disease states (Marx et al. 2000; 
George, SORATHIA, et al. 2003; Wehrens et al. 2005; Yano et al. 2003; Prestle et al. 2001). 
In other studies, treatment of WT single channels treated with drugs that suppress the 
FKBP12.6:RyR2 interaction (rapamycin and FK506) has significant effect of RyR2 channel 
function (Barg et al. 1997; Timerman et al. 1996). Overexpression of FKBP12.6 in mice 
resulted in reduced Ca2+ spark frequency, and enhanced cardiac output and contractility 
(Prestle et al. 2001; F. Huang et al. 2006; Gellen et al. 2008).  More recent studies indicate 
in fact that RyR2-FKBP12.6 association is less than stoichiometric with ~40 % of available 
RyR2 sites occupied in mouse, pig and rabbit heart, suggesting FKBP12.6 saturation is not 
critical for channel function (Zissimopoulos et al. 2012). It has been hypothesized that the 
association of FKBP12.6 and RyR2 is dependent on the phosphorylation state of the 
channel (Wehrens 2003; Marx et al. 2000; Marx, Reiken, et al. 2001). This is discussed 
further in Section 1.4. 
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Figure 1.8 Schematic representation of accessory and associated proteins in the RyR2 
macromolecular complex. Diagram of the RyR2 complex. The left-hand side illustrates components 
involved in phosphorylation of RyR2, while the right-hand side illustrates accessory proteins. 
Tetramers may contain more than one interaction for each protein and proteins may not be 
constitutively bound to RyR2; this can be dependent on physiological conditions (discussed further in 
Section 1.3.4.). Adapted from Terentyev and Hamilton (2016). 
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1.4 Phosphorylation as a posttranslational modification 
 
Phosphorylation is well established in many cellular processes as a regulatory mechanism, 
not just limited to cardiac function. In β-adrenergic stimulation, as part of the ‘fight-or-flight’ 
response, several EC coupling proteins are targets for phosphorylation by protein kinases, 
leading to the upregulation of ion channel activity, increased chronotropy and inotropy 
required in response to increased metabolic demand of the body (Marx et al. 2000; 
Eschenhagen 2010; Bers 2002a). Section 1.2.4 outlines the pathway in more detail.  
 
RyR2 is also a target of protein kinases during β-adrenergic stimulation. The importance of 
RyR2 phosphorylation in channel activity and regulation was first highlighted in 1984, before 
channel [3H] ryanodine binding properties were first investigated by Pessah (Pessah et al. 
1985), and the ryanodine receptor was simply referred to as ‘high molecular weight 
junctional SR proteins’ (Seiler et al. 1984). These proteins were found to not only bind CaM, 
but act as a substrate for endogenous CaMKII and exogenously added cAMP-dependent 
protein kinase; a dual phosphorylation mechanism thought to play a role in mediating Ca2+ 
flux at the SR junction. For the 30 years since, phosphorylation has remained a highly 
investigated and deeply contentious area of cardiac Ca2+ signalling and RyR2 research, as 
to the exact mechanism and functional consequence of such posttranslational modifications.  
 
Figure 1.4 in Section 1.2.4 highlights the kinases and phosphorylation target proteins 
involved in the β-adrenergic stimulation signalling pathway, as well as accessory and 
adaptor proteins that are discussed in more detail in subsequent sections.  
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1.4.1 Effects of protein kinases on RyR2  
 
Early works of Takasago et al. showed that RyR2 could be phosphorylated by many 
exogenous serine/threonine kinases including PKA, PKG, PKC and CaMKII (Takasago et al. 
1989; Takasago et al. 1991). The role of various kinases involved in RyR2 phosphorylation 
is discussed below.  
 
1.4.1.1  Role of PKA 
 
PKA was one of the first protein kinases to be discovered and structurally consists of two 
subunits: regulatory (PKAr) and catalytic (PKAc) (D. A. Walsh et al. 1968). Regulatory 
subunits act as major receptors for secondary messenger cAMP, a product of β-adrenergic 
stimulation. In the inactive form, regulatory subunits sequester catalytic subunits in a 
heterotetrameric holoenzyme. After activation of the β-adrenergic receptor, activatory ligand 
cAMP binds to the PKA regulatory subunit and leads to dissociation of catalytic subunits 
from the holoenzyme, which are then free to phosphorylate EC coupling proteins within the 
cardiomyocyte (see Figure 1.4). Overall, the major physiological role of PKA 
phosphorylation includes increasing Ca2+ influx via LTCCs, as well as increasing SR Ca2+ 
content via PLB phosphorylation, subsequently enhancing SERCa activity (Reuter et al. 
1974; Tada et al. 1975; Eisner et al. 2017). This underlies the positive inotropic, chronotropic 
and lucitropic effects observed in β-adrenergic stimulation (described in Section 1.2.4). 
 
As the effector kinase in the classical β-adrenergic stimulation pathway, PKA-mediated 
phosphorylation of RyR2 has been studied extensively in both health and disease, yet 
whether and how it alters channel gating remains contentious. This is discussed further in 
Section 1.4.2.1 and 1.4.2.2.  
 
1.4.1.2  Role of CaMKII 
 
CaMKII is a serine-threonine specific protein kinase critical for many processes in the 
cardiomyocyte, including EC coupling, chronotropic control of LTCCs and the uptake and 
release of SR Ca2+ via phosphorylation of PLB and RyR2 (Marx and Marks 2013; Kushnir et 
al. 2010). Unlike PKA, CaMKII is not activated by a neurohormonal pathway, but is activated 
by Ca2+-bound CaM. CaMKII monomers contain three subunits: one catalytic, one regulatory 
and an associating subunit that assembles the holoenzyme (Z.-W. Wang 2008; Rosenberg 
et al. 2006). Under basal conditions, catalytic subunits are restrained by regulatory subunits. 
When intracellular Ca2+ concentration is elevated, regulatory subunits bind to CaM, 
29 
 
generating a conformational shift that release catalytic subunits for subsequent substrate 
binding and phosphorylation (Gaertner et al. 2004; Rostas and Dunkley 1992). In a 
physiological setting, CaMKII targets critical ion channels important for cell excitability to 
regulate and maintaining cardiac function (Mohler et al. 2014). This includes voltage-gated 
Na2+ channels, LTTCs and repolarizing potassium channels. CaMKII also alters SR Ca2+ 
release and reuptake via phosphorylation of RyR2 and PLB, altering the activity of SERCa. 
The signalling molecule has a broad range of targets including transcription factors MEF2 
and CREB and is implicated in transcriptional activation of hypertrophy (Mattiazzi et al. 
2015).   
 
The role of CaMKII as a major regulator of RyR2 function in disease is strongly supported 
(Luo and Anderson 2013; Cutler et al. 2012; Pereira et al. 2007; T. Guo et al. 2006; Fischer 
et al. 2013). Studies have provided evidence that chronic CaMKII activity leads to cardiac 
arrhythmia and HF (Anderson et al. 2011; Ling et al. 2009). Patients and animals with HF 
display increased levels of CaMKII expression (Hagemann et al. 2001; Hoch et al. 1999), 
with overexpression of a CaMKII inhibitor, AC3-I, delaying development of HF in mice (R. 
Zhang et al. 2005). There is some agreement of research groups that CaMKII (as opposed 
to PKA) increases SR Ca2+ leak (Ai 2005; Jerald Curran et al. 2007; Bers 2012), but this is 
not universal (Wehrens et al. 2006; D. Yang et al. 2007). This is discussed further in 
Sections 1.4.2.1 and 1.4.2.3.  
 
1.4.1.3  Role of PKC and PKG 
 
Most studies to date have only focused on the role of CaMKII and PKA, but it is likely that 
other serine and threonine kinases can also phosphorylate the protein (Ather et al. 2012; 
Dobrev 2014). Protein kinase C (PKC) and protein kinase G (PKG) were originally implicated 
in RyR2 phosphorylation by Takasago et al. (1991), who suggested that these kinases 
phosphorylated the same fragmented phosphopeptide as CaMKII i.e. possibly the same 
site(s).  
 
PKC phosphorylation of RyR2 has been reported to increase [3H] ryanodine binding, 
suggesting an increase in the Po of PKC-treated channels (Takasago et al. 1991), while 
Carter et al ((Carter et al. 2011)) suggested that endogenous PKC phosphorylation leads to 
RyR2 becoming ‘uncoupled’ from the influence of cytosolic Ca2+, where lowering Ca2+ 
concentrations to sub-activating levels no longer closes the channels  PKCα  activated by β-
adrenergic receptors, phosphorylates many other EC coupling proteins including LTCCs, 
troponin and large number of other substrates (Kooij et al. 2013; L. Yang et al. 2004; 
30 
 
Malhotra et al. 2010; Sumandea 2003; Hidalgo et al. 2009), including those included in 
pathways that lead to β-adrenergic receptor desensitization (Malhotra et al. 2010). 
Moreover, PKCα-overexpression studies suggest a role for this kinase in cardiac remodelling 
(Kooij et al. 2013; L. Yang et al. 2004; Malhotra et al. 2010; Sumandea 2003; Hidalgo et al. 
2009).  
 
PKG is associated with parasympathetic stimulation via the muscarinic receptor 2 (M2R), the 
predominant isoform of muscarinic receptor in cardiac muscle (Hulme 1990; Dhein et al. 
2001). M2R is coupled to an inhibitory G protein (Gi) that inhibits adenylate cyclase and PKA 
(see Figure 1.4). However, this also causes nitric oxide-dependent stimulation of PKG 
(Harvey and Belevych 2003; Massion 2003) and subsequent phosphorylation of EC coupling 
proteins, including RyR2.. In a recent publication from the Györke group, parasympathetic 
stimulation is shown to initiate a novel mode of EC coupling that enhances the efficiency of 
SR Ca2+ store utilization (Ho et al. 2016). This involves reciprocal changes in 
phosphorylation of RyR2 at S2808 and S2814, which increases systolic release at low SR 
Ca2+ content while preventing Ca2+ leak. Activation of PKG via M2R is suggested to mediate 
phosphorylation at S2808, while decreased activation of CaMKII by another muscarinic 
receptor, M3R, led to dephosphorylation at S2814 in WT mouse and canine ventricular 
myocytes. The overall observed effect of these phosphorylation changes in RyR2 included 
an increase in systolic Ca2+ release at a low SR Ca2+ content, yet a reduction in Ca2+ leak.  
 
1.4.1.4  Role of Epac 
 
Exchange factor directly activated by cAMP proteins, known as Epac, is also implicated in 
kinase activity and the phosphorylation of RyR2. Epac is involved in the formation of gap 
junctions in cardiomyocytes, necessary for ions to transverse and coordinate cardiac 
contractions (Somekawa 2005). Traditionally, cAMP was thought to influence contractility 
and relaxation processes in the heart via PKA. However, accumulating evidence suggests 
that both isoforms Epac1 and Epac2 are also targets of cAMP in the cardiomyocyte and play 
important roles in the function of the heart in both physiological and pathological conditions 
(Fujita et al. 2016; Hothi et al. 2008). β-adrenergic stimulation is suggested to activate 
Epac2, inducing SR Ca2+ leak via CaMKII phosphorylation of a specific RyR2 site, S2814 
(Pereira et al. 2013).  
 
PKA and Epac are both expressed in all tissues, so any increase in intracellular cAMP levels 
will activate both pathways. cAMP signalling is therefore more complex than initially believed 
and the classical PKA activation pathway during β-adrenergic stimulation may involve 
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crosstalk between Epac and PKA. Whether the two intracellular cAMP receptors act 
independently, synergistically, or oppose each other in regulating a specific cellular function 
remains to be fully elucidated (X. Cheng et al. 2008; Bers 2007; Ruiz-Hurtado et al. 2012). 
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1.4.2 Potential phosphorylation sites of RyR2  
 
The RyR2 homotetramer contains 46 serine/threonine sites per subunit that can potentially 
be phosphorylated (www.phosphosite.org, (Terentyev and S. Hamilton 2016). To date, five 
serine phosphorylation sites have been investigated in RyR2, located at amino acid 
positions 2808 (S2808), 2811 (S2811), 2814 (S2814), 2031 (S2031) and 2797 (S2797) in 
the human RyR2 (hRyR2) sequence (Witcher et al., 1991; Wehrens et al., 2004; Xiao et al., 
2005; Huke & Bers, 2008), although S2808, S2031 and S2814 are the main sites which 
have been studied.. Most of these sites as well as additional residues have been detected 
as phosphorylated in animal models (Huttlin et al. 2010; Brill et al. 2009) and are discussed 
below. Phosphorylation site nomenclature throughout this thesis follows positioning in the 
hRyR2 sequence.  
 
The phosphorylation domain (P domain in Figure 1.5 A and B, circled domain 6 in Figure 
1.9 below) is predicted at residues 2735-2938 in RyR1 (Yuchi et al. 2013). The analogous 
region in RyR2 contains phosphorylation sites S2808 and S2814. This region 
(corresponding to the domain named RyR3&4 in Figure 1.5) was solved at atomic resolution 
by crystallography (Yuchi et al. 2013). It was initially docked to a corner of the structure 
(where the orange RyR1&2 domain resides in Figure 1.9, labelled 10) but in view of the 
sequence path in higher resolution cryo-EM structures, it has been reassigned (Yuchi et al. 
2015)and lies close to both JSol and SPRY1 (that bind FKBP12.6) in the 3D structure of 
RyR (Georges et al. 2016; Samsó 2016; Yan et al. 2014). 
 
 
 
 
 
 
   
  
 
 
Figure 1.9 The RyR phosphorylation domain location in the 3D channel structure. A side view of 
the RyR channel, with domains labelled numerically as follows; 1. EF hand, 2. NTD, 3. JSol, 4. BSol, 
5. SPRY3, 6. P domain, 7. CTD, 8(a). BSol, 9. SPRY1, 10. RyR1&2, 11. SPRY2, 12. pVSD, 13. U 
motif, 14. CSol. See Figure 1.5 for description and residue spans of these domains. Modified from 
Samso (2016).   
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1.4.2.1  S2808 
 
The serine at residue 2808 was the first phosphorylation site to be identified in RyR2 
(Witcher et al. 1991). In a landmark publication in 2000, the Marks group proposed that the 
action of PKA at the S2808 site alone was responsible for dysfunction and arrhythmia 
observed in HF (Marx et al. 2000). In failing hearts where circulating catecholamines are 
markedly increased, activation of the β-adrenergic signalling pathway generates increased 
cAMP levels and activates PKA. The stoichiometry of back-phosphorylation (see Section 
4.1.2.1) of RyR2 channels from isolated failing hearts was 0.7 ± 0.3 moles of phosphate 
transferred per mole of failing channel, in comparison 3.1 ± 0.1 moles of phosphate 
transferred per mole of non-failing channel. Authors proposed that RyR2-S2808 is 
‘hyperphosphorylated’ in this scenario, a term used to describe this four-fold increase in PKA 
phosphorylation of RyR2 observed in failing hearts from dogs and humans. Three of the four 
PKA sites in the tetrameric channel were phosphorylated in vivo, in comparison to one 
phosphorylated PKA site in RyR2 isolated from non-failing hearts. This 
hyperphosphorylation was suggested to cause FKBP12.6 dissociation from RyR2, which 
directly enhances SR Ca2+ leak and store depletion, contributing to systolic dysfunction in 
HF (see Figure 1.10). The model was later extended, with down-regulation of phosphatases 
in HF suggested to lead to this PKA-dependent hyperphosphorylation and that diastolic SR 
Ca2+ leak also contributes to triggered activity (Bellinger et al. 2008; Wei Chen et al. 2011; 
Shan et al. 2012; Lehnart et al. 2008; Shan, Betzenhauser, et al. 2010; Shan, Kushnir, 
Betzenhauser, Reiken, J. Li, Lehnart, Lindegger, Mongillo, Mohler and Marks 2010b).  
 
The Marks group found that phosphoablation (replacing serine with alanine, preventing 
phosphorylation at this site) at S2808 severely limits the β-adrenergic response and 
increases RyR2 Po in post-myocardial infarct (MI) hearts (Wehrens et al. 2006; Shan, 
Kushnir, Betzenhauser, Reiken, J. Li, Lehnart, Lindegger, Mongillo, Mohler and Marks 
2010a). These data supported the idea that RyR2 phosphorylation at a single residue was 
responsible for normal effects on cardiac contractility and for observed defects in HF.
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Figure 1.10 The Marks original model of the effects of PKA phosphorylation of RyR2 in the 
heart. In the nonfailing heart (left panel) β-agonists bind to receptors (β1 and β2 AR) coupled to G-
proteins (Gprot), which in turn activate adenylyl cyclase (AC), raising cAMP levels and activating PKA. 
PKA phosphorylation of RyR2 induces dissociation of one FKBP12.6 from the channel, shifting the 
Ca2+ dependence for activation to the left, increasing the sensitivity of the RyR2 to activation by Ca2+ 
influx via DHPR (LTCC) and increasing RyR2 channel Po. The result is increased SR Ca2+ release 
and cardiac contractility. The tetrameric RyR2 channel is part of a macromolecular signalling complex 
(components discussed in Section 1.3.4). Ca2+ reuptake into the SR occurs via the SERCA and PLB. 
In failing hearts (right panel), PKA hyperphosphorylation of RyR2 may contribute to the blunted 
response to β-agonists observed in failing heart muscle because the channels cannot be further PKA 
phosphorylated. RyR2 channels in failing hearts exhibit a shift in the Ca2+-dependence for activation 
such that they are activated at resting levels of cytosolic Ca2+. Figure and legend from Marx et al. 
(2002).  
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Although Marks has consistently published data from his laboratory that defends this 
hypothesis, the relevance of PKA phosphorylation at this site and indeed as a mechanism 
for dysfunction has been highly disputed since. Many prominent research groups in the field 
have been unable to replicate or confirm many aspects of the hypothesis (B. Xiao et al. 
2006; Benkusky et al. 2007; Eschenhagen 2010; George 2007b). In newer findings from 
Wehrens (previous co-author of Marks papers) and Dobrev, modifications were made to the 
original hypothesis (referred to here on as the Wehrens-Marks hypothesis) to suggest that 
hyperphosphorylation at S2808 is only evident in selective forms of HF, and that the role of 
phosphorylation of another site, S2814, is the main cause of Ca2+ leak that leads to 
arrhythmia and exacerbates other forms of HF (Chen-Izu et al. 2007). Authors have 
suggested that S2808 genetic ablation in mice protects against ischemic HF but has no 
prominent role in nonischemic HF. This does not fit well with the original Marks hypothesis, 
which was based on S2808 hyperphosphorylation observed in tachypacing-induced heart 
failing dogs, a nonischemic model of HF. Wehrens and colleagues have also found no 
evidence of S2808-RyR2 hyperphosphorylation in any form of human HF (Respress et al. 
2012), although treatment of patients with β-blockers before death may have normalized this 
phosphorylation state (Ai 2005; Jerald Curran et al. 2007; Houser 2014). In hypertrophied 
hearts from human biopsy, a condition that precedes HF, no increase in S2808 
phosphorylation is observed either, although phosphorylation at another phosphorylation 
site, S2814, is increased by 300 % (Fischer et al. 2013b). 
 
Using the same strategy as Marks, introducing a missense mutation to mimic 
dephosphorylation, Houser and Valdivia have also created an S2808A knock in (KI) mouse, 
although not from the same mouse line (Benkusky et al. 2007). Interestingly, results differ to 
that of the Marks group, with no distinguishable differences from WT mice in respect to 
response to β-adrenergic stimulation, channel gating or dysfunction following MI (H. Zhang 
et al. 2012; MacDonnell et al. 2008). There have been calls for S2808A KI mouse models to 
be freely shared between groups to address the stark differences in experimental results, 
but this has yet to take place (Dobrev and Wehrens 2014; Bers 2012; 2012).  
 
Many groups find that the basal phosphorylation status of S2808 is already substantial (at 
least 50 % of PKA sites phosphorylated), which would therefore limit the potential increase 
at this site (Huke and Bers 2008; Rodriguez et al. 2003; B. Xiao et al. 2005; Currie et al. 
2004; Benkusky et al. 2007). RyR2 isolated from non-failing sheep hearts was shown to be 
phosphorylated to 75% of maximum at the S2808 residue. Some groups have failed to 
detect any increase in S2808 phosphorylation in HF models. However, this may well depend 
on the animal species (publications include RyR2 from mouse, rat, canine) or specific 
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phospho-antibodies used (publications include commercial and ‘in house’ antibodies’ 
(Fischer, Herting, Tirilomis, Renner, Neef, Toischer, Ellenberger, Förster, Schmitto, 
Gummert, Schöndube, Hasenfuss, Maier and Sossalla 2013a; Huke and Bers 2008; Carter 
et al. 2011; Terentyev, Rees, W. Li, Cooper, Jindal, Peng, Lu, Terentyeva, Odening, Daley, 
Bist, Choi, Karma and Koren 2014a; Carter et al. 2006; R. Liu et al. 2015; Cooper et al. 
2013; Belevych, Sansom, et al. 2011). Carter et al. suggested that channels are S2808-
phosphorylated up to 75 % of maximum, calculated by Western blotting, comparing against 
a maximally phosphorylated sample (Carter et al. 2006). 
 
When a critical protein involved in EC coupling has been eliminated or altered, adaptive 
remodelling of other Ca2+ regulatory proteins has been shown to occur (Pott et al. 2006; 
Brittsan et al. 2003). In a conditional NCX-deficient mouse with a reduction of Ca2+ efflux 
capacity, LTCC expression is significantly reduced, adapting to reduce the Ca2+ influx, 
helping to preserve basal function (Pott et al. 2006). In studies of RyR2 phosphorylation, 
Western blot analysis revealed that ablation of S2808 is accompanied by marked increase in 
phosphorylation of S2031 and S2814 in the presence of isoproterenol (Iso) suggestive of 
adaptive remodelling. This important finding highlights possible redundancy in these sites, a 
likelihood which is almost always overlooked as the phosphorylation status of all three 
serines is usually not reported in any one study (Terentyev and S. Hamilton 2016; Benkusky 
et al. 2007). Houser and Valdivia however report no alterations in adrenergic regulation of 
Ca2+ current, myocyte Ca2+ transients and contractions, EC coupling, or in vitro/in vivo 
S2808A-RyR2 mouse cardiac function and suggest there were no adaptions in this model 
because there is no role for S2808 phosphorylation in cardiac contractility (H. Zhang et al. 
2012; MacDonnell et al. 2008).  
 
The role of S2808 phosphorylation and FKBP12.6 in the dysfunction of RyR2 activity also 
remains hotly disputed. In the Marks hypothesis, the protein was originally suggested to 
stabilize RyR2 channel gating, preventing long-lasting subconductance states and diastolic 
SR Ca2+ leak (Marx et al. 2000). Depletion of FKBP12.6 has been implicated in an aberrant 
increase in cytosolic Ca2+ concentration as a result of SR leak and has been associated with 
HF, cardiomyopathy and fatal cardiac arrhythmias (Marx et al. 2000; Wehrens et al. 2006; 
Fauconnier et al. 2010; Wehrens 2003; Kushnir et al. 2010). Expression of FKBP12.6 has 
been reported as reduced in both HF and cardiomyopathy as well as a decreased ratio of 
the protein to RyR2, which would indicate dissociation in these instances (Hu et al. 2009; Y.-
S. Cheng et al. 2011; Y. Zhang et al. 2008).  
However, this hypothesis has limited support from other research groups (Barg et al. 1997; 
Timerman et al. 1996; T. Guo et al. 2010; Zissimopoulos and Lai 2004; B. Xiao 2004; T. Guo 
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et al. 2006; Stange et al. 2003; Mukherjee et al. 2012). S2808D KI mice with genetically 
phosphorylated channels have been shown to exhibit normal FKBP12.6 binding (Shan, 
Kushnir, Betzenhauser, Reiken, J. Li, Lehnart, Lindegger, Mongillo, Mohler and Marks 
2010a). In a FKBP12.6 knockout mouse model, the absence of the protein did not alter the 
incidence of spontaneous Ca2+ release or single RyR2 activity in comparison to WT mice (B. 
Xiao et al. 2007).  The location of the S2808 phosphorylation site is 105-120 Å away from 
the FKBP12.6 binding site in RyR2, making direct involvement of S2808 phosphorylation in 
FKBP12.6 binding unlikely (Meng et al. 2007). More recent studies suggest that other 
posttranslational modifications, such as oxidation and S-nitrosylation, combined with 
phosphorylation of RyR2 are required to dissociate FKBP12.6 from RyR2, increasing 
channel Po (Shan, Betzenhauser, et al. 2010; Fauconnier et al. 2010). FKBP12.6:RyR2 
association has also been implicated in arrhythmia caused by mutations in RyR2. This is 
discussed in Section 1.4.1.5 and 1.7.3.1. 
 
There remains disagreement on whether PKA-dependent RyR2 phosphorylation alters 
function in general – if not, this would render the PKA phosphorylation level at S2808 
functionally irrelevant with respect to diastolic Ca2+ release. Early work using single channels 
isolated from the RyR2-S2808A mouse in lipid bilayers suggested that ablation of this site 
led to a significantly reduced Po in comparison to WT after the application of PKA (Wehrens 
et al. 2006). While Marks and Chen groups both report no changes in S2808A activity at 
basal conditions, Xiao and colleagues reported no change in channel activity after treatment 
with PKA (B. Xiao et al. 2007). Also, in direct conflict with the Marks-Wehrens hypothesis, 
Shannon and Bers find that CaMKII and not PKA is responsible for Ca2+ leak from the SR, 
suggesting that PKA phosphorylation of the S2808 site is not critical in RyR2 channel 
dysfunction {Ai:2005ct, Curran:2007de}.  
 
1.4.2.2  S2031 
 
In work of the Chen group in 2005, two-dimensional phosphopeptide mapping (see Section 
4.1.2.2) revealed two major PKA phosphopeptides in RyR2, one of which corresponded to 
the already established S2808 (B. Xiao et al. 2005). The other was identified as a novel 
phosphorylation site, S2031. Using phospho-specific antibodies, this novel site was shown 
to be phosphorylated in Iso-stimulated rat cardiomyocytes, but not in unstimulated cells. 
S2031 was phosphorylated by PKA and not CaMKII and ablation of the site did not alter 
FKBP12.6-RyR2 interactions, nor the Ca2+ dependence of [3H] ryanodine binding. Chen also 
argued that levels of phosphorylation at S2808 were similar in both failing and non-failing 
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canine hearts and therefore that S2031 was in fact the major PKA phosphorylation site in 
RyR2 (B. Xiao et al. 2005). 
 
Basal phosphorylation at this site is consistently reported as very low (Huke and Bers 2007; 
Cooper et al. 2013; Belevych, Sansom, et al. 2011). The Chen group demonstrated that 
recombinant RyR2 S2031A single channels behave similar to WT, which would fit with these 
consistent findings (B. Xiao et al. 2007). On exposure to PKA, S2031A channels displayed a 
reduced sensitivity to luminal Ca2+ in comparison to WT, or the fully phosphorylated 
counterpart (S2031D). However, work of the Marks group, also using recombinant RyR2, 
showed a PKA-mediated increase in the Po of S2031A channels similar to that of WT, while 
S2031D channels (fully phosphorylated) displayed only a small change in activity upon 
phosphorylation , challenging the PKA-mediated functional relevance of the S2031 site 
(Wehrens et al. 2006). Data from the Györke laboratory suggests that S2031 can also be 
phosphorylated by CaMKII (Belevych, Sansom, et al. 2011), suggestive that other kinases 
may confer effects on RyR2 channel function by phosphorylation at this site, or sites in close 
proximity.  
 
1.4.2.3  S2814 
 
S2814 was originally identified by the Marks group as a CaMKII specific site (Wehrens, 
Lehnart, Reiken and Marks 2004). Introducing mutations into human recombinant RyR2, the 
group showed that S2808A could still be phosphorylated by CaMKII, yet S2814A could not, 
indicating this was the unique CaMKII phosphorylation site on recombinant RyR2. The basal 
level of phosphorylation at the S2814 site increases in the presence of phosphatase 
inhibitors and the β-adrenergic agonist Iso, and significantly decreases in the presence of 
phosphatases or the Ca2+ chelator EGTA (Belevych, Terentyev, et al. 2011; Huke and Bers 
2008; Huke and Bers 2007; Terentyev, Rees, W. Li, Cooper, Jindal, Peng, Lu, Terentyeva, 
Odening, Daley, Bist, Choi, Karma and Koren 2014b; Cooper et al. 2013). Increases in 
S2814 basal phosphorylation of up to 300 % at this site have been reported in HF when 
normalized to RyR2 protein expression in Western blot experiments (Fischer et al. 2014). 
 
In myocytes isolated from a S2814A KI mouse model, there were no obvious changes in SR 
Ca2+ release in comparison to WT, yet the fully phosphorylated mimic counterpart S2814D 
exhibited enhanced SR Ca2+ leak and a reduced SR Ca2+ content (van Oort, McCauley, 
Dixit, Pereira, Yang, Respress, Wang, De Almeida, Skapura, Anderson, Bers and Wehrens 
2010b).  An important finding in genetic ablation of the site is that S2814A KI mice showed 
delayed development of HF after transverse aortic constriction (TAC), were protected 
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against ischemia-reperfusion induced arrhythmia and displayed reduced Ca2+ homeostasis 
abnormalities that precede ventricular arrhythmia when crossed with a mouse model of 
Duchenne muscular dystrophy, dmd (Respress et al. 2012; Ather et al. 2013). The induction 
of atrial fibrillation in FKBP12.6 knockout mice was also prevented by the introduction of 
S2814A (N. Li et al. 2012).  
 
It is difficult to discern how sites in RyR2 could be exclusively phosphorylated by a certain 
kinase, given their close proximity in the phosphorylation ‘hotspot’ in RyR2. It has been 
shown that S2808A channels can be fully activated by CaMKII, and S2814A channels by 
PKA (Wehrens et al. 2006; Wehrens, Lehnart, Reiken and Marks 2004; N. Li et al. 2014). 
This indicates that genetic ablation of one site does not prevent phosphorylation of others in 
this region from altering RyR2 channel function (2012). Wehrens and Valdivia more recently 
suggest that PKA and CaMKII do not affect heart rate by a unique target site that governs 
SR Ca2+ release or uptake, including S2808 or S2814 (Wu et al. 2016). Genetic ablation of 
these sites in mice failed to affect heart rate responses in vivo to adrenergic agonists and 
authors argue that RyR2 phosphorylation sites do not control heart rate individually and that 
additional sites may also contribute.  
 
In recent work of Wehrens and Bers, WT and S2814D KI mouse cardiomyocytes under 
acute CaMKII activation displayed increased SR Ca2+ leak, with a reduced CaM-RyR2 
binding affinity and a pathological shift in RyR2 conformation (detected using a structural 
peptide DPc10, discussed in more depth in Section 1.7.3.2) in comparison to S2814A KI 
myocytes (Uchinoumi et al. 2016). These same effects were observed in rabbits with 
pressure/volume-overload induced ventricular fibrillation (VF). Treatment of permeabilized 
S2814D myocytes with excess CaM or dantrolene shifts the pathological conformation back 
to normal, restoring CaM affinity, decreasing SR Ca2+ leak and preventing triggered 
arrhythmias. The authors propose that multiple pathways converge to increase Ca2+ leak in 
pathological conditions (Uchinoumi et al. 2016), including; increased CaMKII activity; RyR2 
structural unzipping between N-terminal and central domains (discussed in Section 1.7.3.2); 
oxidation (see Section 1.5); and reduced CaM binding to RyR2 (Oda 2005; Oda et al. 2015; 
Ai 2005; X. Xu et al. 2010; Uchinoumi et al. 2010). These RyR2 modifications are thought to 
cause a ‘common pathological conformation state’, the shift to which is promoted by CaMKII 
phosphorylation at S2814 (Uchinoumi et al. 2016). The role of CaM in RyR2 channel activity 
adds another layer of complexity to elucidating the effects of phosphorylation. 
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1.4.2.4  Other investigated phosphorylation sites 
 
Mass spectrometry of the RyR2 protein has revealed additional phosphorylation sites, 
including S2811, S2797, threonine 2876 (T2876) and possibly threonine 2810 (T2810) 
(Yuchi et al. 2012; Huttlin et al. 2010).  
 
The S2811 site is another phosphorylatable residue found within the ‘phosphorylation 
hotspot’ (Yuchi et al. 2012) and forms part of the CaMKII phosphorylation consensus 
2805RRISQTSQVSV2815 (underlined). It has been reported as phosphorylated in vitro by both 
CaMKII and PKA and in mice stimulated by β-adrenergic agonists (Yuchi et al. 2012; Huttlin 
et al. 2010). As S2808 and S2814 are well established phosphorylation sites in RyR2, it is 
suggested nearby residues S2797, T2810 and S2811 that are within or near the same 
segment are also accessible to protein kinases for phosphorylation. T2876 does not reside 
in the phosphorylation linker loop and was not detected in vivo by Yuchi et al. (2012) so was 
therefore suggested as inaccessible in full length RyR2 and a possible artefact of 
experimental conditions. 
 
It remains unclear whether the S2811 site, as well as others in close proximity, contribute to 
the effects of CaMKII and PKA phosphorylation (Camors 2014). There are also concerns 
that phosphorylation at this site may distort the signal of phospho-specific antibodies pS2808 
and pS2814 as they are in very close proximity, therefore making it difficult to clarify the 
specificity of kinases for certain residues and the functional relevance of phosphorylation at 
a single site (Huke and Bers 2008; Camors 2014).  
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1.4.3 Effects of serine/threonine phosphatases on RyR2 
 
While RyR2 function is thought to be upregulated by the action of protein kinases and 
phosphorylation in β-adrenergic stimulation, control is restored by the reverse action of 
protein phosphatases, which dephosphorylate the channel and other EC coupling proteins in 
the cardiomyocyte. The degree of phosphorylation of sites in RyR2 and channel activity 
therefore depends on a fine balance between the multiple kinases and phosphatases 
present. Several protein phosphatases (PP) are present in the macromolecular complex and 
associate with RyR2 through adaptor proteins and regulatory subunits (Figure 1.11). 
Serine/threonine phosphatases in the complex include PP1, PP2A and PP2B, also known as 
calcineurin (Weber et al. 2015). These phosphatases are estimated responsible for 90% of 
phosphatase activity in the heart (Cohen and Cohen 1989; MacDougall et al. 1991). The 
structure of these enzymes allows specific subcellular targeting and substrate affinity, where 
a complex combination of regulatory and catalytic subunits provides a mechanism for 
precise control of activity (Heijman et al. 2013).  
 
PP1 consists of catalytic and regulatory subunits in a dimer structure. This phosphatase is 
not freely available within the cardiomyocyte, but instead there is competition of over 200 
regulatory subunits to form a complex with a catalytic subunit, as a holoenzyme (Herzig and 
Neumann 2000; Ceulemans and Bollen 2004; Heroes et al. 2013). The >200 PP1 regulatory 
subunits can be classified by their activity into two groups: those that regulate PP1 activity, 
or those that target PP1 to specific substrates such as myosin or the plasma membrane 
(Cohen 2002; Heroes et al. 2013; Heijman et al. 2013). PP2A structure is more complex, 
being coded for by at least 17 distinct genes with large sequence diversity (T. A. Jones et al. 
1993). It exists as a trimer with catalytic, regulatory and additional structural scaffolding 
subunits. Regulatory subunits can be grouped into four families as opposed to two, and 
some of these have different splice variants and multiple isoforms. B56α of the PP2A-B 
family is one of the most studied isoforms, which is indicated in the RyR2 macromolecular 
complex (Figure 1.11). PP2B also exists as a dimer, with calmodulin-binding catalytic and 
regulatory subunits. The enzyme can also be modulated by interacting proteins, including 
mAKAP or Cain, a PP2B inhibitor (Wolska 2009; H. W. Lim and Molkentin 1999; Y. Wang et 
al. 2014; Heineke and Ritter 2012).   
 
Work of the Marks group showed that PP1 and PP2A are scaffolded to the RyR2 
macromolecular complex by leucine-isoleucine zipper motifs of their regulatory subunits 
(PP1 by subunit spinophilin, PP2A by subunit PR130) (Marx, Reiken, et al. 2001; Marks et 
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al. 2002). PP2A has also been shown to scaffold to mAKAP via regulatory subunit B56δ and 
B56α (Dodge-Kafka et al. 2010; Belevych, Sansom, et al. 2011). Posttranslational 
modifications of catalytic and regulatory subunits can also occur, adding further control of 
local phosphatase activity (DeGrande et al. 2013; Heijman et al. 2012; Dodge-Kafka et al. 
2010; Lei et al. 2015; El-Armouche et al. 2003). For example, phosphorylation at Serine 566 
in PP2A catalytic subunits causes destabilization of interaction with the regulatory subunit, 
reducing phosphatase activity (DeGrande et al. 2013; Dodge-Kafka et al. 2010; J. Chen et 
al. 1992). PP2A phosphorylation also modulates PDE4D3, the phosphodiesterase anchored 
on the mAKAP scaffold within the RyR2 complex (Lei et al. 2015). Specificity of 
phosphatases for RyR2 phosphorylation sites remains to be elucidated. PP1 has been 
demonstrated to dephosphorylate S2808 and S2814, while PP2A dephosphorylated S2814 
only (Huke and Bers 2008). Work of the Györke laboratory in experiments of PP2A 
suppression, through translational inhibition with muscle-specific microRNAs 1 and 133, 
showed control of phosphorylation by this phosphatase at S2814 and S2031 of RyR2, not 
S2808 (Terentyev et al. 2009; Belevych, Sansom, et al. 2011).  
 
Evidence is growing that RyR2 activity is modulated by the action of both kinases and 
phosphatases. Phosphorylation at S2808, S2814 and S2031 to maximal levels is associated 
with increased RyR2 Po and subsequent treatment with PP1 reduces this activity in several 
studies (Carter et al. 2006; Carter et al. 2011). Interestingly in single channel experiments, 
dephosphorylation of RyR2 at S2808 by PP1 also increases Po  (Carter et al. 2006; 
Terentyev et al. 2003). Carter et al. have shown that this activity is not associated with 
changes in sensitivity to cytosolic Ca2+, instead stemming from shortening of the closed 
states of the channel (Carter et al. 2011; Carter et al. 2006).  
 
Györke and colleagues utilized their mouse model of Ca2+-dependent cardiomyopathy 
(CCM), with CSQ2 KO and SERCa1a overexpression, to examine the potential role of 
S2808 phosphorylation in the development of the disease (Ho et al. 2014; Kalyanasundaram 
2013). SERCa1a functionally substitutes SERCa2a in cardiac muscle in this model, and 
overexpression prevents depletion of the SR Ca2+ store. By cross-breeding with RyR2 
S2808A mice, Györke et. al (2014) found that the application of PP1 to permeabilized triple 
mutant mouse cardiomyocytes produced a transient increase in Ca2+ spark frequency at 
unchanged SR Ca2+ content (Ho et al. 2014). Consistent with previous reports, RyR2 was 
found to be highly phosphorylated (75 % of available phosphorylation sites in a tetramer) at 
S2808 in WT and double mutant hearts, while S2808A mutation rendered triple mutant 
mouse hearts either partially or non-phosphorylatable. Given the high basal phosphorylation 
level, it was suggested that dephosphorylation rather than further phosphorylation leads to 
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exacerbated CCM and abnormal Ca2+ cycling in triple mutant mouse by enhancing RyR2 
activity. In another study with WT rat cardiomyocytes, catalytic subunits of PP1 and PP2A 
resulted in a dramatic increase in leak and a rapid depletion of SR Ca2+ stores, suggestive 
that this leak is due to the change in RyR2 function when dephosphorylated (Terentyev et al. 
2003). These data also implicate dephosphorylation in increasing RyR2 channel activity 
 
 
 
Figure 1.11 The RyR2 macromolecular complex with associated accessory proteins that 
influence its phosphorylation status. The action of protein kinases CaMKII and PKA on RyR2 
phosphorylation sites S2031, S2808 and S2814 are opposed by protein phosphatases PP1, PP2A 
and PP2B. PP1c and PP2Ac are directed to the complex via their regulatory subunits, spinophilin and 
PR130 and B56α respectively. In addition, PP2A scaffolds to the complex via B56 and mAKAP, 
which is anchoring PP2B, PKA and PDE4D. Image from Terentyev and Hamilton (2016).  
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1.4.4 Theoretical models of phosphorylation  
 
1.4.4.1  Mark’s hypothesis of phosphorylation causing Ca2+ leak via dissociation of 
FKBP12.6 
 
The original Marks hypothesis, published made in 2000, postulated that PKA 
phosphorylation regulates FKBP12.6 binding to RyR2, an accessory protein thought to 
stabilise the closed state of channel (Marx et al. 2000). According to this theory, FKBP12.6 
dissociation as a result of PKA hyperphosphorylation at the S2808 is thought to increase the 
Ca2+ sensitivity and Po of single RyR2 channels, with long-lasting subconductance states. 
This increase in channel activity led to decreased SR Ca2+ content, diastolic Ca2+ waves and 
arrhythmia in HF (see Figure 1.10). The PKA/RyR2-S2808/FKBP12.6 mediated Ca2+ leak 
mechanism has been extended as a critical pathway in genetic arrhythmias, seizures, and 
even skeletal muscle fatigue (Shan et al. 2010; Lehnart et al. 2008; Shan et al. 2008). 
However, numerous reports fail to reproduce critical aspects of the Marks hypothesis, 
including hyperphosphorylation of RyR2 at S2808 in HF and any major role of PKA in the 
phosphorylation of the channel (Y. Li et al. 2002; Ai 2005; Jerald Curran et al. 2007; M. T. 
Jiang et al. 2002; Stange et al. 2003; B. Xiao et al. 2007; B. Xiao et al. 2005; George 2007b; 
Timerman et al. 1996). Figure 1.12 grades the strength of support for key aspects of Marks’ 
hypothesis.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Schematic of the steps in Marks' working hypothesis of RyR alteration in HF, 
graded by strength of support. P is phosphorylation, PLB is phospholamban, PPase is 
phosphatase, NCX is Na/Ca exchange. Box colour indicates strength of support (green=strong, 
purple=equivocal, red=weak). Figure and legend taken from Bers (2012). 
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The contribution of SR Ca2+ leak through RyR2 to dysfunction in HF remains unclear. Work 
of Eisner, Trafford and Venetucci shows that changes in RyR2 Ca2+ sensitivity have only 
transient effects on systolic function due to an ‘autoregulation’ mechanism 
(Sankaranarayanan et al. 2016; Venetucci et al. 2008; Eisner et al. 2009). The first beat of 
an isolated cardiomyocyte with higher Ca2+ sensitivity has a greater Ca2+ release, which in 
turn drives Ca2+ extrusion from the cell via NCX – an initial fast phase of Ca2+ transient 
decay. SR Ca2+ uptake then progressively decreases, with a new steady state achieved at a 
lower SR Ca2+ content with higher Ca2+ release, but where Ca2+ influx and efflux are 
rebalanced so that the Ca2+ transient is unaltered. However, as diastolic SR Ca2+ leak 
increases (for example due to increased β-adrenergic stimulation) the initial rapid phase of 
Ca2+ transient decay disappears, and a second slow phase of decay occurs, where even at 
low SR Ca2+ content, leak is large enough to oppose the increased action of SERCa. To 
summarize, mild or moderate SR Ca2+ leak through RyR2 will not reduce Ca2+ transient 
amplitude, while severe Ca2+ leak reduces the Ca2+ transient amplitude and slows the rate of 
decay (Sankaranarayanan et al. 2016). 
 
1.4.4.2  Experimental differences due to different models and methods 
 
Potential reasons for such divergent results when investigating the Marks hypothesis include 
the variety of animal and experiment models, reagents and data analysis methods used by 
different research groups (Eschenhagen 2010; Dobrev 2014). However, in the instance of 
the Valdivia-Houser S2808A KI mouse, reasons for such differences are not so easily 
explained. Using the same strategy and similar experimental procedures as the Marks 
group, S2808A KI mice are functionally indistinguishable to WT, in terms of response to β-
adrenergic stimulation, RyR2 channel activity and cardiac dysfunction post-MI (H. Zhang et 
al. 2012; MacDonnell et al. 2008; Benkusky et al. 2007). Marks and colleagues, with the 
same mouse (albeit from a different line), had previously found completely the opposite, 
where genetic ablation of the S2808 site severely limits such responses (Wehrens et al. 
2006; Shan et al. 2010a). The only area of agreement in all studies with S2808A KI mice is 
that it has no basal phenotype, with contractility both in vitro and in vivo the same as WT (H. 
Zhang et al. 2012; Shaen et al. 2010a, Wehrens et al. 2006; MacDonnell et al. 2008; 
Benkusky et al. 2007; Shan et al. 2010b). While mouse models are not shared between 
research groups, reasons for differences remain unexplained.  
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1.4.4.3  Consideration of other RyR2 phosphorylation sites and the action of 
phosphatases 
 
It also remains that the Mark’s model disregards the functional relevance of the S2031 
phosphorylation site as well as other potential sites. In an updated model, Wehrens offered 
an explanation that reconciles the roles of both S2808 and S2814 RyR2 phosphorylation 
(Respress et al. 2014). The group suggest that PKA exclusively phosphorylates S2808 and 
dissociates FKBP12.6, leading to increased RyR2 channel activity, while CaMKII almost 
exclusively phosphorylates S2814, has no effect on FKBP12.6 and still increases RyR2 
channel activity. This was based on observations of S2814A KI mice, where preventing 
phosphorylation at this site protected against nonischemic HF but not ischemic HF.  
 
Doubt has also been cast on the clean targeting of phosphorylation sites described by 
Respress et al. (2012), with suggestions this is oversimplified (2012). Structural data reveals 
that S2808 and S2814 form part of a larger phosphorylation hotspot in RyR2, in a flexible 
linker loop that protrudes on the RyR2 surface (Yuchi et al. 2012; Yuchi et al. 2013). This 
would suggest that the whole phosphorylation hotspot could be accessed by several 
kinases. Valdivia suggests that phosphorylation sites within this hotspot may provide 
‘functional redundancy’, whereby phosphorylation of one site may lead to the same 
downstream effects of another due to such tight clustering (2012). Sequential addition of 
phosphate groups to the hotspot could lead to a graded response of RyR2 to multiple 
kinases, which could aid in explaining the variable response to phosphorylation observed by 
investigators. 
 
Findings imply that altered RyR phosphorylation and function can also be due to changes in 
local phosphatase activity, as evidenced in both acquired and inherited cardiac conditions 
(DeGrande et al. 2013; Gupta et al. 2003; Wijnker et al. 2011; Neumann et al. 1997; 
Belevych, Sansom, et al. 2011). For example, decreased expression of PP2A catalytic 
subunits B56α and B56δ in a canine model of HF was accompanied by excessive RyR2 
phosphorylation at S2031 and S2814 and increased RyR2-mediated diastolic Ca2+ leak 
(Niggli et al. 2012; Belevych, Terentyev, et al. 2011; Wijnker et al. 2011; Belevych, Sansom, 
et al. 2011). Marx et al. (2000) showed that a significant decrease in levels of PP1 and PP2A 
associated with the RyR2 macromolecular complex in failing human and canine hearts, even 
with the rise of cellular levels of PP1. Along with the evidence that dephosphorylation can 
also increase RyR2 channel activity (Carter et al. 2011), this suggests that both maximum 
phosphorylation and incomplete dephosphorylation of RyR2 results in increased activity of 
the channel (Terentyev and S. Hamilton 2016). This hypothesis may aid in the reconciliation 
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of contradicting results from different research groups, where any observed effects of 
kinases or phosphatases depend on initial RyR2 phosphorylation levels at multiple sites, 
which may vary due to experimental method. 
 
The Marks group have evidenced PKA RyR2 hyperphosphorylation in models of human, 
mouse and rat heart failure (Marx et al. 2000; Reiken et al. 2001; Antos et al. 2001; Reiken 
et al. 2003). Inconsistencies described by other groups have been attributed to the activity of 
phosphatases during experimental procedures such as cardiomyocyte isolation and the 
importance of phosphatase inhibitors suggested as paramount (Reiken et al. 2003). It also 
remains that other posttranslational modifications, such as oxidation, can alter RyR2 channel 
function (Gonzalez et al. 2007; J. Sun et al. 2008). 
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1.5 Other posttranslational modifications 
 
1.5.1 Oxidation by reactive oxygen species 
 
There are many sources of reactive oxygen and reactive nitrogen species (ROS/RNS) that 
can alter the intracellular redox potential. Sources of ROS within the cardiomyocyte include 
sarcolemmal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine 
oxidase and the mitochondrial electron transport chain (Niggli et al. 2012). At low 
concentrations, ROS can serve as intracellular messengers, but at higher concentrations 
can lead to oxidative stress and subsequent redox modifications of EC coupling proteins 
with cysteine residues, including RyR2. Early works of the Williams laboratory demonstrated 
effects of ROS on RyR2 Po {Boraso:1994fx, Holmberg:1991vx}. Oxidative conditions 
increase RyR2 Po and in cardiomyocytes leads to a rapid increase in Ca2+ sparks, suggestive 
that the functional consequence of moderate oxidative stress is an immediate enhancement 
of SR Ca2+ release (Eager et al. 1997; Marengo et al. 1998; L. Xu et al. 1998; Salama et al. 
2001). Increased ROS generation and subsequent oxidation and irreversible activation of 
RyR2 has been linked to many cardiovascular conditions, as well as diabetes (Bidasee et al. 
2003; Terentyev, Belevych, et al. 2008; Y. M. Kim et al. 2005; C. Jung et al. 2007; 
Kyrychenko et al. 2012).  There are reports of xanthine oxidase (a source of ROS) 
upregulation in several models of HF and abnormal SR Ca2+ release in myocytes from 
infarcted and failing heart associated with an increase in RyR2 oxidation (Cappola et al. 
2001; Gonzalez et al. 2010; Terentyev, Belevych, et al. 2008; Belevych et al. 2009).  
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1.5.2 Nitrosylation  
 
The major source of RNS in the cardiomyocyte is nitric oxide synthase (NOS) in either 
endothelial or neuronal form (eNOS or nNOS). This enzyme modifies RyR2 channels by the 
addition of nitric oxide (NO) groups to thiol moieties on cysteine residues in a process 
termed S-nitrosylation (Niggli et al. 2012; G. Lim et al. 2007). NOS and xanthine oxidase 
have been shown to physically interact in the left ventricles of mouse hearts and NO has an 
inhibitory effect on ROS production by xanthine oxidase (Khan et al. 2004). NOS has also 
been shown to move from the SR to the sarcolemma in failing hearts, potentially removing 
the cardioprotective effect of xanthine oxidase inhibition in this instance (Hare and Stamler 
2005). Both constitutive isoforms of NOS have been shown to co-immunoprecipitate with 
RyR2 (Bendall et al. 2004). Evidence suggests that NO may regulate RyR2 channel Po in 
both a PKA activity- and concentration-dependent manner (Fauconnier et al. 2010; Petroff et 
al. 2001). The interaction of RyR2 modifications resulting from both ROS and RNS remains 
to be fully elucidated, but it has been suggested that a precise balance of the two species 
within the cell is important, with disequilibrium leading to abnormal channel behaviour (Niggli 
et al. 2012; G. Lim et al. 2007).  
 
1.5.3 Glutathionylation 
 
During oxidative stress, free thiols of RyR2 can be oxidized to form sulfenic, sulfinic or 
sulfonic acid products (Giles and Jacob 2002). Reduced glutathione, a highly abundant 
antioxidant, usually attenuates ROS production by scavenging free radicals. It can also 
readily react with sulfenic acids to form reversible S-glutathionylation of RyR2 and protein-
glutathione-mixed dilsulfide products, thought to have a protective role during cellular 
oxidative changes (Zima and Mazurek 2016; Townsend 2008). In the cardiomyocyte, the 
ratio of oxidized and reduced glutathione is therefore an important indicator of redox state. 
During normal physiological conditions, cytosolic glutathione is mostly reduced. During 
oxidative stress, the ratio can increase significantly, as well as the total amount of protein-
glutathione-mixed dulsulfides (Tang et al. 2011; Werns et al. 1992; Ceconi et al. 1988). An 
increase in these compounds has been implicated as a critical signalling mechanism that is 
causative in cardiovascular disease (Zima and Mazurek 2016).  
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1.5.4 Crosstalk between redox modifications and phosphorylation  
Posttranslational modifications of RyR2 are unlikely to be entirely mutually exclusive, yet 
causal links between them and alterations of RyR2 function are yet to be established. 
Competition between NOS/NO-dependent S-nitrosylation and ROS-dependent thiol 
oxidation has recently been observed, with both suggested to increase Ca2+ leak through 
RyR2 channels (Gonzalez et al. 2007; J. Sun et al. 2008). The Marks group suggested that 
oxidation reduces the affinity of RyR2 for FKBP12.6 and sensitizes the channel for PKA 
phosphorylation at S2808, a cooperative mechanism that increases Ca2+ leak (Shan, 
Betzenhauser, et al. 2010; Shan, Kushnir, Betzenhauser, Reiken, J. Li, Lehnart, Lindegger, 
Mongillo, Mohler and Marks 2010a). Under non-oxidizing conditions, PKA may not 
destabilize FKBP12.6 binding, therefore offering an explanation as to why others did not 
observe this phenomenon (see Section 1.4). Interestingly, genetic inhibition of RyR2 
phosphorylation at S2808 or S2814 phosphorylation sites reduced RyR2 oxidation in mice 
with Duchenne muscular dystrophy (dmd mice) exhibiting progressive cardiac deterioration, 
suggesting a potential interaction between pathways (Kyrychenko et al. 2012; Q. Wang et al. 
2015). Redox conditions can also easily differ between laboratories, protocols and reagents, 
so different redox states of RyR2 channels in question may account for some published 
controversies on the role of phosphorylation on RyR2 channel function (Eschenhagen 2010). 
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1.6 Dysregulation of RyR and disease 
 
1.6.1 Diseases linked to RyR1 
 
Dysfunction of both RyR1 and RyR2 isoforms has been linked to life-threatening conditions 
(MacLennan and Zvaritch 2011). Associated diseases of mutant RyR1 include malignant 
hyperthermia (MH) and central core disease (CCD). MH is triggered by volatile anaesthetics 
or by muscle relaxants, while CCD is characterized by progressive muscle weakness and 
cores (inactive tissue) within muscle fibres (Fujii et al. 1991; Quane et al. 1993; Mulley et al. 
1993; Gillard et al. 1991; Jungbluth et al. 2005). Many of the associated mutations cluster in 
regions highly conserved between species and isoforms in distinct disease ‘hotspots’, with 
diseases of RyR1 and RyR2 found in the N-terminal region (~1-600 residues), a central 
region (~2100-2500 residues), and a C-terminal region (~3900 residues to end) (Van 
Petegem 2012). This suggests functional importance of these regions within RyR isoforms 
(George 2007a; Laitinen et al. 2001; Postma 2005).   
 
1.6.2 Diseases linked to RyR2 
 
Finely tuned cardiomyocyte Ca2+ signalling is critical to normal cardiac function and given 
the central role of RyR2 in this process, any perturbations of SR Ca2+ release through RyR2 
channels is implicated in many cardiovascular diseases. Decreased SR Ca2+ load occurs as 
a result of ‘leaky’ destabilized RyR2 channels in pathophysiology (Marx et al. 2000). This 
Ca2+ leak can result in a decreased Ca2+ transient amplitude and potentially drive inward 
Ca2+ currents through NCX, causing premature AP, early and delayed after depolarizations 
(EADs and DADs, see Section 1.7.1). A downregulation of NCX or upregulation of 
SERCa2a can contribute to this phenomenon, as observed in HF (Bers 2006). An increase 
of SR Ca2+ content may also perturb Ca2+ homeostasis, as it can increase the sensitivity of 
RyR2 to activation and lead to increased Ca2+ sparks, subsequently causing EADs and 
DADs (Carnes 2008; Bers 2008). Cardiac pathologies involving altered Ca2+ handling via 
RyR2 are discussed below.  
 
1.6.2.1  Heart failure and triggered arrhythmia  
 
HF is characterized by a progressive deterioration of cardiac function, with the heart unable 
to pump sufficient amounts of blood to support the metabolic need of body tissues. 
Prevalence is alarmingly high, with ~900,000 people in the UK affected, causing and 
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complicating ~5% of all emergency hospitalizations (Bhatnagar et al. 2016). HF is the final 
common pathway for many cardiovascular conditions, including ischemic heart disease, 
hypertension and genetic abnormalities. The in-hospital mortality rate for those patients 
admitted with acute HF is ~10%, with premature death occurring from haemodynamic 
collapse due to poor cardiac pump function, or from lethal arrhythmias (Bhatnagar et al. 
2016; Henkel et al. 2009).  
 
Characteristics vary depending on the stage of condition, but the failing heart is usually 
pumping against excessive systemic pressures and is dilated, requiring the diseased heart 
to generate an increased systolic wall stress. Cardiomyocytes generate greater forces to 
eject normal or often reduced output. HF is generally acknowledged as a disease state in 
which normal β-adrenergic stimulation is disrupted and with receptors downregulated and 
responsiveness to elevated circulating catecholamines severely attenuated (Fischer et al. 
2012). Patients are dependent on this hyperadrenergic state to maintain cardiac output 
under normal conditions (Houser and Margulies 2003). Myocytes in the failing heart also 
structurally and functionally remodel in response to increased metabolic demand. There are 
changes in the expression and phosphorylation state of many EC coupling proteins 
underlying contractile dysfunction in HF, including LTCCs, SERCa2a, NCX and RyR2 
(Houser and Margulies 2003; X. Chen et al. 2002; Dipla et al. 1999; Houser et al. 2001; 
Piacentino 2003; Gaughan et al. 1999).  
 
Major alterations in the Ca2+ handling of a failing ventricular cardiomyocyte are caused by 
downregulation of SERCa and upregulation of NCX function, thereby increasing Ca2+ efflux 
and reducing SR Ca2+ content (Bers et al. 2006). As Ca2+ transient amplitudes are smaller 
due to a reduced SR content, there may be less Ca2+-dependent inactivation of LTCCs, thus 
a greater integrated Ca2+ influx into the cell. In HF, SR Ca2+ content is also depressed by 
enhanced Ca2+ leak, implicating enhanced RyR2 activity (Eisner et al. 2017).   
 
Enhanced RyR2 activity is implicated in multiple forms of HF, including compensated early 
stages of the disease where Ca2+ transient amplitude remains unaltered (Sossalla et al. 
2010; Jerry Curran et al. 2010; Belevych, Terentyev, et al. 2011). As discussed in Section 
1.4, phosphorylation of RyR2 has been intensely investigated as a means of altering 
channel function, especially in terms of pathophysiological changes in Ca2+ handling during 
HF. The leading cause of death in patients with HF is cardiac arrhythmia, namely ventricular 
tachycardia and fibrillation (Orn and Dickstein 2002). Increased RyR2 activity can lead to 
different patterns of Ca2+ handling including self-propagating waves and triggered activity 
arising from EADS and DADs, events that can lead to ventricular tachycardia (VT) 
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(Venetucci et al. 2008; Monsuez et al. 1995; Janse 2004; Belevych, Terentyev, et al. 2011; 
Xie and Weiss 2009; Pogwizd 2004; Keurs and Boyden 2007).  
 
Atrial fibrillation (AF) is another common form of human arrhythmia, usually attributed to an 
increased substrate for reentry due to tissue fibrosis and altered EC coupling protein 
expression. RyR2 dysfunction is thought to underlie triggered ectopic activity in AF (Hove-
Madsen et al. 2004; Vest et al. 2005; Heijman et al. 2016). The activities of phosphatases 
PP1 and PP2 are increased in AF, and although this increased activity is expected to 
dephosphorylate EC coupling proteins, RyR2 phosphorylation levels are also increased (El-
Armouche 2006; Greiser et al. 2009). It has been proposed that uneven distribution of 
phosphatases between subcellular compartments with decreased activity in the RyR2 
microdomain contributes to this increased RyR2 phosphorylation (El-Armouche 2006). 
Alternatively, enhanced activity of CaMKII may outweigh phosphatase activity, leading to 
increased RyR2 phosphorylation and ultimately an increase in channel activity that 
contributes to AF (Chelu et al. 2009).  
 
1.6.2.2  Arrhythmogenic right ventricular cardiomyopathy 
 
Arrhythmogenic right ventricular cardiomyopathy (ARVC), also known as arrhythmogenic 
right ventricular dysplasia (ARVD) is an inherited condition, distinguished by ventricular 
arrhythmia and right ventricular degeneration (Marcus et al. 2010; Marcus et al. 1982). The 
disease is autosomal dominant in nature and there are more than 10 causative genes linked 
to the condition (Ohno 2016; Ruder et al. 1985). ARVC2 is linked to mutations of RyR2, with 
mutation carriers in the first identified ARVC family showing exercise-induced polymorphic 
ventricular tachycardia much like another disease, catecholaminergic polymorphic 
ventricular tachycardia (CPVT) (Rampazzo et al. 1995). However, instead of having a 
structurally normal heart, ARVC2 patients presented with fibro-fatty replacement of cells in 
the right ventricular myocardium, thereby distinguishing the condition from CPVT. Four 
RyR2 mutations (R176Q, L433P, N2386I and T2504M) from three ARVC families were 
identified, although later suggestions were made that families were presenting with a variant 
of CPVT (Ohno 2016; Tiso et al. 2001). In a KI mouse model of R176Q (heterozygous for 
the mutation, +/-), mice exhibited normal resting phenotype but with β-adrenergic stimulated 
premature ventricular beats (Kannankeril et al. 2006). No fatty-fibrous tissue was found in 
R176Q mouse hearts, suggestive that this mutation in fact causes CPVT.  
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1.7 Catecholaminergic polymorphic ventricular tachycardia 
 
1.7.1 Pathophysiology 
 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited 
arrhythmogenic disease associated with sudden cardiac death (Priori et al. 2001). It causes 
syncopal episodes following stress or exercise with symptoms often beginning in childhood, 
although later onset has been reported. These symptoms only usually occur during β-
adrenergic stimulation, implicitly linking upregulation of EC coupling proteins by 
phosphorylation in disease pathogenesis. It is characterized by delayed after depolarizations 
(DADs, see Figure 1.13) and polymorphic or bidirectional VT, but in contrast to ARVC, this 
is in the absence of any structural alterations to the heart. Both forms of VT can degenerate 
into VF and sudden cardiac death which is often the first manifestation of the condition 
(Swan, Piippo, Viitasalo, Heikkilä, Paavonen, Kainulainen, Kere, Keto, Kontula and Toivonen 
1999b; Allouis et al. 2005). Prevalence of CPVT within the population is estimated at 
1:10,000, with the majority of patients having a family history of syncopal or arrhythmic 
events (Jabbari et al. 2013; Ylänen et al. 2010; Keurs and Boyden 2007). However, 
phenotypic manifestations of the disease are very heterogeneous, sometimes even within 
the same family (George 2007a). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Abnormal Ca2+ handling in cardiomyocytes leading to delayed after 
depolarizations. A. During the plateau phase of action potential, Ca2+ influx occurs through LTCCs 
and triggers CICR, initiating cardiomyocyte contraction during systole. B. Spontaneous Ca2+ release 
through RyR2 channels increases cytosolic Ca2+ concentration during diastole. This is extruded from 
the cytosol by NCX leading to an inward depolarizing current (Iti) that can cause delayed after 
depolarizations (DADs). Phosphorylation (P) is also implicated. Figure from Nattel et al. (2014).  
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1.7.2 ‘Hotspot’ domains of RyR2 CPVT1 mutations 
 
‘Catecholamine-induced’ severe ventricular arrhythmia was first identified in 1978 as a novel 
clinical condition (Coumel 1978). However, it wasn’t until the advancement of molecular 
genetics that linkage studies and direct sequencing revealed mutations linked to the 
condition mapped to chromosome 1q42-q43 and subsequently, the human RyR2 gene 
(Priori et al. 2001; Swan, Piippo, Viitasalo, Heikkilä, Paavonen, Kainulainen, Kere, Keto, 
Kontula and Toivonen 1999a). CPVT can be inherited in either an autosomal dominant 
(CPVT1) or the recessive fashion (CPVT2) (Lahat et al. 2001; Priori et al. 2001; Laitinen et 
al. 2001). CPVT1 is the most common form, caused by mutations in RyR2 and is caused by 
aberrant Ca2+ release from the SR through the RyR2 channel. RyR2 mutations are 
autosomal dominant in nature, so inheritance of a single allele is sufficient to cause the 
disease phenotype. While most patients with the condition have a family history of cardiac 
events, some have been identified as the only symptomatic family member with neither 
parent carrying a mutant allele, suggestive that mutations can arrive de novo (Postma 2005; 
Priori et al. 2001). CPVT2 is linked to chromosome 1p13-21 and the CSQ2 gene (Lahat et 
al. 2001; Lahat et al. 2002). CSQ2 mutations are recessive, so inheritance on both alleles is 
required for the disease phenotype, making this form of CPVT less common (Lahat et al. 
2002). CSQ2 is a Ca2+-buffering protein that regulates Ca2+ release through RyR2 (see 
Section 1.3.4). Mutations in other accessory proteins that regulate RyR2 function have more 
recently been suggestive as causative of CPVT, including in CaM and TRDN (Walweel et al. 
2016; Rooryck et al. 2015; Gomez 2016; M. A. Walsh et al. 2016).  
 
hRyR2 CPVT1 mutations preferentially map to three (or four) distinct ‘hotspots’ or loci in the 
RyR2 polypeptide, with many of these mutations in regions conserved across multiple 
species isoforms. The fourth domain is referred to as the cytoplasmic portion of I domain 
and all domains (N-terminal, central, cytoplasmic portion of the I and transmembrane 
domain) can be visualised in Figure 1.14 (N. L. Thomas et al. 2006; George et al. 2007). 
The conserved nature of these mutation-rich regions reinforces the hypothesis that 
mutations are associated with functional changes in the hRyR2 gene product. To date, there 
are over 170 CPVT1 mutations reported in the literature (www.hgmd.com, (Medeiros-
Domingo et al. 2009), with approximately only ~10% of these mutations functionally 
characterized in some way. The RyR2 domain containing the highest number of mutations is 
the B-solenoid of the central domain, however the domain containing the highest 
density/concentration of mutations is the EF hand domain (Figure 1.15). Interestingly, Guo 
et al. (2016) found that some mutations in the EF-hand motifs or in fact entire deletion of the 
domain did not affect the Ca2+-dependent activation of [3H] ryanodine binding or the cytosolic 
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Ca2+ activation of the RyR2 channel. However, the E4071A mutation in the EF-hand binding 
motif (residues 4081-4127) in RyR2 altered spontaneous Ca2+ release in HEK293 cells, 
increasing the termination threshold for SOICR. Deletion of the entire domain also markedly 
decreased the sensitivity of single RyR2 channels to luminal activation. Authors therefore 
suggest that the EF hand Ca2+ binding domain is important for luminal Ca2+ activation and 
SOICR, but not necessarily cytosolic Ca2+ activation of the channel (W. Guo et al. 2016).  
 
Whether CPVT1 mutation location and severity of clinical phenotype in patients is linked 
remains unclear, with some groups suggesting C-terminal domain mutations may increase 
the odds of non-sustained VT in patients in comparison to N-terminal domain mutations 
(Yamazoe and Furukawa 2016; van der Werf et al. 2012). Others point out that the clinical 
manifestation is highly heterogeneous and that many mutation carriers can appear 
completely asymptomatic of disease (Priori 2002; Tester et al. 2004; Postma 2005; Tester et 
al. 2006; Tiso et al. 2001; Priori et al. 2001; Aizawa et al. 2007; Laitinen et al. 2001). 
Mutations investigated in this thesis are found in the B solenoid and EF hand domain.
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Figure 1.14 Schematic diagram to illustrate the clustering of CPVT1 
mutations in functional domains of the RyR2 polypeptide. CPVT1 mutations 
(red text) are grouped and indicated on the diagram in each domain, with 
mutations in black investigated in this thesis. Domains of the polypeptide defined 
in the table and discussed in more detail in Section 1.3.1. Mutations are 
classified into four groups – N-terminal domain (residues 77-1724), central 
domain (residues 2246-2534), cytoplasmic portion of I domain (residues 3778-
4201), and transmembrane domain mutations (residues 4497-4959). Figure and 
table adapted from des Georges et al. (2016).  
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Figure 1.15 Distribution of CPVT1 mutations in the functional domains of RyR2. A. A pie chart of 
all CPVT1 mutations in Figure 3.1, highlighting the distribution across domains of the polypeptide. 
Most mutations are found in the B-solenoid domain. B. Graph of the percentage of reported CPVT1 
mutations per number of residues. The EF hand domain has the most concentrated area of 
mutations. Colour-coding follows that in Figure 1.14.  
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1.7.3 Mechanisms of RyR2 dysfunction 
 
Controlled intracellular Ca2+ release through RyR2 is key during EC coupling and requires 
precise regulation (Bers 2004; Bers 2002b) with activation of the channel by cytosolic Ca2+ 
underpinning CICR (Fabiato 1985b). However, it has long been established that 
spontaneous Ca2+ release can occur in the absence of cell depolarization (Fabiato 1992), 
caused by a luminal SR Ca2+ ‘overload’, when Ca2+ within the SR reaches a critical threshold 
(Lakatta 1992; Orchard et al. 1983). Such overload can be caused by a variety of conditions, 
including the release of catecholamines during increased metabolic demand during stress or 
exercise; conditions that require a higher cardiac output to deliver more blood to the body via 
β-adrenergic stimulation (Marx and Marks 2013; Bers 2001). The clinical manifestation of 
CPVT1 occurs during these periods (Priori et al. 2001) and disease-causing mutations in 
RyR2 are suggested to reduce the threshold for Ca2+ release, increasing the susceptibility 
for arrhythmogenesis (D. Jiang et al. 2004; Priori and S. R. W. Chen 2011; Venetucci et al. 
2008). The mechanism of pathogenic RyR2 Ca2+ signalling has been intensely investigated 
(Belevych et al. 2013; Venetucci et al. 2008), but it remains to be elucidated how a single 
point missense mutation can have such catastrophic consequences on Ca2+ handling in EC 
coupling, regardless of its location in the RyR2 polypeptide.  
 
With variable penetrance of RyR2 mutations, the sheer number of different mutations in 
different domains of the channel and reported phenotypic heterogeneity of CPVT1 patients, 
it is highly unlikely that these mutations result in dysfunction by a single unifying mechanism 
(Bauce et al. 2002; Marjamaa et al. 2009; George 2007b). Three mechanisms of RyR2 
dysfunction have been proposed:  
 
1.7.3.1  Dissociation of FKBP12.6 and RyR2 ‘hyperphosphorylation 
The hypothesis involving FKBP12.6 dissociation from RyR2 causing channel destabilization 
and Ca2+ leak from the SR proposed by Marx et al. (2000) was extended to explain altered 
Ca2+ homeostasis in CPVT1, with mutant RyR2 channels suggested as having a reduced 
binding affinity for FKBP12.6. However, this has been challenged by other groups, who 
found unaltered FKBP12.6 association to mutant RyR2 expressed in heterologous and 
cardiac cell lines in comparison to WT, before or after stimulation with catecholamines 
(Zissimopoulos and Lai 2005; P. P. Jones et al. 2008; Tester et al. 2007; George, 
SORATHIA, et al. 2003; D. Jiang 2005). In KI mice with CPVT mutations (R2474S and 
R4497C), stress-induced DADs and arrhythmia were observed despite apparent normal 
FKBP12.6:RyR2 association (Fernández-Velasco et al. 2009; N. Liu et al. 2006; Uchinoumi 
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et al. 2010). The role of FKBP12.6 dissociation and RyR2 phosphorylation is discussed in 
more detail in Section 1.4.2.1.  
1.7.3.2  Disruption of interdomain interactions 
 
Interdomain interactions are thought to enable proper protein folding and assembly, 
stabilizing the closed RyR2 channel (Z. Liu et al. 2010; Yamamoto and Ikemoto 2002; 
George et al. 2004).  Disruption of such interdomain interactions by RyR2 mutation, termed 
‘domain unzipping’ has been suggested to weaken this stabilization and make channels 
more sensitive to activating Ca2+, subsequently leading to an open RyR2 channel during 
diastole. Ikemoto and Matsuzaki postulated a model in which there are two coupled domain-
domain interactions: that of the N-terminal and the central domain (See Figure 1.16), and 
that of the I-domain (residues 3722-4610) and the IP-domain (the unidentified putative 
partner of the I-domain (Oda 2005; Yamamoto and Ikemoto 2002; Tateishi et al. 2008; 
Suetomi et al. 2011; Uchinoumi et al. 2010).  Each of these coupled domains forms zipped 
complexes. When disrupted by CPVT1 mutation in the N-terminal or central domain, this 
induces diastolic Ca2+ leak via a destabilization of the N-terminal-central domain interaction, 
followed by destabilization of the I-IP domain interaction. CPVT1 mutations in the I-domain 
however, do not disrupt interactions in the same manner; I-IP domain interactions are 
disrupted, but N-terminal-central domain interactions remain stable.  
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Figure 1.16 Proposed action of unzipping between N-terminal and central domains in RyR2. Postulated domain unzipping is caused by either CPVT1 
mutation or a competitive interaction with domain peptides that mimic a region of the polypeptide. Figure adapted from Yang et al. (2006).
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DPc10 is a short synthetic peptide that is homologous to the central domain of RyR2, 
spanning residues 2460-2495 (Oda et al. 2005). This was used to mimic the effect of 
CPVT1-linked RyR2 mutations, with the authors reporting that the peptide destabilized 
interactions between the N-terminal and central domains of RyR2 (YANG et al. 2006; Oda et 
al. 2005; Z. Liu et al. 2010). Reversal of the unzipped state to a normal zipped state by the 
drug K201 (see Section 1.7.4) was reported by Oda et al. (2005), whereby the drug is 
proposed to stabilize the closed state of the channel by enhancing FKBP12.6 binding. In 
isolated WT rat cardiomyocytes, inserting the R2474S mutation into the peptide abolished 
the effects of DPc10 (Yang et al. 2006). Authors suggest that this mutation in the peptide will 
not interfere with interdomain interactions as does the WT peptide and that this particular 
residue is important in maintaining a stabilized RyR2 channel.  
 
Abnormally strong intradomain interactions are also implicated in dysfunction caused by 
altered interaction within the central domain. Synthetic peptide DP2446, corresponding to 
residues 2232-2266 in the central domain, binds to residues 1741-2270 within the same 
domain. Introduction of the CPVT1-linked mutation S2246L into DP2446 causes what is 
described as an abnormally tight interaction between DP2446 and the K201-binding domain 
(residues 2114-2149), with an increased affinity of peptide binding observed by fluorescence 
quench assay (Suetomi et al. 2011). Authors suggest that this tight interaction opens the 
Ca2+ channel and their dissociation closes the channel. The abnormally tight intradomain 
interaction caused by the S2246L mutation was proposed to explain increased Ca2+ spark 
frequency observed in isolated cardiomyocytes of S2246L (+/-) KI mice.  
 
Peptides that are homologous to the N-terminal (DP163-195) and C-terminal (DP4090-4123) 
domains of CPVT1 have also been utilized, mimicking CPVT mutations R176Q and N4104K 
respectively (Z. Liu et al. 2010; Tateishi et al. 2008). While addition of either peptide to 
isolated WT canine cardiomyocytes induced domain unzipping, increasing Ca2+ spark 
frequency and SR Ca2+ leak, treatment with K201 suppressed these effects induced by 
DP163-195 only. This is suggestive that K201 zipping occurs within only certain domains. 
Authors propose that mutations in the C-terminal region of RyR2 can also induce 
spontaneous Ca2+ leak, but not through communication with the N-terminal and central 
domain interaction, but by disruption of other domain interactions that are yet to be 
identified.  
 
In the latest 3D structure of RyR (see Section 1.3.1), the conduction pathway of the channel 
is formed by membrane regions of the four S6 inner helices, with the intracellular gate 
located in the S6 helix bundle crossing region (Yan et al. 2014). The cytoplasmic region of 
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the S6 helix appears to interact with the U motif of the central domain (Bai et al. 2016; Yan 
et al. 2014). The U motif is formed from the carboxyl-terminal sequences of the central 
domain that form a U-shaped subdomain. It consists of a β-hairpin, an α-helix hairpin at the 
carboxyl-terminus, and an intervening short α-helix  (Yan et al. 2014). In the most recent 
work of the Chen group, authors hypothesized that interactions between the U motif of the 
central domain and the S6 cytoplasmic region was involved in channel stabilization (B. Sun 
et al. 2016). Mutating each residue in the S6 cytoplasmic region, authors found that mutating 
residues either side of the S6 helix that faces the U motif increased RyR2 channel activity. 
Within this region, the V4880A RyR2 mutation not only increased arrhythmogenic 
spontaneous Ca2+ release when expressed in a heterologous cell system but increased 
activity of the single channels in near zero concentrations of activating Ca2+. It was therefore 
proposed that mutations in this region may disrupt interactions between the S6 helix and the 
U motif of the central domain, destabilizing the closed channel state, increasing basal 
activity and the propensity for spontaneous Ca2+ release (B. Sun et al. 2016). 
 
1.7.3.3  Altered RyR2 Ca2+ sensitivity and ‘store overload-induced Ca2+ release’ 
 
CPVT1-linked RyR2 mutations have been suggested to cause altered sensitivity to 
activation by Ca2+. Introduction of the DPc10 peptide to mimic central domain mutation of 
RyR2 induced disruption, causing sustained SR Ca2+ leak by lowering the threshold for 
cytoplasmic Ca2+ activation (YANG et al. 2006). The Chen group have recently investigated 
mutations of the cytoplasmic portion of the I domain (referred to by authors as central 
domain mutations between residues 3778-4201(P. Li and S. R. Chen 2001; Z. Xiao et al. 
2016)).  Eight disease-associated RyR2 mutations in this domain appeared to enhance 
cytosolic Ca2+-dependent activation of single channels. Authors therefore suggested that this 
domain is important in the cytosolic Ca2+ activation of RyR2 and that any alterations of this 
activation and sensitivity to cytosolic Ca2+ may enhance susceptibility to arrhythmia. 
Complicating matters, the RyR2 mutations G230C and K4750Q have been demonstrated to 
exhibit increased sensitivity to both cytosolic and luminal Ca2+ activation in single channel 
experiments(Y. Liu et al. 2013; Uehara et al. 2017). 
 
As many CPVT1-linked RyR2 mutants also appear to exhibit similar cytosolic Ca2+ sensitivity 
in single channel experiments (Tester et al. 2007; Marjamaa et al. 2009; D. Jiang 2005), 
another hypothesis is that the major functional consequence of mutation is enhanced luminal 
Ca2+ sensitivity, with a lowered critical threshold for Ca2+ release from the SR (P. P. Jones et 
al. 2008; D. Jiang et al. 2007; D. Jiang et al. 2004; D. Jiang 2005). ‘Store overload-induced 
Ca2+ release’ (SOICR, see Figure 1.17) was a term first used to describe spontaneous Ca2+ 
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release by Chen’s group in 2004 (D. Jiang et al. 2004). This term was chosen based on its 
occurrence being dependent on the SR Ca2+ store with a critical threshold level for Ca2+ 
release. The group examined a number of CPVT1 mutant (mouse) RyR2 channels 
recombinantly expressed in HEK293 cells and found they showed an increased propensity 
for oscillation i.e. more transfected cells displayed Ca2+ oscillations compared to WT 
transfected cells and at lower extracellular Ca2+ concentrations. Authors looked at the kinetic 
parameter of frequency of spontaneous Ca2+ oscillations, and found this was enhanced in 
mutant transfected cells, as well as a decrease in the ER Ca2+ store (measured by caffeine-
induced Ca2+ release). This observation was accompanied by an increased single channel 
Po in response to luminal Ca2+ compared to WT RyR2 channels, but unaltered [3H]-
ryanodine binding in response to activating Ca2+, thought to reflect an equivalent sensitivity 
to cytosolic Ca2+ concentrations (D. Jiang 2005; D. Jiang et al. 2004). SOICR of CPVT 
mutations has also been investigated in HL-1 cardiomyocytes and enhanced spontaneous 
Ca2+ release was also observed, thought to reflect sensitivity to luminal Ca2+ of CPVT1 
mutations compared to WT (D. Jiang 2005). 
 
Authors suggested these mutations therefore enhance the propensity for SOICR in HEK293 
cells, as well as increase the sensitivity to activation by luminal Ca2+ (which would therefore 
suggest that the critical threshold for Ca2+ release is decreased), increasing susceptibility to 
DADs and triggered activity (D. Jiang et al. 2004; D. Jiang 2005). As mentioned previously, 
during pathological conditions of aberrant Ca2+ release, Ca2+ sparks ignite neighbouring 
clusters by a fire-diffuse-fire mechanism, triggering regenerative CICR-driven Ca2+ waves 
that are proarrhythmic (Bovo et al. 2011; Kunitomo and Terentyev 2011).  
 
The term SOICR is somewhat a misnomer, referring to a lowered threshold and not 
necessarily an actual store ‘overload’. The resting level of SR free Ca2+ may have also 
adapted to such a reduced threshold via autoregulation (Eisner 1998), therefore under 
resting conditions a modest reduction should not elicit pathogenic Ca2+ signalling during 
normal EC coupling, explaining how enhanced SOICR occurs despite the observed 
reduction in ER Ca2+ content. Subsequent experiments with a luminal sensitive indicator 
protein D1ER, which allowed more direct monitoring of Ca2+ within the store, also 
determined that the V4653F RyR2 mutant expressing cells had a reduced threshold for 
SOICR (Palmer et al. 2004; P. P. Jones et al. 2008).  
 
Although enhanced propensity for SOICR and sensitivity to luminal Ca2+ likely plays an 
important role in the dysfunction of some RyR2 mutants, it is unlikely to be the sole 
mechanism of channel dysfunction in CPVT1 (Uchinoumi et al. 2010; Laver et al. 2007; Meli 
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et al. 2011). Increased sensitivity to cytosolic Ca2+-dependent activation via dissociation of 
FKBP12.6 (Lehnart et al. 2004; Meli et al. 2011; Wehrens et al. 2003; Lehnart et al. 2008) as 
well as the induction of defective inter-domain conformational changes have also been 
implicated as mechanisms of RyR2 dysfunction in CPVT (Uchinoumi et al. 2010; Laver et al. 
2007).  
 
The persistence of so many candidate mechanisms of RyR2 dysfunction in CPVT1 may 
indicate more convolution than a general one-fits-all model.
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Figure 1.17 ‘SOICR’: a proposed mechanism for CPVT1 associated with RyR2 mutations. 
Chen’s group proposes that the relationship between the threshold for store overload-induced Ca2+ 
release (SOICR) and the SR-free Ca2+ level in normal (A) and CPVT1 SR (B) is altered. Resting 
states are shown on the left, stimulated states on the right. The threshold for SOICR is depicted by 
the red line and is reduced in the CPVT1 SR as a consequence of RyR2 mutations. The blue area 
depicts the level of free SR Ca2+. An increase in free SR Ca2+ by stimulation via catecholamines or 
stress is shown by the yellow area. When free Ca2+ reaches the SOICR threshold, SOICR occurs 
leading to a large Ca2+ spill over. This can then generate DADs and triggered arrhythmia. Figure from 
D. Jiang et al. (2004). 
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1.7.4 Current treatment 
 
Untreated, CPVT has a high rate of mortality, with 30 % of individuals of classic phenotype 
dying before the age of 40 (Priori 2002; Hayashi et al. 2009). Since the condition was first 
described, β-adrenergic receptor antagonists (β-blockers) remain the cornerstone of therapy 
for patients to date (Priori et al. 2001; Priori et al. 2013). This is to prevent the stimulatory 
effects of the β-adrenergic pathway.  However, a significant number of patients remain 
symptomatic despite β-blocker therapy, or suffer severe side effects. An 8-year study of 101 
patients with CPVT1 found that cardiac fatal and non-fatal effects were not sufficiently low, 
at 27 % and 11 % respectfully (Hayashi et al. 2009). In another cohort of 205 CPVT1 
patients, 25 % of patients taking β-blockers alone experienced at least one treatment failure 
including syncope and/or cardiac arrest (Roston et al. 2015). The inconsistencies between 
patient responses could indicate that not all mutations of RyR2 result in CPVT1 by the same 
pathogenic mechanism, and dysfunction is not entirely dependent on β-adrenergic 
stimulation.  
 
Treatment using implantable cardioverter defibrillator (ICD) is normally administered to 
patients unresponsive to β-blocker therapy; this is a more traumatic course of treatment that 
also is not always successful (Pizzale et al. 2008). In young and active patients, this 
necessitates routine device replacement and is associated with device malfunction and 
infection (Roston et al. 2015; Miyake et al. 2013). Left cardiac sympathetic denervation has 
been suggested as a therapeutic option before ICD implantation, as it has shown to be 
effective in cases of β-blocker contraindication and large multicentre studies have reported 
efficacy for this surgical procedure in decreasing cardiac events in CPVT (De Ferrari et al. 
2015; Schwartz 2004; Schwartz et al. 1991; Moss et al. 2000). However, the technique is 
underutilized and there are also associated risks, including refractory transient arrhythmias 
and Horner syndrome, a disruption of the nerve pathway from the brain to the face (Cho 
2015; Roston et al. 2015).  
 
Verapamil is routinely used in the treatment of supraventricular tachycardia, hypertension 
and chest pain (Al-Zaiti and Magdic 2016; Muijsers et al. 2002). The drug has also been 
used to treat CPVT1, but with limited success. It is an LTCC agonist, reducing spontaneous 
Ca2+ release at high concentrations (injected intraperitoneally, at 8 μg/g of mouse body 
weight), although these exceeded toxicity levels (Alcalai et al. 2010). The drug has not been 
shown to affect disrupted RyR2 intra-domain interactions, nor prevent arrhythmia during 
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exercise-stress testing, but does reduce the threshold of arrhythmia occurrence in 
mice(Sumitomo et al. 2002; Alcalai et al. 2010; N. Liu et al. 2010).  
 
Rycals are 1,4 benzothiazepine derivatives and include K201 (JTV-519) and S107, first 
reported by Kaneko et al. (1994). Many groups have reported that rycals display 
cardioprotective effects and anti-arrhythmic properties in mice (Loughrey et al. 2007; 
Wehrens, Lehnart, Reiken, Deng, et al. 2004; Lehnart et al. 2006; Yano et al. 2003; Kaneko 
1994). K201 is suggested to prevent abnormal Ca2+ leak by stabilizing RyR2 channels and 
inhibiting SERCA, preventing SR Ca2+ overload under pathological conditions (Wehrens et 
al. 2005; Wehrens, Lehnart, Reiken and Marks 2004; Yano et al. 2003; Darcy et al. 2016).  
In three KI mouse models of CPVT1, S107 reduced diastolic SR Ca2+ leak in atrial myocytes 
and decreased burst-pacing induced AF in vivo (Shan et al. 2012). RyR2 from dmd mice 
hearts were S-nitrosylated and depleted of FKBP12.6, resulting in "leaky" RyR2 channels 
and a diastolic SR Ca2+ leak (Fauconnier et al. 2010). Marks et al. reported that in this 
instance, inhibiting depletion of FKBP12.6 with S107 treatment prevented arrhythmia, 
suggesting FKBP12.6 was necessary for the therapeutic action. However, FKBP12.6 
involvement in CPVT1 remains contentious (Barg et al. 1997; J. Xiao et al. 2007; Hunt et al. 
2007). K201 was not shown to alter FKBP12.6 interaction or occurrence of arrhythmic 
episodes in the R4496C mouse and it also abolished spontaneous Ca2+ release in 
heterologous cell lines that do not endogenously express RyR2, independent of FKBP12.6 
association to the channel. SERCa2a has also been suggested as the main target of K201 
rather than RyR2 (Loughrey et al. 2007). In the latest work of Copello, the group suggest 
that K201 is a Ca2+-dependent inhibitor of SERCa2a and a partial agonist of RyR2, with the 
effects of K201 on RyR2 Po in single channel experiments unaltered by adding FKBP12.6 
(Darcy et al. 2016).  
 
Dantrolene is a muscle relaxant used in patients that have malignant hyperthermia caused 
by mutations in RyR1. It has been shown to target a corresponding sequence of RyR1 in 
RyR2, improving intracellular Ca2+ handling in failing canine cardiomyocytes and in a mouse 
model of CPVT1 harbouring the R2474S mutation (S. Kobayashi et al. 2009; S. Kobayashi 
et al. 2010). In patient-derived induced pluripotent stem cell cardiomyocytes (iPSC-CMs) 
from a CPVT1 patient with RyR2 mutation S406L, dantrolene restored normal Ca2+ spark 
properties, rescuing the arrhythmogenic phenotype (C. B. Jung et al. 2012). The drug is 
proposed to stabilize defective intra-domain interactions in RyR2, dependent on the location 
of the mutation. This stabilizing effect was observed in cells expressing the central domain 
mutation R2474S, but had no effect on cells expressing C-terminal mutation N4104K with 
spontaneous Ca2+ release events still evident (N. Liu et al. 2010; D. Jiang et al. 2007; 
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Uchinoumi et al. 2010). It has recently been suggested that CaM is essential in the inhibition 
of RyR2 by dantrolene, whereby the drug caused inhibition of sheep RyR2 in single channel 
experiments (inhibition of Po to 52 % of controls) only after the addition of 100 nM CaM 
(Nishimura et al. 2015; Oo et al. 2015). The mechanism by which CaM facilitates this 
inhibition remains unclear, although Oo et al. (2015) postulate the protein may put RyR2 into 
a conformation that allows dantrolene access to its RyR2 binding site {Seidel:2014kq}.   
 
Flecainide is a Na+ channel antagonist, approved for the suppression of VT since 1984. 
More recently, it was shown to be effective in preventing arrhythmia in CPVT1 patients who 
were not responsive to β-blockers and verapamil and is now considered an ‘emerging 
recommendation’ for patients with the condition (Priori et al. 2013; Watanabe et al. 2009). In 
a CPVT2 mouse model, flecainide decreased the frequency of spontaneous Ca2+ waves. 
The proposed mechanism of action was that apart from Na2+ channel block, flecainide also 
has a direct blocking effect on RyR2 (Hwang et al. 2011; Hilliard et al. 2009; Watanabe et al. 
2009). This has been opposed by two independent groups including our own, who show that 
neither the drug nor its charged derivative is able to block physiologically relevant cation flux 
through RyR2 single channels (Bannister et al. 2016; N. Liu et al. 2011; Bannister et al. 
2015; Sikkel et al. 2013).  
 
It is evident that a clear understanding of the pathological mechanisms of RyR2 CPVT1 
mutations is crucial to not only explain why some patients are responsive to certain 
therapeutic interventions while others are not, but in design of RyR2-targeting therapies in 
the future. 
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1.7.5 Evidence of functional heterogeneity 
 
Current mechanisms and the conventional view of arrhythmogenesis in CPVT is that 
spontaneous Ca2+ release occurs via RyR2 and that hyperactive RyR2 channels are 
essential components of this gain-of-function scheme (Allen 2003; D. Jiang et al. 2002). 
Diastolic Ca2+ release activates an inward NCX depolarizing current and subsequently can 
result in arrhythmogenic activity. In other words, missense mutations in RyR2 lead to altered 
channel sensitivity to opening stimuli, mediating excessive Ca2+ release when the channel 
should be closed. This would be amplified during β-adrenergic stimulation, where 
catecholamine levels are increased to drive enhanced cardiac output.   
 
Analysis of the R4497C mutation by heterologous expression in HEK293 cells supported this 
hypothesis, as [3H] ryanodine binding studies revealed that the mutation showed an 
increased channel activity and sensitivity to pharmacological ligands, as well as more 
frequent spontaneous Ca2+ release events compared to WT-RyR2 transfected cells (D. 
Jiang et al. 2002). Single channel analysis showed that R4497C channels also exhibited 
channel openings at low cytosolic [Ca2+] of less than 5 nmol/L, whereas WT single channel 
activity was almost completely inhibited under the same conditions. These properties were 
therefore expected to promote the SR Ca2+ leak during diastole and subsequent DADs 
observed in CPVT.  
 
Findings by other groups also supported this conclusion; S2246L, R2474S, N4104K and 
R4497C were also identified as gain-of-function RyR2 channels, exhibiting aberrant Ca2+ 
release following channel activation compared to WT (Wehrens 2003; D. Jiang et al. 2004; 
George, Higgs, et al. 2003; D. Jiang et al. 2002; D. Jiang 2005). Three ARVC2 mutations 
linked to sudden cardiac death were characterized by Thomas et al. (2004) and also fitted 
the gain-of-function model of dysfunction, with an increased sensitivity to caffeine compared 
to WT channels. More recent studies of CPVT1 mutations in each peptide domain also 
identify gain-of-function as a unifying mechanism for RyR2 channel dysfunction in both 
HEK293 cell imaging systems and mutant mouse models (Paavola et al. 2007; Zhabyeyev 
et al. 2013; van Oort, McCauley, Dixit, Pereira, Yang, Respress, Wang, De Almeida, 
Skapura, Anderson, Bers and Wehrens 2010a). 
 
Although numerous studies support the concept, the gain-of-function designation of CPVT1 
mutations has been suggested inadequate the explain lethal arrhythmia in patients that 
harbour loss-of-function mutations (Zhao et al. 2015). There are over 170 CPVT1 mutations 
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in RyR2 currently identified, but this list is likely to grow, and therefore it may be an 
oversimplification to classify all these mutations based on the data of a small proportion.  
 
The heterogeneous nature of RyR2 mutations was first proposed by Thomas et al. (2004), 
who investigated CPVT1 and ARVC-linked RyR2 mutations and their Ca2+ release 
properties in HEK293 cells. All mutations investigated appeared to result in an increased 
duration of elevated cytoplasmic Ca2+ levels following channel activation with caffeine, but 
one mutant (L433P) showed a significant decrease in sensitivity to channel activation 
compared to others. This challenged the notion that all RyR2 mutations linked to CPVT1, as 
well as sudden cardiac death in other conditions, resulted in altered RyR2 channel 
functionality (Gómez and Richard 2004).  
 
Work by Chen and colleagues showed that recombinant mutant A4860G-RyR2 channels 
expressed in HEK293 cells displayed a dramatic depression of activity, manifesting as a loss 
of luminal Ca2+ sensitivity (D. Jiang et al. 2007). In work by Zhao et al, the same mutation 
was recombinantly expressed and shows drastic decreases in channel activity in both [3H] 
ryanodine binding and single channel recordings (Zhao et al. 2015). Mice heterozygous for 
the mutation (RyR2-A4860G+/-) exhibited no structural alterations in the heart with basal 
bradycardia, while no homozygotes were detected at birth. This is indicative of a lethal 
phenotype, with sympathetic stimulation of heterozygous mice also eliciting malignant 
arrhythmia. Interestingly, when ventricular myocytes were stimulated with Iso, the peak of 
Ca2+ release during systole was decreased, gradually filling the SR with Ca2+ leading to 
resultant ‘overload’. This scenario is thought to lead to EADs rather than DADs, whereby 
triggered impulses that result from sub-threshold membrane depolarizations occur during 
repolarization of the previous impulse, rather than when repolarization is complete (Scoote 
and Williams 2002). Therefore, unlike the characterization of gain-of-function mutants with 
spontaneous and diastolic Ca2+ release (D. Jiang et al. 2004), the defining feature of this 
loss-of-function mutation appears to be induced and systolic Ca2+ release.  
 
Adding to the complexity of RyR2 mutant classification, the N terminal mutation R420Q has 
been identified as both loss- or gain-of-function, depending on cytosolic Ca2+ concentration 
within the cell (Domingo et al. 2015). Ventricular myocytes from mice heterozygous for the 
central domain mutation V2475F display not only altered sensitivity to luminal [Ca2+] but also 
increased cytosolic Ca2+ activation (Loaiza et al. 2013). Spontaneous Ca2+ release events 
were also more frequent in Iso-stimulated cardiomyocytes from these mice but the SR Ca2+ 
release threshold remained unchanged in comparison to WT. Other channelopathies that 
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are associated with sudden cardiac death are also linked to both gain- and loss-of-function 
mutations in Na+ and K+ channels (Shirai et al. 2002; Baroudi et al. 2002).  
 
Since most CPVT1 mutations investigated to date have been classified as gain-of-function, 
loss-of-function mutations are therefore not included as part of my project.  
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1.7.6 The broad classification of RyR2 mutations as ‘gain-of-function’ 
 
Evidence has accumulated that while mutations may fall within the ‘gain-of-function’ 
classification i.e. causing enhanced Ca2+ release through RyR2, this may be via different 
mechanisms with mutations actually exhibiting functional heterogeneity.  
 
Structural data suggest that a mutation may affect points of contact within the protein and 
disrupt intra-RyR interactions. Further peptide-based studies by the Ikemoto/Matsuzaki 
group have investigated the effects of mutations in the domains of RyR2 and add weight to 
the hypothesis that altered domain interactions are implicated in arrhythmogenesis (Suetomi 
et al. 2011; Tateishi et al. 2008). This suggests a one-fits-all mechanism of dysfunction 
cannot be applicable to all CPVT mutations of RyR2. Other data support functional 
heterogeneity; CPVT1-linked mutations N4104K and R4497C occurring within the I-domain 
cause RyR2 channel instability via defective intra-domain interactions, resulting in 
spontaneous Ca2+ release (George et al. 2006), however introduction of S2246L into a 
domain peptide representing the central domain increased the affinity of peptide binding, 
indicative of an abnormally tight domain-domain interaction (Suetomi et al. 2011). Both 
scenarios however resulted in RyR2-mediated Ca2+ release dysfunction, suggestive of 
diverse mechanisms of channel dysfunction that could be locus-dependent as opposed to a 
unifying mechanism.  
 
Post-translational modifications of RyR2 may also be implicated in functional heterogeneity 
of CPVT1 mutant channels and Ca2+ release. Under conditions that stimulate stress, such as 
PKA phosphorylation, recombinant RyR2 mutant single channels have been shown to 
display a significant gain-of-function phenotype (Tester et al. 2007). One mutation (R2267H, 
central domain) shows normal function under basal conditions but significantly increased 
activity after phosphorylation by PKA. A second mutation (S4565R – cytoplasmic portion of 
the I-domain) shows chronic ‘leakiness’ even under non-stressed conditions and only a 
slight increase in activity after phosphorylation (Figure 1.18). 
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Figure 1.18 Open probability of mutant and WT RyR2 channels with and without PKA treatment 
reveals that phosphorylation significantly alters WT and R2267H RyR2 channel function but 
not S4564R. RyR2-R2267H Po is already significantly left-shifted without PKA treatment in 
comparison to RyR2-WT. Po was measured at Ca2+ concentrations from 90 nM to 2 μM. Each data 
point represents the open probability calculated as an average from several independent experiments 
shown as mean ±SE. Figure taken from Tester et al. (2007). 
 
These data also support the notion that some CPVT1 mutations are dysfunctional at ‘basal’ 
conditions i.e. during rest, while others are not. CPVT1 mutations G230C, S2246L and 
P2328S have altered channel activity at low cytosolic levels of Ca2+, but only after PKA 
phosphorylation (Wehrens et al. 2003; Meli et al. 2011). However, the data from Tester et al. 
(2007) indicate that S4565R RyR2 channels show increased sensitivity to cytosolic Ca2+ 
compared to WT without such modification (Figure 1.18). Interestingly, the mutation was 
first identified in an infant who was not under any exertion and died during sleep. Marks and 
colleagues also found that H29D RyR2 mutant channels also display significantly higher Po 
and opening frequency compared to WT under non-stress conditions (Cheung et al. 2015). 
Although the mechanism for dysfunction of these channels appears at odds with the clinical 
phenotype of CPVT1 (arrhythmia after physical or emotional stress), authors speculated that 
the H29D mutation destabilized domain or protein-protein interactions, which may confer the 
‘leakiness’ of CPVT1 channels sometimes observed in a non-PKA phosphorylated state.  
 
Diverse mechanisms of mutant RyR2 channel dysfunction are also evident in the response 
of patients to pharmacological therapies. It has long been reported that there is a high rate of 
symptom recurrence and sudden cardiac death in CPVT1 patients and the phenotypic 
manifestation appears to be very heterogeneous (Priori 2002; George 2007a; Medeiros-
Domingo et al. 2009). Even in patients adequately medicated with β-blockade, many require 
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ICDs after experiencing syncope or cardiac arrest despite receiving these treatments 
(Ylänen et al. 2010). For example, K201 has been shown effective in treating 
arrhythmogenesis observed in mice and dogs with N-terminal and central domain RyR2 
mutations (Lehnart et al. 2008; Suetomi et al. 2011; Tateishi et al. 2008). However, it was 
not effective in treating RyR2-R4496C+/- mice with VT (N. Liu et al. 2006) and Ca2+ leak 
induced by the I-domain peptide DP4090-4123 was not inhibited by the drug in peptide-
based studies (Tateishi et al. 2008). This is suggestive that K201 is less effective in 
correcting arrhythmogenesis caused by mutations in the I-domain, with point mutations such 
as N4104K seen in CPVT1 possibly inducing weakened domain interactions between the I-
domain and the unidentified IP-domain, independent of interactions between N-terminal and 
central domains.  
 
The varied response to frontline CPVT1 therapies could therefore suggest that RyR2 
channel dysfunction may be different depending on which mutation a patient presents with. It 
follows that if an RyR2 mutant channel is leaky under non-stress conditions, such as H29D 
or S4565R, prevention of phosphorylation via -blockade may not be sufficient to prevent 
arrhythmogenic activity in such patients. Investigating the mechanism of mutant RyR2 
channel dysfunction could therefore enable risk stratification or personalized therapies for 
CPVT1 patients. Drug-binding to RyR2 channels is thought to be state-dependent, with 
some suggested to block the open channel such as class I antiarrhythmic propafenone 
(Hwang et al. 2011) and others suggested to favour binding to the closed state such as 
dantrolene (Paul-Pletzer et al. 2005). The open and dwell closed times of mutant channels 
therefore should also be considered – if a mutation exhibits longer periods of channel 
opening, a closed channel blocker may not be an appropriate treatment, and this may aid in 
explaining the discrepancies of drug efficacy reported in the literature.  
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1.8 Research project aims 
 
As discussed, the broad classification of CPVT1-linked RyR2 mutations as exhibiting a ‘gain-
of-function’ may be too simplistic, with subtleties of dysfunction being masked in previous 
studies, eager to establish a universal mechanism for SR Ca2+ leak. The mere size and 
complexity of RyR2, the varied response to pharmacological agents as well as the fact that 
domains have been assigned discrete functionality is not fully considered. The role of 
phosphorylation during β-adrenergic stimulation may also be implicated in mutant RyR2 
channel dysfunction, when functional heterogeneity of CPVT1 mutants is observed under 
basal conditions. To investigate this hypothesis, the aims of this thesis therefore fall in two 
parts: 
• Investigating in detail Ca2+ release kinetics and expression of two CPVT1-linked 
RyR2 mutants, S2246L and N4104K, within HEK293 cells. These mutations are 
commonly classified as ‘gain-of-function’. Investigation may reveal any common 
perturbations of CPVT1-linked mutations or differences in Ca2+ handling and 
expression between mutant RyR channels (where the mutations in question reside in 
different channel domains). This investigation will validate detailed interrogation of 
spontaneous Ca2+ release events in hRyR2-transfected HEK293 cells as a method of 
identifying functional heterogeneous mutations. 
• Assessing the functional consequences of PKA phosphorylation at the S2808 and 
S2031 sites on WT and mutant RyR2 channels, via a two-fold approach: 
o Basal phosphorylation levels of WT and mutant hRyR2s will be determined, 
as well as the response to PKA phosphorylation initiated using an analogue 
of cAMP. 
o The effects ‘mimicked’ phosphorylation at each site will be investigated by the 
generation of phosphomimetic RyR2 constructs and the subsequent 
investigation of Ca2+ handling and expression in HEK293 cells. This will be 
the first study of its kind to apply this molecular technique in the study of 
CPVT1-mutant RyR2 phosphorylation. In this way the effects of genetic and 
PKA-mediated phosphorylation can be compared in the hope of identifying 
the functional importance of each phosphorylation site.  
 
 
 
 
 
 77 
 
 
 
 
 
 
 
 
 
 
Chapter 2  
 
Materials and Methods 
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2.1 Working in the laboratory 
 
2.1.1 General laboratory equipment and reagents 
 
• Analytical grade chemicals: All chemicals were obtained from Fisher Scientific 
or Sigma-Aldrich. All reagents were dissolved in autoclaved dH2O, stored at 
room temperature (unless otherwise stated). 
• pH meter: Solution pH was measured using a Mettler Toledo FE20 pH meter 
(Camlab) and altered using either 100 mM HCl or 100 mM NaOH. 
• Plastics and glassware: purchased from Greiner or Fisher Scientific. 
Glassware was soaked in detergent and washed before use.  
• Filter sterilisation: solutions were filtered when necessary using a 0.22 μm 
Millex ® syringe filter (Millipore). 
 
2.1.2 Health and safety 
 
Full general health and safety training was received from the WHRI safety officers 
including microbiology, cell culture and centrifuge safety training prior to beginning 
any laboratory work. Experiments were carried out in accordance with COSSH 
regulations and after completion of appropriate risk assessments.   
 
2.1.3 Computer software and data analysis 
 
Microsoft Excel was used to plot generated numerical data. Statistical analyses were 
carried out using GraphPad Prism® (GraphPad Software, Inc.), with graph data 
expressed as mean ± standard error. Statistical analyses depended on normality of 
the data in question, as assessed by D’Agostino-Pearson omnibus normality test. If 
data distribution was normal, t tests and one way ANOVA with Bonferroni posthoc 
tests were applied as appropriate. If data distribution was not normal, Mann Whitney 
tests and Kruskal-Wallis with Dunn’s posthoc tests were applied as appropriate. 
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2.2 Materials  
 
Materials and methods described within this section are common to every following 
results chapter, as the propagation of plasmid DNA was essential for any 
experiments with the eGFP-hRyR2 construct. Methods pertaining to each chapter 
are described in detail therein.  
 
2.2.1 The hRyR2 expression vector 
 
The mammalian expression vector pcDNA™3 (Invitrogen) containing human RyR2 
with an eGFP tag (pcDNA3-eGFP-hRyR2) was obtained from Dr Christopher George 
(Thomas et al. 2004; George et al. 2003). The eGFP tag is placed at the N-terminus 
of hRyR2, separated by a four amino acid spacer (Thr-Ser-Gly-Ser).  
Vectors containing the CPVT-linked RyR2 mutations S2246L, N4104K and R4496C 
were also obtained from Dr Christopher George and Dr N. Lowri Thomas. 
 
2.2.2 Transformation of bacterial cell lines 
 
• MAX Efficiency Stbl2 Competent Cells: provided with SOC medium 
(ThermoFisher Scientific). 
• SOC medium: 20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 0.18 g/L KCl, 
0.95 g/L MgCl2, made up to 1 L with dH2O and autoclaved. Medium was 
cooled to below 50 °C before the addition of glucose at 2 % (w/v) of total stock 
solution concentration. 
• Luria Bertani (LBAMP) broth: 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, 
autoclaved. Ampicillin was added before use. 
• LBAMP agar plates: made with LB broth constituents with the addition of 15 
g/L, autoclaved. Ampicillin was added before setting into 10 cm2 sterile petri 
dishes. 
• Ampicillin 100 mg/ml stock: filter sterilized, stored at -20 °C and used at a 
working concentration of 100 μg/mL. 
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2.2.3 Small-scale plasmid isolation - ‘Miniprep’ 
 
• Zyppy™ Plasmid Miniprep Kit (Zymo Research): 
i. 7X Lysis Buffer (Blue): containing SDS and sodium hydroxide. 
ii. Neutralization Buffer (Yellow): containing guanidium chloride. 
iii. Endo-Wash Buffer: containing guanidium chloride and propan-
2-ol. 
iv. Zyppy™ Wash Buffer (concentrate): containing 
Tris(hydroxymethyl)aminomethane hydrochloride (proprietary), 
192 mL of 100 % ethanol added to 48 mL buffer before use. 
v. Zyppy™ Elution Buffer: containing 10 mM Tris-HCl, pH 8.5 and 
0.1 mM EDTA. 
 
2.2.4 Restriction digest for verification 
 
• Restriction digest enzymes: All High Fidelity (HF) restriction digest enzymes 
were purchased from either ThermoFisher Scientific or New England Biolabs, 
and used with the optimized 10x buffers provided. Enzymes were kept at -20 
°C or -80 °C according to manufacturer instructions. 
• TAE, 50x stock: 2 M Tris, 2 M glacial acetic acid, 50 mM EDTA. 
• Agarose: high purity, added to 1x TAE at 1 % (w/v) for gels. 
• DNA loading buffer:  50 % 1x TAE buffer, 50 % (v/v) glycerol with the addition 
of Orange G to achieve the appropriate detection colour. 
• UltraPure™ Ethidium bromide (Invitrogen): 10 mg/mL stock, used at a 
working concentration of 0.1 μg/mL. 
• 1 Kb Plus DNA Ladder (Invitrogen): molecular weight DNA marker, spanning 
100-12,000 bp. 
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2.2.5 Large-scale plasmid isolation - ‘Maxiprep’ 
 
• HiSpeed Plasmid Maxi Kit (Qiagen): 
i. Buffer P1 (resuspension buffer): 50 mM Tris/HCl pH 8, 10 mM 
EDTA, 100 μg/ml RNase A. 
ii. Buffer P2 (lysis buffer): 200 mM NaOH, 1 % SDS (w/v). 
iii. Buffer P3 (neutralization buffer): 3 M potassium acetate pH 5.5. 
iv. Buffer QBT (equilibration buffer): 750 mM NaCl, 50 mM MOPS pH 
7, 15% isopropanol (v/v), 0.15 % Triton® X-100 (v/v). 
v. Buffer QC (wash buffer): 1 M NaCl, 50 mM MOPS pH 7, 15 % 
isopropanol (v/v). 
vi. Buffer QF (elution buffer): 1.25 M NaCl, 50 mM Tris/HCl pH 8.5, 
15% isopropanol (v/v). 
vii. TE:  10 mM Tris/HCl pH 8, 1 mM EDTA. 
 
2.2.6 HEK293 cell maintenance and subculture 
 
• Dulbecco’s Modified Eagle Medium (Life Technologies): containing 25 mM D-
glucose, 4 mM L-glutamine and 1 mM sodium pyruvate (referred to as 
minimal DMEM or mDMEM). This was supplemented with 10 % (v/v) heat-
inactivated fetal calf serum (FCS) and 2 % (v/v) 100 μg/mL penicillin-
streptomycin-glutamine (PSG) to make complete DMEM (referred to as 
cDMEM). 
• Sodium chloride solution (Fresenius Kabi): supplied as a 0.9 % (w/v) solution 
• Trypsin EDTA 0.05 % (Life Technologies): 1x solution, with phenol red dye. 
• Freezing medium: FCS supplemented with 10 % (v/v) dimethyl sulphoxide 
(DMSO). 
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2.2.7 Calcium phosphate transfection of HEK293 cells 
 
• Calcium chloride (CaCl2): purchased from Sigma-Aldrich, supplied as a 1M 
stock and stored at -20 °C.  
• 2x Hepes Buffered Saline (HBS): 280 mM NaCl, 10 mM NaCl, 10 mM KCl, 
1.5 mM Na2HPO4, 10 mM glucose, 50 mM Hepes. pH was adjusted to 7.05, 
solution was filter sterilised and stored in aliquots at -20 °C. 
• Sodium butyrate (NaB): 1 M stock prepared with autoclaved dH2O. Used as a 
concentration of 2 mM. 
• Zeiss Fluorescence Microscope (Zeiss): uses a Xenon light lamp source with 
a peak excitation of ~488 nm, and a 515 ± 30 nm band-pass filter. 
 
2.2.8 Cell homogenate preparation 
 
• Hypo-osmotic lysis buffer: 20 mM Tris, 1 mM EDTA, 1 mM NaF, 1 mM 
Na3VO4, 1 % (v/v) Triton™ X-100, adjusted to pH 7.4. 1 protease inhibitor 
cocktail tablet (Roche) dissolved per 25ml solution. 
 
2.2.9 Protein assay for quantification  
 
• BCA™ Protein Assay Kit (ThermoFisher Scientific): 
i.  Micro BCA Reagent A: proprietary alkaline tartrate-
carbonate buffer. 
ii. Micro BCA Reagent B: proprietary bicinchonic acid solution. 
iii. Micro BCA Reagent C: proprietary copper sulphate solution. 
Reagents were used in a ratio of 50 Reagent A: 48 Reagent 
B: 2 Reagent C.  
iv. Albumin Standard Ampules: 10 x 1 mL ampules containing 
bovine serum albumin at 2 mg/mL, in solution of 0.9 % saline 
and 0.05 % sodium azide. Samples were serial diluted with 
dH2O. 
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2.2.10 SDS Polyacrylamide Gel Electrophoresis (SDS/PAGE) 
 
• SDS-PAGE Separating buffer: 1.5 M Tris/HCl pH 8.8. 
• SDS-PAGE Running buffer: 25 mM Tris, 250 mM glycine, 0.1 % (w/v) SDS. 
• Acrylamide (Biorad): 40 % (w/v) mix solution of acrylamide/bisacrylamide, in a 
37.5:1 ratio. 
• Ammonium persulphate: a 10 % (w/v) solution, prepared fresh per use. 
• SDS-PAGE loading buffer x5: 0.5M Tris (pH 6.8), 10 % (w/v) SDS, 25 % (v/v) 
β-mercaptoethanol, 10 % (v/v) glycerol, 0.5 % (w/v) bromophenol blue. 
Prepared and filter sterilized immediately before use. 
• Kaleidoscope Precision Plus™ Protein Prestained Standards (Biorad): 
molecular weight protein ladder, with markers from 10 to 250 kD. 
• Mini-gel tank and apparatus (Biorad): all SDS-PAGE gels were poured, and 
electrophoresis performed using Biorad glass plates, well combs, and tanks. 
 
2.2.11 Transfer of protein onto PVDF membrane 
 
• iBLOT® Gel Transfer Device (Invitrogen): a self-contained blotting unit for fast 
dry blotting of proteins. 
• iBLOT® Transfer Stack, PVDF, mini (Invitrogen): 
i. iBLOT® Cathode Stack, Top mini: a copper electrode with 
cathode buffers in a gel matrix to act as an ion reservoir. 
ii. iBLOT® Anode Stack, Bottom mini: a copper electrode with 
anode buffers in a gel matrix, as well as an integrated 
preactivated PVDF membrane. 
iii. iBLOT® Disposable Sponge: a sponge placed on top of the 
transfer stack to absorb excess liquid and to generate even 
pressure across the assembly. 
iv. iBLOT® Filter paper mini: filter paper is soaked in dH2O before 
placed on top of SDS-PAGE gels to protect gel integrity during 
blotting. 
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2.2.12 Western blot analysis by chemiluminescence 
 
• Tris-buffered saline (TBS): 20 mM Tris, NaCl, pH corrected to 7.6 before the 
addition of 1 ml/L Tween 20 to make TBS-T. 
• Blocking solution: 5 % (w/v) low-fat dried milk powder in TBS-T. 
• ab-GFP (B-2) antibody (Santa Cruz Biotechnology):  mouse monoclonal 
primary antibody raised against the full length green fluorescent protein of 
Aequorea victoria origin, provided at 200 μg/mL. Used at 1:1,000 dilution for 
Western blot analysis. 
• Wash buffer/blocking solution: 1 % (w/v) low-fat dried milk powder in TBS-T. 
• (HRP)-conjugated anti-mouse antibody: Used at 1:10,000 dilution for Western 
blot analysis. 
• Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare): 
i. Solution A: luminol solution. 
ii. Solution B: peroxide solution. 
• G:BOX Chemi XX6 (Syngene): a chemiluminescence imaging system. 
• GeneSys software (Syngene): automatic control software for the G:BOX 
imaging system. 
• GeneTools software (Syngene): program used for densitometric analysis of 
Western Blots.  
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2.3 Methods 
 
2.3.1 Transformation of bacterial cell lines  
 
hRyR2 is a large, fragile plasmid (~21kb) prone to spontaneous recombination 
(George et al. 2005) . As such hRyR2 transformation requires super-competent 
bacterial cells to propagate the plasmid. MAX Efficiency Stbl2 Competent Cells were 
used to propagate WT and mutant eGFP-hRyR2 plasmid DNA at a high yield. This 
strain of Escherichia coli (E. coli) is deficient of all known restriction systems, as well 
as recombination (recA-) and endonuclease (endA-) genes, increasing plasmid 
stability and quality.   
 
For the transformation of full-length eGFP-hRyR2 plasmids, 50 μL MAX Efficiency 
Stbl2 cells were thawed on ice. Plasmid DNA (1 ng) was added and mixed gently. 
Cells were incubated on ice for 30 min before heat-shock treatment in a 42 °C water 
bath for 30 sec. Cells were immediately transferred to ice for 2 mins, prior to the 
addition of 500 μL SOC medium and incubation at 37 °C with shaking at 225 rpm for 
1 hr. Cells were then plated onto LBAMP agar plates at two unequal concentrations (to 
allow for single colony isolation) and incubated at 30 °C for ~24-28 hrs before 
examination for colony growth. Single colonies were picked using sterile plastic 
pipette tips and used to inoculate approximately 6 mL of LBAMP broth. Cultures were 
incubated at 30 °C with shaking at 225 rpm for ~15-18 hrs. 
 
Approximately half (3 mL) of the bacterial culture was centrifuged at 13,000 rpm for 1 
min to pellet bacteria (Microfuge R, Beckman). Bacterial pellets were prepared for 
plasmid isolation by resuspension in 600 μL dH2O. 
 
LBAMP broth (3 mL) was added to the remaining bacterial cultures and they were 
incubated at 30 °C with shaking at 225 rpm for an additional 8 hrs to allow for growth 
prior to large-scale culture inoculation (See Section 2.2.5).   
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2.3.2 Small-scale plasmid isolation - ‘Miniprep’ 
 
Plasmid DNA was purified from bacterial cell culture using an alkaline lysis method 
employed by the Zyppy™ Plasmid Miniprep Kit, following manufacturer instructions. 
A blue coloured Lysis Buffer (100 μL) was added and the sample mixed by inverting 
the tube 4-6 times, with a colour change from opaque to clear blue indicating 
complete lysis of cell membranes and the release of cell contents. To avoid further 
lysis which could shear the plasmid, 350 μL cold Neutralization Buffer (yellow) was 
added within 2 minutes and the sample mixed thoroughly. A colour change from blue 
to yellow indicated complete neutralization and that a precipitate would form. 
Samples were centrifuged at 13,000 rpm (5417R refrigerated centrifuge, Eppendorf) 
for 3 min to pellet cell debris. Avoiding disturbance of the pellet, the supernatant 
(~900 μL) was transferred to the provided Zymo-Spin™ IIN column. The column was 
placed in a collection tube and centrifuged for 15 secs to allow DNA binding to the 
resin. Flow-through was discarded, and 200 μL of Endo-Wash Buffer was added to 
the column, followed by centrifugation for 30 secs to wash the plasmid DNA. Zyppy™ 
Wash Buffer (400 μL) was added to the column for a second wash step, and 
centrifuged for 1 minute. The column was then transferred to a clean 1.5 mL 
centrifuge tube and 30 μL of Zyppy™ Elution Buffer was applied directly to the 
column matrix and allowed to stand for 1 min at room temperature, before final 
centrifugation for 30 secs to elute the plasmid DNA. Plasmids were immediately 
verified by restriction digest with appropriate endonucleases with resulting fragments 
visualized by agarose gel electrophoresis. Verified plasmids were stored at -20 °C or 
-80 °C. 
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2.3.3 Restriction digest for verification  
 
Restriction endonucleases were used as a diagnostic tool, producing patterns of 
restriction fragments from digested eGFP-hRyR2 plasmids. These could be verified 
by comparison to a visual digest of the full-length hRyR2 sequence, using 
http://tools.neb.com/NEBcutter2/. Restriction digests were performed at two ‘check 
points’ during propagation of WT and mutant eGFP-hRyR2 plasmid DNA (See 
Figure 2.2). A combination of single digests (EcoRI, HindII, BamHI and BgIII high 
fidelity restriction endonucleases) was used to verify full-length eGFP-hRyR2 
plasmids before and after large-scale amplification. Only plasmids that yielded 
fragments of the correct MW were selected for propagation (See Figure 2.1 below). 
Restriction digests were typically carried out with 1 μg DNA and 1-10 U of High 
Fidelity endonuclease (following manufacturer instructions). Reaction mixtures were 
prepared with 1x endonuclease buffer and made up to a total volume of 20 μL with 
dH2O. Reaction mixtures were incubated at 37 °C in a waterbath for 30 minutes, 
before products were loaded onto an agarose gel and separated by electrophoresis. 
Agarose gel electrophoresis was used to separate DNA fragments according to their 
MW and compared against a 1 kb DNA marker to verify size. A 1 % (w/v) agarose 
gel was formed by the addition of agarose to 1x TAE buffer and warming in a 
microwave oven to dissolve. The agarose mixture was cooled to ~50 °C before the 
addition of ethidium bromide (EtBr) to a working concentration of 0.1 μg/mL. The 
mixture was then set in a Biorad Mini-Sub® cast and assembled with a well comb, 
according to manufacturer instructions. Each gel was placed in a Biorad tank and 
covered with 1x TAE buffer. Samples were prepared with 1x loading buffer (from a 2x 
stock) before gel loading. Electrophoresis was performed under constant voltage of 
80V until the dye front had migrated approximately two thirds down the gel. This 
allowed for sufficient DNA fragment separation. UV transillumination was used to 
view resolved EtBr stained DNA fragments, via the Biorad XRS Chemidoc Imaging 
System®. 
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Figure 2.1 Restriction digest for the verification of full-length eGFP-hRyR2 cDNA. A. 
WT and mutant eGFP-hRyR2 cDNA (1 μg) were digested with restriction enzymes (EcoRI, 
HindIII, BamHI and BglII). Products were run on a 1 % agarose gel against a 1 kb DNA 
ladder. The ladder lane from the same gel has been spliced across in the figure for 
presentation purposes. B. Anticipated digest pattern determined via NEBcutter, using the full-
length eGFP-hRyR2 DNA sequence. C. Table of restriction enzyme specificity and expected 
fragment size.
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Figure 2.2 Schematic for the propagation of WT and mutant eGFP-hRyR2 plasmid DNA.  
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2.3.4 Large-scale plasmid isolation - ‘Maxiprep’ 
 
Plasmids verified by restriction digest or sequencing (site-directed mutagenesis 
products) at the ‘miniprep’ stage were prepared for large-scale isolation. Small-scale 
bacterial cultures (See Section 2.2.1 ii) were used to inoculate 400 mL LBAMP 
cultures at a dilution of 1:100 and grown overnight at 30 °C with shaking at 225 rpm. 
Bacterial suspension was then centrifuged at 6500 xg for 15 min using a JLA16.250 
fixed-angle rotor (Avanti J-25, Beckman) to obtain a cell pellet. 
 
Plasmid DNA was purified from cell pellets of bacterial culture by a modified alkaline 
lysis method using the HiSpeed Plasmid Maxi Kit, which is a gentle method of 
isolating DNA by ion-exchange and prevents shearing of such a large plasmid. 
Bacterial pellets were resuspended in 10 mL Buffer P1 with added RNase A and 
LyseBlue particles, ensuring no clumps remained. Buffer P2 (10 mL) was added, 
mixed thoroughly by inversion and incubated for no longer than 5 minutes at room 
temperature to allow for complete lysis without damaging the plasmid DNA. The 
mixing results in a homogenously blue coloured suspension, which should not have 
cell clumps or colourless regions – this would indicate incomplete lysis. Chilled Buffer 
P3 (10 mL) was added to the lysate, mixed immediately and thoroughly by gentle 
inversion. After the addition of this buffer, a white precipitate formed which contained 
genomic DNA, proteins and cell debris. The lysate was then transferred to a QIAfilter 
Cartridge and allowed to incubate at room temperature for 10 min. This stage was 
essential to allow precipitate to float and form a layer above the solution, preventing 
clogging during filtration. During this incubation, a HiSpeed Maxi Tip was equilibrated 
by 10 mL Buffer QBT. The cap of the QIAfilter cartridge was then removed, and a 
plunger inserted into the cartridge to filter the cell lysate through the equilibrated 
HiSpeed Tip. Cleared lysate entered the resin of the HiSpeed Tip by gravity flow. It 
was then washed with 60 mL Buffer QC. This medium-salt wash removed RNA, 
proteins, dyes and low MW impurities. DNA was then eluted with 15 mL high-salt 
Buffer QF, followed by the precipitation and concentration of DNA with the addition of 
10 mL (0.7 volumes) isopropanol, which was mixed and incubated at room 
temperature for 5 min. A QIAprecipitator Maxi Module (filter) was attached to a 30 mL 
syringe, and eluate/isopropanol mixture plunged through into a waste bottle. 
Precipitated DNA was trapped in the filter as a thin layer. The DNA in the filter was 
then washed with 2 mL 70 % (v/v) ethanol and dried by plunging air through the 
syringe several times. Using a fresh 5 mL syringe, 1 mL of dH2O was plunged 
through the filter using constant pressure to elute the DNA.  
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Plasmids were quantified using the NanoVue™ Plus (See Section 2.2.1 v) and 
verified by restriction digest with appropriate endonucleases and fragments 
visualized by agarose gel electrophoresis, before storage at -20 °C. Site-directed 
mutagenesis products were stored at -80 °C due to fragility.  
 
 
2.3.5 DNA quantification 
 
DNA concentration was determined by spectrophotometric quantification, using the 
NanoVue™ Plus Spectrophotometer (GE Healthcare). This equipment measures the 
DNA absorbance of light at a wavelength of 260 nm (A260) in μg/mL, and can be 
programmed to account for dilution factor. Only 2 μL of DNA sample was required to 
obtain an accurate measurement. The ratio of A260/A280 was also measured; giving a 
value that corresponds to plasmid purity. Contamination of the plasmid DNA with 
protein has peak absorption at A280, so an increased value would lower the ratio. 
Values of ≥1.8 therefore indicated high purity DNA samples. DNA preparations with 
values below this were discarded. 
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2.3.6 HEK293 cell maintenance and subculture 
 
All mammalian cell culture work took place in HEPA filtered Class II laminar flow 
containment hoods, in a designated laboratory. HEK293 cells were purchased from 
the European Collection of Authenticated Cell Cultures (ECACC). Cells were grown 
in T75 cm2 culture flasks with filter caps in cDMEM. They were incubated at 37 °C, 
gassed with 5 % CO2 and kept at a humidity of 98 % in a ThermoScientific HeraCELL 
240i CO2 incubator.  
 
Routine sub-culture (passaging) was essential to maintain a healthy population of 
cells in a monolayer, preventing over-confluency and cell death. On reaching 80 % 
confluency, cells were washed with 10 mL 0.9 % (w/v) saline solution and detached 
from culture flasks by trypsinisation for 1 min. The action of the enzyme was inhibited 
by the addition of 10 mL cDMEM and dissociated cells were collected as a cell 
suspension.  
 
Cell number was calculated using a Luna™ Dual Fluorescence Cell Counter 
(Labtech) following manufacturer instructions. After pelleting of the cells by low-
speed centrifugation (1,000 xg for 3 min in an Allegra 6R centrifuge, Beckman), the 
cell density was adjusted by gentle resuspension in the appropriate volume of 
cDMEM. Typically, cells were passaged biweekly for cell maintenance.  
 
2.3.7 Ca2+ imaging in HEK293 cells  
 
While many fluorescent dyes are available with unique profiles, Fluo-3 (see Table 
2.1) was chosen for these experiments, offering a suitable dynamic range with 
minimal damage to the cells, a low compartmentalization tendency and appropriate 
Ca2+ binding affinity (D. Thomas et al. 2000).  
 
Loading is achieved with the acetoxymethyl (AM) conjugated form of the dye, which 
can cross the cell membrane before hydrolysis by esterases, leaving the fluorescent 
indicator trapped within the cell. Although Fluo-3 has a near identical 
excitation/emission profile to eGFP, relative changes in fluorescence in this system 
are entirely Ca2+-dependent (N. L. Thomas et al. 2004).    
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Calcium 
Indicator 
Excitation 
Peak 
Emission 
Peak  
Ratiometric? Advantages Disadvantages 
Indo-1 338 nm 475 nm + 
400 nm  
 
 
Yes 
  
Free Ca2+ 
and bound 
Ca2+ emit 
different 
wavelengths  
Accurate 
measurement 
of free Ca2+ 
 
Corrects for 
variable 
loading and 
dye leak 
UV 
wavelengths 
can damage 
live cells 
 
Expensive 
equipment 
required 
Fura-2 340 nm + 
380 nm 
510 nm 
Fluo-2 488 nm 515 nm No 
 
Dependent 
on free Ca2+ 
and only 
emits one 
wavelength 
Wavelengths 
are less 
damaging to 
live cells 
 
Can use 
multiple dyes 
at once  
Can be 
dependent on 
other factors 
i.e. differential 
loading 
Fluo-3 488 nm 525 nm 
Fluo-4 506 nm 520 nm 
Calcium 
Green-1 
488 nm 530 nm 
Rhod-2 556 nm 576 nm 
 
Table 2.1 Comparison of Ca2+ indicator dyes used in confocal microscopy. Fluo-3 is 
highlighted, as this was the chosen dye for imaging experiments in this project. 
 
2.3.7.1  Effectene transfection of HEK293 cells 
 
HEK293 cell maintenance is described in Section 2.3.6. The Effectene Transfection 
Reagent (Qiagen, with kit containing reagent, Buffer EC and enhancer) was used to 
introduce eGFP-hRyR2 into HEK293 cells for calcium imaging experiments. This 
gentle method uses a non-liposomal lipid formation in order to achieve highly 
reproducible transfection efficiencies compared to the calcium phosphate method, so 
was deemed optimal for these experiments. Calcium phosphate transfection also 
leads to a higher rate of cell death, unsuitable for live cell imaging experiments. 
 
HEK293 cells were plated onto 10 mm poly-D-lysine coated glass coverslips (Mattek 
Corporation) at a density of 1-2 x105 cells/plate, within 200 μL cDMEM.  Cells were 
incubated at 37°C at 5 % CO2 for 24 hours before transfection. 
 
To transfect 7 coverslips, 0.8 μg of eGFP-hRyR2 DNA was made up to a total 
volume of 100 μL with Buffer EC (a DNA condensation buffer), followed by the 
addition of 6.4 μL of enhancer. The solution was mixed by vortexing, and incubated 
at room temperature for 5 minutes. Effectene (20 μl) was then added to the solution 
and mixed thoroughly by vortexing. The solution was incubated at room temperature 
for 10 minutes, which allowed condensed Effectene-DNA complexes to 
spontaneously form. The solution was then mixed with 600 μL cDMEM and 100 μL 
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was added drop wise to each coverslip. Coverslips were returned to the incubator for 
8 hours, before they were removed from the incubator and flooded with cDMEM to 
prevent cell death. Coverslips were placed back into the incubator for at least 24 
hours post-transfection before any loading for calcium imaging. 
 
2.3.7.2  Loading cells for Ca2+ imaging 
 
Fluo-3 AM (50μg, AAT Bioquest) was dissolved in 15 μL DMSO containing 20 % 
(w/v) Pluronic® F-127 acid, resulting in a 3 mM stock of Fluo-3 AM. This was then 
added to mDMEM at a concentration of 10 μM. cDMEM was removed from the 
coverslips before the addition of a 200 μL meniscus of dye-containing mDMEM. 
Coverslips were incubated at 30 °C and 5 % CO2 for 30 min and then flooded with 
mDMEM for 10 min to allow de-esterification before calcium imaging experiments 
took place. 
 
2.2.7.3 Confocal microscopy for Ca2+ imaging 
 
To visualize calcium-dependent fluorescence, cells loaded with Fluo-3 AM were 
imaged using a laser scanning confocal microscope (Leica SP5) with an x63 
objective oil immersion lens and an Argon laser (See Figure 3.3). Excitation was 
initiated at 488 nm and emission detected at 525 ±25 nm by a photomultiplier tube 
(PMT). mDMEM was removed from a coverslip before the addition of a 200 μL 
Krebs-Ringer-Hepes (KRH: 9 g/L glucose, 7 g/L NaCl, 6 g/L HEPES, 0.35 g/L KCl, 
0.16 g/L KH2PO4, 0.29 g/L MgSO4, 1.3 mM CaCl2, filter sterilized and pH adjusted to 
7.4) meniscus for the experiment. Data were acquired at a rate of 5 frames per 
second, using Leica LAS AF software at 512 x 512 pixel resolution. After a field of 
view was identified to have oscillating cells, data were recorded for a total of 180 sec, 
with the addition of 10 mM caffeine (dissolved in KRH) at 150 sec to identify 
functional hRyR2 channels. Fluorescence intensities were measured from regions of 
interest (ROIs) outlining individual cells (approx. 45-47 µm2). All cells were counted 
but only cells that responded to caffeine were used in Ca2+ oscillation analysis.  
 
2.3.7.4  Analysis of calcium imaging data with SALVO 
 
Calcium imaging experiments have been analysed using ‘SALVO’ (Synchrony-
Amplitude-Length-Variability of Oscillation), a semi-automated program specifically 
designed to look in detail at the spatiotemporal patterns of Ca2+ signals. Parameters 
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of a Ca2+ oscillation (Figure 2.3) determined by analysis with SALVO and the method 
of calculation for each is detailed below: 
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Figure 2.3 Parameters of a Ca2+ oscillation measured in transfected HEK293 cells:  
 
Mean Basal Signal Intensity 
Basal signal intensity (F0) was measured by taking an average of signal intensities 
between each calcium release event. F0 is highlighted by a dashed line in Figure 2.3.  
 
Amplitude 
The amplitude of an oscillation of Ca2+ release was determined by subtracting the 
peak signal intensity (F) from the mean basal signal intensity (F0). The amplitude was 
expressed as a proportion of the basal intensity signal (F-F0/F0 or ΔF/F0). This 
parameter represents the fluorescence change of the Ca2+ indicator following RyR2 
channel activation, and is linked to the Ca2+ ER load.  
 
Duration 
The duration of a Ca2+ release oscillation was determined by subtracting the time at 
which signal intensity begins to increase from the time the signal returned to basal 
intensity (F0). Points of the start and end of an oscillation are highlighted on the 
diagram. Duration was measured in seconds (sec).  This parameter reflects Ca2+ 
release and extrusion of Ca2+ from the cytosol.  
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Inter-event Duration 
Inter-event duration is the time between two Ca2+ release oscillation events. This was 
determined by subtracting the time at which a new event occurred from the time at 
which the previous event ended, returning to basal signal intensity. Inter-event 
duration was measured in seconds (sec). 
 
Frequency 
The frequency was calculated as how many periods occurred per minute (ppm). A 
period is highlighted on Figure 2.3 and includes both the Ca2+ release event duration 
and inter-event duration added together. This parameter is dependent on the Ca2+ 
load of the ER store, the sensitivity of RyR2 to cytosolic Ca2+ concentration, and the 
refractoriness of RyR2 Ca2+ release. 
 
Rate up 
The rate up is a calculation of the rate of initial Ca2+ release, expressed as a change 
in signal intensity per second ((ΔF/F0)/sec). The time of oscillation initiation was 
subtracted from the time of peak signal intensity (F), and the amplitude of the event 
(ΔF/F0) was divided by this time to calculate the rate at which this occurred. This can 
be interpreted as the rate of activation of the RyR2 population.  
 
Rate down 
The rate down is a calculation of the time taken for a spontaneous Ca2+ release 
event to decay and intensity to return to baseline (F0). This parameter is indicative of 
removal of Ca2+ from the cytosol. It is expressed as a change in signal intensity per 
second ((ΔF/F0)/sec). The time at peak oscillation intensity was subtracted from the 
time at which the oscillation event ended, and the amplitude of the event (ΔF/F0) was 
divided by this time to calculate the rate at which this occurred, giving a negative 
value. This is a measure of the time taken for Ca2+ release to terminate.  
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Caffeine-sensitive ER Ca2+ load 
ER Ca2+ load was determined by calculating the amplitude of caffeine-induced Ca2+ 
release (see Figure 2.4), after the addition of 10mM caffeine. The mean basal signal 
intensity (F0) was subtracted from the Ca2+ release peak fluorescence (Fc).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 The ER Ca2+ load was estimated after the addition of caffeine. Mean basal 
signal intensity (F0) was subtracted from the amplitude of caffeine-induced Ca2+ release (Fc).    
 
 
2.3.8 Calcium phosphate transfection of HEK293 cells 
 
The calcium phosphate transfection principle was used to introduce eGFP-hRyR2 
DNA into HEK293 cells (for maintenance of cell cultures see Section 3.2.1.1). A 
modified precipitation method was employed, where a high DNA: cell ratio is used for 
optimal transfection efficiency of mammalian cells (Chen and Okayama 1987). Cells 
were plated onto 10 cm2 petri dishes at a density of 1.5-2x106 cells/dish within 10 mL 
cDMEM and incubated (See Section 2.2.2) for 24 hr before transfection, to allow for 
growth to confluency of ~75 %. Plasmid DNA (12 μg/dish) was mixed with 124 mM 
CaCl2 solution (pH 7) and dH2O to a total volume of 500 μL to generate CaPO4-DNA 
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complexes. The solution was added dropwise to 500 μL of warmed 2x HBS (pH 7.05) 
with continuous vortexing. The DNA/CaCl2/HBS mix was incubated for 20 min at 
room temperature to allow a fine precipitate to form, essential to allow DNA to be 
introduced into the cells via endocytosis. The 1 mL solution per plate was then added 
dropwise to the confluent cell monolayer, before incubation at 37 °C at 5 % CO2 for 
24 hours. Cell media was then replaced with 10 mL of cDMEM containing 2 mM NaB 
for up-regulation of cell expression (Gorman et al. 1983). Cells were incubated at 37 
°C at 5 % CO2 for a further 24 hours before visualisation using a Zeiss fluorescence 
microscope to assess transfection efficiency, by counting the total number of cells 
and the total exhibiting eGFP fluorescence.  Cells were harvested by trypsinisation 
and cell number was calculated using the Luna™ Dual Fluorescence Cell Counter, 
before cells were pelleted by centrifugation at 1,500 xg for 5 min (Allegra 6R 
centrifuge). Pellets were either stored at -80 °C or immediately lysed for cell 
homogenate preparation.    
 
2.3.9 Cell homogenate preparation 
 
After the calcium-phosphate transfection protocol, HEK293 cell pellets were 
immediately resuspended in hypo-osmotic buffer (50 μL per 1 x106 cells) containing 
1 % (v/v) Triton-X-100 on ice. This buffer puts the cells under osmotic stress causing 
them to rupture. Cells were then homogenised by ejection through a 23 G needle 20-
25 times before 6 cycles of freeze-thaw waterbath sonication, using liquid N2 and a 
Decon F5100b sonicator (Decon Laboratories Ltd.). Centrifugation at 1,000 xg for 5 
mins (Eppendorf 5741R) pelleted cell nuclei and the supernatant was removed, 
containing cell homogenates. Preparations were aliquoted into volumes suitable for 
individual experiments and snap-frozen with liquid N2 before being stored at -80 °C. 
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2.3.10 Protein assay for quantification  
 
Total protein in cell homogenate samples was quantified using a colorimetric 
reagent-based protein assay. The BCA™ System relies on two reactions:  
• The reduction of Cu2+ ions from copper (II) sulphate in the BCA solution to 
Cu+ by peptide bonds of protein 
• The chelation of each Cu+ ion to two molecules of bicinchoninic acid, forming 
a purple coloured complex 
The amount of Cu2+ reduced is proportional to the amount of protein present in the 
solution, and the purple complex strongly absorbs light at wavelength of 560 nm.  
Dilutions of samples (1:100, 1:200, 1:500) were prepared as well as protein 
standards (0-500 μg bovine serum albumin, BSA) for the plotting of a standard curve. 
Each sample (100 μL) and each protein standard (in duplicate) was mixed with 100 
μL BCA kit working solution, prior to incubation at 37 °C for 30 mins to allow for 
colour development. Absorbance readings at 560 nm were taken using a Biorad 
iMark™ Microplate Absorbance reader (Biorad), following manufacturer instructions. 
  
A standard curve was plotted of absorbance vs. protein concentration (μg/mL). 
Sample protein concentration could then be derived from the standard curve, using 
the linear equation y=mx+c. (see Figure 2.5).  
 
 
Figure 2.5: Example of a standard curve for protein assay.  
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2.3.11 SDS Polyacrylamide Gel Electrophoresis (SDS/PAGE) 
 
eGFP-hRyR2 protein expression levels were assessed by SDS/PAGE (Laemmli 
1970). Samples were separated using a 4 % (v/v) acrylamide gel, where RyR2 at a 
MW of 565 kDa can be resolved towards the top. The inert, cross-linked structure of 
polyacrylamide gel means larger molecules migrate slower through the pores than 
smaller molecules when an electric field is applied. Separating gels were prepared as 
in Table 2.2, supplemented with 1 % (w/v) agarose to strengthen and eliminate the 
need for an additional stacking gel. Ammonium persulphate acted as a chemical 
initiator and TEMED as a catalyst, causing cross-linking chain reactions between 
acrylamide and bisacrylamide monomers, hence these solutions were added last to 
the mixture. Glass plates in a Biorad gel casting system were cooled for 30 mins on 
ice prior to use. Gel solution was poured between pre-cooled glass plates in a Biorad 
gel casting system with combs inserted to form loading wells. The gel casting system 
was then cooled on ice for 5 minutes and then left to set for at least two hours at 
room temperature before use.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Separating 4 % acrylamide gel composition. Amounts of SDS/PAGE 
components made enough solution for 1 gel.  Samples were prepared for electrophoresis by 
addition of SDS-PAGE x5 loading buffer and 20 min incubation at 42 °C. This denatured and 
linearized proteins. The 10 % (v/v) β-mercaptoethanol in the buffer also reduced the protein, 
dissociating aggregates that would otherwise be difficult to separate. Samples were then 
loaded onto the gel alongside Kaleidoscope protein MW marker. Electrophoresis was carried 
out at a constant current of 0.02 A until the appropriate coloured markers were resolved.  
 
Reagent Volume (μL) 
40 % Acrylamide/Bis 
(37.5:1) 
1,000  
Separating Buffer  2,500  
10 % SDS 100  
dH2O 1,345  
10 % Ammonium 
Persulphate 
50  
TEMED 5  
1 % (w/v) agarose 5,000  
TOTAL 10,000 μL 
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2.3.12 Transfer of protein onto PVDF membrane 
 
Once SDS-PAGE was complete, proteins separated on acrylamide gels were 
transferred onto preactivated 0.2 μM polyvinylidene difluoride (PVDF) membrane 
using the iBLOT™ dry blotting system (Invitrogen) and specialised transfer stacks 
following manufacturer guidelines. The system allowed a fast electrophoretic transfer 
time of 13 min at 20 V. PVDF membranes were chosen because of their high protein 
binding capacity and mechanical strength, ideal for stripping and reprobing 
experiments. 
 
2.3.13 Western blot analysis by chemiluminescence 
 
After transfer, PVDF membranes were immediately incubated for 1 hr in 5 % (w/v) 
blocking solution on a rocker to prevent nonspecific antibody binding. For detection, 
primary antibodies were prepared in 1 % (w/v) wash buffer/blocking solution at the 
appropriate dilution and applied to the membranes. They were incubated for 2 hr at 
room temperature or overnight at 4 °C on a rocker. The HRP-conjugated secondary 
antibody was prepared in 1 % (w/v) wash buffer/blocking solution at the appropriate 
dilution. Membranes were washed three times using 1 % (w/v) wash buffer/blocking 
solution for 5 min on a rocker to remove unbound antibody, before the application of 
the secondary antibody and incubation at room temperature on a rocker for a further 
1.5 hr. Membranes were then washed 5 times using TBS-T for 5 min on a rocker to 
remove background and remaining traces of antibody or blocking solution. 
 
To visualise transferred protein bands, enhanced chemiluminescence reagents were 
used (ECL Prime, GE Healthcare) according to the manufacturer instructions. 
Antibodies conjugated to horseradish peroxidase catalyse the oxidation of luminol 
and results in light emission. Maximum light emission occurs at wavelength of 425 
nm and is detected by the G:BOX Chemi XX6 (Syngene) chemiluminescence 
imaging system, using the GeneSys software (Syngene) and following manufacturer 
instructions.  
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Chapter 3  
 
Investigating the functional heterogeneity 
of CPVT-linked hRyR2 mutants using Ca2+ 
imaging 
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3.1 Introduction 
 
3.1.1 Methods of functional characterization of CPVT1 mutations 
 
Many techniques are employed to unravel the molecular mechanisms by which both 
WT and CPVT1 RyR2 channels release Ca2+ from the SR. Unfortunately, it is difficult 
to interpret data and understand the definitive mechanism of dysfunction when 
multiple assays are employed to investigate RyR2 channel behaviour (George et al. 
2005). While single channel isolation is both valuable and essential to investigate 
gating mechanisms and modulation by physiological ligands, it also remains that 
such studies are not always regarded as physiologically relevant (Bers 2014). 
Conversely, investigating the function of RyR2 channels within intact cell systems 
pose other disadvantages; while perhaps more physiological, it is difficult to delineate 
the exact contribution of RyR2 channels to Ca2+ release when there are many other 
modulators within the complex environment of a cell, including the contribution of the 
SR Ca2+ store. Described below are three of the major experimental methods used to 
investigate Ca2+ release events of the RyR2 channel: 
 
3.1.1.1   Assessing RyR2 function using single channel recordings  
 
RyR2 channels are located within the intracellular network of the SR and are more 
difficult to access than ion channels which span the sarcolemma; therefore 
conventional electrophysiological techniques such as patch-clamping are not viable 
(Mortensen and Smart 2007). Current through RyR2 channels therefore requires the 
incorporation of isolated single channels into an artificial membrane system, namely 
planar lipid bilayers (Favre et al. 1999; Mortensen and Smart 2007). This is the only 
method available to observe mechanistic information about channel gating and the 
effects of channel modulators in real time (Laver 2001; Williams et al. 2001) .  
 
RyR2 channels are incorporated into bilayers either as native membrane vesicles or 
as purified single channels. An advantage of using native membrane vesicles is that 
regulatory proteins that form RyR2 macromolecular complex may remain associated 
with the channel in the bilayer (Tester et al. 2007; Marx et al. 2000). However, this 
will limit the characterization of channel function, as other ion channels (such as K+ 
channels) present will contaminate current measurements. Although Ca2+ can be 
used as the current carrier to eliminate this issue, many studies use monovalent 
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permeant ions rather than divalent ions in order to increase the signal-to-noise ratio 
(Bannister et al. 2015; Mukherjee et al. 2012; Williams et al. 2001). Therefore, it will 
be impossible to delineate conductance of single RyR2 channels in this manner. 
Limitations can be overcome by the use of purified single channels, with RyR2 
separated from other membrane proteins after detergent-solubilisation and isolation 
by density gradient centrifugation.  
 
A dispersion of lipid in n-decane is applied over a small partition between two 
chambers, cis and trans, which contain suitable ionic solutions (See Figure 3.1), 
spontaneously thinning to form a bilayer (White 1986)(Laver 2001). RyR2 will then 
incorporate within the bilayer in a fixed orientation, allowing cytosolic and luminal 
sides of the protein to be defined (Sitsapesan and Williams 1994). Incorporation of 
channels can be detected by conductance changes in the bilayer membrane 
(Coronado et al. 1992). Subsequently, single channel gating and ion translocation 
can be monitored, as well as responses to physiological and nonphysiological 
ligands in a controlled environment under voltage clamp conditions (Rousseau et al. 
1986; Williams et al. 2001; Favre et al. 1999; Holmberg and Williams 1989).  
 
 
 
Figure 3.1 Schematic of planar lipid bilayer setup for recording single RyR2 channel 
currents. Lipid bilayers are formed across a small partition (~200μm in diameter) between 
two chambers, trans and cis, filled with controlled chemical solutions. Recombinant RyR2 
channels are incorporated by the addition of purified RyR2 protein to the cis chamber, 
induced by a chemical gradient. After removal of excess RyR2 protein and perfusion of the 
cis chamber to a symmetrical solution as in the trans chamber, channel behaviour is 
monitored under voltage clamp conditions. 
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Isolation of single channels from the native cellular environment and experiments in 
this fashion however will subject the channel to non-physiological conditions, which 
may alter channel function (Meissner 2004). Detergent lysis may alter molecular 
interactions within single channels, with speculation that subconductance states 
identified in single channel recordings may in fact be an artefact of tetramer 
destabilization following detergent solubilisation (Carter et al. 2006; M. T. Jiang et al. 
2002) Observed effects of solubilisation may be due to the loss of accessory proteins 
and therefore this in vitro functional characterization may not be reflective of in situ 
channel behaviour within a cell (George et al. 2005; Du et al. 2001; George, 
SORATHIA, et al. 2003; Wagenknecht and Radermacher 1997). 
 
3.1.1.2  [3H] Ryanodine binding as a surrogate marker of channel population 
function 
 
Arguably one of the most important contributions to the study of RyR2 is the 
discovery of the plant alkaloid ryanodine (Figure 3.2) (Jenden and Fairhurst 1969), 
followed by the production of radiolabelled [3H] ryanodine (Pessah et al. 1985). This 
led to the subsequent identification, purification, single channel analysis and cloning 
of RyR2 over the following twenty years (Tunwell et al. 1996; Campbell et al. 1987; 
Lai et al. 1989; Hymel et al. 1988; Holmberg and Williams 1989). Ryanodine binds to 
RyR2 with high-affinity in the open conformation only, therefore by exploiting this 
property, changes in [3H] ryanodine binding levels can be used as an indicator of 
changes in RyR2 channel function (Lai and Meissner 1989; Meissner and El-Hashem 
1992). Experimentally, it is a straightforward assay in which multiple conditions can 
be manipulated, where Ca2+ sensitivity of channel populations can be quantified 
(Viero et al. 2012). [3H] ryanodine binding has been used extensively to investigate 
the effects of ligands on RyR2, both physiological and non-physiological (Hunt et al. 
2007; Holmberg and Williams 1989). 
 
 
 
 
 
 
 
Figure 3.2 The chemical structure of ryanodine (C25H35NO9), which binds to the RyR2 
channel in the open state.  
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Investigating CPVT1 mutations with this assay has in some cases shown that mutant 
channels that exhibit increased Ca2+ leak also display increased sensitivity to Ca2+-
dependent [3H] ryanodine binding (Jones et al. 2008; Fernández-Velasco et al. 
2009). However, the technique can produce misleading results when mutant 
channels are examined – some RyR2 mutations alter the [3H] ryanodine binding 
affinity without changing single channel gating (Gao et al. 2000; Wayne Chen et al. 
2002; Zhao et al. 1999). Mutations can also cause inherent RyR2 instability, 
rendering some channels non-functional outside of the cellular environment; 
therefore it would be impossible to study with this technique (Fessenden et al. 2004).  
 
3.1.1.3  Ca2+ release function of RyR2 channel populations as assessed by 
Ca2+ imaging 
 
Although precise mechanisms of channel dysfunction cannot be elucidated without 
analysis in planar lipid bilayers, examination of RyR2 in intact cell systems can 
provide a more physiologically relevant environment for functional characterization. 
Utilizing Ca2+-indicator fluorescent dyes that can bind to free Ca2+ within a cell, as 
well as high-powered laser scanning confocal microscopy (See Figure 3.3 for a 
schematic), intracellular Ca2+ imaging is now a widely used technique to study RyR2 
mutant channel function (N. L. Thomas et al. 2004; D. Jiang 2005; N. L. Thomas et 
al. 2005). Changes in fluorescence intensity indicate changes in the binding of free 
Ca2+ to the indicator and is therefore reflective of Ca2+ release from intracellular 
stores.  
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Figure 3.3 Schematic representation of Ca2+ imaging with a confocal microscope. 
Briefly, excitation light from the Argon laser passes through pinhole filters, before being 
directed by the acousto-optical beam splitter (AOBS) to rotating scanning mirrors. These 
direct excitation light to systematically scan across each point of the sample, exciting 
fluorescent indicators in the sample on a point-by-point basis, decreasing the effects of photo 
bleaching. The rotating scanning mirrors then direct emitted light from the sample towards the 
AOBS. Here light is ‘tuned’ to a particular wavelength before being filtered of light that did not 
originate from the sample. The photomultiplier tube then amplifies the fluorescent signal and 
the output is converted to a signal that reflects the magnitude of fluorescence within the 
sample. Figure constructed based on literature by Leica Microsystems Science Lab.  
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As there are many types of Ca2+ signal that occur during Ca2+ cycling of the cell, 
(influx, reuptake, extrusion, release from other channels), it is difficult to identify the 
precise contribution of RyR2 to experimental observations. Interpretation of Ca2+ 
release events is therefore dependent on the choice of cell line in which to study 
RyR2. There are many cell lines in which recombinant RyR2 can be expressed (see 
Table 3.1), but RyR2-deficient cell lines remain the cell system of choice, without 
accessory proteins or endogenous RyR isoforms to contribute to the complexity of 
Ca2+ signalling. The lack of endogenous RyR in cell lines allows for homotetrameric 
channel expression after transfection with RyR2 cDNA, as well as heterotetrameric 
channel expression after co-transfection with equal ratios of WT and mutant RyR2 
cDNA (Lehnart et al. 2008; Tong, McCarthy, et al. 1999). HEK293 cells are the most 
widely used RyR2-deficient cell line, in both isolation of purified recombinant RyR2 
channels for single channel analysis (Bannister et al. 2015; D. Jiang et al. 2004; M. 
T. Jiang et al. 2002; Mukherjee et al. 2012) and in the investigation of Ca2+ handling 
within the cell (D. Jiang 2005; N. L. Thomas et al. 2004; N. L. Thomas et al. 2005). 
Although HEK293 cells lack the accessory proteins and contractile machinery of a 
cardiomyocyte, they appear to produce comparable functional data to that of RyR2 
isolated from native tissue (Xu and Meissner 1998; Li and Chen 2001; Du 1998; Bhat 
et al. 1999). Functionality of channels expressed in HEK293 cells can also be tested 
by caffeine-induced Ca2+ release (N. L. Thomas et al. 2004), with release of 
intracellular Ca2+ only from those successful transfected with RyR2.    
 
For these reasons, HEK293 cells were chosen as an appropriate heterologous cell 
system for the intracellular characterization of RyR2 mutations in a living-cell based 
context within this project. 
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Table 3.1 Cell lines used in the expression and functional characterization of RyR2 channels. HEK293 cells remain the most widely used in 
characterization of RyR2 mutations. References: 1 (Tjio 1958), 2   (Russell et al. 1977), 3 (Claycomb et al. 1998),  
4 (Tong, McCarthy, et al. 1999),  
Cell Line CHO HEK293 HL-1 
    
Species Chinese hamster Human Mouse 
Tissue Ovary Kidney, embryo Atrial cardiomyocyte 
Cell type Epithelial Epithelial Myocyte 
Method of engineering Sub clone of the 
parental CHO line1 
Transformed with sheared 
human Ad5 DNA2  
Derived from the AT-1 mouse 
atrial myocyte tumour lineage3  
Endogenous RyR No No Yes 
Contractile Machinery No No Yes 
Accessory Proteins No No Yes, full set 
Advantages Can express 
recombinant RyR2 in 
homotetramers 
 
Effects of RyR2 can be 
separated from 
influences of accessory 
proteins 
 
 
Human cell line with no 
endogenous RyR4 
 
Can express recombinant 
RyR2 at high levels in 
homotetramers 
 
Widely used to characterize 
RyR2 mutations, where effects 
of RyR2 can be separated 
from influences of accessory 
proteins 
Contain all the cardiac 
accessory proteins and 
contractile machinery proteins 
 
Can maintain cardiac-specific 
phenotype after repeated 
passaging 
 
 
Disadvantages Cell line is not human 
 
Decreased cell viability 
with high levels of 
recombinant RyR2 
expression  
No accessory proteins or 
contractile machinery present 
Cell line is not human 
 
Endogenous expression of RyR 
isoforms complicates 
interpretation of any 
recombinant RyR2 effects and 
recombinant RyR2 expression 
levels are low 
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3.1.2 Preliminary single channel data on two CPVT1 hRyR2 mutants 
indicating functional heterogeneity 
 
3.1.2.1   The S2246L and N4104K hRyR2 mutations 
 
S2246L and N4104K were two of the first CPVT1-causing mutations to be identified 
in the hRYR2 gene (Priori et al. 2001) and are in different domains of the RyR2 
protein (see Figure 1.14). The clinical phenotype of both mutations has been 
investigated, with functional characterization experiments performed at both the 
single channel level and within a heterologous cell system (D. Jiang 2005; Wehrens 
et al. 2003; George et al. 2006; D. Jiang et al. 2004). KI S2246L and N4104K mouse 
models have also been developed that exhibit the CPVT1 phenotype when 
challenged with β-agonists and caffeine (Suetomi et al. 2011; Nishimura et al. 2015). 
Table 3.2 provides a summary of the functional characteristics of these RyR2 
mutations.  
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 S2246L N4104K 
Base change Serine (S) to Leucine (L) Asparagine (N) to Lysine (K) 
Location Central domain 
B solenoid domain (residues 2145-3613) 
Cytoplasmic portion of the I domain 
EF hand pair domain (4060-4134) 
Patient phenotype First identified in an 8-year-old male who presented with 
recurrent syncopal events induced by exercise. Normal heart 
structure and resting heart rhythm, with bidirectional or 
polymorphic VT induced on stress or exercise1,2,  
First identified in a 14-year-old male who presented with loss of 
consciousness during exercise. Normal heart structure and 
resting heart rhythm, with non-sustained bidirectional VT on 
stress or exercise1,2, 
Mouse phenotype No appreciable changes in functional characteristics at rest, 
with epinephrine inducing VT3. 
No appreciable changes in function at rest, with caffeine plus 
epinephrine infusion to N4104K mice inducing VT/VF9.  
Isolated mouse 
cardiomyocyte 
phenotype 
Increased SR Ca2+-dependent spark frequencies in mouse 
cardiomyocytes, with an abnormally tight interaction in the 
central domain of the peptide3. 
Saponin-permeabilized mouse cardiomyocytes show increased 
spark frequencies in comparison to WT. Spontaneous Ca2+ 
transients were more frequently observed compared to WT 
after the addition of isoproterenol9.  
Single channel 
analysis 
Recombinant mouse RyR2 channels exhibit single channel 
properties similar to WT and displayed functional differences 
only upon activation by PKA phosphorylation, with increased 
Po and gating frequencies4. 
Mouse RyR2 channels display increased Po on high luminal 
Ca2+ activation compared to WT5. 
Recombinant mouse RyR2 channels display a higher Po on 
high luminal Ca2+ activation compared to WT, at low cytosolic 
Ca2+ concentrations6. 
[3H] Ryanodine 
binding 
No alteration of basal level of [3H] ryanodine binding to RyR2 
compared to WT5. 
Enhanced basal level of [3H] ryanodine binding to RyR2 
compared to WT6 
Expression in 
heterologous cell 
systems (i.e. HEK293 
cells) 
Mouse S2246L showed increased frequency of Ca2+ 
oscillations with no effect on amplitude and a decreased ER 
Ca2+ store in HEK293 cells5. 
Recombinant human S2246L perturbed intra-RyR2 domain 
interactions, with augmented Ca2+ release in CHO and HL-1 
cells7. 
Mouse N4104K showed increased frequency of Ca2+ 
oscillations and a decreased ER Ca2+ store in HEK293 cells6. 
Recombinant N4104K perturbed intra-RyR2 domain 
interactions, with augmented Ca2+ release in CHO and HL-1 
cells7. 
 
Table 3.2 A summary of functional characteristics observed in S2246L and N4104K RyR2 mutations in different experimental systems. References: 
1 (Priori et al. 2001), 2 (Priori 2002), 3 (Suetomi et al. 2011), 4 (Wehrens et al. 2003), 5 (D. Jiang 2005), 6 (D. Jiang et al. 2004), 7 (George et al. 2006), 8 (Tester 
et al. 2004), 9 (Nishimura et al. 2015)
 113 
3.1.2.2  Preliminary single channel data indicates functional heterogeneity 
 
Plasmids encoding mutant S2246L and N4104K hRyR2s were previously 
constructed in our laboratory (George, Higgs, et al. 2003) and therefore available for 
characterization at the single channel level in a minimal environment (Mukherjee et 
al. 2012). Preliminary single channel data were obtained by Dr. N.L. Thomas for 
these mutants and provided as supporting evidence in the grant application for this 
project.  
 
The literature on the functional characterization of RyR2 at the single channel level 
shows many inconsistencies because of the wide range of experimental conditions 
used by groups studying the channel in this way. Channels used for bilayer 
experiments have been obtained from many sources, including SR preparations from 
animals (Sitsapesan and Williams 1990a; Sitsapesan and Williams 1990b), 
membrane preparations from cells in which recombinant RyR2 channels have been 
expressed (Li and Chen 2001; Tester et al. 2007) or purified from either of these 
sources (Lindsay et al. 1994; Li and Chen 2001). Some channel preparation 
processes retain accessory proteins with RyR2 channels, while others do not. The 
inclusion of modulators such as ATP, Mg2+, cytosolic and luminal Ca2+ can also alter 
the function of RyR2, as well as posttranslational modifications such as 
phosphorylation and oxidation (Fill and Copello 2002; Carnes 2008; Terentyev 2008) 
. Due to the different starting materials, permeant ions, chemical modulators and 
accessory proteins used within experiments, models of hRyR2 channel behaviour 
are therefore rarely directly comparable (Zahradník et al. 2005; Laver 2007; 
Mukherjee et al. 2012).  
 
This lack of consensus regarding single channel experiments with RyR2 prompted 
the Williams group to study the recombinant hRyR2 in a minimal environment, away 
from accessory proteins and other modulatory ligands, with the sole focus of 
elucidating the role of cytosolic Ca2+ on the intrinsic mechanisms involved in 
modulating the open probability of the channel. They developed a mathematical 
model to describe purified WT recombinant hRyR2 gating kinetics in this system, 
suggesting the physical conformational changes that occur when the channel is 
activated by cytosolic [Ca2+] (Mukherjee et al. 2012). The destabilization of channel 
closure can be measured in the model by the rate of isomerization between two 
closed states, with one that is long and unresponsive.  
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Preliminary gating data obtained under these minimal conditions by Dr N.L. Thomas 
for this project revealed differences between S2246L and N4104K channels. In 
Figure 3.4, N4104K RyR2 channels present an increased Po at 1 μM cytosolic Ca2+ 
concentration in comparison to WT, whereas S2246L does not. When cytosolic Ca2+ 
concentration was buffered to nominally zero (with 1 mM EGTA, 1 mM HEDTA/NTA), 
surprisingly an N4104K channel showed brief open events (<200 μsec) with a Po of 
0.0007 in comparison to a Po of zero for both S2246L and WT RyR2 channels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Preliminary single channel recordings show that N4104K exhibits 
unliganded gating events, whereas S2246L and WT hRyR2 do not. A. Representative 
single channel recordings of gating events in WT and mutant hRyR2 channels. Openings are 
downward from the closed level (black line). Data acquired and analysed by Dr. N.L. Thomas. 
 
Mathematical modelling of Ca2+ activation data for these mutants by Dr N.L. Thomas 
suggests that N4104K RyR2 channels spend less time in the longer Ca2+ 
unresponsive closed state in comparison to S2246L RyR2 channels.  
.  
Preliminary data suggests that the pathogenic N4104K RyR2 mutation is associated 
with increased constitutive opening activity under nominally zero Ca2+ conditions, in 
the absence of activating ligand, demonstrating an intrinsic effect on channel gating. 
Constitutive activity is not evident in both mutations studied: S2246L RyR2 channels 
must require further stimulation (other than cytosolic Ca2+) to unmask the dysfunction 
linked to CPVT1.  
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Previous work on S2246L RyR2 channels show that they activate with cytosolic Ca2+ 
in an identical way to WT, in the absence of luminal Ca2+ (Wehrens et al. 2003). This 
is somewhat reflected in the preliminary data presented here, with channel behaviour 
similar to WT when cytosolic [Ca2+] is the only activating ligand. Jiang et al (2005) 
also report very low open probability of S2246L at 45 nM cytosolic/luminal Ca2+ 
concentrations, similar to WT (Po=0.0002 and 0.0004, respectively). However, this 
superficial analysis only considered Po as a measure of channel function, whereas 
improved methods within our laboratory are more likely to resolve channel activity 
that may have been missed such as dwell open and closed times (Mukherjee et al. 
2012).  
 
Interestingly, unliganded channel opening analogous to that of N4104K channels 
displayed in this data has previously been reported in studies of another CPVT1 
mutation, R4497C (D. Jiang et al. 2002). Single channels exhibited enhanced activity 
at nanomolar concentrations of Ca2+ (controlled by the addition of 0.1M EGTA) in 
comparison to WT, with a Po ~10x greater (0.00013 vs. 0.0000089, respectively). 
This supports the hypothesis that some mutant RyR2 channels display increased 
basal activity in comparison to others.  
  
Ligand-independent activity in other types of channels has been observed, induced 
by specific disease-causing mutations. Disease-causing mutations in the 
acetylcholine receptor also show increased unliganded channel activity, as well as an 
increase in the unliganded equilibrium constant (Purohit and Auerbach 2009; 
Grosman and Auerbach 2000; Milone et al. 1997). Unliganded gating has also been 
reported as increased in the cystic fibrosis transmembrane conductance regulator 
(CFTR) ATP-gated ion channels when there are gain-of-function mutations in cystolic 
loops of the CFTR polypeptide structure (Okeyo et al. 2013). This constitutive gating 
activity can therefore be used as a marker of the functional alteration of RyR2 
caused by CPVT1 mutations (Mukherjee et al. 2012). The observation that N4104K 
hRyR2 channels favour the closed responsive state, leading to subsequent 
unliganded openings is suggestive that this constitutive gating is the product of 
intrinsic structural defects within the channel. Conversely, S2246L hRyR2 channels 
do not display the same gating kinetics; this highlights that RyR2 CPVT1 mutations 
are functionally heterogeneous, even at the single channel level in a minimal 
environment.  
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While both S2246L and N4104K mutant RyR2 channels have been characterized 
using several different methods and there have been few differences in function 
noted (see Table 3.2), our understanding of RyR2 dysfunction remains far from 
complete. While both mutations have been investigated within the heterologous 
HEK293 cell system, a method successful first employed by Chen’s group and later 
others ((Seidel et al. 2014; Kong et al. 2008; N. L. Thomas et al. 2005; D. Jiang et al. 
2004; D. Jiang 2005; N. L. Thomas et al. 2004) ), more recent work has suggested 
assessment of the propensity for Ca2+ release alone is not a clear-cut indication of 
dysfunction. Loaiza et al. (2013) investigated the Ca2+ release of WT and 
heterotetrameric WT/V2475F RyR2 channels in HEK293 cells and found there was 
no statistical difference between the percentages of oscillating cells between groups 
at varying concentrations of extracellular Ca2+. This was in conjunction with an 
abnormal response to PKA phosphorylation, as well as increased cytosolic Ca2+ 
sensitivity and altered luminal Ca2+ concentration regulation in other experimental 
assays. Most CPVT1-linked mutations that have been shown to display a decreased 
threshold for SOICR also display a significant decrease in mean close time (7-20 fold 
shorter than WT channels) (D. Jiang 2005; Kashimura et al. 2010), whereas the 
mutation investigated by Loaiza et al. did not show the same dramatic decrease (1.2 
fold shorter than WT). This is suggestive that the threshold for SOICR does not 
solely determine the arrhythmogenic Ca2+ release in all RyR2 mutations (Loaiza et al. 
2013).   
 
A more detailed investigation of Ca2+ release events in RyR2-transfected HEK293 
cells is therefore warranted, interrogating kinetic parameters in more detail, such as 
rates of release and time periods between release events. This may reveal 
differences undetectable by measure of propensity of release.  
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3.1.3 Chapter aims 
 
There is a growing body of evidence to suggest that within the classification ‘gain-of-
function’, mutations in RyR2 are not identical and are in fact functionally 
heterogeneous (Tateishi et al. 2008; Loaiza et al. 2013; George et al. 2005; Suetomi 
et al. 2011; N. L. Thomas et al. 2005). Based on preliminary single channel data 
generated in the study of a central domain mutation S2246L and a transmembrane 
domain mutation N4104K, it appears that this functional heterogeneity can be 
revealed within a minimal environment, with cytosolic Ca2+ concentration as the only 
activating ligand. S2246L channels exhibit different gating mechanisms to that of 
N4104K channels. Unliganded channel openings observed in N4104K indicate there 
may be an intrinsic structural defect within this RyR2 channel, while S2246L 
channels may require further stimulation to reveal dysfunction, such as 
phosphorylation (Tester et al. 2007). 
 
It is therefore proposed that functional heterogeneity at the single channel level will 
be reflected at the cellular Ca2+ release level, shown by intracellular 
Ca2+ imaging in the heterologous HEK293 cell system, a well-established system 
used in the characterization of RyR2 mutations. This was investigated by: 
 
• Detailed interrogation of the Ca2+ release events of WT, S2246L and N4104K 
hRyR2 within HEK293 cells via confocal microscopy. Interrogating kinetic 
parameters as well as the frequency and propensity for spontaneous Ca2+ 
release in this system will reveal alterations that would have been missed by 
these measurements alone. 
• Assessing the expression levels of WT and mutant hRyR2 channels in 
HEK293 cells by Western blotting to determine whether any observed 
changes in function are attributable to changes in protein expression, of the 
construct or of SERCa, another Ca2+ handling protein within the system. 
• Assessing the formation of functional hRyR2 channels and the ER Ca2+ load 
after transfection into the heterologous cell system, via caffeine-induced Ca2+ 
release. 
• Determining the intracellular localization of hRyR2 within HEK293 cells with 
immunofluorescence to confirm any alterations in Ca2+ handling is not due to 
mislocalization of recombinant mutant hRyR2.   
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3.2 Materials and methods 
 
3.2.1 Evaluating the expression of WT and mutant eGFP-hRyR2 
 
It was important to evaluate the expression of RyR2 in transfected HEK293 cells to 
determine whether differences in calcium imaging between WT and mutant RyR2 
transfected cells were attributable to altered protein expression.  
 
Methods employed to express, prepare cell homogenate and Western blot for RyR2 
protein are detailed in Chapter 2. Briefly, WT and mutant eGFP-hRyR2 DNA was 
transfected into HEK293 cells by the calcium phosphate method. After 48 hours post-
transfection, cells were immediately first assessed for transfection efficiency before 
lysis and preparation as a homogenate to assess protein expression by Western 
blotting. After protein assay to calculate the concentration of these homogenate 
preparations, both 50 μg and 100 μg (normalized to WT transfection efficiency) of 
each construct preparation were incubated with the appropriate amount of x5 loading 
buffer, before loading onto an agarose-strengthened SDS-PAGE gel. Electrophoresis 
was carried out at constant current until the appropriate coloured markers on a 
ladder were resolved. Separated proteins were then transferred onto PVDF 
membranes, before blocking and incubation with primary antibody. This was followed 
by wash steps and incubation with the appropriate secondary antibody.  
 
Antibodies used in this chapter included: 
• Ab-GFP (B-2) antibody (Santa Cruz Biotechnology): mouse monoclonal 
primary antibody raised against the full-length green fluorescent protein of 
Aequorea victoria origin. Used at 1:1,000 dilution. 
• Ab-Vinculin (ab129002, [EPR8185]) antibody (Abcam): rabbit monoclonal 
primary antibody raised against human vinculin. Used at 1:10,000 dilution as 
a loading control. Loading controls are proteins with high and ubiquitous 
expression and can be utilized to account for loading error across 
experiments – expression levels of these proteins should remain consistent. 
Vinculin was chosen as an appropriate loading control in this instance, as at 
molecular weight of ~117 kDa, this protein can still be visualised after the long 
period of electrophoresis required to separate hRyR2 protein. 
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• Ab-SERCA (1/2, clone Y/1F4) antibody (Badrilla): mouse monoclonal 
antibody specific to both human SERCa1a and SERCa2a. Used at 1: 2,000 
dilution. 
• Ab-β-tubulin (ab6046) antibody (Abcam): rabbit polyclonal antibody specific to 
β-tubulin. Used at 1:500 dilution as a loading control, with a molecular weight 
of 50 kDa. 
 
After several wash steps to remove excess HRP-conjugated secondary antibody 
from the membranes, protein bands were visualized by enhanced 
chemiluminescence, detected by the G:BOX Chemi XX6 (Syngene) system. 
Densitometric analysis of visualized bands was then performed with GeneTools 
software (Syngene) and data then analysed with Microsoft Excel and GraphPad 
Prism as appropriate. 
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3.2.2 Immunofluorescence (IF) analysis of cells expressing eGFP-hRyR2 
 
Immunofluorescence (IF) is a technique that uses the specificity of antibodies to their 
antigen to target fluorescent dyes to specific molecular targets within a cell. IF 
analysis was carried out to confirm correct trafficking of recombinant hRyR2 
constructs to the ER and that observed functional consequences of CPVT1 
mutations were not due to incorrect localization. The ER in HEK293 cells is thought 
to be the equivalent cellular compartment to the junctional SR of cardiac muscle 
(Knollmann 2010). 
 
Cells were prepared and transfected on poly-lysine coated glass coverslips as 
described previously (see Section 3.2.1.2). Assays were started 48 hours post 
transfection. Cells were washed 3 times in Phosphate Buffered Saline (PBS: 137 mM 
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH adjusted to 7.4, filter 
sterilized) and fixed with 4 % (v/v) paraformaldehyde in PBS solution for 10 minutes 
in the dark. Cells were then washed and rehydrated in PBS for at least 1 hour at 
room temperature. Coverslips were washed with dH2O and mounted on glass slides 
with drops of Fluorsave (Calbiochem). To detect hRyR2 in fixed cells, 
permeabilization was achieved by incubation in 0.1 % (v/v) Triton X-100 detergent 
(Sigma Aldrich) in PBS for 30 minutes. Solution was removed and cells were washed 
with PBS. A blocking solution of 10% (v/v) FCS in PBS was used to prevent 
nonspecific immune-reactivity and was applied for 90 minutes at room temperature. 
Primary antibody (pAb-1093: rabbit polyclonal antiserum raised to residues 4514-
4564 of RyR2, without cross reactivity to RyR1) was then applied at a 1: 1,000 
dilution in PBS for 90 minutes. Coverslips were washed and fluorescent secondary 
antibody (Alexa Fluor 546) was applied at the appropriate dilution in PBS for a further 
90 minutes. Coverslips were washed in PBS before final fixing with Fluorsave. Slides 
could then be stored a 4°C until viewing with a Leica SP5 confocal microscope. To 
visualize eGFP fluorescence, an Argon laser was used, with excitation at 488 nm 
and emission 525 ±25 nm. To visualize Alexa-546 fluorescence, a Helium/Neon laser 
was used with excitation at 546 nm and emission at 572 ±30 nm.  Images of cells 
were acquired with Leica AS software.  
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3.2.3 Ca2+ imaging in a heterologous cell system 
 
HEK293 cells were chosen as the heterologous cell system for experimentation, due 
to their wide use in RyR2 characterization and lack of accessory proteins that may 
complicate data interpretation. Spontaneous Ca2+ release events were visualized 
with confocal microscopy via a fluorescent calcium-indicator Fluo 3. Further details 
are found in Chapter 2.  
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3.3 Results 
 
3.3.1 Do S2246L and N4104K differ in their recombinant expression level 
compared to WT hRyR2? 
 
Given that differing expression levels of hRyR2 cDNA within HEK293 cells will affect 
Ca2+ release, it was important to assess this prior to detailed analysis of Ca2+ release 
event kinetics. WT and mutant hRyR2 cell homogenate preparations were analysed 
by Western blotting at loads of 50 μg and 100 μg, normalized to WT transfection 
efficiency, such that expression level per hRyR2 expressing cell could be estimated. 
This should mean that all lanes in the blot displayed equivalent signal, if the 
expression level of hRyR2 per cell was equivalent for each construct. The intensity of 
bands at 50 μg for each preparation was low and variable across six separate 
experiments and it was sometimes difficult to visualize these via enhanced 
chemiluminescence in comparison to the equivalent 100 μg band. Choosing 
normalization points with low quantified intensities is suggested to result in high data 
coefficient of variance (CV), increasing false negatives (Degasperi et al. 2014). 
Consequently, expression levels were analysed only at 100 μg of loading (Figure 
3.7), although original blots and graphs for 50 μg protein expression can be found in 
Appendix III and IV.  
 
Expression of WT or mutant eGFP-hRyR2 was assessed using the intensity of signal 
given at the expected molecular weight of ~565kDa after probing using an anti-GFP 
antibody (see Section 2.2.12 and 2.3.12). This signal was corrected for loading error 
by normalising to the signal obtained for the endogenous, constitutively expressed 
cytoskeletal protein vinculin and expressed as a proportion of this signal. An average 
was then taken from at least three separate blots. Densitometric analysis revealed 
that N4104K protein expression levels were significantly higher than WT at 100 μg of 
loading (Figure 3.7 B, one way ANOVA with Bonferroni posthoc test, p<0.005 *, 
n=6).  
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Figure 3.6 Western blot analysis of WT and mutant eGFP-hRyR2 reveals that protein expression levels are not equivalent. A. Representative protein 
bands achieved from Western blot analysis of WT, S2246L and N4104K hRyR2, detected in cell homogenate preparation. hRyR2 bands are 565 kDa in size, 
indicated by comparison to 250 kDa protein marker. After reprobing with vinculin antibody (right image), the blot contains some RyR2 remnant bands. L refers 
to ladder. Original and additional Western blots are found in Appendix I. B. Anti-GFP signal was normalized to the equivalent vinculin signal (117 kDa). 
Densitometric analysis of the 100 μg expression levels of WT and mutant hRyR2 preparations revealed that N4104K signals were significantly higher. Data 
were analysed by one way ANOVA with Bonferroni Posthoc test in GraphPad Prism, p <0.05, n=6 experiments. 
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3.3.2 Does CPVT1 mutation alter the expression of SERCa in HEK293 
cells expressing hRyR2? 
 
Expression of SERCa was also determined for WT and mutant hRyR2 homogenate 
preparations by Western blotting (Figure 3.8) as an alteration in expression of 
SERCa may account for altered Ca2+ release kinetics observed in hRyR2-transfected 
HEK293 cells. This isoform of SERCa is SERCa1 not SERCa2a, as the cardiac 
isoform is not present in HEK293 cells (Tong, McCarthy, et al. 1999; Tong, Du, et al. 
1999). In the assessment of vinculin expression as a loading control, bands were 
very close together (the molecular weight of SERCa and vinculin is ~109 kDa and 
~117kDa, respectively, Appendix III) and therefore β-tubulin was chosen instead 
with a molecular weight of ~50 kDa. This loading control cannot be used when 
assessing RyR2 expression due to the required separation for this high molecular 
weight protein. Attempts were made to use a gradient gel to visualize hRyR2 GFP 
expression and β-tubulin on the same Western blot, but they were unsuccessful 
(Appendix IV). Although electrophoresis was carried out for >6 hours, no GFP 
expression was present while β-tubulin was successfully probed. Band separation is 
much more visible between SERCa and β-tubulin on the same standard blot. 
Densitometric analysis when SERCa expression is normalized to β-tubulin follows 
the same pattern as when normalized to vinculin and although more pronounced, 
changes of mutant SERCa expression remain non-significant when compared to WT 
expression (Figure 3.8 A and B). 
 
 
 
 
 
 
 
 
 
Figure 3.8 Endogenous HEK293 SERCa expression is not significantly altered after 
expression of mutant, as opposed to WT, eGFP-hRyR2. A. Representative bands of 
SERCa and β-tubulin protein. Bands are clearly separated. B.Densitometric analysis of 
SERCa expression normalized to β-tubulin expression, n=4 experiments, presented as mean 
±SEM. No significant differences were detected in either analysis by one way ANOVA with 
Bonferroni posthoc in GraphPad Prism.
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3.3.3 Do recombinant CPVT1-linked hRyR2 mutants undergo altered 
cellular trafficking or form functional release channels in a heterologous 
cell system? 
 
The size and morphology of cells expressing mutant hRyR2 channels were 
indistinguishable from those expressing WT hRyR2, which is consistent with previous 
studies (Wehrens et al. 2003; N. L. Thomas et al. 2004; George, Higgs, et al. 2003). 
 
Fluorescence colocalization analysis was used to determine whether an Alexa546 
conjugated antibody to the C-terminus of the hRyR2 protein (pAb-1093) and the N-
terminal eGFP tag were observed in the same cellular compartment, thereby 
suggesting that the eGFP-hRyR2 protein is fully transcribed/translated and is intact 
(Figure 3.9). The ‘lace-like’ reticular pattern of these fluorescent signals suggests 
that the cellular compartment targeted is the ER (Porter et al. 1945). 
 
The total co-incidence between eGFP fluorescence and immunolocalization via IF 
labelling of recombinant RyR2 was calculated by Manders overlap coefficient using 
ImageJ software (MANDERS et al. 1993)(Dunn et al. 2011). This calculates two 
values: the colocalization of pAb-1093 pixels to eGFP pixels, (red to green) and vice 
versa (green to red). A value closer to 1 indicates positive cooccurrence. The two 
calculated values can be different – for example, all red pixels may overlap green 
pixels, but green pixels may appear alone in a region where no red signal is present 
(Adler and Parmryd 2012). High coefficient values would indicate the expression of 
intact, full-length recombinant hRyR2 within the ER, as pAb-1093 binds to RyR2 at 
residues 4455-4474 of the C terminus.  
 
Colocalization of green to red gave coefficients between 0.8844-0.9083 and 
colocalization of red to green gave lower coefficients of 0.6830-0.7536, although no 
significant differences between colocalization of WT and mutant hRyR2 constructs 
were detected by one way ANOVA. This is suggestive that while some red antibody 
signal was identified without eGFP (i.e. that some hRyR2 channels were degraded 
from the N-terminus), this was comparable for WT and mutant constructs, indicating 
that mutation does not affect hRyR2 trafficking. 
 
Transfected cells expressing hRyR2 were easily identified by their caffeine-induced 
Ca2+ release, with a sharp increase in Fluo-3 signal amplitude after caffeine addition 
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(10 mM) and no further Ca2+ release events. This signified the expression of 
functional hRyR2 channels within the HEK293 cell and is shown in Figure 3.10 A. 
This figure also demonstrates that untransfected HEK293 cells do not exhibit a 
caffeine-induced response (C), confirming the lack of functional RyR in these cells as 
previously reported (Tong, McCarthy, et al. 1999). The ER Ca2+ content, measured 
by determining the amplitude of the Ca2+ transient induced by application of caffeine 
(10 mM), was calculated as described in Section 3.2.3.4, (see Appendix V for 
scatter plot).  
 
Figure 3.11 B. shows that the ER Ca2+ content was not significantly altered by the 
expression of either mutant compared to that of WT hRyR2, suggesting that any 
heterogeneity in channel dysfunction did not result from a reduced Ca2+ store.  
 
Calculation of the percentage of cells exhibiting eGFP fluorescence following 
Effectene-mediated transfection demonstrated comparable efficiencies (22-37 %) for 
WT and mutant RyR2 constructs, with no significant difference following statistical 
analysis (p>0.05 by Kruskal-Wallis with Dunn’s posthoc) (Figure 3.15). 
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Figure 3.9 WT, S2246L and N4104K eGFP-hRyR2 
constructs exhibit correct intracellular trafficking. 
HEK293 cells transfected with hRyR2 constructs were 
examined for eGFP fluorescence (ex. 488 nm, em. 525±25 
nm, left images) and immunofluorescence of Alexa546 
secondary antibody targeted to hRyR2 primary antibody 
pAb-1093 (em. 546 nm, ex. 572±30 nm, centre images). 
Colocalization (of green to red and red to green) was 
calculated by Manders overlap coefficient, with no significant 
differences calculated by one way ANOVA, n = 4-5 cells per 
construct. The scale bar represents 10 µm. 
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Figure 3.10 Caffeine-induced Ca2+ release from hRyR2 
transfected HEK293 cells as a measure of function. A. 
Representative traces of WT and mutant transfected HEK293-cells 
release Ca2+ on the addition of 10mM caffeine (at the red line time 
point) indicating that RyR2 channels are functional. B. WT and 
mutant hRyR2 expressing HEK293 cells have comparable 
caffeine-sensitive ER Ca2+ loads as determined by addition of 
caffeine. n WT = 54, SL = 45, NK = 56, Kruskal-Wallis with Dunn’s 
posthoc test. C. Untransfected HEK293 cells loaded with Fluo-3AM 
do not exhibit any Ca2+ release events of respond to caffeine. ROIs 
refer to individual cells; the red arrow indicates the addition of 10 
mM caffeine.  
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Figure 3.11 Expression of WT or mutant eGFP-hRyR2 in 
HEK293 cells following Effectene-mediated transfection. A. 
Bright field (left) and fluorescence (right) images of transfected cell 
populations. Untransfected HEK293 cells do not exhibit eGFP 
fluorescence. B. Transfection efficiencies of each hRyR2 construct 
using the Effectene reagent were comparable, with no statistically 
significant difference (Kruskal-Wallis with Dunn’s posthoc, 
p>0.05). The total number of transfections for each hRyR2 
construct: WT n=8, SL n=7, NK n=6. Transfection efficiency was 
calculated by comparing the total number of cells in the bright field 
of view to the total number of cells visible under fluorescence.  
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3.3.4 Is Ca2+ imaging data normally distributed?  
 
The D’Agostino-Pearson test for normality was used by the GraphPad Prism software. This 
‘omnibus K2’ test calculates skewness and kurtosis, calculating how far a distribution is from 
Gaussian normality in terms of shape and symmetry, giving a single P value from the sum of 
discrepancies for these values. If the given p value is less than 0.05, deviations from normal 
Gaussian distribution are statistically significant. (D'Agostino 2005). The following table 
(Table 3.4) shows such values for the Ca2+ imaging data acquired (shown in Section 3.3.5). 
 
 
 
 
 
 
 
 
 
 
Table 3.4 Tests for normality of Ca2+ imaging data show that distribution is not normal. n 
WT=164, n SL=109, n NK=97. D’Agostino-Pearson test, p<0.05 is significantly different to normal 
Gaussian distribution, indicated with red font. 
 
Within each parameter, all groups have data that are not normally distributed (Table 3.4). 
Although parametric tests are not very sensitive to deviations from normality, the assumption 
cannot be made when the set so clearly deviates from Gaussian distribution; therefore it is 
most appropriate to use non-parametric test equivalents when comparing groups i.e. Kruskal-
Wallis tests with Dunn’s posthoc, as opposed to one way ANOVA with Bonferroni correction 
(Lix et al. 1996; Harwell et al. 1992; Glass et al. 1972). All analysis of Ca2+ imaging data 
within this Chapter uses Kruskal-Wallis tests where appropriate. For a comparison of the 
statistical analysis between parametric and nonparametric tests, see Appendix IV.  
  
Post-hoc power analysis tests were also conducted using G*Power*3.19.2 software (Table 
3.5, www.gpower.hhu.de) to determine whether appropriate numbers of experiments were 
completed, and to confirm that where differences were determined non-significant, this was 
not a product of lower power. All studies were calculated using this method as highly 
powered. However, amplitude and inter-event duration appears lower powered compared to 
other parameters in analysis of S2246L HEK293 cells, even though this is above a suitable 
Ca2+ oscillation 
event parameters 
WT S2246L N4104K 
Amplitude 0.0015 0.0086 <0.0001 
Duration <0.0001 <0.0001 0.0001 
Inter-event duration <0.0001 <0.0001 <0.0001 
Frequency 0.0002 0.0267 0.0113 
Rate up <0.0001 <0.0001 <0.0001 
Rate down <0.0001 <0.0001 0.0063 
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threshold for detecting differences in the data (Beck, 2013). When considering the total 
number of cells observed in the experiments, as opposed to the number of oscillating cells 
only, post-hoc analysis shows that power increases to >99 %. It is therefore reasonable to 
suggest that the number of samples for each group was more than adequate for detecting 
differences between groups.   
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5 Posthoc power analysis of Ca2+ imaging data. All experimental groups have power of >80 
%, calculated with G*Power*3.19.2 software (Faul et al. 2009). n WT=164, SL=109, NK=97. 
 
 
Ca2+ oscillation 
event parameters 
S2246L 
vs WT 
N4104K 
vs WT 
Amplitude 80 % 99 % 
Duration >99 % >99 % 
Inter-event duration 83 % 99 % 
Frequency 98 % 98 % 
Rate up >99 % >99 % 
Rate down 97 % >99 % 
 132 
3.3.5 Do mutant hRyR2 channels exhibit heterogeneity in their spontaneous 
Ca2+ release?  
 
SOICR-events in hRyR2-transfected HEK293 cells were observed in calcium-containing 
external solution (KRH buffer containing 1.3 mM Ca2+), which were not observed in 
untransfected HEK293 cells in accordance with Jiang et al (2004).  
 
The number of cells that exhibited a response to Ca2+ or caffeine (black column in Figure 
3.12) within this system was generally equivalent to the number of cells expected to respond 
as calculated by transfection efficiency (grey column) for both WT and N4104K hRyR2 
transfected cells, suggesting that expression is closely correlated with function. However, the 
number of caffeine-responsive S2246L transfected cells was found to be significantly lower 
than anticipated by the determined S2246L transfection efficiency (p<0.05 by Mann Whitney 
U test). This was also significantly lower than the number of WT caffeine-responsive cells 
(p<0.05 by Kruskal-Wallis and Bonferroni posthoc test). Although most caffeine-sensitive 
cells exhibited oscillatory Ca2+ release events, some did not (~2%).  
 
 
 
Figure 3.12 Comparison of percentage of caffeine responsive cells vs the percentage of 
expected responders, as calculated by transfection efficiency. Differences between the 
parameters was calculated by Mann Whitney in GraphPad Prism, p<0.05. S2246L hRyR2 transfected 
cells responded to calcium or caffeine significantly less than expected. Total number of cells n WT 
=1003, SL=1274, NK=981. Number of transfections n WT=6, SL=7, NK=4. 
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The propensity for SOICR events was determined and found to be significantly decreased in 
S2246L hRyR2 transfected cells in comparison to WT (Figure 3.13, p<0.05 by one way 
ANOVA with Bonferroni posthoc). Cells expressing N4104K hRyR2 were not found to have a 
significantly different propensity, in contrast to work by Jiang et al (2004 and 2005). Changes 
in propensity were not due to altered transfection efficiency, as these were comparable.  
 
  
 
 
 
 
 
 
 
 
  
Figure 3.13 Propensity of transfected HEK293 cells for Ca2+ release – S2246L transfected cells 
have a decreased propensity. Data displayed as mean percentages ± SEM. Total number of 
transfections n WT=8, SL=7, NK=6. Analysis by Kruskal-Wallis with Dunn’s posthoc in GraphPad 
Prism, p <0.05 is indicated on the graph by *. The propensity for calcium release was significantly 
decreased in HEK293 cells expressing S2246L hRyR2. 
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As illustrated in Figure 3.14, representative traces for WT and mutant-expressing HEK293 
cells appear markedly different from one another, with altered Ca2+ handling. An in-depth 
analysis of Ca2+ oscillation events is presented as a series of bar graphs in Figure 3.15, with 
Ca2+ handling kinetic parameters calculated as described in Section 3.2.3.4 with SALVO 
analysis software. Scatter plots showing the spread of these data can be found in Appendix 
V.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Representative traces of spontaneous Ca2+ release events in WT and mutant hRyR2 
expressing HEK293 cells, measured by changes in Fluo-3 Ca2+ dye fluorescence. Representative 
traces indicate that there may be differences in Ca2+ release dynamics between mutant and WT 
expressing cells, with S2246L RyR2 expressing cells appearing to exhibit less frequent release events 
in the same period as N4104K and WT RyR2 expressing cells.  
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Figure 3.15 Assessment of the spontaneous Ca2+ release events in HEK293 cells expressing 
WT or mutant hRyR2. All parameters were calculated as described in Section 3.2.1.4. n WT=164, 
SL=109, NK=97 cells. Data are presented as mean ± SEM, p<0.01 is denoted by **, p<0.001 by ***, as 
calculated by Kruskal-Wallis with Dunn’s posthoc analysis with GraphPad Prism. Scatter plots of this 
data are found Appendix V.  
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The S2246L mutation only results in an alteration in the rate up of an oscillation in 
comparison to WT, which appears significantly decreased (Figure 3.15, E). N4104K 
transfected cells also have a decreased rate up, but also exhibit many other changes in 
comparison to WT. This includes a decreased Ca2+ oscillation amplitude (Figure 3.15, A), a 
decreased inter-event duration and rate down (Figure 3.15, C and F respectively), as well as 
an increased frequency (Figure 3.15, D)).  Table 3.6 summarizes the differences in calcium 
handling parameters between WT and mutant RyR2 transfected HEK293 cells. 
 
Ca2+ oscillation 
event parameters 
WT S2246L 
 
N4104K 
 
Amplitude 1.133 ± 0.05 1.011 ± 0.05 0.7556 ± 0.06 
Duration 10.29 ± 0.30 11.35 ± 0.50 9.611 ± 0.35 
Inter-event duration 12.38 ± 0.64 12.56 ± 0.89 8.773 ± 0.81 
Frequency 3.047 ± 0.13 2.975 ± 0.15 3.709 ± 0.18 
Rate up 6.510 ± 0.29 5.042 ± 0.30 2.861 ± 0.33 
Rate down -1.313 ± 0.07 -1.076 ± 0.07 -0.578 ± 0.05 
 
Table 3.6 Summary of Ca2+ handling parameters in transfected HEK293 cells. Mean values for 
calcium handling parameters of WT and mutant hRyR2-expressing HEK cells, ± SEM. Red indicates a 
statistically significant increase compared to the equivalent parameter in WT hRyR2-expressing 
HEK293 cells, whereas blue indicates a statistically significant decrease, (Kruskal-Wallis with Dunn’s 
post hoc test, p<0.01).  
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3.4 Discussion 
 
Loaiza et al (2013) recently demonstrated that a CPVT1 mutant (V2475F) exhibited a 
pronounced gain-of-function in [3H] ryanodine binding and single channel assays, but 
displayed a similar external Ca2+ threshold to WT for spontaneous Ca2+ release. This 
is suggestive that the measurement of propensity and incidence of Ca2+ release 
alone is not sufficient in explaining mutant channel dysfunction. Rather than 
evaluating the incidence of spontaneous Ca2+ release as a function of extracellular 
Ca2+ concentration, the parameters of Ca2+ release themselves were investigated in 
this project. It is apparent that kinetics of Ca2+ release events of N4104K are 
significantly different (in comparison to WT) within the HEK293 cell expression 
system and that mutant channels appear functionally heterogeneous within this 
assay. Kinetics of Ca2+ release events of S2246L are comparable to WT, but the rate 
up is different by a small but significant margin. Examining the spontaneous Ca2+ 
release events of CPVT1 mutant hRyR2 channels in HEK293 cells therefore appears 
to be an effective technique to reveal differences in Ca2+ release kinetics and 
functional heterogeneity that has been indicated at the single channel level caused 
by different hRyR2 mutations. 
 
Major chapter findings include: 
• Mutant hRyR2 constructs traffic to the ER correctly but have different 
expression levels in HEK293 cells, which affects analysis of Ca2+ handling 
kinetics 
• Assessment of Ca2+ release kinetic parameters of hRyR2-transfected 
HEK293 cells reveals functional heterogeneity of mutant hRyR2 channels 
• The S2246L mutation does not appear as a ‘gain-of-function’ mutation in this 
heterologous cell system 
 
 
 
 
 
 
 
 138 
3.4.1 Both mutant hRyR2 constructs traffic to the ER in HEK293 cells, 
but have different expression levels  
 
Visualization of recombinant hRyR2 using eGFP fluorescence or immunofluorescent 
detection via anti-RyR antibodies revealed high co-incidence (Figure 3.10) indicating 
the expression of full-length hRyR2 within the ER of HEK293 cells.  
 
In calculations of Mander’s overlap coefficients, colocalization of red to green gave 
lower coefficients in comparison to colocalization of green to red, although no 
significant differences between WT and mutant hRyR2 constructs were detected by 
one way ANOVA. This observation of N-terminus degraded hRyR2 channels (hence 
isolated red antibody signal) could be contributed to the action of calpain cleavage. 
Calpains are Ca2+-dependent cysteine proteases expressed ubiquitously in mammals 
and generate a characteristic ~400 kDa proteolytic fragment after cleavage at an N-
terminal site (Pedrozo et al. 2010; Zissimopoulos et al. 2013). Evidence of this 
fragment can be observed in many Western blot experiments presented in this 
thesis, as a strong band below that of hRyR2 protein (see Appendix I, VIII-XII, XX 
and XXV).  
 
Transfection efficiencies of WT and mutant hRyR2 constructs were reproducible and 
comparable (Figure 3.11). However, it was important to assess the expression of 
mutant hRyR2 constructs within HEK293 cells in comparison with WT via Western 
blotting, as this may have influenced Ca2+ handling. It was revealed that N4104K 
hRyR2 expression in HEK293 cells was significantly increased in comparison to WT 
(Figure 3.7). An altered expression level of mutant RyR2 channels in this system is 
in contrast to some studies (N. L. Thomas et al. 2005; Cheung et al. 2015), but is 
observed in others (Guo et al. 2016). Specifically, N4104K RyR2 has been previously 
reported to have an equivalent expression level in HEK293 cells to that of WT 
transfect cells (D. Jiang et al. 2004). The recombinant RyR2 construct used by 
Chen’s group is mouse recombinant cDNA however, as opposed to a recombinant 
human construct as used within this project. It is very difficult to speculate as to why 
N4104K hRyR2 expression is increased in HEK293 cells in comparison to WT 
hRyR2. This could be an artefact of the heterologous expression system or the 
method of normalization used, or may be a direct effect of mutation on protein 
turnover in the cell.    
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3.4.2 Functionality, as measured by spontaneous Ca2+ oscillation and 
caffeine-induced Ca2+ release, does not tally with expression for S2246L 
 
To confirm expression of functional hRyR2 channels after transfection, caffeine 
(10mM) was added at the end of every Ca2+ imaging experiment, resulting in a large 
Ca2+ transient, followed by no further spontaneous Ca2+ oscillations, indicating 
depletion of the store through release via functional hRyR2 channels (Figure 3.9). 
Both WT and mutant-transfected HEK293 cells release Ca2+ after application of 
caffeine, indicative of functional RyR2 channels that undergo appropriate regulation 
and can operate in this setting. This also confirms that the N-terminal eGFP tag of 
the RyR2 construct does not interfere with channel function in agreement with 
previous studies (Hiess et al. 2015; George, Higgs, et al. 2003; N. L. Thomas et al. 
2004; Liu et al. 2005; Zhang et al. 2003). 
 
Interestingly, there was a discrepancy between the percentage of S2246L hRyR2-
transfected cells exhibiting eGFP fluorescence and the percentage of cells which 
displayed caffeine-induced Ca2+ release, whereby the latter was significantly 
decreased (Figure 3.12). This was also reflected in a decreased propensity for 
spontaneous Ca2+ release events (Figure 3.13). Although channels may be present 
in HEK293 cells with the eGFP tag, there are less functional channels. This could 
indicate that the S2246L mutation is fundamentally affecting channel function.  
Interestingly Jiang et al. (2005) reported that a greater fraction of S2246L-expressing 
cells displayed Ca2+ oscillations as compared with WT cells, with similar findings in 
the study of N4104K (D. Jiang et al. 2004). This is contrary to the findings presented 
in this chapter, where the propensity of S2246L-transfected cells to release Ca2+ was 
significantly lower than those expressing WT hRyR2 and there were less responders 
than anticipated for the S2246L mutant construct compared to the calculated 
transfection efficiency than WT. No significant change in the propensity of N4104K-
transfected cells was detected, contrary to previous reports. Power calculations 
indicate that these findings are robust (<99% power for each parameter, see Table 
3.5) and n numbers are higher than those in the aforementioned studies (n 
WT=1003, SL=1274, NK=1405 vs. Jiang 2004/2005: n WT=563, SL=unclear 
(described as 3-7 experiments), NK=327). 
 
Given that a caffeine responsive is indicative of functional hRyR2 channels within a 
HEK293 cells and as expected, the percentage of cells that exhibit spontaneous Ca2+ 
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release events tallies closely with the percentage of cells that exhibit caffeine-
induced Ca2+ release (Figure 3.12 and Figure 3.13), caffeine-induced Ca2+ release 
can be used in future chapters as a marker of propensity.  
 
3.4.3 Store load and SERCa expression remains unaltered after 
transfection of HEK293 cells with hRyR2 constructs 
 
It was also important to explore the possibility that the expression of SERCa may 
have been altered in this system. SERCa cycles Ca2+ back into the ER in a HEK293 
cell after release into the cytoplasm, so any expression changes caused by 
transfection of a mutant hRyR2 plasmid need to be considered. Assessment by 
Western blotting and densitometry, however, found no significant changes in SERCa 
expression for over expression of mutant vs WT hRyR2 (Figure 3.8). This is in line 
with work of Thomas et al. (2005), SERCa expression of WT and mutant hRyR2-
transfected HEK293 cells was normalised to that of untransfected HEK293 cells, with 
no significant differences observed. Although the trend appears that in N4104K 
transfected cell SERCa expression is increased, this was not shown to be significant 
by one way ANOVA, with n =4-6. This therefore suggests that any changes in Ca2+ 
release kinetics are due to mutant hRyR2 expression alone. Caffeine-sensitive ER 
Ca2+ loads were also calculated as comparable between WT and mutant hRyR2-
transfected HEK293 cells, which further suggests that SERCa levels are equivalent 
(see Figure 3.6). 
 
In a cardiomyocyte, phosphorylation and upregulation of PLB could also be 
implicated in Ca2+ release – changes in expression or function will in turn modulate 
SERCa, increasing Ca2+ re-entry into the store. However, PLB expression has been 
shown not to express in HEK293 cells (Kurzydlowski 1996; Asahi et al. 2003; 
Toyofuku et al. 1994), therefore the expression of this protein was not investigated in 
this project.  
 
Estimation of ER Ca2+ content, calculated by the amplitude of caffeine-induced Ca2+ 
release in transfected HEK293 cells, showed that there was no significant difference 
between WT and mutant hRyR2 expressing cells (Figure 3.11). This is in agreement 
with other studies of mutant RyR2 channels in this system (N. L. Thomas et al. 2004) 
(Loaiza et al. 2013; George et al. 2006), but not with others (D. Jiang 2005; D. Jiang 
et al. 2004; D. Jiang et al. 2007). Specifically, D. Jiang et al (2004) showed that 
 141 
HEK293 cells expressing N4104K or two other I-domain CPVT1 mutants R4496C 
and N4895D had a decreased Ca2+ store content as compared to WT cells.  
 
Direct and time resolved measurements of free Ca2+ in the SR/ER have become 
much more desirable since the emergence of the pathological importance of the 
store (Niggli 2016). The application of the RyR2 agonist caffeine as described within 
this chapter allows an estimate of ER Ca2+ by recording the amplitude of the 
subsequent Ca2+ transient. This method has been used widely (D. Jiang et al. 2007; 
Loaiza et al. 2013; George et al. 2006; D. Jiang 2005) but is not without limitation; it 
is an indirect static measurement that can be rendered inaccurate by Ca2+ release 
events occurring before caffeine application (Fernández-Velasco et al. 2009). 
Therefore, while the addition of caffeine at 150 sec for each experiment maintained 
consistency, the application would not have been at the same point in a Ca2+ 
oscillation, a time point that would have been impossible to predict. This could 
therefore explain the discrepancies seen between some papers in the relative store 
load in WT of mutant RyR2-expressing HEK293 cells. There is also evidence that 
HEK293 cells expressing recombinant RyR have a functionally compartmentalized 
ER Ca2+store, which consists of a significant caffeine-insensitive component (Tong, 
McCarthy, et al. 1999). It would be advantageous to utilize chemical low affinity Ca2+ 
indicators (such as Fluo-5N) to quantify the changes of free Ca2+ in the ER directly 
(Kubalova et al. 2005; Brochet et al. 2005; Shannon et al. 2003), but this will not give 
an estimate of the total Ca2+ in the store, nor does this method come without 
drawbacks, with cytosolic indicator dye contamination and the physically small 
volume of the ER an issue (Fernández-Velasco et al. 2009).  A genetically encoded 
Ca2+ indicator such as D1ER could also alleviate the uncertainty of ER Ca2+ 
measurements – this construct signal is ratiometric, permitting single-cell resolution 
without quenching and the potential to monitor Ca2+ simultaneously in both the ER 
and the cytosol when used in conjunction with another high-affinity Ca2+ indicator 
(Palmer et al. 2004).  
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3.4.4 Assessment of Ca2+ release kinetic parameters in hRyR2-
transfected HEK293 cells reveals that S2246L mutants are similar to WT, 
while N4104K mutants are dysfunctional  
 
HEK293 cells transfected with S2246L hRyR2 exhibited no change in frequency of 
spontaneous Ca2+ release events (Figure 3.14 D). This is in contrast to work with 
stable-inducible HEK293 cells transfected with S2246L RyR2, which displayed 
increased frequency and a decreased amplitude of Ca2+ oscillations, as well as an 
overall decreased ER Ca2+ load (D. Jiang 2005). These data challenge both the 
hypothesis that this mutation is ‘gain-of-function’ and the mechanism of dysfunction 
described by Jiang et al. (2004). If frequency of events was the only measure of 
dysfunction and this dysfunction is caused by increased luminal Ca2+ sensitivity, the 
S2246L hRyR2 mutation could not be classified as such. One would assume this 
mutation is barely dysfunctional if the only change recorded is that the rate up 
decreases in comparison to WT. Expression and function do not tally in the same 
way as in WT hRyR2-transfected HEK293 cells as discussed above.  
 
Detailed interrogation of Ca2+ handling kinetics reveals only a decreased rate up of 
Ca2+ release. This therefore could suggest that the channel opening is at a 
significantly slower rate than WT, but channels must compensate for that during the 
release period, as inter-event duration remains unaltered. This change in kinetics 
could be due to altered individual channel activation, or also an altered distribution of 
mutant channels within the cell. Less dense clustering of S2246L-hRyR2 channels in 
the ER would mean less Ca2+ release event propagation across the population. 
However, increased clustering of RyR2 has previously been evidenced in 
spontaneously hypertensive rats with heart failure {Chen-Izu:2007hm}. Clustering of 
RyR2 channels in disease is discussed further in Section 4.1.1.  
 
As illustrated in Figures 3.14 and 3.15, spontaneous Ca2+ release events in cells 
expressing N4104K hRyR2 were found to be markedly different to S2246L and WT 
hRyR2. Expression of this mutant led to altered kinetics of Ca2+ release. The rate up 
of Ca2+ release was significantly decreased, the rate down significantly decreased 
and the inter-event duration in turn also decreased. This explains increased 
frequency and the altered shape of Ca2+ transient in comparison to S2246L hRyR2 
expressing cells. This may suggest that N4104K hRyR2 channels have difficulty 
shutting down, with the total duration of Ca2+ release remaining equivalent to WT, 
 143 
similar to S2246L hRyR2 expressing cells. RyR2 channels may also be in denser 
clusters within the ER as expression calculated by Western blotting is significantly 
increased in comparison to WT. The time taken to stop CICR would therefore be 
decreased, meaning Ca2+ release events could repeat more quickly, hence the 
increased frequency reported here, in line with previous SOICR studies of HEK293 
cells (D. Jiang et al. 2004)  
 
It could be that the density of channel clustering is altered, or also that sensitivity to 
Ca2+ concentration (luminal, cytosolic, or both) is changed. The EF hand domain is 
the location of the N4104K mutation and has the highest number of CPVT1 
mutations per number of residues, as highlighted in Figure 1.5. In a recent 
publication investigating the effect of mutations in the EF-hand motif or deletion of 
the entire domain, unaltered Ca2+-dependent activation of [3H] ryanodine binding and 
cytosolic Ca2+ activation in single channel experiments was reported (Guo et al. 
2015). Furthermore, mutations studied appeared to raise the threshold for SOICR 
termination. Chen and colleagues therefore suggested that the EF-hand is not 
required for RyR2 activation by cytosolic Ca2+, but plays an important role in luminal 
Ca2+ activation and SOICR. It is important to note however, that N4104K is outside of 
the domain that Chen and colleagues label as the EF hand (residues 4036-4082) 
and therefore may explain why, in single channel experiments in preliminary data, 
N4104K RyR2 channels display a fundamental gating defect, whereby the channel 
opens in a minimal experimental system devoid of agonist.   
 
After RyR2 channel activation, Ca2+ release from the store is terminated, at least in 
part due to the effect of the reduced Ca2+ levels within the store after release 
(Terentyev 2008). This refractory period of Ca2+ signalling allows Ca2+ released into 
the cell to be sequestered back into the store, ready for release in the next cycle 
(Belevych et al. 2012). While one could suggest that the decreased inter-event 
duration in fact shows a decreased refractory period of Ca2+ release, it must be 
considered, however, that the data presented in this chapter have been obtained 
from resting, non-stimulated cells, in an expression system lacking endogenous 
accessory proteins such as CSQ2 that contribute to any refractory period.  
 
While assessment of Ca2+ release kinetic parameters reveals differences in this 
setting, it remains that the data is difficult to interpret while we do not have data on 
Ca2+ fluxes across the membrane (Trafford et al. 2000). 
 144 
3.4.5 Does functional heterogeneity in single channel recordings relate 
to observations in HEK293 cells? 
 
Observations at the single channel level provided as preliminary data for this project 
by Dr N.L. Thomas demonstrated that in contrast to N4104K, S2246L channels did 
not show significantly more unliganded openings than the WT hRyR2 channels in the 
absence of other activatory ligands. This is in line with previous single channel 
analysis which found that under basal conditions, S2246L RyR2 exhibited normal 
single channel properties, indistinguishable from WT (Wehrens et al. 2003). This is 
unsurprising when CPVT1 patients do not present with symptoms at rest (Priori 
2002). Interestingly, in Ca2+ imaging assays, S2246L hRyR2-expressing HEK293 
cells in fact appeared to have unchanged frequency of spontaneous Ca2+ release 
oscillations in comparison to WT (Figure 3.14, B) contrary to previous reports (D. 
Jiang 2005). Within the HEK293 expression system, S2246L hRyR2 channels, much 
like in preliminary single channel data, appear to behave very similarly to WT. 
 
Another observation from single channel data is that N4104K exhibit unliganded 
channel openings in the absence of activating ligand (Figure 3.4). This is therefore 
indicative of an intrinsic structural defect within the channel, which impairs the correct 
response to Ca2+. This is somewhat reflected within HEK293 cells, as N4104K RyR2 
transfected cells exhibit altered rates of Ca2+ release within an oscillation cycle, 
suggestive of channel defects in the response to cytosolic or luminal Ca2+ 
concentrations.   
 
Both methods of functional characterization have their merits and drawbacks (see 
Section 3.1), but in conjunction with one another reveal functional heterogeneity of 
RyR2 CPVT1 mutations, in contrast to previous reports. There may not be a 
straightforward unifying mechanism of dysfunction, which therefore has 
consequences for therapeutic targeting of dysfunctional RyR2. This work has clearly 
shown investigation of RyR2 within a heterologous cell expression system can reveal 
dysfunction that is mirrored in single channel analysis.  
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3.4.6 Why doesn’t S2246L appear as a gain-of-function mutation in 
HEK293 cells? 
 
Within the single channel data presented in this chapter, it is impossible to 
distinguish dysfunction of the S2246L RyR2 channel. Without detailed interrogation 
of Ca2+ handling in HEK293 cells, it is also difficult to discern how channel function 
may be altered, with a frequency of spontaneous Ca2+ release unaltered compared to 
WT transfected cells, even though it is classically defined as a gain-of-function 
mutation. Even under more detailed interrogation of Ca2+ release kinetics, only the 
rate up of Ca2+ release is altered in comparison to WT. The channels appear to 
therefore function in a comparable way to the WT in this system. However, it also 
remains that Ca2+ release kinetics remain difficult to interpret in this system as there 
is no data on Ca2+ fluxes across the membrane (Trafford et al. 2000).   
 
RyR2 channels also undergo posttranslational modifications within the 
cardiomyocyte (Niggli et al. 2013), as discussed in detail in Section 1.4 and 1.5. 
S2246L dysfunction has only been reported as apparent after treatment with PKA 
(Wehrens et al. 2003; Lehnart et al. 2004), which would stimulate posttranslational 
phosphorylation of the channel. It could therefore be reasoned that S2246L may 
appear as WT without PKA phosphorylation. The central domain mutation R2267H in 
the work of Tester et al. (2007) shows normal function under basal conditions in 
comparison to WT. However, phosphorylation uncovers RyR2 channel dysfunction, 
whereby R2267H activity is significantly increased after phosphorylation by PKA in 
comparison to WT channels treated in the same way. This aids in the explanation of 
functional heterogeneity of the two mutant RyR2 channels studied within this project. 
It may be that S2246L is analogous to R2267H in the work of Tester et al., requiring 
activation under stress conditions and channel phosphorylation before dysfunction 
becomes apparent. Notably, both mutations are located in the CPVT1 mutant 
‘hotspot’ central domain of the RyR2 polypeptide. Work of the Marks group has 
investigated the effects of PKA on S2246L within single channel experiments, finding 
that phosphorylation significantly increased Po and gating frequencies in comparison 
to PKA phosphorylated WT channels (Wehrens et al. 2003). These finding also 
support the clinical observation that patients carrying CPVT1 mutations do not 
present with arrhythmogenic activity unless exposed to factors associated with 
increased sympathetic activity.  
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It may also be that N4104K channel activity is analogous to that of S4565R, both 
mutations also located in the same domain. N4104K as evident in preliminary single 
channel data displays augmented Ca2+ release even without activatory ligand; 
S4565R shows enhanced channel activity at basal conditions (Tester et al. 2007). 
The sensitivity of these channels at basal was in fact similar to PKA-treated WT 
channels. In light of this, it could be hypothesized that N4104K RyR2 channels will 
not therefore exhibit significant functional differences after phosphorylation, whereas 
S2246L will, revealing the classic gain-of-function phenotype that has not been 
observed in HEK293 cells. Investigating the role of phosphorylation on RyR2 mutant 
channel function will allow not only a deeper appreciation of CPVT1 disease 
phenotype and mechanism, but offer an explanation for functional heterogeneity. 
This therefore leads on to my next results chapter, in elucidating the effects of 
phosphorylation of both WT and mutant RyR2 channels.    
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Chapter 4  
 
The influence of phosphorylation at the S2808 
and S2031 sites on WT and CPVT mutant hRyR2 
function  
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4.1 Introduction 
 
4.1.1 Phosphorylation of RyR2 in CPVT1 
  
Abnormal phosphorylation of RyR2, leading to defective Ca2+ release has not only been 
implicated in the pathogenesis of HF but also in that of CPVT1. As discussed in Section 1.8.3, 
the data of Tester et al. (2007) suggest that the response of mutant RyR2 channels to 
phosphorylation is altered, not only in comparison to WT channels but to each other. Few 
published studies have investigated the functional effects of CPVT1-linked mutant RyR2 
channel phosphorylation, and those few focus mostly on the more controversial S2808 site. 
 
According to Wehrens et al. (2003), in single channel studies of S2246L, R2474S and R4497C 
mutant RyR2, under basal conditions (cytosolic Ca2+ at 150 nM) all mutant channels exhibited 
single channel activity indistinguishable from that of WT channels. While PKA phosphorylation 
increased the activity (Po) of both WT and mutant RyR2 single channels, the Po of mutant 
channels was significantly increased in comparison to WT, indicating that CPVT1 mutant 
channels were more sensitive to activation by PKA phosphorylation. Only upon treatment with 
PKA was mutant channel dysfunction apparent in this study.  
 
In an early investigation of the effect of β-adrenergic activation in HL-1 cells expressing mutant 
hRyR2 (George et al. 2003), using a pan-phosphoserine antibody, authors found that 
endogenous RyR2, WT and mutant hRyR2 were all phosphorylated to equivalent levels in 
untreated cells, as well as upon β-adrenergic stimulation with isoproterenol. Importantly, while 
Iso activation of the β-adrenergic cascade disrupted the RyR2:FKBP12.6 interaction in both WT 
and mutant hRyR2-expressing HL-1 cells, this extent of dissociation was equivalent. 
Hyperphosphorylation of RyR2 and RyR2:FKBP12.6 dissociation was proportional to the 
elevation in cAMP concentration on treatment with Iso. Mutants did however exhibit a left-shifted 
dose response of Ca2+ release to Iso as well as a significant increase in the duration of Ca2+ 
release events, in comparison to cells expressing WT hRyR2. While differential phosphorylation 
of mutants was not evidenced in this study, it could be the case that in stimulated cells, a 
differential sensitivity to equivalent phosphorylation may underpin abnormal Ca2+ release under 
such conditions. This data is also suggestive that selective dissociation of FKBP12.6 from 
CPVT1-linked hRyR2 mutants does not occur. 
149 
 
Ikemoto and Matsuzaki suggest that PKA-dependent phosphorylation induces defective inter-
domain interactions between N-terminal and central domains in CPVT1-mutant RyR2 channels, 
leading to defective Ca2+ release (see Section 1.7.4.2,  (Uchinoumi et al. 2010). In R2474S (+/-) 
RyR2 KI mice, the increase in phosphorylation level of S2808 of RyR2 after the addition of 
cAMP was equivalent to that of WT mice under the same conditions (Xu et al. 2010). The affinity 
of CaM binding to mutant RyR2 was reduced in response to cAMP (1 μmol/L) compared to that 
for the WT, but not before treatment. In WT hearts, CaM binding to RyR2 was unchanged in 
response to cAMP but decreased in the presence of peptide DPc10 (which mimics central 
domain mutations). Addition of this peptide didn’t further decrease RyR2-CaM binding in cAMP 
treated R2474S KI hearts. The authors suggest that PKA phosphorylation at the S2808 site 
induces domain unzipping in CPVT1 mutant RyR2 but not WT RyR2, reducing the binding 
affinity of the channel for CaM. As CaM inhibits the activity of RyR2 channels at physiological 
concentrations of Ca2+ and is essential for normal channel function, reduced binding is 
suggested to cause spontaneous Ca2+ release and lethal arrhythmia seen in CPVT1 (Oda et al. 
2005; Xu et al. 2010; Uchinoumi et al. 2010).  
 
In more recent work of the Valdivia group, V2475F CPVT1 mutant RyR2 channels display 
multiple mechanisms of dysfunction (Loaiza et al. 2013) including an abnormal response to PKA 
phosphorylation in comparison to WT recombinant mouse RyR2 channels. Treatment of WT or 
V2475F RyR2 channels with the PKA catalytic subunit, increased the phospho-signal at the 
S2808 and S2031 sites. This is the only published study to investigate changes in 
phosphorylation at both PKA phosphorylation sites in CPVT-related RyR2 dysfunction. In 
measuring the Ca2+-dependence of [3H] ryanodine binding, the authors found that PKA 
phosphorylation did not change the Ca2+ sensitivity of WT channel activation but did exaggerate 
the abnormal sensitivity of V2475F for cytosolic Ca2+. These data suggest that PKA 
phosphorylation of V2475F RyR2 exacerbates channel dysfunction, leading to uncontrollable 
Ca2+ release.  
 
A study of RyR2-R2474S(+/-) mice suggested that interval treadmill exercise training could 
reduce VT by decreasing CaMKII-dependent phosphorylation of RyR2 (Manotheepan et al. 
2016). Isolated cardiomyocytes from exercise-trained mice showed less diastolic SR Ca2+ leak 
and decreased phosphorylation at the CaMKII-specific S2814 site, compared to those from 
control mice. This further suggests changes in RyR2 phosphorylation level are associated with 
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dysfunction of mutant RyR2 channels and is also the only investigation of the CaMKII-specific 
S2814 phosphorylation site in a CPVT1 mutant.  
 
Increased clustering of RyR2 has already been evidenced in a disease setting, in tandem with 
increased RyR2 phosphorylation at the S2808 site {Chen-Izu:2007hm}. In work of Asghari et al. 
(2014), dual-tilt electron tomography was utilized to produce views of dyads in rat ventricular 
myocytes. Treatment with a phosphorylation cocktail (10 µmol/l cAMP, 10 µmol/l 3-isobutyl-1-
methylxanthine, 10 µmol/l okadaic acid, 0.5 µmol/l calyculin A and 1 µmol/l thapsigargin) moved 
RyR2 tetramers into a checkerboard configuration (see Section 1.3.2), while a concentration of 
Mg2+ (4 mmol/L) induced a dense side by side arrangement. A checkerboard association was 
also associated with a significant increase in Ca2+ spark frequency compared to control where 
RyR2 arrangement was mixed (Asghari et al. 2014). Increased hRyR2 channel clustering 
means an enhanced ‘fire-diffuse-fire’ mechanism, whereby single Ca2+ release events can 
easily ignite neighbouring channels, resulting in events that are large enough to be quantifiable 
by fluorescence (Kunitomo and Terentyev 2011).   
 
Others have shown that disease and increased phosphorylation in fact causes fragmentation of 
RyR2 clusters. Sobie et al. (2006) suggest there is a decrease in coupled gating between 
clustered RyR2s in response to phosphorylation in disease, as well as the existence of ‘rogue’, 
unclustered RyR2 channels which may respond differently to local Ca2+ concentrations. RyR2 
clusters in fixed atrial myocytes from sheep with persistent AF showed ultrastructural 
reorganization, with increased fragmentation associated with overactive Ca2+ release 
(Macquaide et al. 2015). If phosphorylation does lead to less dense RyR2 clusters, this may 
destabilize tightly regulated Ca2+ release from the SR, while rogue channels may each 
contribute a fraction to an overall increased Ca2+ leak (Sobie et al. 2005).  
 
In summary, although phosphorylation of RyR2 has been extensively investigated and remains 
controversial, studies on the effect of phosphorylation of RyR2 in CPVT are very few and the 
conclusions disparate and complicated by the use of different disease models and conditions. 
This experimental chapter will describe attempts to characterise the functional effects of cAMP 
mediated phosphorylation, characterised at both S2808 and S2031 PKA-specific sites, in WT, 
S2246L and N4104K hRyR2.  
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4.1.2 Investigating RyR2 phosphorylation: commonly used experimental 
strategies 
 
4.1.2.1  In vitro kinase assays and ‘back phosphorylation’ 
 
The method first used to investigate phosphorylation of cardiac proteins involved labelling the 
intracellular ATP pool with radioactive phosphorous-32 (32P), a technique used to reveal that 
both PLB and troponin I are phosphorylated in response to β-adrenergic stimulation (Manning et 
al. 1980; England 1976; Lindemann et al. 1983). However, this method does not allow 
discrimination between the kinases responsible, nor between different phosphorylation reactions 
(Karczewski 1991).  
 
Back-phosphorylation was employed to overcome this issue, and was first used to describe 
protein phosphorylation in brain tissue (Forn and Greengard 1978). Early works of RyR2 
phosphorylation involved this technique (Hohenegger and Suko 1993; Witcher et al. 1991; 
Takasago et al. 1989; Takasago et al. 1991; Seiler et al. 1984). Utilizing the principle that the 
capacity to incorporate phosphate is dependent on kinases and phosphatases linked specifically 
to the protein in question, this assay comprises fixing of the phosphorylation state of a protein 
and extraction from the rest of the cell, before back-phosphorylation of the remaining phosphate 
capacity, with [γ-32P]ATP and exogenous protein kinase (Karczewski 1991). The 
phosphorylation state of the protein before extraction, in vivo, is therefore indirectly assessed. 
This technique is not without limitation; it does not address the role of potential endogenous 
kinase activity in the assay, or reveal much information about the expression or functional state 
of the protein in question (Karczewski 1991). The high energy particles emitted and short half-
life (~14 days) of 32P also makes the technique potentially harmful in the laboratory, and safety 
precautions such as lead shielding are necessary to protect the body.   
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4.1.2.2  Phosphopeptide mapping 
 
In this procedure, a radiolabelled protein is proteolytically digested, and the resulting 
phosphopeptides are separated in two dimensions on a Thin Layer Chromatography (TLC) 
plate. The phosphopeptides are also analysed by High Pressure Liquid Chromatography 
(HPLC) and mass spectrometry (MS) or peptide microsequencing. This mapping gives 
information about the number of phosphorylation sites present in the protein, and can also be 
used to find out if sites of phosphorylation on a protein change upon treatment of cells with 
specific compounds (Dephoure et al. 2013, Meisenhelder et al. 2008). 
 
In work of Takasago et al. (1991), phosphopeptide mapping provided evidence that PKA, PKC 
and PKG predominantly phosphorylated serine resides in the same fragmented 
phosphopeptide, whereas CaMKII phosphorylated serine residue(s) in a different 
phosphopeptide. This led to the first suggestion that site-specific phosphorylation in RyR2 is 
dependent on different kinases. 
 
Unfortunately, as the phosphate moiety is relatively labile, it is often released during 
fragmentation leading to reduced quality MS spectra (Dephoure et al. 2013) and as such, many 
phosphorylation sites within a protein can appear as low occupancy – i.e. a small fraction of the 
protein molecules appear to be phosphorylated in this experiment (Olsen et al. 2010). It may 
also be difficult to identify a specific site of phosphorylation, as peptides with the same 
sequence phosphorylated on different residues will still have identical masses (Dephoure et al. 
2013).  
 
4.1.2.3  Phospho-epitope antibodies 
 
Phosphorylation-state specific antibodies take advantage of the sensitivity and selectivity of 
immunochemical methods to detect changes in phosphorylation of a protein at a particular site, 
with relatively simple preparation and broad application.  
 
Few groups have successfully generated and utilized RyR2-phospho specific antibodies ‘in-
house’ (Rodriguez et al. 2003; Xiao 2004; Wehrens et al. 2003) and antibodies that target both 
phosphorylated and dephosphorylated protein are commercially available from Badrilla Ltd, 
Leeds, with use cited in some recent publications (Miyazaki et al. 2012; Chakraborty et al. 2014; 
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Beca et al. 2012; Uchinoumi et al. 2010; Sedej et al. 2010). A study comparing the residue-
specific phospho-antibodies used by different research groups demonstrated that the 
sensitivities of the antibodies and the results they obtained varied significantly (Huke and Bers 
2008), possibly providing an explanation for the discrepancies between publications from 
different groups (Dobrev 2014). However, they remain an invaluable, inexpensive and popular 
tool for probing the effects of phosphorylation on RyR2 channel function.   
 
4.1.2.4  Pharmacological phosphorylation 
 
β-adrenergic agonists (e.g. Iso and epinephrine) are routinely used to activate the signalling 
cascade leading to the phosphorylation of RyR2. These act on the cell surface and do not 
permeate through cell membranes, resulting in the activation of adenylyl cyclase, increasing 
intracellular concentrations of cAMP and leading to subsequent phosphorylation of EC coupling 
proteins primarily by PKA, but also by CaMKII (Section 1.4). In experiments within a cellular 
environment, drugs that activate further down the pathway (such as adenylate cyclase) must be 
able to cross the cell membrane or activate other mechanisms coupled to phosphorylation of the 
channel. 
 
cAMP is a downstream secondary messenger in β-adrenergic stimulation, responsible for the 
activation of PKA and subsequent phosphorylation of RyR2.  A cell-permeable cAMP analogue 
was utilized by Paavola et al. (2007) to simulate sympathetic stimulation in the study of two 
CPVT1 RyR2 mutations, P2328S and V4653F. The authors reported that at baseline (no 
treatment), both WT and mutant RyR2-transfected HEK293 cells showed a low frequency of 
Ca2+ release events, in contrast to earlier reports of increased basal activity of RyR2 carrying 
these ‘gain-of-function’ mutations (Lehnart et al. 2004; Jiang et al. 2002). Treatment with 1-50 
µM dioctanoyl-cAMP (DcAMP, a cell-permeable cAMP derivative that mimics the effects of 
exogenous cAMP but with approximately 100 times greater activity), increased the propensity of 
Ca2+ release events in RyR2-transfected cells. The authors also reported that a significantly 
larger number of cells transfected with P2383S or V4653F RyR2 exhibited Ca2+ release events 
on treatment with DcAMP, in comparison to WT.
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Pharmacological treatment is frequently used in the study of RyR2 activity and dysfunction. 
However, without the addition diagnostic techniques (e.g. with phospho-epitope antibodies or 
phosphopeptide mapping) it isn’t possible to attribute any observed changes to phosphorylation 
(or lack of phosphorylation) to one particular site in RyR2. It is also likely that all PKA target 
proteins within the assay will be phosphorylated, and as discussed in Section 1.4, PKA activity 
may also be linked to Epac and activation of CaMKII, which is also thought to have RyR2 site-
specific and other targets that could be phosphorylated in this process, all of which must be 
considered in data interpretation. 
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4.1.2.5  Genetic phosphorylation 
 
Genetic phosphorylation was first used by Marks’ group in the study of the functional effects of 
RyR2 phosphorylation (Marx et al. 2000; Marx et al. 2001). This method exploits the fact that 
some non-phosphorylated amino acids appear chemically similar to phosphorylated amino acids 
(Figure 4.1).  
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
Figure 4.1 The use of phosphomimetics takes advantage of the chemical similarities between 
amino acids to mimic phosphorylated or dephosphorylated sites within a protein. A. Genetic 
phosphorylation involves the substitution of serine for aspartic acid, as aspartic acid is chemically similar 
to phosphorylated serine. B. Genetic phospho-ablation involves the replacement of serine by alanine, 
which renders the site unphosphorylatable.  
 
By the introduction of missense mutations at phosphorylation sites, a phosphorylated amino 
acid could be mimicked in terms of structure and charge.  When an aspartic acid replaces a 
serine, it is therefore a ‘phosphomimetic’ of serine. Genetic phospho-ablation of RyR2 refers to 
the replacement of serine by alanine at a particular site, amino acids that are structurally similar. 
Phospho-ablation is a term used to indicate that the site can no longer be phosphorylated after 
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this substitution, so mimics a dephosphorylated serine site. The protein is then assumed to 
maintain the level of activity caused by phosphorylation or dephosphorylation at this site.   
 
Many research groups have applied this technique to the investigation of RyR2 phosphorylation, 
including the Meissner, Marks, Chen and Wehrens groups. Studies using phospho-ablative or 
mimicking mutations remain invaluable to study effects at specific phosphorylation sites (Dobrev 
and Wehrens 2014). The technique allows for precise control over the phosphorylation status of 
one site within RyR2, avoiding misinterpretation of results due to phosphorylation of other EC 
coupling proteins as with pharmacological phosphorylation. However, genetic 
phosphorylation/phospho-ablation of RyR2 (especially in KI/KO mouse models) may lead to 
adaptive remodelling, with increased expression of EC coupling proteins to compensate for 
altered RyR2 activity (Pott et al. 2006; Brittsan et al. 2003).  
 
Further discussion on the many different phosphomimetic mouse models and recombinant 
cDNA studies can be found in Chapter 5.  
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4.1.3 Chapter aims 
 
CPVT1-linked arrhythmia occurs, by definition, after acute β-adrenergic stimulation following 
stress or exercise. However, it remains unclear whether sympathetic stimulation is an obligatory 
step to elicit the abnormal Ca2+ release observed from mutant RyR2 channels, or simply 
exacerbates dysfunction (Loaiza et al. 2013). PKA is the principal effector kinase in the β-
adrenergic stimulation pathway. The data of Tester et al. (2007) also indicate that diverse 
functional effects of different mutations may result in an equally diverse response to PKA 
phosphorylation (see section in CH3). It is therefore reasonable to hypothesize that PKA 
phosphorylation of hRyR2 channels in HEK293 cells may reveal CPVT1-linked channel 
dysfunction. As evidenced in the previous Chapter, S2246L-hRyR2 transfected HEK293 cells 
display little alteration in the kinetics of Ca2+ release events in comparison to WT-hRyR2 
transfected cells. It follows to hypothesize that phosphorylation at PKA sites S2031 and S2808 
may lead to dysfunction of S2246L RyR2 channels, but not necessarily N4104K channels, 
which already display dysfunction in Ca2+ imaging experiments (i.e. their dysfunction may not be 
able to be further exacerbated by phosphorylation). This investigation will attempt to provide an 
explanation for why functionally heterogeneous hRyR2 mutant channels result in similar 
arrhythmogenic outcomes.   
 
This was investigated by: 
• Western blot analysis of WT and mutant hRyR2 expression, using antibodies specific to 
the S2808 and S2031 phosphorylation sites, to determine basal phosphorylation levels. 
• Treatment of cells expressing WT or mutant hRyR2 cells with  a cell-permeable cAMP 
analogue (DcAMP, previously used with recombinant RyR2 in HEK293 cells (Paavola et 
al. 2007)) to stimulate PKA phosphorylation and subsequent Western blot analysis to 
detect any changes between WT and mutants in the level of phosphorylation of hRyR2 
at these two sites.   
• Further Western blot analysis of DcAMP treated hRyR2-transfected HEK293 cells to 
assess any changes in SERCa expression. This was to ensure changes in Ca2+ release 
events were most likely due to the alteration of hRyR2 phosphorylation levels, as 
opposed to increased Ca2+ efflux into the store via an increased number of SERCa 
pumps. HEK293 cells do not endogenously express PLB or CSQ2 (Kurzydlowski 1996; 
Asahi et al. 2003; Toyofuku et al. 1994), other proteins that are physiologically 
phosphorylated by PKA in the cardiomyocyte.  
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• Detailed interrogation of the Ca2+ release events of WT and mutant hRyR2-transfected 
HEK293 cells, as previous, before and after stimulation with DcAMP to identify changes 
after pharmacological phosphorylation, as well as determination of the ER Ca2+ store 
load and propensity for spontaneous Ca2+ release. 
 
Given that PKA phosphorylation is reported as site-specific to S2808 and S2031, 
phosphorylation at the CaMKII site S2814 was not investigated in this project. While there is 
evidence of both PKA and CaMKII being endogenously expressed in HEK293 cells (Tian et al. 
2002; Ashpole et al. 2012), it is not yet known whether these cells endogenously express Epac. 
If Epac is not present in the cell, this means there should not be crosstalk between pathways 
(see Section 1.4.1.4). 
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4.2 Materials and methods 
 
4.2.1 Evaluation of hRyR2 phosphorylation levels at S2031 and S2808 
using phospho-antibodies 
 
4.2.1.1  Cell homogenate preparation 
 
Methods to express, prepare cell homogenate and Western Blot for the eGFP-hRyR2 
protein are detailed in Chapter 2, with minor alterations implemented for subsequent 
experiments. To prevent the action of phosphatases and preserve phosphorylation 
status of hRyR2, cells were harvested and immediately resuspended in hypo-osmotic 
lysis buffer containing phosphatase inhibitors (20 mM Tris, 1 mM EDTA pH 7.4, 1 
mM NaF, 1 mM Na2VO4, 1 % Triton X 100, and 1 cOmplete™ EDTA-free protease 
inhibitor tablet (Roche) per 25 mL of solution). Cells were then immediately lysed by 
freeze-thaw sonication as described previously and prepared for Western blot 
analysis.  
 
4.2.1.2  Western blotting for protein expression 
 
The expression of eGFP-hRyR2 phosphomimetic constructs was assessed by 
methods described in Section 3.2.3. Antibodies used in this chapter included: 
• Ab-GFP (B-2) antibody (Santa Cruz Biotechnology): mouse monoclonal 
primary antibody raised against the full-length green fluorescent protein of 
Aequorea victoria origin, provided at 200 μg/mL. Used at 1:1,000 dilution. 
• Ab-Vinculin (ab129002, [EPR8185]) antibody (Abcam): rabbit monoclonal 
primary antibody raised against human vinculin (loading control), provided at 
100 µL at 0.054 mg/mL. Used at 1:10,000 dilution.  
• Ab-SERCA (1/2, clone Y/1F4) antibody (Badrilla): mouse monoclonal 
antibody specific to both human SERCa1 and SERCA2a (skeletal and 
cardiac isoforms). Used at 1:2,000 dilution. 
• Ab-β-tubulin (ab6046) antibody (Abcam): rabbit polyclonal antibody specific to 
β-tubulin (loading control). Used at 1:500 dilution.  
• Ab-pSer2808 RyR2 (A010-30AP) antibody (Badrilla): rabbit polyclonal 
antibody to S2808-phosphorylated RyR2, raised to amino acids 2801-2810. 
Used at a 1:2,000 dilution. Referred to as Ab-pS2808 in Figures. 
160 
 
• Ab-pSer2030 RyR2 (A010-32) antibody (Badrilla): rabbit polyclonal antibody 
to S2030-phosphorylated RyR2, raised to amino acids 2023-2033. Used at a 
1:1,000 dilution. Referred to as Ab-pS2030 in Figures. S2030 is equivalent to 
the human S2031 residue in RyR2, hence the different name for the antibody.  
 
4.2.1.3  PVDF membrane stripping for reprobing 
 
The Western blot signal obtained when using RyR2 phospho-specific antibodies is of 
course dependent on the level of phosphorylation at that specific site, but is also 
influenced by the RyR2 expression level itself, which may vary slightly between 
experiments (as reflected by the range of transfection efficiencies (Figure 3.12) and 
the changes in expression between WT and mutant constructs (Figure 3.7). The 
phosphorylation level was therefore expressed as a proportion of the protein 
expression level.   
 
PVDF is suitable for membrane stripping since it incurs a comparatively minimal loss 
of sample. It was therefore deemed appropriate to strip membranes probed for 
phosphorylated hRyR2. This allowed subsequent probing of membranes using the 
anti-GFP antibody and assessment of the S2808/S2031 hRyR2 phosphorylation 
level as a proportion of eGFP-hRyR2 expression.  
 
Each blot to be stripped, was placed in a tube containing 50 mL pre-warmed 
stripping buffer (50 mM Tris/HCl, pH 6.8, 2 % SDS and 0.1M β-mercaptoethanol, 
made up with dH2O) and incubated at 50 °C for 10 minutes in a waterbath set in a 
fume cupboard, before 3x 5 minute washes in excess TBS-T solution to remove any 
traces of β-mercaptoethanol, which would affect antibody binding. Blots were then 
placed in blocking solution (5 % milk in TBS-T) for at least one hour, before probing 
with anti-GFP antibody as outlined previously in Chapter 2. Optimization of stripping 
conditions and integrity of protein before and after the process is discussed in 
Section 4.3.1 and 4.4.5.   
 
A sample of mouse cardiac SR preparation was acquired from Dr S. Zissimopoulos 
and 100 µg was loaded as a positive control for the detection of phospho-RyR2 on 
each blot (labelled ‘CONT’ in all Western blot figures), though it was not used for 
quantitative purposes. This signal should not be visible after stripping and re-probing 
with the anti-GFP antibody and so its subsequent absence was also used as a 
measure of successful blot stripping.
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4.2.2 Investigating phosphorylation status after stimulation with DcAMP 
 
4.2.2.1  Preparation of a PKA-phosphorylated control 
 
For in vitro phosphorylation of cell homogenate samples, PKA (catalytic subunit from 
bovine heart, ≤9 units/µg, Sigma-Aldrich) was prepared in dH2O containing 
dithiothreitol (DTT, 0.6 mg/mL) and left to stand for 10 minutes at room temperature, 
before suitable size aliquots were frozen at -80oC, ready for use. This reducing agent 
prevented loss of enzyme activity and maintained reduced thiol groups. 
 
In the presence of ATP, the catalytic subunit of PKA will transfer the terminal 
phosphate of ATP to serine/threonine residues in the protein sample, without the 
presence of cyclic AMP, which would normally be required to bind to the regulatory 
subunit of PKA and catalyse a reaction.  
 
Cell homogenate protein samples (100 μg) were incubated with phosphorylation 
buffer (50 mM histidine, 5 mM MgSO4, 1 mM EGTA, 5 mM NaF in dH2O, pH 7) and 
PKA (1 U/ 2 µL) for 5 minutes in a waterbath at 37 °C (Rodriguez et al. 2003). ATP 
(magnesium salt, Sigma-Aldrich) was prepared immediately before use, in dH2O at a 
concentration of 5 mM. A final concentration of 200 µM was added to the reaction 
and incubated at 37 °C for 1 minute. The reaction was then terminated by addition of 
the appropriate amount of SDS PAGE loading buffer, before incubation at 40 °C and 
loading as described in Section 2.3.10. An example of a typical in vitro 
phosphorylation reaction mixture is described below in Table 4.1. 
 
Reagent Amount 
Cell homogenate preparation  100 µg 
PKA  2.5 U 
ATP  200 μM 
PKA phosphorylation buffer  Up to 50 μL 
 
Table 4.1 Example of an in vitro PKA phosphorylation reaction for Western blotting. 
The reaction was incubated at 37 °C in a waterbath, before the addition of SDS PAGE x5 
loading buffer to terminate the reaction. 
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4.2.2.2  Preparation of DcAMP analogue and treatment of transfected HEK293 
cells 
 
DcAMP (Na salt, Santa Cruz Biotechnology), provided as a lyophilized 50 mg solid, 
was prepared at a concentration of 50 mM in DMSO as per manufacturer 
instructions. Stock solutions in DMSO were then made at 10 µM and 100 µM for 
subsequent experiments. HEK293 cells expressing WT or mutant hRyR2 were 
prepared (as described previously in Section 2.3.6 and 2.3.7) and used to assess 
the effects of DcAMP for 30 minutes on the phosphorylation level at the S2808 site of 
hRyR2. One large scale transfection was completed per hRyR2 DNA variant (i.e. 3 in 
total, WT, SL and NK), divided into a total of 36 dishes. These dishes were arranged 
into 6 groups of 6 dishes, with each group receiving a drug or control treatment (final 
DcAMP concentrations of 1 µM, 10 µM, 100 µM and 1 mM, DMSO carrier only 
negative control, and a PKA treatment positive control as described in Section 
4.2.2.1). This allowed for the administration of each dose of DcAMP to cells from the 
same transfected population, in order to minimize variation in hRyR2 expression 
level between groups.  A cell homogenate preparation of untransfected HEK293 cells 
was also collected as an additional negative control. The DMSO control is referred to 
as DMSO, the PKA control as PKA and the HEK293 control as HEK in subsequent 
Western blotting figures.  
 
4.2.2.3  Assessment of DcAMP stimulated phosphorylation at S2808  
 
Cell homogenate preparation and Western blotting were carried out as described in 
Chapter 2, with assessment of S2808 phosphorylation and eGFP-hRyR2 expression 
as described in Section 4.2.1. As cells treated with concentrations of DcAMP in 
DMSO were all from the same transfection (i.e. 6 dishes were treated with each 
concentration, with a total of 36 dishes assessed from the same transfection of each 
hRyR2 DNA type), it was therefore not necessary to normalize densitometric values 
to eGFP-hRyR2 expression, as this should be equal for each sample.  
 
Phosphorylated hRyR2 expression was normalized to vinculin to account for loading 
error as described previously.  
 
S2031 phosphorylated hRyR2 expression was not investigated at this stage due to 
technical issues with the pSer-2030 antibody, discussed further in Section 4.3.2 and 
4.4.
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4.2.3 Ca2+ imaging after stimulation with DcAMP 
 
Although there was no obvious effect of DMSO on treated HEK293 cells in 
preparation for Western blot analysis, it is known that the vehicle can affect Ca2+ 
imaging experiments, given that DMSO is an osmolyte (Lang et al. 1998; Gordeliy et 
al. 1998; Cheng et al. 2015). While any osmotic effect would equilibrate in the cells 
over time, there is an acute effect which would likely be visible during Ca2+ imaging 
experiments that measure the immediate effects of drug addition on spontaneous 
Ca2+ release kinetics. Prior to these experiments, it was therefore important to test 
DMSO as a drug delivery vehicle.  
 
To minimise any possible effects of the vehicle, concentrated stocks, near saturation 
were prepared. However, the solubility of DcAMP in DMSO was not optimal (with 
final concentrations of 100 µM and 1 mM requiring an additions equivalent to 1% v/v) 
and so another vehicle, methanol, was also tested.  
 
HEK293 cells were transfected with hRyR2 WT and mutant constructs and prepared 
for Ca2+ imaging experiments as described previously (Section 3.2.3). Spontaneous 
Ca2+ release events of DcAMP treated HEK293 cells expressing WT or mutant RyR2 
were recorded as in Section 3.2.1 (with modifications discussed below), to observe 
any changes in cell activity or toxic effects of drug and/or vehicle. Oscillating cells 
were identified in a field of view and recorded for 3 minutes, before the addition of 
methanol, DMSO or DcAMP in either vehicle at a working concentration of 100 µM or 
1 mM, within the 200 µL meniscus of KRH solution on the Mattek dish. Controls 
included the maximum volume used of each drug vehicle. The recording was then 
continued for a further 3 minutes, before the addition of caffeine and recording for a 
final 30 sec. Recordings were therefore for a total of 6 minutes 30 sec, with the 
experiment repeated for HEK293 cells transfected with either WT, S2246L or 
N4104K hRyR2 constructs. Data were collected and analysed as described in 
Section 3.2.1.4. 
 
4.2.3.2  Cell viability assay 
 
The effects of DcAMP on cell viability were assessed using a Trypan blue assay. 
Trypan blue is a diazo dye that stains dead cells blue – live cells do not absorb the 
compound through the cell membrane, so remain unstained. Cell viability after 
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treatment with DcAMP in DMSO was not assessed, given that this drug vehicle was 
inappropriate for experiments that measure the effects immediately after addition 
(see Section 4.3.5).  
 
The Luna™ Dual Fluorescence Cell Counter (Labtech) and the dye exclusion 
method was utilized to assess cell viability after 30 minutes of treatment with 
concentrations of DcAMP dissolved in methanol. Readings were collected from three 
separate transfected wells per treatment and construct.  
 
HEK293 cells were seeded in a Greiner CELLSTAR® 12-well dish (4 cm2 surface 
area) at a density of 3 x 105 cells per well in 1 mL cDMEM. Cells were incubated at 
37 °C at 5 % CO2 for 24 hours before transfection using Effectene (Qiagen). 
Transfection of each well was carried out as follows: plasmid DNA (eGFP-hRyR2, 
0.3 μg) was made up to a total volume of 75 μL with Buffer EC, followed by the 
addition of 2.4 μL of enhancer. Effectene reagent (8 μL) was then added to the 
solution before mixture with 300 μL cDMEM before dropwise addition to the cells. 
Dishes were placed back into the incubator for at least 24 hours post-transfection 
and expression assessed by eGFP visualisation before any treatment with drug for 
cell viability studies.  
 
Media was removed from each well and replaced with either 1 mL fresh cDMEM (3 
wells), 1 mL cDMEM with 2 % methanol (3 wells), cDMEM with 100 µM DcAMP in 
methanol (1 % of final concentration (v/v), 3 wells) or cDMEM with 1 mM DcAMP in 
methanol (2 % of final concentration (v/v), 3 wells). Cells were incubated at 37 °C, 5 
% CO2 for 30 minutes before harvesting by trypsinisation (Section 2.3.7). 
 
Each cell suspension was mixed at a 1:1 ratio with 0.4 % trypan blue (provided in the 
Luna™ Dual Fluorescence Cell Counter kit, Labtech), before counting as per 
manufacturer instructions. 
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4.3 Results 
 
4.3.1 What are the optimal conditions for use of Badrilla phospho-hRyR2 
antibodies for assessment of phosphorylation levels by Western blotting?  
 
Western blots were prepared with hRyR2-transfected HEK293 cell homogenate samples and 
cut in half, down the marker lane such that the same samples were on each side of this same 
marker (Figure 4.2 A). Samples on the left side of the blot were probed for eGFP-hRyR2 
expression and samples on the right were probed for S2808-phosphorylated hRyR2. Clear 
signals were obtained with both antibodies. Blot images were overlaid using GBOX software to 
confirm the bands were of the same molecular weight. The right half of the blot was then 
stripped and reprobed (1 hour) for eGFP-hRyR2 expression (lower panel). The lack of native 
mouse control (CONT) present in the lower panel indicates that the strip was successful. Even 
under harsh membrane stripping conditions (i.e. 10 % (w/v) SDS at 50 °C), signal intensities for 
eGFP-hRyR2 were strong and reliable as seen previously in this laboratory (George et al. 2004; 
Thomas et al. 2004).  
 
Probing samples with the pAb-S2030 proved much more difficult (Figure 4.2 B, see Appendix 
VIII for further blots). In contrast to results with pAb-S2808, no signal for phosphorylated hRyR2 
was detected after 1 hour incubation with the antibody. Instead, overnight incubation was 
required. The antibody did not produce a clean signal, picking up bands at disparate molecular 
weights, not corresponding that of hRyR2 (see Figure 4.2 B centre panel). The control signal 
also appeared weak and in other blots, no signal was detected (Appendix VIII). It was difficult 
to assess which band corresponded to S2031-phosphorylated hRyR2 until after stripping and 
reprobing with the more reliable GFP antibody and comparing the molecular weights of the 
signals using GeneTools software. It took a total of 17 attempts to obtain n=4 of suitable blots 
for subsequent experiments.  
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Figure 4.2 Optimization of stripping conditions for probing with phospho-RyR2 antibodies. A. 
Samples on the left side of the blot were probed for eGFP-hRyR2 expression and samples on the right 
were probed for S2808-phosphorylated hRyR2 (upper panel). The right half of the blot was stripped and 
reprobed (1 hour) for eGFP-hRyR2 expression (lower panel). B. A Samples on the left side of the blot 
were probed for eGFP-hRyR2 expression and samples on the right were probed for S2031-
phosphorylated hRyR2 (upper panel). Signal for pS2031 was poor, but incubation overnight in antibody 
produced a better signal (centre panel) though the CONT signal appears very weak. The right half of the 
blot was stripped and reprobed (1 hour) for eGFP-hRyR2 expression (lower panel). For both stripped 
blots, the lack of native mouse control (CONT) present in the lower panels indicates that the strip was 
successful.  
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4.3.2 Does Western blot analysis with phospho-antibodies reveal differences in 
basal phosphorylation between mutant and WT RyR2 at S2808 and S2031? 
 
WT and mutant hRyR2 cell homogenate preparations were analysed by Western blotting at 
loads of 50 μg and 100 μg. Although 50 µg loads were assessed, protein expression levels were 
analysed only at 100 µg of loading, for reasons discussed in Section 3.3.1. While original blots 
can be found in Appendix I, VII and VIII, blots in Figures hereafter have been spliced to show 
only 100 µg loads for this reason. Antibody signals that were compared to each other were only 
on the same blot.  
 
Densitometric analysis was used to assess the level of phosphorylation at S2808 and S2031 
sites in WT and mutant hRyR2 channels. The signal detected from cell homogenate samples by 
these phospho-specific antibodies was expressed as a proportion of the signal for eGFP-hRyR2 
expression. This was obtained by stripping membranes and reprobing with an anti-GFP 
antibody. A comparison is made within the same lane but with a different antibody and so this 
would make the use of a loading control redundant, as even if different amounts were loaded for 
WT and mutant hRyR2-transfected cell homogenate samples, normalization in this instance 
would account for it. 
 
Using this method of densitometric analysis, basal phosphorylation at the S2808 site of hRyR2 
appears increased in both S2246L and N4104K hRyR2 cell homogenate preparations in 
comparison to WT (Figure 4.3). In fact, S2808 phosphorylation of S2246L hRyR2 appeared to 
be approximately 4x that of WT, significant by one way ANOVA with Bonferroni posthoc test 
(p<0.01) while N4104K S2808 phosphorylation levels appear roughly 2x that of WT, but due to 
variation in the dataset, the increase is not significant.  
 
Basal phosphorylation at the S2031 site of hRyR2 appears decreased in both S2246L and 
N4104K hRyR2 cell homogenate preparations in comparison to WT (Figure 4.4). 
Phosphorylation levels at S2031 are ~half that of WT in S2246L-transfected cells (p<0.05), 
while levels are approximately a quarter of that of WT in N4104K-transfected cells (p<0.01). 
However, it was very difficult to obtain blots suitable for analysis when probing with pAb-S2030, 
(see Section 4.3.1). The antibody also often led to an inaccurate signal on chemiluminescence 
(discussed in Section 4.4.1 and see Appendix VIII) and while the significant differences appear 
to be robust, the reliability of the antibody must therefore be considered when interpreting these 
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data. This antibody also does not always give a signal for the native mouse control (CONT), yet 
signal is seen for hRyR2-transfected homogenate samples. 
 
For this data set, it should be kept in mind that normalization of expression levels may have 
influenced these results, especially where n numbers are low. Protein load of mutant hRyR2-
transfected cells was first normalized based on transfection efficiency in comparison to that of 
WT-transfected cells (see Section 3.3.1). Expression level of phospho-hRyR2 and total hRyR2 
was also normalized to WT hRyR2 expression level, loading control expression level, or the 
expression level before treatment with DcAMP. It remains that these normalizations leave room 
for uncertainty and potential error, especially in the case of the pSer-2030 antibody and data 
with N4104K.  
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Figure 4.3 Western blot analysis of hRyR2-transfected HEK293 cells with phospho-antibodies reveals that basal phosphorylation at the 
S2808 is increased in S2246L. A. Representative protein bands achieved from Western blot analysis of 100 μg cell homogenate from HEK293 
cells expressing WT, S2246L or N4104K hRyR2. Samples were first assessed for S2808-phosphorylated hRyR2 expression (left) before 
membrane stripping and assessment of eGFP-hRyR2 expression (right). L refers to ladder of defined MW proteins. CONT refers to 100 μg of 
mouse cardiac SR preparation. All original and additional Western blots are found in Appendix VII. B. Anti-pS2808 hRyR2 signal was normalized 
to the equivalent anti-GFP signal. Densitometric analysis revealed that S2246L signals were significantly higher than WT. Data are displayed as 
mean ± SEM and were analysed by one way ANOVA with Bonferroni posthoc test in GraphPad Prism, p <0.001 indicated by ***, n=4 experiments. 
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Figure 4.4 Western blot analysis of hRyR2-transfected HEK293 cells with phospho-antibodies reveals that basal phosphorylation at the 
S2031 site is decreased in both S2246L and N4104K. A. Representative protein bands achieved from Western blot analysis of 100 μg cell 
homogenate from HEK293 cells expressing WT, S2246L or N4104K hRyR2. Samples were first assessed for S2808-phosphorylated hRyR2 
expression (left) before membrane stripping and assessment of eGFP-hRyR2 expression (right). L refers to ladder of defined MW proteins. CONT 
refers to 100 μg of mouse cardiac SR preparation. All original and additional Western blots are found in Appendix VII. B. Anti-pS2030 hRyR2 
signal was normalized to the equivalent anti-GFP signal. Densitometric analysis revealed that S2246L and N4104K signals were significantly lower 
than WT. Data are displayed as mean ± SEM and were analysed by one way ANOVA with Bonferroni posthoc test in GraphPad Prism, p <0.001 
indicated by ***, n=4 experiments. 
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4.3.3 Does treatment with DcAMP affect the PKA-mediated phosphorylation level 
of recombinantly expressed WT and mutant hRyR2? 
 
In this experiment, cells from one transfection each for WT, SL and NK were split into several 
groups of dishes and treated with different concentrations of DcAMP or vehicle (DMSO). Since 
each treatment/control group was from the same transfected population for each construct, all 
should have the same eGFP-hRyR2 expression. With this being the case phosphorylated 
hRyR2 signals were normalized to the vinculin loading control, eliminating the need for stripping 
membranes, as the two proteins of interest are of different molecular weight. 
 
For WT hRyR2 (Figure 4.5), phosphorylation at the S2808 site increases as the concentration 
of DcAMP increases. In comparison to cells treated with DMSO alone, 100 µM cAMP, 1 mM 
DcAMP and PKA-treated positive control samples have significantly higher levels of S2808-
phosphorylated hRyR2 as calculated by one way ANOVA with Bonferroni posthoc test, p<0.05. 
 
In both S2246L and N4104K-hRyR2 transfected HEK293 cells (Figure 4.6 and 4.7), DcAMP 
treatment does not increase phosphorylation in the same manner. While it appears that 1 mM 
DcAMP and treatment with PKA (treatment of microsomes from the same transfection with the 
enzyme to achieve maximum phosphorylation, acting as a positive control) increases S2808-
hRyR2 phosphorylation levels in the samples, these increases are not statistically significant. 
 
Assessment of phosphorylation at the S2031 site of hRyR2 was not carried out due to issues 
encountered with the pAb-S2030 antibody, discussed in Section 4.3.1 and 4.4.1. There are no 
other commercially available antibodies that target this specific site. 
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Figure 4.5 Western blot analysis of DcAMP treated WT hRyR2-transfected HEK293 cells with the 
S2808 phospho-antibody. A. Samples prepared as in Section 4.2.2. were assessed for S2808-
phosphorylated hRyR2 expression (upper panel) and vinculin expression (lower panel). PKA refers to a 
PKA-treated sample, representing maximal phosphorylation. HEK refers to an untransfected HEK293 
sample, as a negative-RyR2 control. All original blots can be seen in Appendix X. B. S2808-
phosphorylated hRyR2 signal was normalized to that for vinculin in each lane. Densitometric analysis 
shows that S2808 phosphorylation increases significantly after treatment with 100 µM and 1 mM DcAMP. 
Data are displayed as mean ±SEM and statistical analysis was by one way ANOVA with Bonferroni 
posthoc in GraphPad Prism, p<0.05 indicated on the graph by *, p<0.01 by **, n=3. 
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Figure 4.6 Western blot analysis of DcAMP treated S2246L hRyR2-transfected HEK293 cells with 
the S2808 phospho-antibody. A. Samples prepared as in Section 4.2.2. were assessed for S2808-
phosphorylated hRyR2 expression (upper panel) and vinculin expression (lower panel). PKA refers to a 
PKA-treated sample, representing maximal phosphorylation. HEK refers to an untransfected HEK293 
sample, as a negative-RyR2 control. All original blots can be seen in Appendix XI. B. S2808-
phosphorylated hRyR2 signal was normalized to that for vinculin in each lane. Densitometric analysis 
shows that S2808 phosphorylation shows no significant differences after treatment with DcAMP 1 mM 
DcAMP. Data are displayed as mean ±SEM and statistical analysis was by one way ANOVA with 
Bonferroni posthoc in GraphPad Prism, p<0.05 indicated on the graph by *, p<0.01 by **, n=3. 
174 
 
 
 
Figure 4.7 Western blot analysis of DcAMP treated N4104K hRyR2-transfected HEK293 cells with 
the S2808 phospho-antibody. A. Samples prepared as in Section 4.2.2. were assessed for S2808-
phosphorylated hRyR2 expression (upper panel) and vinculin expression (lower panel). PKA refers to a 
PKA-treated sample, representing maximal phosphorylation. HEK refers to an untransfected HEK293 
sample, as a negative-RyR2 control. All original blots can be seen in Appendix X. B. S2808-
phosphorylated hRyR2 signal was normalized to that for vinculin in each lane. Densitometric analysis 
shows that S2808 phosphorylation shows so significant difference to control after treatment with DcAMP. 
Data are displayed as mean ±SEM and statistical analysis was by one way ANOVA with Bonferroni 
posthoc in GraphPad Prism, p<0.05 indicated on the graph by *, p<0.01 by **, n=3. 
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4.3.4 Which vehicle solvent for DcAMP is suitable for use in Ca2+ imaging 
experiments? 
 
Dose-dependent DcAMP stimulated phosphorylation of WT and mutant hRyR2 was assessed 
by Western blot using phosphospecific antibodies prior to functional studies. As a result, only 
concentrations of agonist which changed phosphorylation (i.e. 100 µM and 1 mM, see Section 
4.3.3) were used during Ca2+ imaging experiments.  
 
Although recommended by the manufacturer of DcAMP (Santa Cruz Biotechnology) as a 
vehicle for drug delivery, the effects of DMSO on Ca2+ imaging in HEK293 cells was assessed 
(Figure 4.8 A) as the use of this solvent is known to be problematic when used in this type of 
experiment. In > 90 % (n =77 of 85) of oscillating hRyR2-transfected HEK293 cells, a large 
increase in fluorescence was recorded approximately 20 seconds after the addition of DMSO 
(only) at 1 % (v/v) (2 µL in a KRH meniscus of 200 µL on a Mattek dish). No further oscillations 
were observed in the following 30 minutes after this increase in fluorescence, suggesting that 
DMSO was stopping SOICR or interfering with Fluo-3 dye and was therefore unsuitable for use 
in Ca2+ imaging experiments. It was not possible to use a smaller volume of DMSO in 
subsequent experiments, as DcAMP was already at its limit of solubility in this solvent.  
 
Methanol was also recommended by the manufacturers as a suitable solvent for DcAMP. The 
addition of methanol to a final volume equivalent to that required for the addition of 1 mM 
DcAMP in this solvent had no effect on Ca2+ release events observed in recordings of 600 sec 
after addition in 36/36 oscillating WT hRyR2-transfected HEK293 cells (Figure 4.8 B), 
suggesting it would be a more suitable vehicle for the delivery of DcAMP in these experiments.  
 
Oscillating cells were recorded for 60 seconds before the addition of DcAMP (reconstituted in 
methanol) at final concentrations of 100 µM (Figure 4.8 C) or 1 mM (Figure 4.8 D) and 
recorded for a further 600 secs in the presence of the agonist.  Upon treatment with 1 mM 
DcAMP in methanol, the spontaneous Ca2+ release in cells expressing WT hRyR2 remained 
unperturbed for ~2 min before a sudden, irreversible increase in fluorescence (examples shown 
in Figure 4.10 D), which was observed in ~75 % (n=64 of 88) of oscillating cells.  
 
Oscillating cells treated with 100 µM DcAMP in methanol appeared to change the initial Ca2+ 
transient after addition (increasing amplitude and or duration, see examples in Figure 4.8 C), in 
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38/103 hRyR2-transfected oscillating cell. The increased fluorescence observed in previous 
treatments was also seen in 54/103 hRyR2-transfected oscillating cells, at approximately 250 
seconds after addition (ROI1= 252 sec, ROI2=306 sec after addition, ROI3=no increase after 
addition, Figure 4.8 C). This therefore suggested that the DcAMP compound could be delivered 
to HEK293 cells in methanol, but that it was affecting Ca2+ release behaviour and stopping 
SOICR activity after longer periods of time or at a higher concentration. Spontaneous Ca2+ 
release events were subsequently recorded for 180 secs only and cells that exhibited a sharp 
upstroke in fluorescence were not included in analysis.  
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Figure 4.8 Testing of DMSO and methanol as vehicles for DcAMP drug delivery for WT hRyR2-
transfected cells in Ca2+ imaging experiments. HEK293 cells expressing WT-hRyR2 were assessed 
for changes in Ca2+ release after the addition of DcAMP solvents/concentrations. Three coverslips were 
observed for each experiment A. Addition of 2 µL DMSO (the volume equivalent for 100 µM DcAMP) at 
180 secs caused the cessation of Ca2+ oscillation, with an evident increase in fluorescence at ~200 secs 
(64 of 88 cells that oscillated). B. The addition of 4 µL methanol (the volume equivalent for 1 mM DcAMP) 
at 180 secs, caused no observable change in Ca2+ oscillation (36 of 36 oscillating cells). C. Addition of 
100 µM DcAMP in methanol at 60 secs, has no effect on the presence of Ca2+ oscillation in most cells (37 
of 46 cells) while some displayed an increase in fluorescence with no subsequent oscillations (9 of 46 
cells).  D. Addition of 1 mM DcAMP in methanol at 60 secs, results in an increase of fluorescence at ~250 
secs in approximately 80 % of oscillating cells (34 of 44 cells).  
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A cell viability assay was used to assess whether methanol itself, or DcAMP in methanol 
damaged cells after an incubation period of 30 minutes (Figure 4.9). No significant differences 
in viability between untreated cells and methanol only treated cells were detected. For cells 
transfected with each hRyR2 construct, 1 mM DcAMP in methanol decreases the cell viability 
significantly after 30 minutes, to <60 % (WT=36.3 ±4.1 %, S2246L=58 ±2.5 %, N4104K=39.7 
±2.7 %). A concentration of 100 µM DcAMP in methanol only significantly decreases viability in 
N4104K-transfected cells, to 75.3 ±5.2 %.  
 
Cumulatively, these data therefore suggest that the compound in methanol is damaging to cells 
at higher concentrations and after longer periods of incubation. A concentration of 100 µM 
DcAMP in methanol was decided as most appropriate to investigate in Ca2+ imaging 
experiments, with recording after treatment for three minutes only. 
 
 
Figure 4.9 Trypan blue cell viability assay suggests minimal toxicity of 2 % v/v methanol but 
significant cell death with 1mM DcAMP after 30 minutes’ incubation.  Untreated and methanol only 
treated cells transfected with each hRyR2 DNA plasmid showed no differences in cell viability WT=90.7 
±1.2 vs 89.0 ±1.0 %, SL=89.6 ±0.9 vs 90 ±0.6 %, NK=88.7 ±0.9 vs 89.7 ±1.2 %). However, 1 mM cAMP 
in methanol decreases the cell viability significantly after 30 minutes in comparison to methanol only 
treatment, to <60 % (WT=36.3 ±3.5 %, S2246L=58 ±2.5 %, N4104K=39.7 ±2.7 %). A concentration of 
100 µM cAMP in methanol decreases viability only in N4104K-transfected cells (75.3 ±5.2 %). Data are 
presented as mean ± SEM of n=3 wells per construct and treatment. Analysis was by one way ANOVA 
and Dunn’s posthoc test (data was calculated as normal by D’Agostino Pearson’s test), p<0.05 indicated 
on the graph by *, p<0.001 indicated by ***. 
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4.3.5 Is the propensity for Ca2+-induced Ca2+ release and store load of hRyR2-
transfected cells modified by the addition of DcAMP? 
 
D’Agostino-Pearson tests for normality found that the Ca2+ imaging data in this chapter were not 
normally distributed (see Appendix XIV) and so were analysed using non-parametric statistical 
tests.  
 
Post-hoc power analysis tests were also conducted using G*Power*3.19.2 software 
(www.gpower.hhu.de) to determine whether appropriate numbers of experiments were 
completed. In this Chapter, the results are paired i.e. any change in Ca2+ handling is a direct 
comparison of before and after treatment with DcAMP, therefore it would be inappropriate to 
compare treated cells to untreated cells from different experiments (other than for comparisons 
of ER load where this is unavoidable). All data sets (found in Appendix XV) were calculated as 
highly powered (≥80 %) and above the suitable threshold for detecting differences (Beck, 2013). 
 
The ER Ca2+ content was measured by determining the amplitude of the Ca2+ transient induced 
by application of caffeine (10 mM) as described in Section 3.2.1.5. While the ER Ca2+ content 
of cells expressing WT or N4104K was not altered, that of cells expressing S2246L-hRyR2 was 
significantly decreased after treatment with 100 µM DcAMP when compared to S2246L-hRyR2 
before treatment (Figure 4.10 B, Mann-Whitney test, p<0.01). However, in cells treated with 
DcAMP, those transfected with mutant hRyR2 (either S2246L or N4104K) both showed a 
significantly decreased store load when compared to the load of those transfected with WT 
hRyR2 (Figure 4.10 D, Mann-Whitney test, p<0.01).  
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Figure 4.10 Treatment with 100 µM DcAMP decreases the ER Ca2+ store load in cells expressing 
S2246L hRyR2. DcAMP refers to the addition of 100 μM dioctanoyl-cAMP. n WT=41, WT +DcAMP =64, 
S2246L=43, S2246L +DcAMP =31, N4104K=25, N4104K +DcAMP=48. Statistical significance calculated 
by Mann-Whitney with Dunn’s posthoc test, p<0.01 indicated by **. Scatter plots of these data are found 
in Appendix XVI.
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The propensity for Ca2+ oscillation was calculated by dividing the number of cells that 
spontaneously release Ca2+ by the total number of cells in a field of view. This parameter was 
not significantly altered after treatment with 100 µM DcAMP for each variant of hRyR2 (Figure 
4.11). Given that propensity differences between untreated WT and mutant hRyR2-transfected 
HEK293 cells were investigated previously (see Figure 3.13), data were normalized to 
propensity before drug additions.   
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.11 There is no significant alteration in the propensity for Ca2+ release after treatment of 
transfected cells with 100 μM DcAMP. Data were normalized to propensity for Ca2+ release before 
treatment and displayed as mean ± SEM. Total number of cells showing Ca2+ oscillations WT= 110 of 
609, WT+ DcAMP=117 of 609, S2246L=64 of 464, S2246L+ DcAMP=75 of 464, N4104K=43 of 424, 
N4104K+ DcAMP=43 of 424. Analysis by Mann-Whitney test in GraphPad prism, with no significant 
differences calculated between no treatment and treatment for each construct.  
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4.3.6 Are the kinetic parameters of Ca2+ release altered after treatment with 
DcAMP? 
 
As in the previous Chapter, spontaneous Ca2+ release event kinetics were analysed with 
SALVO software. Figure 4.12 shows representative traces for WT and mutant-expressing 
HEK293 cell, illustrating the altered Ca2+ handling seen on the addition of 100 µM DcAMP. 
Although the representative traces, appear to show a shift in baseline fluorescence after the 
addition of DcAMP, no significant differences were found when these data were analysed 
(Figure 4.13). 
 
An in-depth analysis of Ca2+ oscillation events is presented as a series of bar graphs and dot 
plots in Figure 4.14, 4.15 and 4.16, with Ca2+ handling kinetic parameters calculated as 
described in Section 3.2.1.4 with SALVO analysis software.  
 
Table 4.2 summarizes the differences in calcium handling parameters between WT and mutant 
RyR2 transfected HEK293 cells on treatment with 100 µM DcAMP, displayed in bar graphs in 
Figures 4.14, 4.15 and 4.16. It is apparent that DcAMP treatment of WT transfected cells 
decreases the amplitude and rate up, as well as increases the duration and decreases the rate 
down of Ca2+ release. However, treatment of mutant-hRyR2 transfected HEK293 cells leads to 
fewer differences in Ca2+ release. Both S2246L and N4104K hRyR2-transfected HEK293 cells 
display decreased Ca2+ release amplitude and rate up, as well as a decreased rate down in 
response to DcAMP. For a summary table that compares all Ca2+ release kinetics to untreated 
WT-hRyR2 HEK293 kinetics, (as opposed to the untreated equivalent) see Appendix XX.  
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Figure 4.12 Representative fluorescence traces of hRyR2-transfected HEK293 cells, treated with 
100 μM DcAMP. Red arrows indicate time of addition of DcAMP (in methanol).  
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Figure 4.13 Changes in baseline fluorescence of WT and mutant hRyR2-transfected HEK293 cells 
are not induced by the addition of DcAMP.   Baseline fluorescence (F0) was calculated as described in 
Section 3.2.1.4. DcAMP refers to the addition of 100 μM dioctanoyl-cAMP. n WT=110, WT+ 
DcAMP=117, SL=64, SL+ DcAMP=75, NK=43, NK+ DcAMP=43. Data are presented as mean ± SEM, 
with no significant differences calculated by Mann-Whitney analysis with GraphPad Prism. Scatter plots 
can be found in Appendix XIII.
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Figure 4.14 Assessment of spontaneous Ca2+ release events in WT hRyR2-expressing HEK293 
cells before and after treatment with DcAMP. All parameters were calculated as described in Section 
3.2.1.4. DcAMP refers to the addition of 100 μM dioctanoyl-cAMP. n WT=110, WT+ DcAMP=117. Data 
are presented as mean ± SEM, p<0.05 is denoted by *, p<0.01 as ** and p<0.001 as ***, calculated by 
Mann-Whitney analysis with GraphPad Prism. Scatter plots can be found in Appendix XVII.
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Figure 4.15 Assessment of spontaneous Ca2+ release events in S2246L hRyR2-expressing HEK293 
cells before and after treatment with DcAMP. All parameters were calculated as described in Section 
3.2.1.4. DcAMP refers to the addition of 100 μM dioctanoyl-cAMP. n SL=64, SL+ DcAMP=75. Data are 
presented as mean ± SEM, p<0.05 is denoted by *, p<0.01 as ** and p<0.001 as ***, calculated by Mann-
Whitney analysis with GraphPad Prism. Scatter plots can be found in Appendix XVIII.
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Figure 4.16 Assessment of spontaneous Ca2+ release events in N4104K hRyR2-expressing 
HEK293 cells before and after treatment with DcAMP. All parameters were calculated as described in 
Section 3.2.1.4. DcAMP refers to the addition of 100 μM dioctanoyl-cAMP. n NK=43, NK+ DcAMP=43. 
Data are presented as mean ± SEM, p<0.05 is denoted by *, p<0.01 as ** and p<0.001 as ***, calculated 
by Mann-Whitney analysis with GraphPad Prism. Scatter plots can be found in Appendix XIX. 
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Table 4.2 Summary of Ca2+ handling parameters in WT and mutant hRyR2-transfected HEK293 cells. Mean values for calcium handling 
parameters of WT and mutant hRyR2-expressing HEK cells, ± SEM. Differences are calculated compared to the equivalent parameter in hRyR2-
expressing HEK293 cells before treatment i.e. data is paired. Red indicates a statistically significant increase whereas blue indicates a statistically 
significant decrease as calculated by Mann-Whitney or Kruskal-Wallis with Dunn’s/Bonferroni post hoc test, p<0.01. 
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4.3.7 Does DcAMP treatment result in compensatory changes in the expression of 
SERCa?  
 
Given the changes in ER Ca2+ store identified in S2246L hRyR2-transfected HEK293 cells after 
treatment with DcAMP, as well as changes in amplitude and rate of Ca2+ release upon treatment 
of WT and mutant hRyR2-transfected HEK293 cells, it was important to assess the expression 
of SERCa. Any changes in expression levels of this protein could affect the amount of Ca2+ 
sequestered into the store and available for subsequent Ca2+ release events. Western blots 
were not probed for other proteins that modify the store load (CSQ, SERCa) as they are not 
thought to be present in HEK293 cells (Kurzydlowski 1996; Asahi et al. 2003; Toyofuku et al. 
1994). 
 
The expression of SERCa was determined for cells expressing WT or mutant hRyR2 incubated 
for 30 min in the presence or absence of 1 mM DcAMP (Figure 4.17). This concentration was 
chosen as it altered phosphorylation levels at S2808 in WT hRyR2 transfected cells. The signal 
intensity of bands was normalized to β-tubulin expression in the same lane as a loading control 
as described in Section 3.3.1. Densitometric analysis revealed no significant differences in 
SERCa expression of WT or mutant cell homogenate preparations after treatment with DcAMP 
(Figure 4.19 B, student’s t test). No significant differences were seen in SERCa expression 
between WT and mutants before treatment (as in Chapter 3), or between WT and mutants after 
treatment, as calculated by one-way ANOVA. There will be further discussion of SR related 
proteins (including PLB and CSQ2) and their modification in these experiments in the discussion 
section of this chapter. 
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Figure 4.17 Assessment of cell homogenate from WT and mutant hRyR2-transfected HEK293 cells reveals no significant difference in 
SERCa expression after treatment with 1 mM DcAMP. A. Representative bands of SERCa and β-tubulin signal of transfected HEK293 cells 
treated with DMSO only, (WT, SL and NK lanes), and of cells treated with 1 mM dioctanoyl-cAMP in DMSO (+DcAMP lanes). L refers to protein 
ladder. Original and additional blots can be found in the Appendix B. Densitometric analysis of SERCa signal normalized to β-tubulin expression, 
n= 2-4 experiments (WT, SL and NK bands from 4 blots, +DcAMP from 2 blots). Data are displayed as mean ± SEM. No significant differences 
were detected before or after treatment by t test in GraphPad Prism. 
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4.4 Discussion 
 
Major chapter findings include: 
• Mutant hRyR2s show different basal levels of phosphorylation in comparison to WT at 
S2808 and S2031 sites 
• DcAMP has a limited effect on the S2808 phosphorylation status of mutant hRyR2. This 
implies that S2808 phosphorylation plays little or no role in influencing channel function 
• DcAMP may not be suitable as an analogue to elicit endogenous PKA phosphorylation 
of hRyR2 in Ca2+ imaging experiments  
  
4.4.1 Is the Badrilla phospho-S2030 RyR2 antibody reliable? 
 
Probing cell homogenate samples with commercially available pS2808 RyR2 antibody (Badrilla) 
gave strong, clear signals for phosphorylated hRyR2 protein (Figure 4.2 A and 4.3). The 
antibody appears specific and reliable, could be applied to blots at lower dilutions than the pSer-
2030 antibody (1: 5,000 as opposed to 1: 1,000) and bands could be visualized after only one 
hour of primary antibody incubation. Probing with the pSer-2030 antibody, produced by the 
same manufacturer, was not so successful (Figure 4.2 B). PVDF membranes required at the 
minimum overnight incubation in primary antibody and often, no signal was detected by 
chemiluminescence. It took 17 separate attempts to obtain blots for n=4 (an unworkable ~24% 
success rate) because signal was so poor (see Figure 4.4 and Appendix VII).  
 
According to the CiteAb website (www.citeab.com) and a search of the literature, the pS2030 
RyR2 antibody has only one citation (Beca et al. 2012). This is in comparison to 56 citations for 
the pS2808 RyR2 antibody, also produced by Badrilla. In the publication by Beca et al. (2012), 
antibody signal for the assessment of S2030-phosphorylated RyR2 in mouse heart lysate shows 
no non-specific background. This is in complete contrast to antibody signal identified by 
chemiluminescence in the many assessed for this Chapter. In each of these experiments, a 
native mouse control (although a cardiac SR preparation, rather than homogenate as in Beca et 
al. (2012)) was also included and in 2/4 cases no signal was exhibited under 
chemiluminescence for this preparation. While this control was a cardiac SR preparation, rather 
than a homogenate preparation as in Beca et al. (2012), the mouse species was the same. This 
is suggestive that the lack of signal is not because hRyR2-transfected homogenate cell samples 
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come from a recombinant source and that they aren’t phosphorylated because of an absent 
kinase. Conversely, this could suggest that mouse RyR2 isn’t phosphorylated at S2030, but this 
is highly unlikely given the body of evidence supporting phosphorylation at this site in mouse 
studies (Huke and Bers 2008; Xiao et al. 2006; Xiao et al. 2005; Jones et al. 2008). 
 
Supplementary data in Beca et al. (2012) does not indicate any differences in antibody 
incubation, other than the use of milk in PBS as opposed to TBS-T. Manufacturers do not 
specify which buffer diluent is appropriate. There appears to be no indication in the literature as 
to why PBS-T would be advantageous over TBS-T. As well as experimental differences 
mentioned above, method of transfer may also account for differences, but it is not evident in 
the manuscript how this was achieved.  
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4.4.2 Mutant hRyR2s show different levels of basal phosphorylation in 
comparison to WT at S2808 and S2031 sites 
 
The level of basal phosphorylation of RyR2 and therefore the scope for subsequent change in 
phosphorylation level has often been investigated as an indicator of the functional relevance of 
phosphorylation at a particular site. As with much of the research surrounding the role of 
phosphorylation in physiological and pathological RyR2 Ca2+ release, reports are often disputed. 
Previously, discrepancies between data of groups investigating the phosphorylation status of 
RyR2 have been partly attributed to the unaccounted activity of phosphatases (Reiken et al. 
2003). Given that HEK293 cell lysis releases phosphatases from the cytosol that may degrade 
phosphorylation at specific sites of RyR2, serine/threonine phosphatase inhibitors NaVO4 and 
NaF were included in all preparations for Western blotting.  
 
A RyR2 channel exists as a tetramer with available phosphorylation sites on each of the four 
subunits (Lai et al. 1989). Some channels within a population may have none of four specific 
sites in a tetramer phosphorylated, while other channels may have all of the four sites 
phosphorylated, and other channels may have a combination of 
phosphorylated/unphosphorylated subunits. Therefore, basal phosphorylation signal in this 
Chapter is a mean for a population of RyR2 channels. 
 
4.4.2.1  Basal phosphorylation of S2246L vs. WT hRyR2 
 
In the assessment of S2808-hRyR2 phosphorylation, S2246L-transfected cells had a basal 
phosphorylation level approximately 4x that of WT-transfected cells, calculated as statistically 
significant (see Figure 4.3 and Appendix VI).  
 
Given that S2246L-hRyR2 transfected HEK293 cells do not appear dysfunctional under basal 
conditions, nor as isolated single channels in a minimal environment of no cytosolic or luminal 
Ca2+ (see Figure 3.4), it is interesting that they exhibit very high basal phosphorylation levels at 
the S2808 site in comparison to WT. These data can be interpreted in many ways. One 
hypothesis is that subsequent further phosphorylation at this site is irrelevant as a means of 
increasing RyR2 channel activity, given it is already substantially phosphorylated, equivalent to 
maximal phosphorylation levels achieved with PKA treatment.   
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The S2246L mutation is also located in close proximity to the phosphorylation domain of the 
channel (see Figure 1.15). Valdivia argues that clean targeting of RyR2 phospho-epitopes by 
kinases is an oversimplification of a complex mechanism of channel regulation by 
phosphorylation (2012). He suggests that phosphorylation of one site in the phosphorylation 
domain could lead to functional redundancy i.e. phosphorylation of one residue within this 
hotspot of different sites may be undistinguishable by the channel’s gating domains. S2811 has 
been identified as a potential phosphorylation site in RyR2 and in particular is very close to the 
S2808 site (Yuchi et al. 2012; Huttlin et al. 2010). It would not be unreasonable to suggest that 
phosphorylation of S2808 may confer the same effects of phosphorylation at a site four amino 
acids downstream. Also, it may not be unreasonable to suggest that the S2246L mutation itself 
could confer effects or disrupt interactions of the nearby phosphorylation domain, and may 
account for increased baseline phosphorylation levels observed in this chapter. In a previous 
study of mouse S2246L RyR2, the mutation has been reported to induce an abnormally tight 
local subdomain interaction within the central domain involving the mutation site (Suetomi et al. 
2011). This in turn induces a defective interaction between the N-terminal and central-domain 
and was suggested to explain the increase in cAMP-dependent spark frequency of saponin-
permeabilized S2246L KI cardiomyocytes and VT observed in KI mice after exercise.  
 
While basal phosphorylation levels are high in comparison to WT hRyR2, it also remains that 
very modest alterations in phosphorylation at this site within S2246L hRyR2 may be enough to 
elicit increased channel activity as observed in β-adrenergic stimulation. It was only upon 
treatment with PKA that single channels displayed an altered activity in comparison to WT in 
work of Wehrens et al. (2003).  
 
In the assessment of S2031-hRyR2 phosphorylation, S2246L-transfected cells had a basal 
phosphorylation level approximately 0.5x that of WT-transfected cells, calculated as significantly 
different (see Figure 4.4 and Appendix VII). While differences appear robust in this 
assessment of basal phosphorylation of WT and mutant hRyR2 with small errors (WT=1.712 
±0.34, S2246L=0.7708 ±0.15, N4104K=0.5117 ±0.02), the reliability of the pS2030 antibody 
should be taken into consideration and any interpretation based on these results made with 
caution.  Dephosphorylation by protein phosphatases may also elicit a change in activity, given 
such high basal phosphorylation. This posttranslational modification has been evidenced as 
upregulated in many disease settings {Terentyev:2016jf}. Carter et al. (2006, 2011) have shown 
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that WT single channel Po can be increased by either the action of PKA or by PP1 on the S2808 
site. Perhaps dephosphorylation of S2031 could also increase mutant hRyR2 Po.  
 
4.4.2.2  Basal phosphorylation of N4104K vs. WT hRyR2 
 
In contrast to S2246L, N4104K hRyR2 channels do not display a significant increase in basal 
S2808 phosphorylation in comparison to WT hRyR2 in HEK293 cells, yet in Ca2+ imaging 
experiments, transfected cells appear dysfunctional without further stimulation. This is 
suggestive that dysfunctional Ca2+ release in HEK293 cells by N4104K mutant hRyR2 channels 
is not necessarily caused by altered basal phosphorylation of hRyR2 at S2808, or that it only 
requires a modest change in phosphorylation level at this site to elicit a functional change. It 
could also point to lack of functional relevance of this site, given that channel dysfunction is 
observed without any significant change in phosphorylation levels. The N4104K mutation itself 
is located within the EF hand domain, far away from the phosphorylation (P) domain and the 
S2808 site (Figure 1.16). Dysfunction of N4104K may be caused by disrupted interdomain 
interactions of the C-terminal domain and an unidentified domain, as discussed in Section 
1.7.4.2 (Suetomi et al. 2011; Uchinoumi et al. 2010). Given that the phosphorylation domain is 
not part of these inter-domain interactions and is located within the central region of the RyR2 
polypeptide, it may be that phosphorylation of these sites does not equate to alteration of 
function in what is already a dysfunctional channel. This hypothesis is somewhat supported by 
the data of Tester et al. (2007), where authors found that RyR2 channels with a mutation 
located in the C-terminal domain (S4546R) displayed higher Po in comparison to WT in basal 
conditions (in the absence of PKA), with enhanced sensitivity to cytosolic Ca2+. Further 
phosphorylation by PKA did not further increase Po during single channel Ca2+ activation.   
 
A clear finding of these data is that increased basal S2808 phosphorylation in mutant hRyR2 
channels expressed in HEK293 cells does not seem to equate to Ca2+ release dysfunction. 
S2246L, a CPVT1 hRyR2 mutant that displays similar Ca2+ release events to WT in the absence 
of PKA stimulation, has a significantly higher basal phosphorylation at the S2808 site. 
Meanwhile, N4104K, a CPVT1 mutant that displays dysfunctional Ca2+ release events in the 
absence of PKA stimulation, does not show increased basal phosphorylation at S2808. 
 
N4104K hRyR2 channels also displayed a decreased basal phosphorylation level at S2031, at 
approximately 0.25x that of WT hRyR2.  N4104K hRyR2 channels are dysfunctional in a 
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minimal environment in single channel experiments, as well as in the Ca2+ imaging experiments 
shown in this study. It could be that lower basal phosphorylation levels at S2031 lead to mutant 
channel dysfunction in this instance, thereby implicating dephosphorylation in the regulation of 
channel activity.  
 
Conversely, the data may suggest that the S2031 site is of little functional relevance in N4104K 
mutant hRyR2 channels, or in fact any hRyR2 channel.  Basal phosphorylation at the S2031 site 
in S2246L hRyR2 is also significantly lower than WT, yet the channel appears much like WT in 
both single channel experiments in minimal conditions and during Ca2+ imaging experiments 
without the addition of any kinases. Work of the Marks group, also using recombinant RyR2, 
showed a PKA-mediated increase in the Po of WT S2031A (not phosphorylatable) channels 
similar to that of WT, while untreated S2031D channels (fully phosphorylated) displayed a low 
Po in single channel experiments in comparison to WT channels treated with PKA 
{Wehrens:2006fq}. These data challenge the functional relevance of increased phosphorylation 
at the S2031 site and either point towards enhanced channel activity as a result of 
dephosphorylation (given that N4104K hRyR2 is dephosphorylated to a greater extent than WT 
or S2246L), or as a result of PKA phosphorylation at another site.  
The methodology used to assess basal phosphorylation in this Chapter however does not 
identify whether these phosphorylation sites are PKA-specific and therefore direct targets during 
β-adrenergic stimulation, during which CPVT1 pathogenesis in patients is revealed.  
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4.4.3 The effects of DcAMP treatment on the phosphorylation level of WT hRyR2-
transfected HEK293 cells 
 
Both S2808 and S2031 phosphorylation sites have been implicated in enhanced RyR2 channel 
activity during β-adrenergic stimulation, although the functional relevance of both sites remains 
controversial (Marx et al. 2000; Huke and Bers 2008; Dobrev and Wehrens 2014; Bers 2012; 
2012; Xiao et al. 2006). Therefore, simulating β-adrenergic stimulation by treatment of RyR2 
channels with PKA may reveal enhanced or altered channel activity at either or both suggested 
sites.   
 
The cAMP analogue DcAMP was chosen as a method of hRyR2 phosphorylation in this setting. 
DcAMP activation of endogenous PKA within a HEK293 cell and subsequent Western blot 
analysis of S2808 phosphorylation levels could reveal whether the S2808 site is in fact a target 
of PKA phosphorylation.  
 
A control hRyR2 sample, exogenously treated with the PKA enzyme (following the protocol of 
Rodriguez et al. (2003)) was included in Western blot experiments to demonstrate maximum 
phosphorylation levels. Given cells are lysed and homogenized, PKA can access hRyR2 
channels in prepared sample easily. A negative control i.e. fully dephosphorylated sample was 
unable to be obtained due to the methods of lysis and protein preparation used. To obtain a 
negative control for these experiments, cell homogenate from the same transfection would need 
to be treated with alkaline phosphatase. However, the lysis buffer used throughout this thesis 
incorporates phosphatase inhibitors, which prevent alkaline phosphatase from working.  
 
Unfortunately, given the poor signal obtained when using the pS2030 antibody, investigation of 
PKA-mediated phosphorylation at the S2031 site was not investigated. Research groups 
consistently report that basal phosphorylation of WT at the S2031 site is low (Huke and Bers 
2007; Cooper et al. 2013; Belevych et al. 2011). This may still apply to these data, as the 
maximally phosphorylated PKA-treated WT sample was not investigated using the pS2030 
antibody in this thesis given its caveats.  
 
Densitometric analysis shows that S2808 phosphorylation increases as DcAMP increases in 
this setting (Figure 4.5). Concentrations of 100 µM and 1 mM elicited significant increases in 
S2808 phosphorylation level of WT hRyR2 in comparison to DMSO (control) treatment. The 
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increase in phosphorylation level was ~x6 that of control sample. This WT PKA control also 
displays an increased hRyR2 phosphorylation level at S2808 compared to control.  
 
Such a large increase in S2808 phosphorylation of WT hRyR2 not only signifies that PKA does 
in fact phosphorylate hRyR2 at this site, but that basal phosphorylation levels must be low or 
moderate in HEK293 cells to allow for such a change. This is in contrast to published studies, 
where basal phosphorylation levels of WT RyR2 isolated from sheep hearts have been reported 
as high as 75 % of stoichiometry (Carter et al. 2006). Many groups have reported that basal 
phosphorylation at the S2808 site in WT RyR2 is substantial in rat, mouse and rabbit 
cardiomyocytes, to at least 50 % of full stoichiometry (Huke and Bers 2008; Rodriguez et al. 
2003; Xiao et al. 2005; Currie et al. 2004; Benkusky et al. 2007). Carter el al. (2006) suggest 
that higher levels of phosphorylation at this site ‘optimizes channel control’ by phosphorylation 
or dephosphorylation, allowing for dramatic changes in function after stimulation with PKA. This 
implicates the action of not only kinases but phosphatases at this site and suggests that modest 
alterations in basal phosphorylation levels may elicit functional change (Terentyev and Hamilton 
2016; Carter et al. 2011; Carter et al. 2006). Others have argued that phosphorylation at the 
S2808 site is categorically not implicated in enhanced dysfunctional RyR2 channel activity 
observed in HF and is suggestive also that this site is not implicated in CPVT1 dysfunction 
(Houser 2014; Xiao et al. 2006). 
 
As discussed previously, these experiments are most often based on RyR2 channels isolated 
from cardiomyocytes in comparison to HEK293 cells. It could be suggested that data presented 
in this thesis are more pertinent in terms of physiological RyR2 phosphorylation in human 
disease, given that experiments are with hRyR2 as opposed to animal RyR2. However, animals 
have a physiological PKA response, whereas in this instance, this response is imposed in a 
recombinant RyR2 channel. This finding therefore may be a result of the in vitro environment, as 
other assessments of basal phosphorylation have involved different animal models and RyR2 
isolation from a cardiomyocyte, rather than a heterologous cell system that is devoid of other 
cardiac proteins that cycle Ca2+ in and out of the cell in the same manner {Bers 2008; Rodriguez 
et al. 2003; Xiao et al. 2005; Currie et al. 2004; Benkusky et al. 2007). The type and extent of 
post translational processing, including phosphorylation, is therefore likely to vary between cell 
types and endogenous levels of kinase may vary that could potentially phosphorylate RyR2 at 
this site. The level of basal phosphorylation could also be antibody dependent, given that 
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groups often use ‘in house’ as opposed to commercially available antibodies (Rodriguez et al. 
2003; Xiao 2004; Wehrens et al. 2003; Huke and Bers 2008; Eschenhagen 2010).  
 
It should also be noted that FKBP12.6 is not endogenous to HEK293 cells and therefore does 
not form a macromolecular complex with transfected hRyR2 in these cells. The contribution of 
FKBP12.6 also remains disputed, with some groups finding depletion from the RyR2 
macromolecular complex is key to enhanced channel activity while others do not (Marx et al, 
2000; Wehrens et al. 2006; Fauconnier et al. 2010; Wehrens et al. 2003; Kushnir et al; 2010; 
Guo et al. 2006; Shan et al. 2010). Given the evidence that suggests FKBP12.6: RyR2 
interaction is irrelevant to RyR2 channel function, especially in terms of CPVT1 (George et al. 
2003; Zissimopoulos et al. 2009), this was not investigated in this thesis.   
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4.4.4 DcAMP-mediated changes in Ca2+ release kinetics of WT hRyR2-transfected 
HEK293 cells 
 
Western blot analysis of the effects of varying concentrations of DcAMP informed the choice of 
100 µM to be used in Ca2+ imaging experiments, given that this was the lowest concentration to 
elicit a significant change in WT hRyR2 phosphorylation at the S2808 site. There was no 
change in the propensity of WT or mutant hRyR2-transfected HEK293 cells for Ca2+ release 
events after treatment with DcAMP (Figure 4.11). This was surprising given that the Chen 
group propose altered propensity for Ca2+ release as a marker of enhanced channel activity in 
CPVT1 mutant RyR2 channel dysfunction (Jiang et al. 2007; Jiang et al. 2010; Jiang et al. 2004; 
Jiang 2005), Arguably, this should not be utilized as a marker of enhanced hRyR2 channel 
activity in disease or conditions of stress or exercise, as discussed in Section 3.1.2.2. 
 
As previously mentioned, it is difficult to interpret changes in Ca2+ release parameters in the 
absence of information of Ca2+ fluxes across the cell. However, treatment of WT hRyR2-
transfected HEK293 cells with DcAMP did lead to measurable changes in kinetics of Ca2+ 
release. The amplitude, rate up and rate down of Ca2+ release events were significantly 
decreased. The net result of these changes is a longer duration of release (Figure 4.14). The 
decreased rate down is indicative that it takes longer for Ca2+ release to terminate from the 
PKA-phosphorylated RyR2 population. It could also be that sensitivity either to luminal Ca2+ 
concentration, cytosolic Ca2+ concentration or both concentrations is altered, given that the ER 
load for DcAMP treated WT hRyR2-transfected HEK293 cells is decreased. Luminal Ca2+ 
sensitivity of single RyR2 mouse channels has previously been reported as altered after PKA 
phosphorylation (Ullrich et al. 2012). In the Chen hypothesis of SOICR, authors suggest that 
mutations in RyR2 increase the occurrence of SOICR and the frequency of Ca2+ oscillation, as 
well as reduce the store Ca2+ content (Jiang et al. 2004). As SOICR is triggered by SR Ca2+ 
overload, or rather, a reduced threshold for Ca2+ release, it is likely that CPVT1 RyR2 mutations 
alter the channel sensitivity to activation by luminal Ca2+. Taken together, Chen and colleagues 
suggested that RyR2 luminal Ca2+ sensitivity is a critical determinant of the threshold for SOICR 
and consequently for the SR Ca2+ content. The amplitude of Ca2+ release events in experiments 
here after treatment of cells with DcAMP also decreases, possibly indicating a small decrease in 
ER Ca2+ store due to leak that cannot be observed as spontaneous Ca2+ release. A decreased 
amplitude with longer duration and no change in frequency could suggest a change in wave 
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propagation or a change in Ca2+ buffering within the cell. However, for WT hRyR2-transfected 
cells, the store is not decreased after treatment with DcAMP.    
 
It is also interesting that the changes in amplitude, rate up and rate down upon treatment of WT 
hRyR2-transfected HEK293 cells with DcAMP are similar to those changes in Ca2+ imaging 
experiments upon introduction of the N4104K mutation to hRyR2 in Chapter 3 (see Figure 3.14 
and Table 3.6). Perhaps these changes that lead to the enhanced WT hRyR2 activity during β-
adrenergic stimulation lead to the dysfunctional Ca2+ release of N4104K hRyR2 during basal 
conditions in the context of CPVT1.  It would not be expected that any of these observed 
changes are due to altered RyR2 channel clustering within a cell, as drug is only applied, and 
release events assessed for a very short period of time (3 min).  
 
It is also interesting to note that no changes in the frequency of Ca2+ release events were 
observed upon treatment of hRyR2-transfected cells with DcAMP. An increased frequency of 
events is another hallmark of enhanced channel activity proposed by Chen and colleagues 
(Jiang et al. 2007; Jiang et al. 2004). PKA phosphorylation is thought to upregulate channel 
activity during β-adrenergic stimulation in the cardiomyocyte in response to increased metabolic 
demand in a physiological setting. PKA-mediated phosphorylation may increase single channel 
Po by increasing the length of open time, rather than the frequency of open events (Carter et al. 
2011). In HEK293 cells, a population of RyR2 channels may stay open longer rather than 
opening and closing more frequently. Longer Ca2+ release events are more likely to recruit other 
channels to make a more global spontaneous Ca2+ release event, whereas frequently opening 
channels will not contribute to the ‘fire-diffuse-fire’ mechanism and instead will represent a 
small, invisible Ca2+ leak from the ER store (Kunitomo and Terentyev 2011).  In light of this it 
could be argued that the frequency of Ca2+ release events is not an adequately sensitive 
indicator of enhanced channel activity in hRyR2-transfected HEK293 cells.  
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4.4.5 DcAMP treatment has limited effect on the S2808 phosphorylation status of 
mutant hRyR2, compared to WT - but has similar effects on spontaneous Ca2+ 
release 
 
In contrast, treatment of S2246L and N4104K hRyR2-transfected HEK293 with increasing 
concentrations of DcAMP (Figure 4.6 and Figure 4.7) resulted in no further significant increase 
in phosphorylation at S2808 compared to basal levels. No significant differences were detected 
between PKA control (maximally phosphorylated) and DMSO control (basally phosphorylated) 
samples. This is interesting given the differences calculated in basal phosphorylation of each 
mutant hRyR2, with S2246L hRyR2 channels displayed higher S2808 phosphorylation level 
than WT hRyR2. N4104K hRyR2 does not display a significant difference in basal S2808 
phosphorylation in comparison to WT hRyR2.  
 
These data could indicate that both hRyR2 mutants have a diminished response to 
phosphorylation at this site, or are already substantially phosphorylated. It is logical that S2808 
in S2246L hRyR2 may not be further phosphorylated by PKA given such high basal 
phosphorylation levels calculated previously (Figure 4.3). However, in the case of N4104K 
hRyR2 this argument does not follow. Basal phosphorylation was not calculated as significantly 
different to WT hRyR2 at the S2808 site. The data may therefore imply that N4104K hRyR2 
channels are unable to undergo phosphorylation beyond the basal level at this site. Altered 
inter-domain interactions caused by the N4104K mutation may have rendered post translational 
modification at this site impossible due to disruption of the phosphorylation domain. 
 
Despite not being able to significantly increase the phosphorylation of N4104K at S2808, 
DcAMP is reported as a highly efficient analogue of cAMP. While HEK293 cells may be devoid 
of cardiac Ca2+ cycling proteins that could be upregulated by phosphorylation mediated by either 
kinase (see Section 3.4.3), there may be other cellular targets that are activated or upregulated, 
given the role of cAMP in many cellular processes (Hofer and Lefkimmiatis 2007). The 
effectiveness of DcAMP in mediating phosphorylation is discussed further in Section 4.4.6. 
 
Assessment of the phosphorylation status of the S2031 site after DcAMP treatment would have 
further informed the change in the nature of Ca2+ oscillations seen, in particular as the 
preliminary results collected suggested that phosphorylation at this site was significantly lower in 
mutants than it was for the WT under basal conditions (i.e. before stimulation with DcAMP). 
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However, as discussed, this was not possible due to the variable quality of results produced 
using this antibody (see Section 4.4.1.).  
 
While treatment of mutant hRyR2-transfected cells with increased concentrations of DcAMP did 
not increase phosphorylation at the S2808 site, it appeared that the expression of loading 
control, vinculin, decreased (see Figure 4.5-4.7).  This points to the fact that DcAMP (or its 
effects) may be damaging over the course of 30 mins, with less viable cells and therefore 
protein present for the Western blot experiments. The potential damaging effects of DMSO are 
discussed further in Section 4.4.6.  
 
It is interesting that both S2246L and N4104K transfected cells display the same changes in 
Ca2+ release kinetics, in response to DcAMP treatment (Figure 4.15 and 4.16 respectively). 
Both exhibit a decreased amplitude, a decreased rate up and an increased rate down of Ca2+ 
release. This pattern of change is also observed in WT-hRyR2 transfected cells treated with the 
drug (albeit additional changes are also seen, see Table 4.2). It could be that PKA-mediated 
changes in Ca2+ release kinetics are not due to phosphorylation at the S2808 site in mutant 
hRyR2, since phosphorylation at this site does not significantly increase for either mutant with 
DcAMP stimulation (Figure 4.6 and 4.7). This could implicate either PKA-mediated 
phosphorylation at S2031, or at other potential phosphorylation sites in hRyR2. It could also 
implicate another protein which may influence Ca2+ signalling in the cell. As discussed in 
Section 4.4.3, DcAMP may also upregulate other cellular signalling pathways which account for 
common changes in Ca2+ release kinetics that are not necessarily due to changes in RyR2 
S2808 phosphorylation. 
 
However, when you compare the Ca2+ release kinetics of DcAMP-treated WT hRyR2-
transfected cells with treated mutant hRyR2-transfected cells, differences are evident (see 
Table 4.2). While changes caused by treatment of S2246L and N4104K-hRyR2 transfected 
cells follow the same pattern of changes as in treated WT, they are to a lesser extent. Treated 
N4104K-hRyR2 transfected cells show additional differences in Ca2+ release kinetics via this 
analysis, whereby the inter-event duration is decreased in comparison to treated WT. This 
suggests that the N4104K hRyR2 mutant is dysfunctional, regardless of phosphorylation status. 
N4104K hRyR2 also displays a dysfunctional response to pharmacological phosphorylation in 
this setting.  
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When ER Ca2+ store load was assessed by the addition of caffeine, S2246L hRyR2-transfected 
HEK293 cells displayed a significantly decreased load after the addition of DcAMP (Figure 4.9).  
Considering the decreased amplitude and the decreased ER Ca2+ load of WT and mutant 
hRyR2-transfected HEK293 cells when treated with DcAMP, it was important to assess the 
expression of SERCa given its role of Ca2+ sequestration back into the ER. No significant 
differences were calculated in SERCa expression between WT and mutant hRyR2-transfected 
HEK293 cells (see Figure 3.8). As anticipated, no differences were calculated in SERCa 
expression after treatment of hRyR2-transfected cells for 30 min with DcAMP, in comparison to 
untreated hRyR2-transfected cells (Figure 4.17). Given a HEK293 cell cycle takes ~24 hr, it 
would be implausible that pharmacological phosphorylation of transfected hRyR2 could cause 
subsequent adaptive remodelling to account for enhanced activity (Weber et al. 2014; Alberts et 
al. 2002; Brittsan et al. 2003). While SERCa expression is unaltered, SERCa activity may be 
modified by DcAMP, as well as various other Ca2+ cycling proteins within a HEK293 cell that 
may contribute to the altered store load. As discussed in Section 3.4.3, there is no evidence of 
PLB expression in HEK293 cells that would modify SERCa activity (Kurzydlowski 1996; Asahi et 
al. 2003; Toyofuku et al. 1994). The expression of Ca2+ handling proteins in HEK293 cells and 
the Ca2+ fluxes within this heterologous expression system are not yet fully elucidated so it 
remains difficult to speculate as to whether changes in ER load are due to hRyR2 mutation in 
this instance. It could be suggested that while S2808 phosphorylation doesn’t seem to affect the 
spontaneous Ca2+ release, it may be affecting small quark/spark-type Ca2+ release that is not 
measurable in this system. 
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4.4.6 The suitability of DcAMP as an analogue to elicit endogenous PKA 
phosphorylation of hRyR2 in Ca2+ imaging experiments 
 
Paavola et al. (2007) used DcAMP to simulate sympathetic stimulation in mutant RyR2-
transfected HEK293 cells and these data in fact informed the choice of the cAMP analogue for 
experiments within this Chapter.  
 
Western analysis concluded that treatment of hRyR2-transfected HEK293 cell homogenate 
sample with PKA increased phosphorylation at S2808 to levels similar to those observed after 
treatment with 100 µM or 1 mM DcAMP in DMSO (see Figure 4.5). It could therefore be 
assumed that cellular toxicity or osmolyte effects of DcAMP in DMSO were not to a level that 
could stop phosphorylation from occurring. However, as discussed in Section 4.4.5, it was 
apparent that less viable protein/cells may have been present after treatment with higher 
concentrations of DMSO, given a decreased signal for loading control vinculin.  
 
In Ca2+ imaging experiments, DMSO affected Ca2+ imaging. DMSO was applied to HEK293 
cells expressing WT hRyR2 and DMSO was applied in Ca2+ imaging experiments (1% (v/v) - 
equivalent to the volume added for 100 µM DcAMP in this solvent). It appeared that DMSO was 
stopping spontaneous Ca2+ release events and leading to a gradual increase in basal 
fluorescence of dye-loaded HEK293 cells (Figure 4.8 A). At 1% (v/v), this falls below the 
reported cytotoxicity of cells to the drug, at a level of 2-4 % (Galvao et al. 2013), suggestive that 
DMSO is not necessarily killing cells. It is well known that DMSO can affect the structure of lipid 
membranes because it is hydrophobic and is an osmolyte (Lang et al. 1998; Gordeliy et al. 
1998; Cheng et al. 2015). A reduction or increase in osmolality of solution surrounding a cell in 
vitro can lead to cell swelling or cell shrinkage. These actions may be responsible for the 
ceasing of Ca2+ release events. While DMSO osmolality will eventually equilibrate (as DMSO 
can cross the cell membrane, osmolality will increase both inside and outside of the cell until 
both environments remain isotonic), this is not practical for Ca2+ imaging experiments, especially 
in obtaining data for a large number of different hRyR2-transfected HEK293 cells, from several 
fields of view for each type. Long periods to allow for equilibration were also not feasible given 
compartmentalization of Fluo-3 AM dye after ~45 min (see Section 4.3.4). DMSO has also 
been recently reported to affect Ca2+ fluorescent dye kinetics (Menorval et al. 2012). The 
maximum value of fluorescence of Fluo-4 AM was shown to be dependent on the DMSO 
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concentration in experiments with CHO cells. Authors also observed a plateau of the 
fluorescence value at higher volumes of DMSO (15 vol %).  
 
The observation that methanol alone does not appear to stop or change Ca2+ release events of 
WT hRyR2-transfected HEK293 cells (Figure 4.8 B), suggests that it is DcAMP itself that is 
causing the increases in signal fluorescence seen in Figure 4.8 D.  A cell viability assay 
revealed the toxic effect of 1mM DcAMP on hRyR2 transfected cells over a period of 30 
minutes, whereas treatment with 100uM DcAMP or with methanol alone did not result in a 
decrease of cell viability. It is possible that the maximal dose of DcAMP causes a large release 
of Ca2+ (which could explain the increases in fluorescence seen) from maximally phosphorylated 
and therefore activated RyR2s. According to the mechanism put forward by Carter et al. (2006), 
an increase from three to four subunits being phosphorylated would cause this significant 
change in channel open duration, in other words a relatively small (25%) change in 
phosphorylation level between 100uM and 1mM DcAMP would result in a profound change in 
function. This small change in phosphorylation would not be deemed as significant in the data 
set presented in Figure 4.5. due to the variability therein. However, it is most likely that the 
effects of 1mM DcAMP on Ca2+ imaging are unlikely to be due to any effects on hRyR2 alone, 
especially considering the similarity to the effects produced by DMSO alone (which is not known 
to be an RyR2 agonist), signifying that this is more likely to be a general toxic/osmotic effect on 
the cells.  
 
In the manuscript and supplemental material of Paavola et al. (2013), the solvent used to deliver 
DcAMP to cells is not described. However, authors applied lower concentrations of the drug to 
RyR2-transfected HEK293 cells (1, 10 and 50 µM) and this could explain why the addition of 
DcAMP did not prevent further Ca2+ release events. These concentrations did not elicit changes 
in S2808 phosphorylation levels as assessed by Western blot (Figure 4.5), nor in Ca2+ release 
events assessed by Ca2+ imaging within this Chapter. It should also be noted that experiments 
of the authors were very short (≤20 sec recordings), were not in any way quantified and authors 
did not assess cells that characteristically oscillated upon stimulation with either caffeine or 
DcAMP. It is interesting to note that RyR2-transfected cells in the work of Paavola et el. (2007) 
displayed an extremely low number of spontaneous Ca2+ transients, with no difference in 
occurrence of these events between WT and mutant RyR2 transfected cells, even at similar 
levels of extracellular Ca2+ as used in this thesis (1.8 mmol/l). While authors do report that RyR2 
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transfection was confirmed by the application of caffeine, they do not state the transfection 
efficiency. A low transfection efficiency may account for this finding. 
 
While it is clear that dysfunction of S2246L and N4104K hRyR2 mutant channels may be 
attributed to the altered basal phosphorylation of PKA-specific sites, it remains that the influence 
of phosphorylation of other components within the HEK293 cell cannot be accounted for or 
easily eliminated in this system. Estimation of basal phosphorylation is this Chapter assesses 
phosphorylated RyR2 in a population of channels and does not account for varying 
phosphorylation status of each individual channel. The phosphorylation status of an individual 
channel can only be controlled by genetic phosphorylation or ablation. Homogeneous genetic 
phosphorylation may aid in revealing the functional relevance of a specific site on hRyR2 
channel function individually and separated from the influence of other factors within a HEK293 
cell.  
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Chapter 5  
 
Cloning, expression and functional evaluation of 
phosphomimetic hRyR2 mutants - S2808D and 
S2031D 
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5.1 Introduction 
 
5.1.1 Previous use of phosphomimetic amino acid substitutions to study RyR2 
channel function  
 
Phosphomimetic amino acid substitutions have been used to investigate the phosphorylation of 
various proteins implicated in EC coupling, including troponin C, phospholemman, PLB and 
cardiac voltage-gated sodium channel Nav1.5 (T. Zhang et al. 2010; Guo et al. 2015; Glynn et 
al. 2015; Schlecht et al. 2014). The method has extensively been applied in the study of RyR2 
phosphorylation by several groups in both recombinant RyR2 cDNA studies and the use of 
KI/KO mouse models (Marx et al. 2000; Stange et al. 2003; Xiao et al. 2007; Benkusky et al. 
2007; Kushnir et al. 2010; Chelu et al. 2009) to mimic (S to D) or ablate (S to A) phosphorylation 
at the S2808, S2814 and S2031 sites.  
 
It would be anticipated that KI/KO WT mouse models of the same phosphomimetic or ablative 
amino acid substitution would provide similar, independently corroborated results. However, as 
Tables 5.1-3 outlines, this is not the case. Most notable is the stark contrast in results between 
the Marks and Valdivia/Houser S2808A RyR2 KI mouse (Benkusky et al. 2007; Shan, Kushnir, 
Betzenhauser, Reiken, Li, Lehnart, Lindegger, Mongillo, Mohler and Marks 2010b). The Marks 
group report blunted chronotropic responses to Iso and reduced exercise capacity in this mouse 
model (Shan et al. 2010) and the authors suggest these data support a key role for S2808 
phosphorylation in the PKA-mediated β-adrenergic regulation of RyR2 (as well as a role for PKA 
phosphorylation in the progression of HF (Marx et al. 2000; Reiken et al. 2003; Marx et al. 2001; 
Antos et al. 2001). Conversely, Valdivia/Houser S2808A KI mice exhibit normal myocyte 
shortening and Ca2+ transients, normal responses to Iso and normal PKA-mediated 
incorporation of radioactive phosphate into RyR2, despite the elimination of the S2808 
phosphorylation site (H. Zhang et al. 2012; Liu et al. 2014; Benkusky et al. 2007). These data 
suggest that the S2808 site is of little relevance, and that other site(s) (notably S2031) are more 
likely to be phosphorylated by and transduce the functional effects of PKA in this channel. 
These conflicting results, the Marks group argues, were due to the use of a different mouse 
strain in this study providing a change in genetic background which affected the authors’ 
findings. However, even when using S2808A mice backcrossed with the same C57BI/6J strain 
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used by Marks, the Valdivia group found a normal cardiac adrenergic response and an 
unaltered progression towards HF in comparison to WT mice (Alvarado et al. 2017). 
 
The relative importance of the S2031 site over S2808 is supported by single channel recordings 
of recombinant mouse S2031D RyR2, where channels exhibit an increased response to luminal 
Ca2+ compared to WT (Xiao et al. 2007). Work by Stange et al. (2003) also indicates little 
relevance of phosphorylation at the S2808 site, as recombinant rabbit S2808D RyR2 single 
channels show no subconductance states, an apparent feature of phosphorylation at this site 
(Marx et al. 2000)  and no change in Ca2+ activation of the channels as assessed by [3H] 
ryanodine binding in comparison to WT RyR2. No changes were observed in the caffeine-
sensitive ER Ca2+-stores of S2808D RyR2-transfected HEK293 cells in comparison to WT 
either.  
 
While discrepancies between results remain, there is no doubt that precise control of 
phosphorylation at a specific site in RyR2 has advantages over other, less controlled methods 
of investigating phosphorylation (see 4.1.2.5). In the main, it aids in determining the exact effect 
of phosphorylation of RyR2 at each individual site, away from the influence of other 
phosphorylatable targets. While many groups have investigated the effects of phosphomimetic 
mutations on WT RyR2 channel function, whether in recombinant cDNA or in mouse models, 
there is no published research to date that has investigated the effects of genetic 
phosphorylation or ablation on CPVT1 mutant hRyR2 function. 
 
Work in the previous Chapter demonstrated that basal phosphorylation and the ability to be 
phosphorylated upon stimulation was different between WT and mutant hRyR2. This chapter 
will assess whether genetic phosphorylation at a given site (i.e. S2808 or S2031) emulates the 
functional effects of kinase phosphorylation with a view to being able to attribute the functional 
consequences seen to phosphorylation at one site or the other. This should be straightforward 
in the case of the WT, since the functional data collected in Chapter 4 (in the presence of 
100uM DcAMP) were from a maximally phosphorylated population of channels and, if this 
maximal state represents full stoichiometry, should be comparable with that of cells expressing 
S2808D hRyR2, if this site is functionally relevant. One might expect to see that genetic 
phosphorylation at the S2808 site in S2246L hRyR2 does not elicit a response, given that it is 
already maximally phosphorylated under basal conditions. However, since the phosphorylation 
status of N4014K in the presence or absence of PKA activation via DcAMP is not so clearly 
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defined, it is difficult to predict whether genetic phosphorylation would likely bear any 
resemblance to that seen using kinase activating via DcAMP. 
 
It is also difficult to comment on the likely effects of genetic phosphorylation at the S2031 site, 
as maximal phosphorylation levels were not investigated in experiments with DcAMP. However, 
mutants were dephosphorylated in comparison to WT hRyR2 in the absence of PKA activation, 
so it is reasonable to expect that genetic mimics of phosphorylation at S2031 in mutant hRyR2 
may display different functional characteristics to their kinase equivalents. Given that the 
Badrilla anti-pSer2030 antibody was determined as too difficult to work with in subsequent 
experiments, utilizing phosphomimetic mutations in this Chapter also offers a further opportunity 
to investigate the functional relevance of phosphorylation at the S2031 site in hRyR2, which was 
not investigated using DcAMP in the previous Chapter. 
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 S2808A (Marks) S2808A (Meissner) S2808A (Valdivia#1) S2808A (Valdivia#2) S2808A (Chen) 
References (Ather et al. 2012; Marx et 
al. 2000; Wehrens et al. 
2006; Sarma et al. 2010) 
(Stange et al. 2003) (H. Zhang et al. 2012; Liu et al. 
2014; Benkusky et al. 2007) 
Alvarado:2017wg} (Xiao et al. 2007) 
Species of 
RyR2 and 
model 
Mouse: S2808A, dmd, 
also rRabbit, rHuman in 
HEK293 cells 
rRabbit:  HEK293 cells Mouse: S2808A and triple 
model, (S2808A, CSQ2(-/-), 
SERCa1a overexpression) 
Mouse: S2808A and S2808A 
with MI (different genetic 
background to Valdiva#1) 
Mouse: S2808A and 
S2808A with MI 
Phenotype 
of mouse 
model 
Phospho-ablation at 
S2808A improved dmd 
phenotype, protecting 
against Iso induced HF. 
N/A Phospho-ablation doesn’t 
impact HF remodelling. Triple 
mutant showed exacerbated 
cardiovascular disease. 
Phospho-ablation didn’t affect 
post-MI survival, no effect on 
basal or Iso stimulated 
functions or heart structure. 
Phospho-ablation resulted in 
better cardiac function post-
MI, reduced remodelling, 
cardioprotective effect. 
Ca2+ 
release/ 
functional 
data 
Phospho-ablation 
decreased the frequency 
of spontaneous Ca2+ 
release in dmd mice on 
application of Iso, in 
comparison to dmd mice. 
No effect on caffeine-
sensitive ER Ca2+ store, 
nor on Ca2+ activation 
(3H-ryanodine binding) in 
the presence /absence 
of FKBP12.6. 
No effect on SR Ca2+ load or 
kinetic parameters of Ca2+ 
release either before or after 
treatment with Iso, increased 
phosphorylation at the other 
sites. Western blots showed 
dephosphorylation of S2808 
and phosphorylation of S2808 
and S2031 by PKA. 
Phospho-ablation has no 
effect on Ca2+ release in 
response to Iso and no effect 
on expression of other cardiac 
proteins involved in this 
process. 
N/A 
Single 
channel 
function 
Po of S2808A channels 
from mouse hearts was 
comparable to that of WT 
channels under basal 
conditions, not affected by 
PKA phosphorylation. 
S2808A channels did 
not exhibit 
subconductance states 
in the presence 
/absence of FKBP12.6. 
PKA phosphorylated RyR2-
S2808A channels displayed 
increased Po compared to WT. 
N/A S2808A channels increased 
in Po after PKA 
phosphorylation. No 
subconductance states were 
observed, even in channels 
from post-MI model. 
Significance Suggests that enhanced 
PKA-mediated 
phosphorylation at S2808 
contributes to abnormal 
Ca2+ homeostasis that is 
associated with dystrophic 
cardiomyopathy. 
Does not support 
significance of single site 
phosphorylation in RyR2 
channel function, or the 
relevance of FKBP12.6 
dissociation upon PKA 
phosphorylation. 
Suggests S2808 
hyperphosphorylation by PKA is 
not implicated in pathogenesis 
of cardiovascular disease, but 
implicates dephosphorylation 
and S2031 phosphorylation. 
Given that preventing 
phosphorylation at S2808 
does not alter adrenergic 
response or HF progression, 
suggests phosphorylation at 
this site is not functionally 
relevant. 
Implicates PKA-specific 
phosphorylation site in RyR2 
other than S2808. 
 
Table 5.1 Summary of the effects of genetic ablation at the S2808 site of RyR2. Diverse interpretation of data from studies of S2808A mutation. 
Key for abbreviations in legend of Table 5.3 below. 
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Table 5.2 Summary of the effects of genetic phosphorylation at the S2808 site of RyR2. Diverse interpretation of data from studies of S2808D mutation. 
Key for abbreviations in legend of Table 5.3 below.  
 
 
 
 
 
 
 S2808D (Meissner) S2808D (Chen) S2808D (Marks) 
References (Stange et al. 2003) (Xiao et al. 2007) (Wehrens et al. 2006) 
Species of 
RyR2 and 
model 
rRabbit: HEK293 cells rMouse: HEK293 cells rHuman: HEK293 cells 
Phenotype of 
mouse model  
N/A N/A N/A 
Ca2+ release/ 
functional 
data 
No significant differences in caffeine-
sensitive Ca2+ stores observed 
between mutant and WT rRabbit 
RyR2 expression HEK293 cells. 
S2808D did not alter Ca2+ activation 
in ryanodine binding experiments in 
comparison to WT, with or without 
co-expression of FKBP12.6. 
N/A N/A 
Single 
channel 
function 
No subconductance states observed 
in S2808D single RyR2 channel 
recordings in the presence/absence 
of FKBP12.6 co-expression.  
S2808D RyR2 single channels 
exhibited a significantly increased Po 
after PKA treatment, in a manner similar 
to WT channels.  
S2808D RyR2 single channels displayed 
the same activity as PKA-phosphorylated 
WT channels, in contrast to S2031D 
channels. 
Significance Results do not support the view that 
phosphorylation of one site in RyR2 
substantially modulates channel 
function, or that dissociation of 
FKBP12.6 occurs upon PKA 
phosphorylation of the channel. 
Suggests there is another PKA-specific 
RyR2 phosphorylation site and that the 
S2808 site may not be functionally 
relevant.  
Suggests S2808 is the only PKA 
functional site. 
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 S2031A (Marks) S2031A (Chen) S2031D (Chen) 
References (Wehrens et al. 2006) (Xiao et al. 2007) (Xiao et al. 2007) 
Species of 
RyR2 and 
model 
rHuman: HEK293 cells rMouse: HEK293 cells rMouse: HEK293 cells 
Phenotype of 
mouse model  
N/A N/A N/A 
Ca2+ release/ 
functional 
data 
N/A N/A N/A 
Single 
channel 
function 
S2031A RyR2 channels displayed 
an increased Po in response to 
PKA phosphorylation in 
comparison to S2808A channels. 
PKA did not affect S2031A single 
channel activity in comparison to 
WT, with no increase in Po. In a 
double mutant construct 
(S2031A/S2808A), there was no 
alteration in response to PKA 
either.  
S2031D mutation increased 
luminal Ca2+ response of single 
RyR2 channels, while PKA 
potentiated the luminal Ca2+ 
response, in comparison to WT 
single channels.  
Significance Suggests that S2031 is not a 
functionally relevant PKA 
phosphorylation site in RyR2. 
Suggests that S2808 is not a 
functionally relevant PKA 
phosphorylation site in RyR2.  
Suggests activation of RyR2 by 
PKA is largely mediated by 
phosphorylation at the S2031 site. 
 
Table 5.3 Summary of the effects of genetic phosphorylation and ablation at the S2031 site of RyR2. Diverse interpretation of data from studies of 
S2808D mutation. Key: (+/-): heterozygous mutation, (-/-): homozygous mutation, CSQ2: cardiac calsequestrin, dmd: Duchenne muscular dystrophy, 
FKBP12.6: FK506 binding protein 12.6, Iso: isoproterenol, MI: myocardial infarction (induced by surgery), PKA: protein kinase A, rMouse/rRabbit/rHuman: 
recombinant mouse/rabbit/human RyR2, SERCa: sarco/endoplasmic reticulum Ca2+-ATPase. 
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5.1.2 Chapter aims 
 
In comparison to pharmacological phosphorylation, genetic phosphorylation will allow for 
complete control to elucidate the effects of this modification at the S2808 and S2031 PKA-
specific RyR2 sites individually. While genetic phosphorylation and ablation have extensively 
been investigated in WT recombinant cDNA and KI/KO mouse studies, no publications to date 
have utilized the method of phosphomimetic amino acid substitutions to investigate the role of 
phosphorylation in the dysfunction of CPVT1 RyR2 mutant channels.  
 
In order to assess the effects of site-specific phosphorylation on WT and mutant hRyR2 
function, the aims were to: 
• Engineer phosphomimetic substitutions (i.e. serine to aspartic acid to mimic complete 
phosphorylation) in WT, S2246L and N4104K plasmids at both the S2808 and S2031 
sites 
• Assess the expression of WT and mutant phosphomimetic hRyR2 in HEK293 cells by 
Western blotting to determine whether changes in function are attributable to changes in 
protein expression caused by ‘genetic phosphorylation’ 
• Determine the intracellular localization of hRyR2 within HEK293 cells with 
immunofluorescence to confirm that molecular alterations of the constructs do not cause 
mislocalisation of recombinant mutant hRyR2  
• Analyse the Ca2+ handling of HEK293 cells expressing these constructs to a) determine 
whether phosphomimetic mutations emulate the effects of phosphorylation and b) 
determine the functional effects of phosphorylation at the S2808 and S2031 sites 
216 
 
5.2 Materials and methods 
 
5.2.1 Generation of eGFP-hRyR2 phosphomimetic constructs 
 
The following six phosphomimetic hRyR2 constructs were first engineered using site directed 
mutagenesis and a cassette-based cloning strategy: 
• WT with S2808D mutation (referred to in figures as WT08) 
• WT with S2031D mutation (referred to in figures as WT31) 
• S2246L with S2808D mutation (referred to in figures as SL08) 
• S2246L with S2031D mutation (referred to in figures as SL31) 
• N4104K with S2808D mutation (referred to in figures as NK08) 
• N4104K with S2031D mutation (referred to in figures as NK31) 
 
The method of cassette-based site-directed mutagenesis (SDM) was employed to generate full-
length eGFP-hRyR2 WT and mutant phosphomimetic constructs. The protocol allows the 
introduction of nucleotide substitutions using Pfu DNA polymerase to amplify DNA. This process 
exploits the polymerase chain reaction (Mullis et al. 1986) to replicate mutagenic primer-directed 
plasmid strands and is limited to amplification of DNA sequences ~6-8 kb, which makes it 
unsuitable for mutagenesis of full length eGFP-hRyR2, a plasmid of >21 kb.  
 
This was overcome by using the intermediate superlinker vector, pSL1180 (GE Healthcare). 
pSL1180 vectors altered to contain fragments of hRyR2 or ‘cassettes’ were obtained from Dr. 
CH George and Dr. NL Thomas. These cassettes are coding DNA fragments of hRyR2 
bordered by specific restriction sites, meaning that a fragment can be digested from one vector 
and inserted into the other (Figure 5.1). Intermediate ‘cassette’ vectors used in SDM were as 
follows: 
• KN1 cassette – plasmid size 7666 bp in length. This cassette contains the hRyR2 coding 
sequence 7553 bp (2518aa) to 11,857bp (3953aa) and contains the target amino acid 
S2808 (amino acids TCT beginning at nucleotide position T8422). Bordering the coding 
sequence are restriction sites KpnI and NheI (hence plasmid name KN1). Restriction 
site FseI is also present in this cassette and digesting with KpnI and FseI removes the 
correct fragment for insertion back into RyR2. 
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• SK1 cassette – plasmid size 5455 bp in length. This cassette contains the hRyR2 DNA 
coding sequence from 5421bp (1807aa) to 7553bp (2518aa) and contains the target 
amino acid S2031 (amino acids TCC beginning at nucleotide position T6091, derived 
from the ATG start codon). Bordering the coding sequence are restriction sites SanDI 
and KpnI (hence plasmid name SK1).  
 
A schematic representation of pSL1180 cassettes and full-length mutagenized phosphomimetic 
constructs is found in Figure 5.1. After mutagenesis of the intermediate vector, the hRyR2-
coding fragments were excised and ligated into the full-length hRyR2 sequence vector, using 
corresponding restriction enzymes (Figure 5.2).  
 
5.2.1.1  Primer design for site-directed mutagenesis 
 
Oligonucleotide primers for the purpose of site-directed mutagenesis were designed with the 
following considerations, sequences for which are in Table 5.4: 
• Both mutagenic primers must contain the desired mutation, annealing to the same 
sequence on opposite strands of the DNA plasmid 
• The desired mutation should be at the centre of the primer, with at least 10-15 bases of 
complementary sequence either side 
• The melting temperature of primers (Tm) should be above 78 °C 
• The primers should have a minimum GC content of 40 % and should terminate with one 
or more G or C bases 
• Primers must be purified by High Performance Liquid Chromatography (HPLC) or 
polyacrylamide gel electrophoresis (PAGE) 
 
Custom oligonucleotide primers were ordered and purified using reverse phase High Pressure 
Liquid Chromatography (HPLC) from Sigma Genosys, supplied as lyophilized pellets. Primers 
were complementary to the WT hRyR2 sequence, aside from two mismatched nucleotides that 
resulted in the desired amino acid substitution by site-directed mutagenesis. Pellets were 
resuspended in 250 μL dH2O following manufacturer guidelines and stored at -20 °C. Primers 
were diluted to a concentration of 150 ng/mL for application in site-directed mutagenesis.  
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Table 5.4 Site-directed mutagenesis oligonucleotide primers.  Mutagenesis primers used to insert the mutations S2031D and S2808D into 
mutagenesis cassettes (See Figure 5.1 for cloning strategy). Sequences are given in the 5’ to 3’ direction, with nucleotides in red indicate those 
undergoing substitution. Positions of nucleotides are derived from the RyR2 ATG start codon.  
Name Sequence Nucleotide 
position 
Amino acid 
substitution 
Length 
(bp) 
Tm (°C) GC 
content 
(%) 
Description 
S2031DF GAGGGCGTCTGCTAGAC
CTGGTAGAAAAGGTGAC 
G6077 S2031D 34 77.7 55 Forward primer for 
the mutagenesis of 
hRyR2 (S2031D) 
S2031DR GTCACCTTTTCTACCAGG
TCTAGCAGACGCCCTC 
C6077 S2031D 34 77.7 55 Reverse primer for 
the mutagenesis of 
hRyR2 (S2031D) 
S2808DF CCGGACTCGTCGTATTGA
TCAGACAAGCCAGGTTTC 
C8406 S2808D 36 81.3 53 Forward primer for 
the mutagenesis of 
hRyR2 (S2808D) 
S2808DR GAAACCTGGCTTGTCTGA
TCAATACGACGAGTCCGG 
C8406 S2808D 36 81.3 53 Reverse primer for 
the mutagenesis of 
hRyR2 (S2808D) 
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5.2.1.2  Site-directed mutagenesis 
 
The QuikChange II site-directed mutagenesis kit (Agilent) was utilized to introduce mutation into 
intermediate vectors. A schematic of the process is outlined in Figure 5.1.  
 
Site-directed mutagenesis reaction mixtures were prepared as in Table 5.5 and following 
thermal cycling as in Table 5.6, 1 μL DpnI enzyme was added and the reaction product 
incubated at 37oC for 90 minutes. This restriction endonuclease is specific for methylated and 
hemi methylated DNA and was used to digest the plasmid DNA pre-mutagenesis, taking 
advantage of the fact that DNA isolated from E. coli strains is methylated by deoxyadenosine 
methylase and susceptible to digestion. XL1 Blue cells were then transformed (according to 
manufacturer’s instructions) with this DpnI-treated DNA for propagation of this plasmid. 
Mutagenesis of cassettes was confirmed by DNA sequencing (Cardiff Biotechnology Services), 
before progressing to construction of full-length eGFP-hRyR2 plasmids. 
 
 
 
 
 
 
 
 
 
Table 5.5 Sample reaction for site-directed mutagenesis reaction. 
 
Table 5.6 Thermal cycling parameters for QuikChange II site-directed mutagenesis.
Reagent Volume 
10x reaction buffer 5 μL 
dsDNA template 5-50 ng 
Oligonucleotide primer (forward) 125 ng 
Oligonucleotide primer (reverse) 125 ng 
dNTP mix (proprietary) 1 μL 
Deionized dH2O up to final volume of 50 μL 
Step Stage Duration Temperature Number of cycles 
1 Denaturation 30 secs 95 °C 1 
2 Denaturation 30 secs 95 °C  
16 Annealing 1 min 55 °C 
Extension 1 min/kb of plasmid 
length 
68 °C 
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Figure 5.1 Schematic of the QuikChange II site-directed mutagenesis method. SDM was carried out 
to make nucleotide substitutions within RyR2 mutagenesis cassettes (plasmid insert DNA) in intermediate 
vectors (plasmid vector DNA). Adapted from the Agilent product manual. 
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Figure 5.2 Schematic illustration of cDNA constructs 
produced by cloning with the pcDNA3-eGFP-hRyR2 plasmid 
and pSL1180 superlinker cassette. A-C highlights the cassette 
and hRyR2 plasmid used to construct each phosphomimetic, 
with blue lines representing the coding part of the hRyR2 
sequence. KN1 contains KpnI and FseI restriction sites and SK1 
contains SanDI and KpnI restriction sites. pcDNA-eGFP-hRyR2 
constructs, including mutation sites (S2246L and N4104K), as 
well as introduced phosphomimetic mutation (S2808D or 
S2031D marked in yellow) are indicated in the lower half of each 
diagram. Note that in the case of S2246L-S2031D, the SK1 
cassette had to be modified to contain S2246L and S2031D 
mutations, before ligation with the remaining coding sequence of 
WT hRyR2 plasmid DNA. 
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For the construction of S2031D phosphomimetics, the appropriate full length eGFP-hRyR2 
plasmid DNA, together with the mutagenized SK1 shuttle vector (see Figure 5.2) underwent 
double-digest with SanDI and KpnI endonucleases (High Fidelity, New England Biolabs) for 30 
minutes at 37°C. The resulting fragments were separated by agarose gel electrophoresis (see 
Section 2.3.3), shown in Figure 5.3.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Double digest of the S2031D mutagenized SK1 cassette and full length hRyR2 plasmid 
to obtain fragments for ligation. SanDI and KpnI are bordering restriction sites in the SK1 cassette. 
Upon a double digest of the cassette, 3326bp and 2129bp fragments are obtained as indicated in the gel 
electrophoresis image (left). The band at approximately 5400 bp is undigested/linearized SK1 plasmid. 
The table outlines the double digest reaction. Enzyme stock concentration: 20,000 U/ml. Both enzymes 
are compatible with Buffer 1.1 according to the New England Biolabs Double Digest Finder Tool. SanDI is 
now commercially known as KflI (ThermoFisher Scientific). 
 
The process of fragment generation for ligation was not as straightforward for S2808D 
phosphomimetic constructs. While full-length eGFP-hRyR2 plasmid DNA was digested with 
restriction enzymes corresponding to the sites bordering the fragment for insertion (i.e. KpnI and 
FseI), the S2808D mutagenized KN1 plasmid was digested with an additional enzyme (i.e. a 
triple digest using KpnI, FseI and XhoI) in order that the fragment of interest could be effectively 
resolved by electrophoresis from that which remains (see Figure 5.4).  
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Figure 5.4 Triple digest of the S2808D mutagenized KN1 cassette and full length hRyR2 plasmid to 
obtain fragments for ligation. Top left is a schematic of the KN1 cassette, with hRyR2 coding sequence 
(blue), showing KpnI and FseI bordering restriction sites and the XhoI site, outside of this coding 
sequence. Upon double digest with KpnI and FseI, the resultant fragments, at 3839bp and 3827p, cannot 
be resolved using agarose gel electrophoresis (see illustration from NEB cutter v2.0, top right). Upon 
triple digest with KpnI, FseI and XhoI, fragments (3827 bp, 3291 bp and 548 bp) are obtained as indicated 
in the gel electrophoresis image. Enzyme stock concentration: KpnI and XhoI 20,000 U/ml, FseI 2,000 
U/ml. Both enzymes are compatible with Buffer 1.1 according to the New England Biolabs Double Digest 
Finder Tool. 
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DNA fragments were purified using the QIAEX II kit (Qiagen). Briefly, resolved fragments were 
identified using UV trans illumination (very briefly to avoid DNA cross-linking), before removal 
using a scalpel. Gel slices were solubilized separately in the high salt QX1 buffer containing 
guanidium thiocyanate, at 3 volumes of buffer to 1 volume of gel. QIAEX II silica beads were 
resuspended by vortexing for 30 secs, before the addition of 30 μL to the sample. Samples were 
incubated at 50 °C in a waterbath for 10 minutes to allow agarose solubilisation and the binding 
of DNA to the silica beads. To keep the beads in suspension, the samples were gently inverted 
every 2 minutes of this incubation period. Samples were then centrifuged for 30 seconds at 
13,000 rpm (5417R centrifuge, Eppendorf) and the supernatant carefully removed. Pellets were 
then washed with 500 μL QX1 wash buffer and centrifuged for a further 30 seconds to remove 
residual agarose contaminants. The pellets were then washed twice with 500 μL of ethanol-
containing PE buffer, to remove residual salt contaminants. To elute DNA, 20 μL of dH2O was 
added to pellets, which were resuspended by gentle inversion. After 30 seconds of 
centrifugation at 13,000 rpm the supernatant, containing the purified DNA was removed into a 
clean tube. The DNA Nanovue Plus (GE Lifesciences) was used to determine DNA 
concentration (see Section 2.3.5). 
 
Ligation was carried out using the Roche Rapid DNA ligation kit (Roche), following manufacturer 
guidelines. Briefly, the digested insert was mixed with plasmid vector (50 ng) in a 3:1 molar 
ratio, with T4 DNA ligase (5 U/ μL) and ligase buffer (containing ATP) to join insert and vector 
‘sticky-ends’ together. Ligation reaction mixtures were incubated at 4 °C for 16 hrs before being 
used to transform XL10-Gold competent bacterial cells (See Section 2.3.1) to begin the 
amplification process of full-length eGFP-hRyR2 plasmid DNA. LBAMP broth and NZY broth (16 
g/L NZ casein, 50 g/L yeast extract in dH2O, autoclaved) were used as cell culture media in 
these experiments. For a sample ligation, see Figure 5.5 below.  
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Figure 5.5 Sample ligation reaction to construct pcDNA3 eGFP-hRyR2-S2031D. In the ligation 
reaction, a ratio of 1 molar part of vector fragment to 3 parts insert fragment was used. Ligation was 
catalysed by T4 DNA ligase from the Roche Rapid DNA ligation kit (Roche).  
 
5.2.1.3  Sequencing of the SDM site and restriction boundaries 
 
After large scale plasmid preparation (see Section 2.3.4), mutated constructs were sequenced 
by Central Biotechnology Services, Cardiff University. Both the mutagenesis site and restriction 
boundaries were sequenced using appropriate primers (See Table 5.7). Data were compared to 
the hRyR2 sequence using the BLAST sequencing alignment tool. Electropherograms were 
visualized by 4peaks software.  
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Primer Name Direction Sequence Start 
Nucleotide 
Length 
(bp) 
GC 
content 
(%) 
Use 
B23R1 Reverse GGAAACTTTGGTGCTGCCTCAG G5762 22 55 Verification of 
SanDI restriction 
site  
B23F7 Forward CTGCCAGAGCCAGTTAAATTGCAG C5692 24 50 Verification of 
S2031D 
mutagenesis 
B38R1 Reverse GGATAGAAGCCATTGTAGCC G7873 20 50 Verification of 
KpnI restriction 
site 
SPFOR.8305-
22 
Forward CCATGACAAATGGTCAAT C8184 18 39 Verification of 
S2808D 
mutagenesis 
B6/10(-) Reverse TTATGAACAAGAAATCAAGTTC C8847 22 28 Verification of 
S2808D 
mutagenesis 
24F Forward GGCACTAAGAGAGTTGATCCTC G10969 22 50 Verification of FseI 
restriction site  
 
Table 5.7 Sequencing oligonucleotide primers. ‘In house’ primers used in automated sequencing to verify correct mutagenesis and ligation of 
hRyR2 fragments at restriction boundaries. Sequences are given in the 5’ to 3’ direction. Start nucleotides are derived from the ATG start codon. 
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5.2.2 Evaluating the expression of phosphomimetic hRyR2 in HEK293 cells 
 
Methods for the expression, preparation of cell homogenates and detection of hRyR2 proteins 
by Western Blot are detailed in Chapter 2. The expression of eGFP phosphomimetic hRyR2 
constructs was assessed by methods described in Section 3.2.3. 
 
5.2.3 Confocal microscopy and Ca2+ imaging 
 
The kinetic parameters of Ca2+ release in HEK293 cells expressing phosphomimetic hRyR2 
channels were assessed using the methods described in Section 3.2.1. 
 
5.2.4 Immunofluorescence analysis of cells expressing eGFP-hRyR2 
 
Localization of phosphomimetic hRyR2 channels, recombinantly expressed in HEK293 cells 
was assessed by IF as described in Section 3.2.2. 
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5.3 Results 
 
5.3.1 Generation of phosphomimetic hRyR2 constructs 
 
Cloning of hRyR2 cDNA plasmids is notoriously problematic (George et al. 2005) and 
construction of the six hRyR2 phosphomimetics described in Section 5.2 was not 
straightforward. To engineer both S2031D and S2808D phosphomimetic mutations in each 
different hRyR2 construct (WT, S2246L and N4104K), 4-12 ligations were carried out in each 
case, with a total of 40 attempts made (see Figure 5.6.C). For each of these ligation attempts, 
36-60 bacterial colonies were screened, with plasmids digested with restriction enzyme EcoRI 
to identify clones with the characteristic digest pattern (see Figure 5.6 A and 2.3.1). These are 
referred to as positive clones.  
 
Average ligation efficiency did not surpass 50% for any of the full length hRyR2 phosphomimetic 
expression plasmids generated (with a range of 5.5-47.5% positive clones obtained). While 
ligation of the S2031D cassette fragment with either the WT or S2246L hRyR2 vector fragment 
led to the highest % of positive clones (42.5-47.5 %), and ligation success with the N4104K 
hRyR2 vector fragment was low at 19.8 %. Ligation of the S2808D cassette fragment with all 
the hRyR2 fragments (WT, S2246L or N4104K) led to a much lower % of positive clones in 
each case (5.5-23.3 %) in comparison to S2031D.    
 
Yielding a positive clone from the ligation of either phosphomimetic fragment with the N4104K 
hRyR2 vector fragment was most difficult, with only 3 of 9 ligation attempts yielding any positive 
clones at the miniprep stage. The average % of positive clones in these cases was very low 
(5.5-19.8 %), with as few as three colonies out of a total of 60 identified with the characteristic 
EcoRI digest pattern.    
 
While some of the positive clones that were sequenced at the mini-prep stage were verified as 
phosphomimetics, all efforts to culture these bacterial colonies at a larger scale in XL10 cells to 
yield usable quantities of DNA failed, with recombination of plasmids seen in all of 21 attempts 
(Figure 5.6 B and C).  
 
To address the issue of recombination of positive clones when attempting to culture XL10 
bacterial cells at a larger scale, multiple experimental conditions were tested (see Table 5.8). 
229 
 
Changing incubation conditions, including growing at a lower temperature of 27 ºC and 
incubating for 15 hours as opposed to 18 hours, showed no success. Using a different culture 
media, NZY broth failed to yield any positive large-scale cultures, neither did using a smaller 
volume of media.  
 
Number of maxi preparation 
attempt 
Temperature Growth media Incubation time Successful? 
1 30 °C LBAMP broth 15 hours X 
2 27 °C LBAMP broth 18 hours X 
3 27 °C LBAMP broth 15 hours X 
4 30 °C NZY broth 15 hours X 
5 27 °C NZY broth 18 hours X 
6 27 °C NZY broth 15 hours X 
7 30 °C LBAMP broth 15 hours X 
 
Table 5.8 Experimental conditions trialled in XL10 bacterial cell maxi preparation of 
phosphomimetic hRyR2 plasmid DNA. Changing experimental conditions of the large-scale culture of 
positive clones obtained from mini preparation of XL10 cells did not lead to the yield of any correctly 
digesting phosphomimetic plasmid DNA. The temperature, growth media and incubation time were all 
altered, with no success (indicated by a red X in the table).  
 
All positive miniprep clones made in XL10 cells (verified by both digest and sequencing), scaled 
up under the careful culture conditions tabulated above, recombined and failed to show the 
correct digest pattern at the maxi prep stage (see Figure 5.9 and Table 5.8). Verified miniprep 
cDNA was also re-transformed into XL10 cells an attempt to propagate further, but this was also 
unsuccessful, as plasmids again recombined at the large-scale culture stage. 
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Figure 5.6 Attempts to propagate phosphomimetic hRyR2 constructs in XL10 E. coli cells. A. A representative gel electrophoresis image of 
a mini preparation with XL10 cells digested with restriction enzyme EcoRI, with 15 picked colonies and 1 positive result (blue arrow).  The 
illustration to the left shows expected positive digest result for the complete plasmid (simulation produced by NEB cutter). B. A representative gel 
electrophoresis image of digested plasmid DNA isolated following large-scale culture in XL10s after a positive sequencing result. EcoRI, HindIII, 
BamHI and BgIII were used to digest DNA and illustration to the left shows expected positive result. This shows failure to culture on the larger 
scale and recombination of clones. C. Table summarizing the cloning efficiency of phosphomimetics in XL10 cells. Data in row 5 are given as ± 
SEM.
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In our laboratory’s experience, XL10 E. coli cells are most suitable to culture more unstable 
hRyR2 constructs or introduce mutations by cloning. However, even after further optimisation of 
growing conditions, expansion of bacterial culture for large scale plasmid isolation was 
unsuccessful. As a result, it was decided to attempt retransformation of sequence-verified mini 
preparation plasmid DNA into Stbl2 E. coli cells. Stbl2 cells are not recommended for cloning by 
manufacturers, but have been routinely used in our laboratory to propagate WT hRyR2 DNA. 
Only one retransformation was attempted for each of the six phosphomimetic hRyR2 plasmids, 
with 7-24 bacterial colonies screened in each instance (Figure 5.7 C). Stbl2 cells showed a very 
high percentage of positive clones that displayed the correct EcoRI digest pattern at the 
miniprep stage (65-100 %, see Figure 5.7 A and C).  After large scale culture of positive 
bacterial colonies, hRyR2 DNA displayed the correct restriction digest pattern (Figure 5.7 B 
and C) and were verified by sequencing. Alignment to the WT sequence confirmed that the 
correct nucleotide substitution had taken place and that no additional nucleotides were inserted.  
The primers described in Table 5.8 were used to sequence over the mutation site and cassette 
insertion boundaries, with sequence chromatograms found in Figure 5.8. All six 
phosphomimetic constructs required for this project were successfully generated after 
retransformation of positive clones into Stbl2 cells. 
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Figure 5.7 Attempts to retransform and propagate phosphomimetic hRyR2 constructs in Stbl2 E. coli cells. A. A representative gel 
electrophoresis image of eGFP-hRyR2 WT-S2808D phosphomimetic mini prep clones obtained after the transformation of Stbl2 cells with verified 
phosphomimetic constructs made in XL10 cells (see Figure 6 above), which all show the correct EcoRI digest pattern (two appear incompletely 
digested). Ladder shows expected positive digest result (simulation produced by NEB cutter: http://nc2.neb.com/NEBcutter2/). B. A representative 
gel electrophoresis image of eGFP-hRyR2 WT-S2808D phosphomimetic plasmid cDNA obtained by large scale culture in Stbl2 cells, showing the 
correct anticipated digest patterns using EcoRI, HindIII, BamHI and BgIII. C. Table showing the number of attempts to generate positively 
sequenced phosphomimetic constructs using Stbl2 cells. All constructs were successfully generated and propagated by this method.
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Figure 5.8 Phosphomimetic mutant pSL1180-cassette-hRyR2 chromatograms. A. WT-S2031D, B. 
WT-S2808D, C. S2246L-S2031D, D. S2246L-S2808D, E, N4104K-S2031D, and F. N4104K-S2808D. 
DNA sequencing was successful for all constructs, with desired point mutations verified. The codon 
substitution is highlighted in blue. 
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5.3.2 Do hRyR2 phosphomimetics traffic correctly in HEK293 cells? 
 
Direct visualization of recombinant protein eGFP fluorescence or IF localization with an anti-
RyR2 antibody (pAb-1093) with Alexa546-conjugated secondary antibody suggests that the 
phosphomimetic RyR2 proteins target to the ER in HEK293 cells. The total co-incidence 
between eGFP fluorescence and immunolocalization was calculated by Manders overlap 
coefficient in ImageJ software as described previously in Section 3.2.2 (Manders et al. 1993). 
WT phosphomimetic constructs all showed a high degree of colocalization (Figure 5.9). 
Analysis of green to red pixels gave coefficients between 0.79-0.96, and of red to green pixels 
between 0.75-0.93. No significant differences between WT and phosphomimetic constructs 
were found. S2246L constructs also displayed a high degree of colocalization (Figure 5.10), 
with Manders coefficients of green to red pixels between 0.85-0.92 and red to green pixels 
between 0.76-0.89 and no significant differences calculated between constructs. This indicates 
that the N-terminus and C-terminal end of the construct localize together in the ER, with little 
degradation.  
 
However, one-way ANOVA found significant differences between N4104K and its S2808D and 
S2031D variants (Figure 5.11). N4104K phosphomimetics displayed a significantly lower 
degree of colocalization for green to red pixels (N4104K=0.9083 vs. NK4104K-S2808D=0.7447 
and NK4104K-2031D=0.7048, p<0.05 by one way ANOVA with Bonferroni posthoc test). 
However, in the coefficient calculation of red to green pixels, no significant differences were 
calculated. Approximately one third (30 %, n=10) of HEK293 cells transfected with N4104K 
phosphomimetic constructs that were visualized did not have the characteristic reticular pattern 
of fluorescence and instead appeared ‘blobby’. Given the finding of lone red pixels in regions 
without green and the ‘blobby’ appearance of N4104K phosphomimetic hRyR2-transfected 
HEK293 cells, this indicates there may be some issue with protein integrity within the cell. 
However, all coefficients were calculated to have relatively strong cooccurrence, ranging 
between 0.683-0.9083, and this would indicate the expression of some intact, full-length 
recombinant hRyR2 within the ER.
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Figure 5.9 WT phosphomimetic hRyR2 constructs appear 
to exhibit correct intracellular trafficking. HEK293 cells 
transfected with hRyR2 constructs were examined for eGFP 
fluorescence (ex. 488 nm, em. 525±25 nm, left images) and 
immunofluorescence of Alexa546 secondary antibody targeted 
to hRyR2 primary antibody pAb-1093 (em. 546 nm, ex. 572±30 
nm, centre images). Colocalization (of green to red and red to 
green) was calculated by Manders overlap coefficient (B), with 
no significant differences calculated by one way ANOVA with 
Bonferroni posthoc, n = 4-5 cells per construct. The scale bar 
represents 10 µm. 
10 µm 
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Figure 5.10 S2246L phosphomimetic hRyR2 constructs 
appear to exhibit correct intracellular trafficking. HEK293 
cells transfected with hRyR2 constructs were examined for 
eGFP fluorescence (ex. 488 nm, em. 525±25 nm, left images) 
and immunofluorescence of Alexa546 secondary antibody 
targeted to hRyR2 primary antibody pAb-1093 (em. 546 nm, ex. 
572±30 nm, centre images). Colocalization (of green to red and 
red to green) was calculated by Manders overlap coefficient (B), 
with no significant differences calculated by one way ANOVA 
with Bonferroni posthoc, n = 4-5 cells per construct. The scale 
bar represents 10 µm. 
 
10 µm 
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Figure 5.11 N4104K phosphomimetic hRyR2 constructs appear to exhibit 
mostly correct intracellular trafficking, although some cells appear unusual. 
HEK293 cells transfected with hRyR2 constructs were examined for eGFP 
fluorescence (ex. 488 nm, em. 525±25 nm, left images) and immunofluorescence 
of Alexa546 secondary antibody targeted to hRyR2 primary antibody pAb-1093 
(ex. 546 nm, em. 572±30 nm, centre images). Colocalization (of green to red and 
red to green) was calculated by Manders overlap coefficient (B), with significant 
differences calculated by one way ANOVA with Bonferroni only in analysis of 
green to red pixels, not in red to green (n = 4-5 cells per construct). As indicated 
by images labelled ‘blobby’, some colocalization appears unusual in NK 
phosphomimetic constructs (~30 % of cells investigated). The scale bar 
represents 10 µm. 
 
10 µm 
238 
 
5.3.3 What is the transfection efficiency and Ca2+ release channel functionality of 
hRyR2 phosphomimetics in HEK293 cells? 
 
HEK293 cells expressing WT or mutant phosphomimetic hRyR2 constructs were identifiable by 
their caffeine-induced Ca2+ release, with a sharp increase in fluo-3 signal amplitude after 
caffeine addition (10 mM) and no further spontaneous Ca2+ release events. This signified the 
expression of functional hRyR2 channels within the HEK293 cell as previously discussed 
(Section 3.3.2). Images used to assess the efficiency of transfection of HEK293 cells with each 
mutant and phosphomimetic hRyR2 DNA construct can be found in Appendix XIX-XVI.  
 
Calculation of the percentage of cells exhibiting eGFP fluorescence following Effectene-
mediated transfection did not demonstrate comparable efficiencies for all phosphomimetic 
hRyR2 DNA constructs (Figure 5.12). A significantly decreased mean transfection efficiency 
was calculated for WT08 hRyR2-transfected cells in comparison to WT (A). SL31 hRyR2-
transfected cells also exhibited a significant decrease in comparison to S2246L, whereas SL08-
transfected cells showed a similar transfection efficiency. Cells transfected with either N4104K 
phosphomimetic hRyR2 DNA construct (NK08 or NK31) showed a dramatic decrease in 
transfection efficiency in comparison to the parent mutant N4104K. However, low transfection 
efficiencies were reproducible with different DNA preparations for each construct, with 3 
separate plasmid DNA preparations used in 3 transfections of each N4104K phosphomimetic 
hRyR2 DNA.    
 
While every construct showed functional caffeine-induced Ca2+ release, indicative of the 
presence of functional hRyR2 channels, Figure 5.13 shows that the ER Ca2+ content 
(calculated as described in Section 3.2.3.4) was significantly altered by the expression of some 
phosphomimetic hRyR2s. In comparison to WT, cells transfected with WT08 or WT31 were 
found to have a significantly increased ER Ca2+ load. Following a similar pattern, cells 
expressing SL08 also showed a significantly increased ER Ca2+ load in comparison to those 
expressing S2246L. The increase in load of cells expressing SL31, NK08 or NK31 was not 
significantly different to that of the parent mutant.  
 
Heterogeneity in channel dysfunction (in particular the amplitude of a Ca2+ release transient) 
may result from an increased or reduced Ca2+ store and this therefore must be considered in 
data interpretation of these constructs. This is addressed in Section 5.4.2. 
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5.3.4 What is the expression level of hRyR2 phosphomimetics in HEK293 cells? 
 
WT and mutant phosphomimetic hRyR2 cell homogenate preparations were generated and 
analysed by Western blotting as described in Chapter 2. Load was normalized to transfection 
efficiency as discussed in Section 3.3.1, such that expression level per hRyR2 expressing cell 
could be estimated. At loads of 100 μg (or equivalent after normalization), the signal detected 
for eGFP-hRyR2 (~565 kDa) for each lane was normalized to that for vinculin (~117 kDa) for 
each blot. An average was then taken for 3-9 separate blots (for WT, S2246L and N4104K 
expression, data were pooled from previous blots hence the higher n numbers). Figure 5.14 A 
shows an example of a Western blot for this assessment.  
 
Densitometric analysis revealed comparable levels of expression in comparison to the 
equivalent parent hRyR2 (i.e. WT vs. WT08, WT vs. WT31) as assessed by one way ANOVA 
with Bonferroni posthoc (p<0.05, Figure 5.14 B).  
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Figure 5.12 Most phosphomimetic hRyR2-expressing HEK293 cells do not have a comparable 
transfection efficiency to parent hRyR2. n transfection WT=6, WT08=2, WT31=2, SL=7, SL08=2, 
SL31=2, NK=4, NK08=3, NK31=3. Data are displayed as mean ± SEM and were analysed by Kruskal-
Wallis with Dunn’s posthoc or in GraphPad Prism, with p<0.05 indicated by *, p<0.01 by **, p<0.001 by 
***. Where no error bars are shown, error was calculated as very small. 
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Figure 5.13 Mimic of phosphorylation at the S2808 site increases ER Ca2+ store load in cells 
expressing WT or S2246L but not N4104K hRyR2. n cells WT=41, WT08=44, WT31=63, SL=43, 
SL08=43, SL31=21, NK=25, NK08=7, NK31=34. Data are presented as mean ± SEM, p<0.05 is denoted 
by *, p<0.01 by ** and p<0.001 by *** as calculated by Kruskal-Wallis with Dunn’s posthoc analysis with 
GraphPad Prism.  
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Figure 5.14 Assessment of WT, mutant and phosphomimetic hRyR2 protein in HEK293 cells reveals no significant differences in eGFP-
hRyR2 expression. A. Representative protein bands achieved from Western blot analysis hRyR2 in HEK293 cells, detected in cell homogenate 
preparation. eGFP-hRyR2 band signals are 565 kDa in size. Vinculin was used as a loading control. Original and additional Western blots are 
found in Appendix I and XXIII. B. Densitometric analysis of the 100 μg signal of WT and mutant hRyR2 preparations revealed that N4104K levels 
were significantly higher, normalized to the vinculin signal. Data are displayed as mean ± SEM and were analysed by one way ANOVA with 
Bonferroni posthoc in GraphPad Prism. n=3-9 experiments (n WT, SL and NK=9, n WT08, WT31, SL08 and SL31=4, n NK08 and NK31=3).  
243 
 
5.3.5 What is the effect of hRyR2 phosphomimetics on the percentage of cells 
expected to respond to caffeine/show agonist-induced Ca2+ release, according to 
transfection efficiency? 
 
The propensity for hRyR2-transfected HEK293 cells to undergo spontaneous Ca2+ oscillations 
was calculated as in Section 3.3.4. Figure 5.15 compares the transfection efficiency of WT and 
mutant hRyR2 phosphomimetics (grey bars) with the number of cells responsive to caffeine 
(black bars), and therefore assumed to be expressing functional hRyR2 channels. It is important 
to compare these two parameters to determine whether changes in Ca2+ release propensity are 
attributed to altered transfection efficiency (see Section 5.3.3). 
 
Compared to WT, WT31 hRyR2-transfected cells show an increased propensity for Ca2+ release 
(A). This is not due to an increased transfection efficiency – in fact, the number of oscillating 
cells is far higher than expected (significant by Mann-Whitney test, p<0.001). There is no 
significant difference in propensity for Ca2+ release between WT and WT08 hRyR2-transfected 
cells. 
 
Compared to S2246L, SL31 hRyR2-transfected cells also show an increased propensity for 
Ca2+ release which cannot be attributed to an increased transfection efficiency (B). The number 
of oscillating cells is far higher than expected (p<0.001).  
 
In comparison to N4104K, both NK08 and NK31 hRyR2-transfected cells exhibit a decreased 
propensity for Ca2+ release (C). This was anticipated, as transfection efficiencies cells 
expressing these DNA plasmids were calculated as very low (0.24 and 1.43 %, respectively), 
although the number of oscillating cells in both instances were significantly higher than expected 
when compared to the calculated transfection efficiency (p<0.001).
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Figure 5.15 Some mutant and phosphomimetic hRyR2-transfected HEK293 cells showed an 
altered percentage of cells displaying agonist-induced Ca2+ release in comparison to WT, but not 
as a result of altered transfection efficiency. Graphs show the propensity of hRyR2-transfected cells to 
respond to caffeine (black bars) in comparison to the calculated transfection efficiency (grey bars), as 
shown in Figure 5.12. Total number of cells recorded for caffeine response data WT=1003, WT08=439, 
WT31=514, SL=1274, SL08=1032, SL31=369, NK=1405, NK08=508, NK31=529. For transfection 
efficiency, n transfections WT=6, WT08=2, WT31=2, SL=7, SL08=2, SL31=2, NK=4, NK08=3, NK31=3. 
Data are displayed as mean ± SEM and where no error bar is present, error was very small. Data were 
analysed by Kruskal-Wallis with Dunn’s posthoc (propensity of variants) or Mann-Whitney tests 
(responders vs. propensity for each variant) in GraphPad Prism, with p<0.001 indicated by ***. Black lines 
represent statistical differences in transfection efficiency compared to the proportion of caffeine 
responsive cells, while red lines represent statistically significant differences in caffeine response only. 
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5.3.6 How do phosphomimetic mutations modify the spontaneous Ca2+ release 
kinetics of hRyR2-transfected HEK293 cells? 
 
A schematic representation of the Ca2+ release events from phosphomimetic hRyR2-transfected 
HEK293 cells is shown below.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 A schematic representation of spontaneous Ca2+ release events from WT, 
mutant and phosphomimetic hRyR2-transfected HEK293 cells. These are drawn, based on 
the mean values of the data sets (see Table 5.9).  
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An in-depth analysis of Ca2+ oscillation events is presented as a series of bar graphs in Figures 
5.17-19, with Ca2+ handling kinetic parameters calculated as described in Section 3.2.3.4 with 
SALVO analysis software. Scatter plots of imaging data can be found in Appendix XXVIII-XXX.   
 
Amplitude, rate up and rate down are significantly increased in WT31 and WT08 expressing 
HEK293 cells in comparison to WT, resulting in a shorter duration of event while inter-event 
duration is significantly decreased. Frequency is only altered on introduction of the WT31 
mutation in comparison to WT hRyR2-transfected cells (Figure 5.17).  
 
Interestingly, the introduction of phosphomimetic mutations did not have quite such a profound 
effect on the function of S2246L channels expressed in HEK293 cells. SL08 expressing cells did 
however exhibit an increased amplitude and rate up of oscillation event with significantly 
decreased inter-event duration and rate down. On the other hand, the only change in Ca2+ 
release kinetics observed in SL31-expressing cells was a significant decrease in the duration of 
a release event (Figure 5.18).  
 
Phosphomimetic mutation had even less of an effect on N4104K spontaneous Ca2+ release 
function with NK08 showing only an increased rate up and down and NK31 exhibiting an 
increased rate up and amplitude (Figure 5.19).  
 
Table 5.9 summarizes the differences in Ca2+ handling parameters between phosphomimetic 
hRyR2-transfected cells in comparison to parent hRyR2-transfected cells.  
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Figure 5.17 Assessment of spontaneous Ca2+ release events in HEK293 cells expressing WT 
phosphomimetic hRyR2. All parameters were calculated as described in Section 3.2.1.4. n WT=164, 
WT08=49, WT31=73. Data are presented as mean ± SEM, p<0.05 is denoted by *, p<0.01 by ** and 
p<0.001 by *** as calculated by Kruskal-Wallis with Dunn’s posthoc analysis with GraphPad Prism.  
 
248 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 Assessment of spontaneous Ca2+ release events in HEK293 cells expressing S2246L 
phosphomimetic hRyR2. All parameters were calculated as described in Section 3.2.1.4. n SL=109, 
SL08=51, SL31=120. Data are presented as mean ± SEM, p<0.05 is denoted by *, p<0.01 by ** and 
p<0.001 by ***, as calculated by Kruskal-Wallis with Dunn’s posthoc analysis with GraphPad Prism.
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Figure 5.19 Assessment of spontaneous Ca2+ release events in HEK293 cells expressing N4104K 
phosphomimetic hRyR2.  All parameters were calculated as described in Section 3.2.1.4. n NK=97, 
NK08=38, NK31=12 cells. Data are presented as mean ± SEM, p<0.05 is denoted by *, p<0.01 by ** and 
p<0.001 by *** as calculated by Kruskal-Wallis with Dunn’s posthoc analysis with GraphPad Prism.
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Table 5.9 Summary of Ca2+ handling parameters in WT, mutant and phosphomimetic hRyR2-
transfected HEK293 cells. Mean values for calcium handling parameters of WT and mutant hRyR2-
expressing HEK cells, ± SEM. Differences are calculated compared to the equivalent parameter in parent 
hRyR2-expressing HEK293 cells i.e. WT08 and WT31 are compared to WT, SL08 and SL31 are 
compared to SL, NK08 and NK31 are compared to NK. Red indicates a statistically significant increase 
whereas blue indicates a statistically significant decrease as calculated by Mann Whitney or Kruskal-
Wallis test with Dunn’s post hoc test, p<0.01.  
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5.3.7 Is there an effect of hRyR2 phosphomimetic expression on that of the 
endogenous HEK293 SERCa? 
 
Given that expression of some hRyR2 phosphomimetics altered ER Ca2+ store load (Figure 
5.13) and increased Ca2+ release amplitude in Ca2+ imaging experiments (Figure 5.17-19), it 
was important to assess whether an alteration in the expression of SERCa could be contributing 
to these findings.  
 
The expression of SERCa was determined for all hRyR2 homogenate preparations by Western 
blotting as described in Section 3.3.1. Loading was normalized by transfection efficiency as 
discussed in Section 3.3.1 and β-tubulin (~50 kDa) was assessed as a loading control. 
Densitometric analysis of SERCa (~109 kDa) signals shows significant differences in 
expression for cells expressing WT or SL phosphomimetics and those expressing the parent 
construct (Figure 5.20). In particular introduction of the S2808D mutation into both WT and 
S2246L hRyR2s resulted in higher SERCa expression, going some way to explaining the 
increased store load observed in these cells (Figure 5.13). While introduction of S2031D into 
the S2246L hRyR2 also affected the expression of this pump in the absence of any 
measureable load change. As a result of a large variance, expression of SERCa in cells 
expressing N4104K phosphomimetics were comparable to that of the parent mutant.  
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Figure 5.20 Assessment of cell homogenate from WT, mutant and phosphomimetic hRyR2-HEK293 reveals differences in SERCa 
expression. A. Representative bands of SERCa and β-tubulin signal of transfected HEK293 cells and of cells. L refers to protein ladder. Original 
and additional blots can be found in the Appendix B. Densitometric analysis of SERCa signal normalized to β-tubulin signal, n= 2-4 experiments 
(WT, SL and NK bands from 4 blots, phosphomimetic bands from 2 blots). Significant differences were detected by one way ANOVA with 
Bonferroni posthoc in GraphPad Prism, p<0.05 indicated by *, p<0.01 by **. Original and additional blots can be found in Appendix XI and XX. 
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5.4 Discussion 
 
Major findings of this chapter include: 
• Genetic phosphorylation affects N4104K channel expression and trafficking in HEK293 
cells, highlighting that generating phosphomimetic mutations at S2808 and S2031 
makes the N4104K hRyR2 channel unstable and likely causes it to break down 
• Genetic phosphorylation profoundly alters the ER Ca2+ load, mainly by affecting SERCa 
expression even after transient transfection, highlighting the importance of 
understanding Ca2+ flux across a HEK293 cell 
• Genetic phosphorylation does not have as profound an effect on CPVT hRyR2 mutant 
function as it does on that of the WT in HEK293 cells 
• Effects of genetic phosphorylation are different to those of agonist-induced 
phosphorylation 
 
 
5.4.1 Six phosphomimetic hRyR2 DNA plasmids were successfully generated via 
site-directed mutagenesis  
 
After thorough optimization of the process, and use of supercompetent bacteria not normally 
used for hRyR2 cloning, all six phosphomimetic hRyR2 DNA plasmids were generated by SDM 
using the cassette-based strategy outlined in Section 5.2.1. and produced in sufficient quantity 
for transfection. This process was not straightforward and required many ligation attempts to 
produce a full-length hRyR2 plasmid in XL10 cells (Figure 5.6), following this, recombination 
was a major issue during large scale bacterial cell culture. This could not be overcome by 
changing incubation conditions or growth media (Table 5.8), nor by retransformation of XL10 
cells with plasmid DNA generated during small scale plasmid isolation.  
 
It is unclear why scaling up of hGFP-hRyR2 phosphomimetic plasmid cultures was possible in 
Stbl2 but not XL10 cells. Stbl2 competent Escherichia coli cells are described as high-efficiency 
chemically competent cells specifically designed for unstable inserts, with an efficiency of 1 x109 
transformants/μg plasmid DNA for cloning rare sequences. XL10 Gold competent (Epicurean 
coli) cells are for ‘extremely demanding cloning’, with an average transformation efficiency of ≥5 
x109 transformants/μg of plasmid DNA. The most notable difference between the two types of 
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cells (apart from being from a different genus) is that XL10 cells contain the F’ episome, 
whereas Stbl2 cells do not. This F’ fertility factor episome is a plasmid that can integrate itself 
into the bacterial chromosome by homologous recombination. Perhaps the presence of this 
episome in XL10 cells leads to recombination of plasmid DNA when large quantities of cells and 
DNA are present as in large scale culture. Stbl2 cells were specifically designed to reduce 
recombination in this setting.  
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5.4.2 Genetic phosphorylation affects N4104K channel expression and trafficking, 
while these fundamental properties remain unaltered for S2246L and WT 
phosphomimetics  
 
Immunofluorescence was used to confirm that all six phosphomimetic hRyR2 channels localized 
to the ER of HEK293 cells, observing a reticular pattern of fluorescence as in Chapter 3 
(Figures 5.9-11). Manders overlap coefficient was calculated to indicate the overlap of green 
pixels (the inherent eGFP fluorescence of the recombinant protein) to red pixels (antibody 
raised to a portion of the hRyR2 C terminal), and vice versa. All values calculated indicated 
good cooccurrence of pixels (0.68-0.96), but of all WT and mutant phosphomimetic hRyR2 
constructs, NK08 and NK31 hRyR2-transfected HEK293 cells were calculated to have the 
lowest coefficient values. In particular, red pixels (the C terminal of hRyR2) were found in 
regions alone and without green pixels (the eGFP tag). It could be suggested that with 
breakdown of protein, calpain cleavage would remove the N-terminal eGFP tag, leaving the C-
terminal behind, visualized as lone red pixels in IF experiments. The staining pattern in 30 % of 
these cells also had a ‘blobby’ appearance, rather than the characteristic reticular pattern, a 
type of distribution more consistent with that of lysosomes within HEK293 cells. This suggests 
that N4104K phosphomimetic protein is more unstable and prone to degradation within the cell, 
with less ER targeting of intact protein and channels forming in an abnormal way. As well as 
this, N4104K hRyR2 phosphomimetic DNA plasmids were the most difficult to generate, 
requiring the highest number of ligation and transformation attempts. It can therefore be 
suggested that the combination of pathogenic and phosphomimetic amino acid mutation makes 
the hRyR2 protein unstable in this instance. This is reflected in significantly lower transfection 
efficiencies for NK08 and NK31 hRyR2 DNA in HEK293 cells in comparison to N4104K (0.24 % 
and 1.43 % vs. 31.14 % respectively, see Figure 5.12) and very low n numbers obtained for 
subsequent Ca2+ imaging experiments (see Figure 5.19).  
 
For all constructs, a population of hRyR2-transfected cells displayed caffeine-induced Ca2+ 
release, indicative of the presence of functional hRyR2 channels (Figure 5.13, discussed further 
in Section 5.4.4). Western blot analysis also confirmed the expression of all WT and mutant 
eGFP-hRyR2 phosphomimetics at the correct molecular weight in HEK293 cell homogenates. 
No significant differences in expression level between phosphomimetics and their parent hRyR2 
variant were found by one way ANOVA with Bonferroni posthoc test (Figure 5.14). Samples 
were assessed by Western blotting at least three times each. It is notable however that the 
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expression of NK08 and NK31 does appear to be lower than N4104K, albeit the differences 
were not calculated as significant. Lower expression may have been expected given cells 
transfected with these hRyR2 plasmids showed some protein degradation in the cell as 
evidenced by immunocolocalization (see above) and a lower transfection efficiency. Samples 
were loaded in a way that was normalized for transfection efficiency (i.e. more protein was 
loaded for N4104K phosphomimetics than N4104K in HEK293 cells). While this should mean 
that all lanes in the blot display equivalent signal, this would only be the case if the expression 
level of hRyR2 per cell was equivalent for each construct. As differences are not significant, this 
suggests that hRyR2 protein expression is not different between cells expressing N4104K and 
N4104K phosphomimetic hRyR2, although expression in this assay does not necessarily equate 
to functional channels in the cell. It should also be noted that N4104K hRyR2 expression in 
HEK293 cells was originally calculated as significantly increased in comparison to WT hRyR2 
(see Figure 3.3.7). This likely means that expression of hRyR2 per cell is higher for N4104K but 
not for N4104K phosphomimetics, in comparison to WT, where there is suspected degradation. 
Changes in spontaneous Ca2+ release events caused by phosphomimetic mutations in both 
S2246L and N4104K hRyR2-transfected HEK293 cells is discussed in Section 5.4.6.  
 
5.4.3 Genetic phosphorylation profoundly alters the ER Ca2+ load, mainly by 
affecting SERCa expression 
 
ER Ca2+ load was estimated by the addition of a maximal dose of caffeine as described in 
Section 3.2.3.3. Both WT08 and WT31 hRyR2-transfected HEK293 cells exhibited an 
increased Ca2+ store load in comparison to WT-transfected cells (Figure 5.20). This is in 
contrast to work by Stange et al. (2003), who found that the caffeine-sensitive ER-Ca2+ store 
loads of S2808D mouse RyR2-transfected cells did not increase in comparison to WT. The 
effect of this genetic phosphorylation is in contrast to that of the pharmacological 
phosphorylation discussed in Chapter 4 (Section 4.12), where the store load of cells expressing 
WT hRyR2 was decreased on application of DcAMP.  
 
As the Ca2+ content of the ER is increased for WT phosphomimetic hRyR2-transfected HEK293 
cells, it was important to assess SERCa expression levels given its role in sequestration of Ca2+ 
back into the store. Enhanced expression or activity of SERCa could account for the presence 
of more Ca2+ in the store. Introduction of plasmid vectors that are under the control of the CMV 
promoter (which is the promoter present in pcDNA3, the hRyR2 plasmid vector) forces the 
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translation of gene products in HEK293 cells by ‘hijacking’ the cell’s protein machinery (Thomas 
and Smart 2005). An advantage of using transient transfection is that high levels of expression 
can be achieved without integrating the nucleic acid sequence within the host chromosome. The 
effects are therefore only temporary, and it would be reasonable to suggest that adaptive 
remodelling of other cellular components would not be observed within such a short period of 
expression (24-72 hr).  
 
However, Western blot analysis of hRyR2-transfected HEK293 cell homogenate samples 
revealed that transfection with some phosphomimetic hRyR2 DNA plasmids (WT08, SL08, 
SL31) led to increased SERCa expression. This provides an explanation for the discrepancy 
seen between the effects of genetic vs pharmacological phosphorylation on the ER load for 
these phosphomimetics. In particular, phosphorylation of cells expressing S2246L hRyR2 
exhibited a decreased Ca2+ store load (in Section 4.12), whereas genetic phosphorylation in 
this chapter resulted in increased ER load for SL08.  SERCa expression/Ca2+ load was also 
increased in cells expressing WT08, suggesting that genetic phosphorylation at this site has 
resulted in an overall similar response in cells expressing these variants. N4104K 
phosphomimetic hRyR2-transfected HEK293 cells exhibited no change in ER Ca2+ store load in 
comparison to N4104K-transfected cells, but n numbers were very low (n: NK08=38, NK31=12).  
 
In the majority of studies, phosphorylation at other sites is not assessed in tandem to the site of 
interest, nor is the expression of other Ca2+ cycling proteins such as SERCa or PLB. In terms of 
KI/KO mouse models and stable-transfected cell lines, adaptive remodelling may explain huge 
discrepancies between data (Brittsan et al. 2003). This is evident in S2808A cardiomyocytes of 
the Valdivia mouse model, where phosphorylation at S2031 and S2814 was increased in the 
presence of isoproterenol in comparison to WT as assessed by Western blotting (Benkusky et 
al. 2007).  
 
In the assessment of Ca2+ release events from RyR2-transfected HEK293 cells, expression of 
SERCa or any alterations that transient expression of RyR2 may have on other proteins in the 
cell is not discussed in the literature, aside from Thomas et al. (2005), where no significant 
changes were seen in the store load or SERCa expression of WT, L433P, N2386I and 
R176Q/T2504M hRyR2-transfected HEK293 cells. Considering SERCa expression is revealed 
here as altered upon expression of certain hRyR2 phosphomimetics, future studies should 
consider that Ca2+ release events may also be influenced by enhanced Ca2+ sequestration into 
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the ER by SERCa in this setting. Given the length of a HEK293 cell cycle is approximately 24 hr 
(Bernard et al. 2007; Unsal-Kaçmaz et al. 2005), it is plausible that expression of hRyR2 for 48 
hr (approximately the time at which Ca2+ imaging experiments take place after transfection) 
could lead to increased expression of SERCa in cells during this time. It is difficult to speculate 
as to how and why this occurs. Increased SERCa expression may be a process of adaptive 
remodelling, whereby the cell responds to increased influx of Ca2+ from the ER into the cytosol 
by increasing SERCa-mediated reuptake. Expression and phosphorylation levels of PLB should 
be also considered in cardiomyocytes when investigating RyR2 phosphorylation status, but this 
does not apply to HEK293 cells which are devoid of this protein (Kurzydlowski 1996; Asahi et al. 
2003; Toyofuku et al. 1994). 
 
While increased expression of SERCa may account for changes in Ca2+ release kinetics 
observed in WT08 hRyR2-transfected HEK293 cells (Figure 5.17, discussed in Section 5.3.6), 
this cannot account for changes observed on introduction of WT31 or SL31 mutation. An 
increased store load in this case could be indicative of an altered sensitivity of hRyR2 to 
luminal/cytosolic Ca2+, since phosphorylation of RyR2 has previously been suggested to affect 
luminal Ca2+ sensing (Wehrens et al. 2004; Ullrich et al. 2012; Xiao et al. 2006).  
 
5.4.4 eGFP fluorescence may misrepresent the proportion of cells expressing 
hRyR2 phosphomimetics 
 
A proportion of all cell populations expressing WT or mutant phosphomimetic hRyR2 displayed 
caffeine-induced Ca2+ release, indicative of functional hRyR2. However, these experiments 
revealed a discrepancy between transfection efficiency (cells exhibiting eGFP fluorescence) and 
the proportion of cells showing spontaneous Ca2+ release.  
 
While some phosphomimetic derivatives of S2246L and N4104K hRyR2 exhibited low 
transfection efficiency in HEK293 cells, compared to that of the parent hRyR2, this was not the 
case for WT hRyR2 phosphomimetics. While SL31-transfected HEK293 cells did have a lower 
transfection efficiency and a significantly increased proportion of caffeine responsive cells 
compared to S2246L, a disproportionately large number of caffeine responsive cells were 
recorded (see Figure 5.12, and 5.15).  
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A discrepancy in the number of caffeine-responsive cells and calculated transfection efficiency 
may be due to detection limits. In cells where expression is at a low level, function can more 
easily be detected by caffeine-induced Ca2+ release, but there may not be enough protein to 
observe eGFP fluorescence. 
This explanation does not follow for WT phosphomimetic mutations (Figure 5.15). Propensity 
was significantly decreased in WT08 hRyR2-transfected HEK293 cells and was not a result of 
an increased transfection efficiency (see Figure 5.12 and 5.15). This would suggest that 
transfection efficiency may have been overestimated in this instance.  
 
The Chen group propose that enhanced propensity for spontaneous Ca2+ release events in this 
setting is a hallmark of dysfunction caused by CPVT1 mutation (Jiang et al. 2004; Jiang 2005). 
An enhanced propensity for caffeine-induced Ca2+ release is observed in HEK293 cells 
expressing SL31 in comparison to those expressing SL. Given the structure of the RyR2 
channel with 4 subunits and 4 S2031 sites within the complex, genetically phosphorylated 
channels have phosphorylation mimicked at all 4 sites. In WT or mutant hRyR2-transfected 
HEK293 cells, channels may exist with 0-4 S2031 sites phosphorylated. Even the addition of 
DcAMP to activate PKA may not elicit phosphorylation at all four S2031 sites in these channels, 
therefore propensity does not increase. In contrast, no increase in propensity was observed on 
DcAMP-mediated phosphorylation in Chapter 4. While DcAMP-mediated phosphorylation will 
cause more channels in the population of a cell to be active, genetic phosphorylation at S2031 
to full stoichiometry may cause all the hRyR2 channels in the population to have an increased 
Po. These data may indicate functional relevance of PKA-mediated phosphorylation at the 
S2031 site in S2246L hRyR2 channels. However, functional relevance within a heterologous 
expression system does not necessarily equate to physiological relevance within a ventricular 
myocyte in vivo, given the artificial nature of the system. 
 
Although differences have been observed in this instance when calculating caffeine-responsive 
cells as a percentage of the population, arguably propensity is generally not a good indicator of 
CPVT1 RyR2 channel dysfunction in HEK293 cells, given that others also have not observed a 
change in propensity for spontaneous Ca2+ release events when investigating disease-linked 
mutations (Loaiza et al. 2013). No differences in propensity for caffeine-induced Ca2+ release 
events between WT and mutant hRyR2-transfected HEK293 cells in previous experiments 
(Figure 3.14 and 4.13).  
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5.4.5 Genetic phosphorylation at S2808 and S2031 have similar effects on WT 
hRyR2 Ca2+ release 
 
HEK293 cells were transfected with WT or mutant phosphomimetic hRyR2 for Ca2+ imaging 
experiments as in Chapter 3. Genetic phosphorylation at S2808 and S2031 resulted in similar 
changes to the Ca2+ release kinetics of HEK293 cells expressing hRyR2 i.e. an increased 
amplitude, a decreased inter-event duration, an increased rate up and an increased rate down 
(Figure 5.17).  
 
Increased amplitude is indicative of phosphorylated hRyR2 channels releasing more Ca2+ from 
the store, however, rather than being due to any sensitization of the channel to agonist it is likely 
the result of the increased store loads observed in cells expressing WT08 and WT31 channels 
(Figure 5.13). Although the decreased inter-event duration would suggest that less Ca2+ can be 
sequestered into the cell during this shorter period, store load and amplitude of Ca2+ release 
events are also increased, likely because of an increase in SERCa expression observed in 
WT08 and WT31-transfected cells (Figure 5.18). In work of the Hajjar laboratory utilizing gene 
therapy to transduce SERCa2a into guinea pigs, isolated cardiomyocytes with overexpression 
of SERCa2a displayed accelerated reuptake of cytosolic Ca2+ as measured by τ, the Ca2+ 
transient decay time constant (Cutler et al. 2012). This also equates to a shortening of inter-
event duration caused by SERCa.    
 
While a change in propensity observed in WT phosphomimetics may be explained in the most 
part by changes in transfection efficiency and store load, density of hRyR2 clusters could also 
be affected, as mentioned in Section 3.4.4 and Section 4.1.1.  
 
Unlike WT08, expression of WT31 increases the frequency of Ca2+ release events in HEK293 
cells compared to WT. An increased frequency of events may be an expected effect of 
phosphorylation, given that in a native cardiomyocyte, PKA-mediated phosphorylation of EC 
coupling proteins and enhanced Ca2+ cycling is a key response to increased metabolic demand. 
This was one of the effects of the N4104K mutation in the absence of PKA activation (see 
Figure 3.16). However, this was not due to phosphorylation at the S2031 site, as this was 
shown to be low (compared to that of the WT) in this mutant. It might be that this 
dephosphorylation of S2031 is responsible for higher channel Po, as similar conditions have 
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been shown to result from dephosphorylation at the S2808 site (Carter et al. 2011; Carter et al. 
2006). Imaging data of N4104K phosphomimetic hRyR2 is discussed in the next section.   
 
5.4.6 Genetic phosphorylation does not have as profound an effect on mutant 
function as it does on that of the WT 
 
The Ca2+ release kinetics of phospho-CPVT1 mutants were compared to the parent mutant 
hRyR2 in order to assess the effects of genetic phosphorylation at each site e.g. Ca2+ release 
kinetics of SL08 and SL31 hRyR2-transfected cells were compared to SL rather than WT 
hRyR2. 
 
SL31 hRyR2-transfected cells also display an increased propensity for caffeine-induced Ca2+ 
release in comparison to S2246L (Figure 5.15). This was also not because of increased 
transfection efficiency. Phosphorylation at the S2031 site must cause more channels to be 
active within a population of transfected cells. This suggests that enhanced channel activity 
caused by this CPVT1 mutation is exacerbated after PKA stimulation, (Section 4.4.2). As these 
changes in propensity follow that of WT upon phosphorylation at this site, it remains to be seen 
whether other changes will reveal S2246L channel dysfunction that has not been observed in 
previous experiments. No changes were identified in propensity of N4104K phosphomimetic 
hRyR2-transfected HEK293 cells, but n numbers were very low for these experiments. 
 
In contrast to S2031D, introduction of S2808D to S2246L has a more marked effect on channel 
function – similar to the effects of this phosphomimetic on the WT i.e. increasing amplitude, rate 
up and down and decreasing inter-event duration (Figure 5.18). This could suggest that 
phosphorylation to full stoichiometry at this site could be instrumental in revealing S2246L 
dysfunction, however the changes seen are not in excess of those seen in WT08 (with WT and 
S2246L being largely comparable to begin with, see Table 3.6), suggesting that phosphorylation 
at this site has similar effects on WT and S2246L.  
 
Analysis of Ca2+ release kinetics of N4104K phosphomimetic hRyR2-transfected HEK293 cells 
revealed very few changes in comparison to N4104K (Figure 5.19). NK08 hRyR2-transfected 
HEK293 cells (n=38) displayed an increased rate up and decreased rate down in comparison to 
N4104K-transfected cells, but no change in the overall Ca2+ release event duration. NK31 
hRyR2-transfected cells displayed an increased rate up and an increase in amplitude (n=12) 
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that was not due to an alteration in ER Ca2+ store load (Figure 5.13). These alterations give rise 
to Ca2+ release kinetics which appear more analogous to those observed in WT hRyR2-
transfected HEK293 cells.  
 
On the basis of these results, we might conclude that phosphomimetic modification of either site 
in this mutant channel does not affect function in the same way as it does the WT. Given that 
cells expressing N4104K hRyR2 already exhibit altered Ca2+ release kinetics in comparison to 
WT before phosphorylation (Figure 3.16), phosphorylation of the mutant channel may not elicit 
the normal physiological response. The N4104K mutation is thought to cause disruptions to 
inter-domain interactions away from the phosphorylation domain that renders phosphorylation at 
this site irrelevant, or disrupts the phosphorylation domain (Tateishi et al. 2008). However, 
conclusions here are made on data with very low n numbers, given the very low transfection 
efficiencies obtained when using N4104K hRyR2 DNA plasmids. 
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5.4.7 Effects of genetic phosphorylation are different to those of agonist-induced 
phosphorylation 
 
It is interesting that many of the observed changes caused by phosphomimetic amino acid 
substitution to hRyR2 are different to those caused by treatment of transfected cells with 
DcAMP. The discrepancy between results using DcAMP and genetic phosphorylation could be 
due to additional effects of the agonist used to promote phosphorylation. DcAMP may activate 
alternative endogenous kinases such as CaMKII and other cell signalling pathways given the 
role of cAMP as a ubiquitous secondary messenger (Hofer et al. 2007). Alterations in SERCa 
expression, occurring as a result of genetic phosphorylation (described in Section 5.3.7), may 
also account for differences.  
 
An alternative explanation is that genetic phosphorylation can lead to an alteration of hRyR2 
clustering. Transient treatment of WT hRyR2-transfected HEK293 cells with drug may not alter 
the clustering of RyR2 channels within the cells. However, the transfection of phosphomimetic 
hRyR2 DNA into cells over 48 hrs could lead to the expression of channels that are distributed 
more densely. As mentioned previously, work of Chen-Izu et al. (2007) highlighted that in the 
spontaneously hypertensive rat showing HF, RyR2 showed not only increased phosphorylation 
in this setting but also shortened spacing between RyR2 clusters in comparison to non-diseased 
controls. It should also be noted that in the work of Asghari et al. (2013) a change as fast and as 
transient as cytosolic Mg2+ concentration can modify the orientation of RyR2 tetramers relative 
to one another.  
 
Genetic phosphorylation targets just one of the potential phosphorylation sites of RyR2. This 
method is very useful to elucidate the effects of phosphorylation on an individual site without 
modulation of other sites in the channel. Mimicked phosphorylation of one site however does 
not emulate phosphorylation in a physiological setting, therefore effects observed at one site 
alone may not be seen when other sites are phosphorylated. In an in vitro setting with the use of 
recombinant hRyR2 DNA plasmid, all four subunits of the RyR2 channel would be genetically 
phosphorylated, while physiologically, this may not happen.  
 
While potentially more physiological, phosphorylation via treatment with an analogue of cAMP 
and activation of endogenous PKA could phosphorylate other sites in RyR2, in addition to the 
ones investigated. It cannot also be clarified exactly how many subunits of the RyR2 channel 
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are phosphorylated at each site, nor if all the channels in the population are phosphorylated to 
the same level. The phosphorylation level observed with 1mM DcAMP was the physiological 
maximum possible, as it wasn’t significantly different from the PKA control included in these 
experiments. However, this may not equate to the assumed full stoichiometry of 
mimicked/genetic phosphorylation.  
 
Given that in these experiments, a 48 hr window of hRyR2 expression was sufficient to alter the 
expression level of SERCa, it cannot be conclusively deduced that effects of genetic 
phosphorylation are solely due to a change in hRyR2 function. Any change in caffeine-sensitive 
ER Ca2+ load is likely not due to a change in hRyR2 Ca2+ sensitivity, but due to increased store 
filling by SERCa.  The Chen group have previously utilized a stable, tetracycline-inducible 
HEK293 cell line expressing WT or mutant RyR2 to investigate spontaneous Ca2+ release 
events within this system (Jiang et al. 2004). In these stable cells a repressor of RyR2 
expression is constantly expressed until the inducer, tetracycline, is added to the growth 
medium. If expression could be repressed until required such as in this system, reducing 
changes in the expression of other cellular proteins, the effects of genetic phosphorylation may 
be more similar to the effects of biochemical phosphorylation of DcAMP observed in Chapter 4.  
 
Findings from this chapter reveal that genetic phosphorylation of hRyR2 has a different effect on 
spontaneous Ca2+ release than that induced by activating PKA. While changes in basal 
phosphorylation could explain why mutant channels displayed fewer changes in spontaneous 
Ca2+ release behaviour compared to WT following DcAMP-mediated PKA phosphorylation, 
adaptive changes in the expression of other ER resident proteins (namely SERCa) cloud our 
interpretation of any possible changes in function induced by genetic phosphorylation. However, 
both modes of phosphorylation have in common that their effects were diminished on mutant, 
compared to WT hRyR2 – even though basal function was profoundly different for each of these 
mutants. 
 
Arguably, genetic phosphorylation of hRyR2 is a useful method to identify functional changes to 
channel activity caused by modification of one site, away from the influence of other 
modifications. In parallel with other methods, such as single channel analysis, this can allow the 
role of RyR2 phosphorylation at a single site to be untangled, while pharmacological 
phosphorylation allows investigation in a more physiological setting. Further experiments to 
expand on these findings are discussed in Chapter 6.  
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6.1 General discussion and future work  
 
The principal aim of this study was to investigate whether CPVT1 RyR2 mutations from different 
channel domains are functionally heterogeneous, as single channel preliminary data had 
suggested (Section 3.1.2). Investigations involved the biochemical and functional examination 
of two CPVT1-linked hRyR2 mutations - S2246L of the central domain and N4104K of the 
cytoplasmic portion of the I domain (see Figure 1.15).  
 
Findings of this study are summarized in Figure 6.1, 6.2 and 6.3, and are described in the 
following sections.  
 
 
6.1.1 N4104K hRyR2 exhibits more obvious dysfunction at the spontaneous Ca2+ 
release level than S2246L  
  
Spontaneous Ca2+ release events in hRyR2-transfected HEK293 cells were assessed to 
determine whether a) this method could reveal differences between WT and mutant hRyR2 Ca2+ 
release kinetics and b) Ca2+ release between mutants was functionally heterogeneous. This 
method has previously been applied to study RyR2 (D. Jiang 2005; N. L. Thomas et al. 2004; N. 
L. Thomas et al. 2005), allowing interrogation of RyR2 channels away from other influencing 
proteins, a factor important for this study. HEK293 cells also appear to produce comparable 
functional data to that of RyR2 from native sources (Du 1998; Bhat et al. 1999; Li and Chen 
2001; L. Xu and Meissner 1998). While the interaction of RyR2 with cytosolic and luminal 
cardiac proteins (not present in HEK293 cells) is known to modulate channel function, probing 
such interactions was not the goal of this study. Instead, transfected HEK293 cells permitted the 
investigation of fundamental hRyR2 channel defects caused by mutation alone. In the absence 
of any accessory proteins, preliminary single channel experiments with purified hRyR2 revealed 
that the N4104K mutation may cause fundamental functional defects, whereby channel gating 
occurred in the absence of activating ligand (Section 3.1.2.2). However, as a limitation to this 
method, it remains difficult to interpret changes in Ca2+ release kinetics while data on Ca2+ fluxes 
across the membrane in HEK293 cells are lacking.  
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As well as investigating the effects of mutation on the spontaneous Ca2+ release kinetics of 
hRyR2-transfected HEK293 cells (Section 3.5), expression level and intracellular trafficking 
were also assessed for any changes (Section 3.3.1 and 3.3.3, respectively). As a measure of 
functionality, the proportion of hRyR2 expressing cells exhibiting agonist-induced Ca2+ release 
was assessed (Section 3.3.3). This application of caffeine to hRyR2-transfected HEK293 cells 
also served to estimate the amount of Ca2+ within the ER Ca2+ store (Section 3.3.3).  
 
The spontaneous Ca2+ release of cells expressing N4104K hRyR2 appeared dysfunctional in 
comparison to that of those expressing WT, with a smaller amplitude, slower rate of transient 
ascent/descent, shorter inter-event duration and an increased frequency of spontaneous Ca2+ 
release events (Section 3.4.4). The expression of N4104K was also increased compared to WT 
and S2246L (whose expression levels were comparable in HEK293 cells, Section 3.3.1). 
Western loading was normalised for batch transfection efficiency and so this increase in 
expression represented an increase in the protein production per cell and was not as a result of 
increased efficiency of transfection. More channels per cell could change the kinetics of 
spontaneous Ca2+ release from transfected HEK293 cells, but this may not account entirely for 
the result, given that preliminary single channel data indicated N4104K hRyR2 channels 
displayed a fundamental gating defect in comparison to WT. However, while normalisation for 
transfection efficiency was necessary for discovering changes in expression of hRyR2 per cell, 
this method may have exaggerated the expression levels observed. N4104K transfection 
efficiencies were often lower than that of the WT (though not significantly so on average, see 
Figure 3.11), meaning that an increased protein concentration was often loaded, which may 
have skewed the results slightly.  
 
The increase in N4104K channel expression did not affect trafficking or have a significant 
downstream effect on SERCa expression or ER Ca2+ load (Section 3.3.2 and 3.3.3, 
respectively). The latter is somewhat surprising, given that more hRyR2 channels per cell that 
are ‘leakier’ than WT hRyR2 would suggest a decrease in total ER Ca2+.  
 
As evidenced in the work of MacLennan’s group, the intracellular Ca2+ store of HEK293 cells is 
not entirely depleted by the addition of caffeine and there remains Ca2+ present that is caffeine-
insensitive but thapsigargin-sensitive (Tong, McCarthy, et al. 1999; Tong, Du, et al. 1999). 
Thapsigargin increases the intracellular Ca2+ store by irreversible inhibition of SERCa, 
preventing Ca2+ reuptake. As an additional experiment, thapsigargin could be added to cells 
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after caffeine to ensure complete emptying of the ER Ca2+ store. However, caffeine-induced 
Ca2+ release remains a relevant measure to assess channel functionality (limitations and 
alternatives are discussed in Section 3.4.3) and is closely correlated to thapsigargin-induced 
Ca2+ release, indicating that it likely does reflect the size of the ER Ca2+ store (Tong, McCarthy, 
et al. 1999; Tong, Du, et al. 1999). 
 
S2246L hRyR2 was different to the WT in a way that N4104K was not, in that with this mutant, a 
~25 % discrepancy was evident between the transfection efficiency (percentage of green cells) 
and the percentage of cells showing channel functionality in the form of a caffeine-induced 
response (Section 3.3.3). This was also reflected in the effect of the S2246L on the propensity 
for cells expressing this hRyR2 mutant to undergo Ca2+ release, which was decreased in 
comparison to WT (Section 3.3.3). However, in the absence of exogenously stimulated 
phosphorylation, it was evident that S2246L hRyR2-transfected cells displayed similar Ca2+ 
release kinetics to those expressing WT, albeit with a slower rate up (Section 3.3.5). Even 
though experiments were calculated as adequately powered (Section 3.3.4) small magnitude 
changes for S2246L, which were not found to be statistically significant, could still possibly 
result in global dysfunction in a cardiac setting. 
 
To summarise, data in Chapter 3 pointed towards the ‘gain-of-function’ classification, often 
used as a blanket term for the dysfunction caused by CPVT1 RyR2 mutations that cause 
enhanced channel activity, as an oversimplification. While S2246L and N4104K may indeed 
both be gain-of-function mutations, hRyR2 channel dysfunction is manifested differently, as 
S2246L barely appeared dysfunctional when expressed in a heterologous system.  
 
Given that S2246L and N4104K hRyR2 mutants appear to have different functional effects (see 
Section 1.7.2, Figure 1.5), the role of mutation location could be further explored. As discussed 
in Section 1.7.3.2, defective domain-domain interactions within RyR2 have previously been 
suggested to underlie channel dysfunction (Liu et al. 2013; Laver et al. 2007; Uchinoumi et al. 
2016; Tateishi et al. 2008; Suetomi et al. 2011; Uchinoumi et al. 2010; Z. Xiao et al. 2016).  
Further mutations could be investigated from both the central domain and the C-terminal 
domain, to see if Ca2+ release kinetics are similar to those caused by mutations in the same 
domains. Cryo-EM structures of Yan et al. (2015), des Georges et al. (2016) and Zalk et al. 
(2015) could be utilized to determine whether mutations are in close vicinity or may interact with 
others in the overall RyR structure, interactions that may not be evident from the linear 
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polypeptide (as in Figure 1.5). This would further implicate the importance of domain 
interactions in RyR2 channel dysfunction and determine whether CPVT1 phenotype is locus 
dependent.  
In recent work of Uehara et al. (2017), the functional effects of transmembrane (c-terminal) 
domain CPVT-linked mutation K4750Q were compared to those caused by central domain 
mutation R2474S. RyR2-K4750Q not only causes a more severe phenotype in patients, but 
mutant channels displayed more aberrant activity in comparison to both WT and R2474S 
channels in multiple experimental systems, including heterologous cells. HEK293 cells 
expressing RyR2-K4750Q displayed an increased frequency and a decreased amplitude of 
spontaneous Ca2+ release events in comparison to cells expressing WT. These parameters 
were also altered by RyR2-R2474S in the same manner, but to a significantly smaller extent. 
Modelling of single channel data revealed that K4750Q mutant recombinant mouse RyR2 single 
channels displayed not only more frequent closed state to open state transitions, but less 
frequent open state to closed state transitions, leading to prolonged channel openings. 
Essentially, the point mutation stabilizes the open state of the cytosolic and luminal Ca2+ 
activated RyR2 channel. K4750Q mutation also locked the channel in the open configuration at 
higher cytosolic Ca2+ concentrations, resulting in an increased Po. Not only do these data 
support the kinetic scheme of Mukherjee et al. (2012), but highlight that a point mutation can 
simultaneously modify multiple control mechanisms of RyR2 – in this case, leading to increased 
luminal and cytosolic Ca2+ sensitivity, as well as a loss of Ca2+/Mg2+ mediated inactivation 
(Uehara et al. 2017) 
 
There is no evidence so far to suggest a locus-dependent effect on the severity of the clinical 
phenotype of CPVT1, however, it is possible that differences in mutant Ca2+ release dysfunction 
could be responsible for the different manifestations of clinical phenotype and responses to 
therapy seen with this arrhythmia syndrome. As discussed in Chapter 1, Section 1.7.4, ß-
blocker treatment is often inadequate, with some patients suffering further arrhythmogenic 
events which are potentially fatal (Laitinen et al. 2001). It could be speculated that the 
identification of CPVT1-linked RyR2 mutations (and potentially mutation domains) that exhibit 
exaggerated dysfunction under basal conditions (as is the case for N4104K hRyR2 both in 
single channel experiments, Section 3.1.2, and in a heterologous cell system, Section 3.3.5) 
may aid in identifying more high-risk patients who require further interventions. Carvedilol 
analogues (such as VK-II-86) are β-blockers that display direct effects on RyR2 channel gating 
independent of their ability to inhibit β-adrenergic stimulation (Zhou et al. 2011). A combination 
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therapy of such an analogue with a standard β-blocker may improve the responses to therapy in 
patients with such a severe ‘gain-of-function’ mutation. However, data on disease penetrance 
and expression of inherited RyR2 mutations in families are scarce (van der Werf et al. 2012). 
Not all family members with a CPVT1-associated RyR2 mutation are symptomatic (Haugaa et 
al. 2010), so it remains that reduced penetrance, epigenetic and environmental factors also play 
a role in the severity of disease phenotype (van der Werf et al. 2012).  
 
6.1.2 Basal phosphorylation levels at S2808 and S2031 are different for WT and 
mutant hRyR2 - but not necessarily in the way expected 
  
Since the spontaneous Ca2+ release of S2246L-hRyR2 expressing cells was not very different 
from those expressing WT, it was concluded that an additional stimulus might be required to 
reveal channel dysfunction. Luminal Ca2+, which is proposed to cause spontaneous Ca2+ 
release events (D. Jiang et al. 2004), did not reveal the dysfunction of S2246L hRyR2 in the 
heterologous system of HEK293 cells in this thesis and it was hypothesized that the additional 
stimulus of phosphorylation could be important for this. Posttranslational modification of RyR2, 
including phosphorylation, has been substantially investigated for over 30 years, yet remains a 
contentious subject, as discussed in detail in Section 1.4. In this study, the contribution of PKA-
mediated phosphorylation to functional heterogeneity of mutant hRyR2 channels was explored, 
given that CPVT1 in patients occurs under periods of exercise or stress where the β-adrenergic 
signalling pathway is activated. In Chapter 4, this involved a) Western blot assessment of basal 
phosphorylation at both reported PKA-specific phosphorylation sites in RyR2-S2808 and S2031 
and b) the investigation of Ca2+ release events under stimulated conditions, utilizing a cAMP 
analogue (DcAMP).  
 
Basal phosphorylation of RyR2 is often assessed as an indicator of the functional relevance of 
phosphorylation at a particular site, where subsequent changes in phosphorylation level upon 
endogenous or exogenous stimulation may be linked to altered channel function 
{Terentyev:2016jf}.  Investigation of basal phosphorylation at S2808 and S2031, via Western 
blotting using Badrilla phospho-RyR2 antibodies, found levels to be different in mutant 
compared to WT hRyR2s expressed in HEK293 cells (Section 4.3.2 and 4.4.2). Increased 
basal S2808 phosphorylation in mutant hRyR2 channels did not equate to Ca2+ release 
dysfunction in HEK293 cells. S2246L hRyR2 had a significantly higher basal phosphorylation at 
the S2808 site, yet displayed similar Ca2+ release events to WT (Section 3.4 and 4.4.2.1). 
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N4104K hRyR2 did not show significantly increased basal phosphorylation at S2808, but 
displayed dysfunction without further stimulation in the form of activated PKA phosphorylation 
(Section 4.4.2.2). 
 
Both CPVT1 mutant hRyR2 channels exhibited a significantly decreased basal phosphorylation 
level at S2031 compared to WT-hRyR2 (see Section 4.3.2 and 4.4.2). Differences appeared 
robust, albeit levels were assessed with the unreliable Badrilla pS2030 antibody (see Section 
4.4.1). Dephosphorylation by protein phosphatases may also elicit a change in activity in RyR2 
and has been shown to be upregulated in many disease settings (Terentyev and Hamilton 
2016). It also remains that a balance of phosphorylation levels at each of the PKA-specific sites 
may be important for RyR2 channel function, a possibility that was not feasible to investigate 
during the timeframe of laboratory work presented here.  
 
The interaction of FKBP12.6 with RyR2 was originally proposed to be destabilized in disease 
settings such as HF, with arrhythmogenic Ca2+ release occurring through a hyperactive, 
‘hyperphosphorylated’ RyR2 channel (Wehrens et al. 2003; Marx et al. 2000; Marx et al. 2001). 
The relevance of FKBP12.6 to channel dysfunction remains disputed (Barg et al. 1997; 
Timerman et al. 1996; Guo et al. 2010; Zissimopoulos et al. 2004; Xiao et al. 2004; Guo et al. 
2006; Stange et al. 2003; Mukherjee et al. 2012). Rycal drugs (such as K201, see Section 
1.7.4) are proposed to stabilize FKBP12.6 binding to RyR2, thereby normalizing channel 
dysfunction (Wehrens et al. 2004; Yano et al. 2003; Wehrens et al. 2005; Darcy et al. 2016). 
According to www.fda.gov, similar rycal derivatives targeting RyR1 in the treatment of 
Duchenne Muscular Dystrophy (Armgo Pharma, Inc.) were designated ‘orphan drugs’ by the 
United States Food and Drug Administration (FDA), allowing for a fast-track to Phase 2 clinical 
trials in humans after successful completion of Phase 1. However, there is currently no further 
information available on the outcome of the Phase 1 trial, nor any suggestion of recruitment for 
additional trials with rycals and their derivatives.   
 
To explore the role of the FKBP12.6 accessory protein in CPVT1-linked hRyR2 channel 
phosphorylation and dysfunction, FKBP12.6 could be co-transfected with mutants in HEK293 
cells. Coimmunoprecipitation experiments as described by Zissimopoulos et al. (2009) would 
elucidate the level of protein-protein interaction, while Ca2+ imaging experiments would reveal 
the effects (or lack of) of FKBP12.6 on spontaneous Ca2+ release kinetics through hRyR2 in this 
system. However, in the investigation of three CPVT-linked RyR2 mutations (R176Q, S2246L 
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and R4497C), FKBP12.6 binding affinity with mutant hRyR2 was unaltered or in fact increased 
in comparison to WT, when the proteins were coexpressed in HEK293 cells. These data provide 
evidence that CPVT-linked RyR2 mutations do not decrease the affinity of the channel for 
FKBP12.6.  
 
Due to time restraints and difficulties encountered generating phosphomimetic mutations in 
hRyR2, the role and influence of CaMKII-dependent phosphorylation at S2814 was not 
investigated in this study.  
 
6.1.3 Stimulation of PKA phosphorylation significantly increases WT, but not 
mutant, hRyR2 phosphorylation at S2808 
  
Experiments to investigate changes in hRyR2 function after phosphorylation stimulated by PKA 
activation were carried out using DcAMP, a choice informed by experiments investigating RyR2 
mutation by Paavola et. al (2007). Maximal phosphorylation was indicated by the inclusion of 
PKA-treated homogenate from WT hRyR2-transfected HEK293 cells, as per the methodology of 
Rodriguez et al. (2003) and homogenate from DMSO treated hRyR2-transfected cells was used 
as a vehicle control.  
 
Concentrations of 100 µM and 1 mM elicited significant increases in S2808 phosphorylation 
level of WT hRyR2 in comparison to DMSO (control) treatment. A large increase in S2808 
phosphorylation of WT hRyR2 from the basal level not only signified that PKA does in fact 
phosphorylate hRyR2 at this site, but that basal phosphorylation levels must be low to moderate 
in HEK293 cells to allow for this change. 
 
In contrast to WT, treatment of S2246L and N4104K hRyR2-transfected HEK293 with 
increasing concentrations of DcAMP (Section 4.3.3 and 4.4.5) did not result in significantly 
increased phosphorylation at S2808 compared to basal levels. S2808 in S2246L hRyR2 may 
not have been phosphorylated any further by PKA given such high basal phosphorylation levels. 
However, in the case of N4104K hRyR2 this argument does not necessarily follow, as N4104K 
basal phosphorylation at S2808 was not calculated as significantly different to WT hRyR2, 
though low n numbers and normalization of expression levels may have influenced this result as 
discussed in Section 4.3.2. The data may therefore imply that N4104K hRyR2 channels were 
unable to undergo phosphorylation beyond the basal level at this site. 
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6.1.4 Phosphorylation at S2808 alters WT hRyR2 function - this is less 
straightforward for mutant hRyR2, but does not trigger dysfunction 
 
Treatment of WT hRyR2-transfected HEK293 cells with DcAMP led to altered kinetics of Ca2+ 
release (Section 4.4.3). This would be anticipated as in the physiological setting, 
phosphorylation upregulates RyR2 channel function (Section 1.4). DcAMP treatment had 
limited effect on the S2808 phosphorylation status of mutant hRyR2 compared to WT, and this 
was reflected as a corresponding limited effect on spontaneous Ca2+ release (Section 4.4.4). 
Both S2246L and N4104K transfected cells displayed the same, minimal changes in Ca2+ 
release kinetics in response to DcAMP treatment. These changes may have been due to very 
minimal PKA phosphorylation at the S2808 site, or PKA-mediated phosphorylation at S2031 or 
other potential sites (see Section 1.4.2 and 4.4.5). However, toxicity-related side effects were 
observed with this reagent and Ca2+ signalling and expression of hRyR2 was altered in 
experiments (as discussed in Section 4.4.6).  
 
In Ca2+ imaging experiments, it appeared that DMSO was stopping spontaneous Ca2+ release 
events (Figure 4.8 A), likely due to hydrophobic and osmotic properties of the chemical.  
Use of an alternative vehicle solvent (methanol) revealed a toxic effect of 1mM DcAMP on 
hRyR2 transfected cells over a period of 30 minutes, which was not observed with vehicle 
alone, indicating a toxic effect of the reagent itself at this high concentration. Future experiments 
could include trying other membrane-permeable cAMP analogues instead, including 8-bromo-
cAMP (thought to be a less active version of DcAMP, according to manufacturers, Santa Cruz) 
which has previously been utilized in the study of transfected HEK293 cells (Shen et al. 2011).  
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6.1.5 Genetic phosphorylation induces compensatory changes in SERCa 
expression, making it difficult to interpret Ca2+ release data 
  
As well as agonist (DcAMP) induced phosphorylation, genetic phosphorylation was also utilized 
as a technique to investigate the functional heterogeneity of these CPVT1 mutations (see 
Section 5.1.1). Introduction of phosphomimetic mutations to chemically mimic a phosphorylated 
site is a useful technique, as it allows the controlled investigation of the functional effects of that 
mutation, with the assumption that this prevents influences of other factors. Six phosphomimetic 
hRyR2 DNA plasmids were successfully generated by site-directed mutagenesis (Section 
5.4.1), mimicking phosphorylation at PKA-specific sites: S2808 or S2031 (B. Xiao et al. 2006; 
Witcher et al. 1991). 
 
The genetic phosphorylation technique was chosen to avoid the influence of other endogenous 
proteins to the cell that were likely modified upon stimulation with DcAMP, that may confound 
the interpretation of spontaneous Ca2+ release data. Surprisingly, the introduction of particular 
genetically phosphorylated hRyR2 mutants (WT08, SL08, SL31) induced changes in SERCa 
expression (Section 5.3.7 and 5.4.3). Adaptive remodelling is a characteristic of cardiac 
disease in a physiological setting, such as upregulation and increased expression of CaMKII, 
occurring in response to the increased demand to pump blood around the body through a failing 
heart (Anderson et al. 2011; Ai 2005). However, changes in endogenous protein expression 
after the introduction of hRyR2 were not expected in transiently transfected HEK293 cells, 
where hRyR2 was only expressed for ~48 hrs. Whether this was the result of the transfection of 
recombinant hRyR2, or the genetic phosphorylation of a specific site in hRyR2, is somewhat 
difficult to untangle. Further investigation (transfection of HEK293 cells with more hRyR2 
CPVT1 mutants as well as phosphomimetics) would be necessary to elucidate how and why 
this may occur. In the literature, when using KI mice with a hRyR2 site genetically 
phosphorylated or ablated, very few studies assess the levels of phosphorylation at other sites 
in RyR2 (aside from Loiaza et al. (2013) and Terentyev et al. (2014) for example), let alone the 
expression of other key Ca2+ cycling proteins such as SERCa. Data presented in this thesis 
serve as a caution when interpreting data and highlights the importance of investigating 
changes of other endogenous Ca2+ handling proteins of a cell.  
 
Genetic phosphorylation also affected the expression and trafficking of N4104K hRyR2 in 
HEK293 cells (Section 5.3.2 and 5.4.2). This indicated there was some issue with this mutant 
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protein’s integrity, limiting the ability to obtain meaningful or well powered data from Ca2+ 
imaging experiments with N4104K phosphomimetics (Section 5.3.6 and 5.4.6). It could be 
suggested this may be a symptom of recombinant technology, whereby genetic phosphorylation 
prevents expression of functional channels. It could also be that fully phosphorylated N4104K 
channels may in fact be unstable or broken down and that this may potentially cause the CPVT 
phenotype in patients with this RyR2 mutation. CPVT-associated exon-3 deletion in RyR2 
causes reduced protein expression and in this instance the lack of expression (because of 
reduced mutant allele) causes arrhythmia (Liu et al. 2014). In recent work of the Van Petegem 
and Chen groups, the CPVT-associated mutation G357S enhances arrhythmogenic SOICR 
activity in HEK293 cells and reduces total RyR2 expression (Liu et al. 2017).  Alternatively, the 
combination of full stoichiometric phosphorylation (of all four phosphorylation sites within a 
tetramer) at S2808 or S2031 plus the N4104K mutation in hRyR2 may have caused the channel 
to be unstable and this phosphorylation to maximal stoichiometry would not be seen in vivo. 
Equally, working with homotetramers (four phosphorylated monomers) likely exacerbated this 
stability problem, which may not be equivalent in heterotetramers (a mixture of phosphorylated 
and unphosphorylated monomers). 
 
Interestingly eGFP fluorescence, used as an indicator of transfection efficiency, was found to 
misrepresent the proportion of cells expressing hRyR2 phosphomimetics (Section 5.3.3 and 
5.4.4). The discrepancy in the number of increased caffeine-responsive cells compared to 
calculated transfection efficiency may have been due to detection limits, whereby low-level 
expression of hRyR2 would have been more easily detected by caffeine-induced Ca2+ release. 
In the case where transfection efficiency was significantly higher than the number of caffeine-
responsive cells, this may have been due to overestimation. While propensity in this thesis was 
calculated instead as the number of caffeine-responsive (as opposed to spontaneously Ca2+ 
responsive) cells as a percentage of the total, this finding also supported the suggestion that 
propensity (as described by D. Jiang et al. (2004)) is not a good indicator of CPVT1 RyR2 
channel dysfunction in HEK293 cells, given that the number of transfected cells cannot be 
robustly calculated. Others also have not observed changes in propensity for spontaneous Ca2+ 
release events when investigating disease-linked mutations (Loaiza et al. 2013). 
 
These additional changes and observations confounded the interpretation of spontaneous Ca2+ 
release events in hRyR2-transfected HEK293 cells in this study, and such occurrences must be 
considered for future experiments when utilizing a heterologous system.  
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6.1.6 S2808D and S2031D have similar functional effects in WT hRyR2, but 
different effects in S2246L and N4104K 
  
Genetic phosphorylation at S2808 and S2031 had similar effects on the spontaneous Ca2+ 
release events of WT hRyR2-transfected HEK293 cells (Section 5.4.6), while genetic 
phosphorylation of mutant hRyR2 had less profound effects (Section 5.4.7).  
 
For S2246L, genetic phosphorylation at S2808 influenced channel function with effects similar 
to those of S2808D on the WT i.e. increasing the amplitude of spontaneous Ca2+ release events 
and decreasing event duration and the time between them (Figure 5.18). Since these changes 
were not in excess of those seen upon introduction of the phosphomimetic to the WT (Table 
5.9), this suggests that phosphorylation to full stoichiometry at S2808 is not key in revealing 
S2246L dysfunction. While introduction of S2031D affected WT Ca2+ release in a comparable 
way to S2808D, its introduction to the S2246L hRyR2 resulted only in a decreased duration of 
Ca2+ release event.  
 
Notably, modification of either site in N4104K channels did not affect function as the same way 
in WT hRyR2 channels with few changes in Ca2+ release kinetics induced by introduction of 
phosphomimetic (Figure 5.19). N4104K hRyR2 already appears dysfunctional in Ca2+ imaging 
experiments in comparison to WT (Figure 3.16), so phosphorylation may not elicit the normal 
physiological response. However, phosphomimetic mutation of N4104K did have an effect on 
functionality, since it significantly decreased the number of caffeine-responsive cells (see 
Section 5.4.2).  
 
As a future direction, single channel experiments could be used to verify findings of Ca2+ 
imaging studies with phosphomimetic hRyR2, given that HEK293 cells exhibited endogenous 
protein remodelling. This would eliminate any potential influence of the increased expression of 
SERCa on spontaneous Ca2+ release kinetics.  
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6.1.7 Genetic phosphorylation likely represents a vast oversimplification of the 
physiological state 
 
The effects of genetic phosphorylation are different to those caused by the agonist-induced 
phosphorylation of hRyR2, as discussed in Section 5.4.7. This discrepancy may be due to 
additional effects of DcAMP, including activation of other endogenous kinases (Hofer et al. 
2007). While genetic phosphorylation modified SERCa expression (see Section 5.4.3), this was 
almost certainly as a result of a change this mutation caused in RyR2 function, in line with an 
increase in channel activity. The mechanism for this cannot be deciphered from the data 
acquired here, but may include increased agonist sensitivity or changes to the dynamics of Ca2+ 
release through altered channel clustering. 
 
It remains that genetic phosphorylation to full stoichiometry, as investigated in Chapter 5, is not 
necessarily representative of the physiological state. Important work of Carter et al. (2006) 
determined that RyR2 was phosphorylated to 75 % of maximum at the S2808 site under 
unstimulated conditions, meaning that only three available sites were phosphorylated, while one 
was not. Therefore, the co-expression of phosphomimetic hRyR2 with WT or mutant hRyR2 
cDNA in HEK293 cells may give an insight into the consequences of phosphorylation on 
channel function under unstimulated conditions. Transfection in equal molar quantities will result 
in a mixed population of homo- and heterotetramers of different types (i.e. monomer ratios of 4 
WT, 3 WT:1 S2808D, 2 WT: 2 S2808D, 1 WT: 1 S2808D) whose distribution, if assuming equal 
association can be calculated according to binomial theory (Loaiza et al. 2013). Skewing the 
ratio of molar quantities in the transfection will favour distribution towards a heterotetramer 
containing the required proportions of different monomers, but these will never constitute 100 % 
of the population. Furthermore, control of the phosphorylation status at S2808 would require 
genetic ablation of WT (introduction of S2808A) and these experiments were beyond the scope 
of this investigation.  
 
It also remains that genetic phosphorylation of one site does not take into consideration that 
physiological phosphorylation at one site in hRyR2 alone is unlikely, with both S2808 and S2031 
suggested as PKA-specific sites. A limitation to this investigation, as noted in Figure 6.1, is that 
upon genetic phosphorylation at one site, the phosphorylation status of others in hRyR2 were 
not assessed. It cannot be assumed that they would not change, especially given that alteration 
in basal phosphorylation levels was observed after introduction of a mutation (Section 4.4.2) 
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Generation of double phosphomimetics, with genetic phosphorylation of both the S2808 and 
S2031 sites, would be an interesting comparison to data presented in this thesis. However, 
N4104K hRyR2 phosphomimetics proved very difficult to work with, given low transfection 
efficiencies and the difficulty obtaining n numbers for Ca2+ imaging experiments (Section 5.4.2). 
It is reasonable to suggest that the addition of a further mutation to N4104K hRyR2 cDNA would 
only add to the plasmid fragility. Data presented in this thesis suggest that genetic 
phosphorylation may not be able to be applied to all CPVT1 mutant hRyR2 constructs. To 
instead utilize plasmids that have already been constructed, phosphomimetic hRyR2 
transfected-HEK293 cells could also be treated with a cAMP analogue. As no changes would 
occur at the genetically phosphorylated site after treatment, this may highlight functional 
changes caused by phosphorylation at the other PKA-specific site(s) in hRyR2.  
 
To explore and elucidate mechanisms of dysfunction caused by mutations and potentially 
phosphorylation of RyR2, it is important to apply multiple methods in the laboratory. Even so, it 
has been suggested that the use of so many different techniques to investigate RyR2 
dysfunction contributes to disparity in findings (George 2007). As is particularly evident in the 
study of RyR2 phosphorylation, this is exacerbated by variation of methods between groups, 
such as transgenic mouse background, mode of recombinant expression and choice of antibody 
(Bers 2008; Respress et al. 2012; Jiang et al. 2004, Benkusky et al. 2007; Wehrens et al. 2014;  
Mukherjee et al. 2012). This thesis reinforces that these differences must be taken into account 
when applying other complimentary systems to study RyR2 dysfunction.
279 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Schematic of the major findings in this study for WT hRyR2. Each larger square indicates an individual hRyR2 channel tetramer, 
with the four smaller squares indicating each monomer. Basal conditions are defined as being in the absence of PKA activation (by DcAMP) or 
genetic phosphorylation (by introduction of a phosphomimetic mutation at S2808 or S2031). Under basal conditions, HEK293 cells expressing WT 
hRyR2 displayed spontaneous Ca2+ release events, considered ‘normal’ in these figures. S2808 hRyR2 phosphorylation was moderate, similar to 
that of WT, but S2031 phosphorylation was low (although this was inferred only by comparison to mutant hRyR2 basal phosphorylation levels). 
Under PKA activating conditions, Ca2+ release was enhanced and the level of S2808 phosphorylation was maximal (as inferred by comparison to 
a PKA-treated control). S2031 phosphorylation was not investigated further due to difficulties with the antibody. Genetic phosphorylation at either 
site (S2808D or S2031D) enhanced spontaneous Ca2+ release kinetics of transfected cells.  
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Figure 6.2 Schematic of the major findings in this study for S2246L hRyR2. Basal conditions are defined as being in the absence of PKA 
activation (by DcAMP) or genetic phosphorylation (by introduction of a phosphomimetic mutation at S2808 or S2031). Each larger square 
indicates an individual hRyR2 channel tetramer, with the four smaller squares indicating each monomer. Under basal conditions, HEK293 cells 
expressing S2246L hRyR2 displayed normal spontaneous Ca2+ release events, similar to those of WT. However, as indicated by the *, the 
propensity of cells for caffeine-induced Ca2+ release was significantly decreased compared to that of WT, but was not as a result of altered 
expression. S2808 hRyR2 phosphorylation was increased in comparison to WT, while S2031 phosphorylation was decreased. Under PKA 
activating conditions, there were no significant changes in the level of S2808 phosphorylation, and only a very small change in the Ca2+ release 
events in comparison to release events under basal conditions. Genetic phosphorylation (S2808D) similarly only induced a small change in 
spontaneous Ca2+ release kinetics of transfected cells, while the change induced by S2031D was very small.  
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Figure 6.3 Schematic of the major findings in this study for N4104K hRyR2 Basal conditions are defined as being in the absence of PKA 
activation (by DcAMP) or genetic phosphorylation (by introduction of a phosphomimetic mutation at S2808 or S2031). Each larger square 
indicates an individual hRyR2 channel tetramer, with the four smaller squares indicating each monomer. Under basal conditions, HEK293 cells 
expressing N4104K hRyR2 displayed dysfunctional spontaneous Ca2+ release events in comparison to WT, as well as an increased expression of 
channels per cell. S2808 hRyR2 phosphorylation was moderate, similar to that of WT, but S2031 phosphorylation was decreased. Under PKA 
activating conditions, there were no significant changes in the level of S2808 phosphorylation, and only a small change in the already 
dysfunctional Ca2+ release. Genetic phosphorylation (S2808D or S2031D) similarly only induced a small change in spontaneous Ca2+ release 
kinetics of transfected cells.  N numbers for cells transfected with phosphomimetic N4104K hRyR2 were very low, given that the protein seemed to 
degrade in IF experiments.  
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6.1.8 Study limitations and future experiments 
 
While limitations of this study and future works have been integrated throughout this Chapter 
when pertaining to experimental design, major points to be highlighted include: 
 
The lack of assessment of CaMKII phosphorylation 
There is substantial evidence for a major role of CaMKII-dependent phosphorylation of RyR2 in 
modulating channel function, in both physiological and disease settings (Bers, 2006; Uchinoumi 
et al. 2010; 2016), as discussed in Section 1.4.1.2 and 1.4.2.3. Due to difficulties encountered 
generating phosphomimetic hRyR2 constructs, CaMKII-dependent phosphorylation of RyR2 
and the potential influence on functional heterogeneity of CPVT hRyR2 mutants was not 
assessed here, nor were the phosphorylation levels of S2814-hRyR2 via Western blotting. In 
future works, these investigations would be high priority to strengthen this thesis.  
  
The need to assess membrane Ca2+ fluxes in the heterologous HEK293 expression system 
The Ca2+ flux balance of cardiomyocytes has been long investigated in multiple species and it is 
well established that in the steady state, the amount of Ca2+ entering the cell must equal the 
amount of Ca2+ that leaves in (Eisner et al. 2017). While using HEK293 cells as a heterologous 
cell system to investigate changes in hRyR2 function induced by mutation has its advantages as 
discussed in Section 3.1.1.3, it also remains that the Ca2+ fluxes of this cell type remain poorly 
characterized. In future works, investigation of Ca2+ influx and efflux systems and the expression 
level and activity of Ca2+ handling proteins would be paramount to properly interpreting changes 
in Ca2+ release kinetics after transfection with hRyR2.  
 
The limitations of ER Ca2+ content with caffeine 
The amplitude of Ca2+ transient amplitude is steeply dependent on the Ca2+ content of the SR 
(ER in HEK293 cells). While application of high-dose caffeine is frequently used to determine 
the store content (D. Jiang et al. 2007; Loaiza et al. 2013; George et al. 2006; D. Jiang 2005), 
as discussed in Section 3.4.3, it is an indirect measurement dependent on the timing of Ca2+ 
release events prior to application. Genetically encoded biosensors are now more commonly 
used to monitor Ca2+ and would be utilized in future experiments for more accurate 
measurements (Palmer et al. 2004).  
283 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
284 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
Appendix I Western blotting of WT and mutant eGFP-hRyR2 expression in HEK293 cells. Following SDS PAGE of cell homogenate 
preparations, blots A-F were assessed for GFP-hRyR2 expression (left image) and vinculin expression as a loading control (right image) at loads 
of 50 µg and 100 µg for each construct. Molecular weight of bands was estimated against the prestained Kaleidoscope ladder (Biorad, lane 
marked L). For clarity, these images were obtained after stripping of a phospho-antibody in experiments described in Chapter 4, see Appendix 
VIII A and B, Appendix VIV A-D. Membrane stripping does not appear to degrade the sample, see Figure 3.7.  
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Appendix II Densitometric analysis of WT and mutant eGFP-hRyR2 expression in HEK293 cells at 50 µg and 100 µg of loading reveals larger error 
at lower sample loads.  Densitometric analysis of Western blots found in Appendix III, by normalization of anti-GFP signal to vinculin signal as described in 
Section 3.2.1, reveals significant differences between results at 50 µg and 100 µg of sample loading. Data are presented as mean ± SEM, with p<0.05 
indicated by * as calculated by one way ANOVA with Bonferroni posthoc test
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Appendix III SERCa expression cannot be normalized to vinculin in Western blot experiments. A. Representative bands of SERCa and vinculin protein. 
Bands appear very close together. Bands are spliced together from the same blot – original blots can be found in Appendix XVII and XXIX. B. Densitometric 
analysis of SERCa expression normalized to vinculin expression, n=4 experiments. Data are presented as mean ± SEM, with p<0.05 indicated by * as 
calculated by one way ANOVA with Bonferroni posthoc test. 
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Appendix IV Attempts to assess both eGFP-hRyR2 and β-tubulin protein expression on a gradient 
gel were unsuccessful.  
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Appendix V Scatter plots of ER Ca2+ store load of WT and mutant hRyR2-transfected HEK293 
cells. Equivalent bar graphs are found in Figure 3.6.  
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Appendix VI Table of comparison of parametric and non-parametric test results from Ca2+ imaging 
data discussed in Chapter 3. Imaging data was analyzed with GraphPad Prism, either by parametric 
one way ANOVA with Bonferroni posthoc, or by nonparametric Kruskal-Wallis with Dunn’s posthoc test.  
The are no differences in results, aside from inter-event duration significance when a comparison of WT 
and N4104K data is made. This difference is only by a matter of one degree – the result remains 
significant with both parametric and non-parametric tests.
  
 
 
 
PARAMETRIC 
One way ANOVA with 
Bonferroni posthoc 
test 
NON-PARAMETRIC 
Kruskal-Wallis with 
Dunn’s posthoc test 
hRyR2 construct 
vs. WT 
Amplitude S2246L ns ns 
N4104K p<0.001 p<0.001 
Duration S2246L ns ns 
N4104K ns ns 
Inter-event 
duration 
S2246L ns ns 
N4104K p<0.01 p<0.001 
Frequency S2246L ns ns 
N4104K p<0.01 p<0.01 
Rate up S2246L p<0.01 p<0.01 
N4104K p<0.001 p<0.001 
Rate down S2246L ns ns 
N4104K p<0.001 p<0.001 
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Appendix VII Scatter plots of Ca2+ release kinetics of WT, S2246L and N4104K hRyR2-transfected 
HEK293 cells. Equivalent bar graphs and statistics are found in Figure 3.1.
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Appendix VIII Western blotting of the basal phosphorylation at the S2808 hRyR2 site. Following SDS PAGE of cell homogenate 
preparations, blots A-D were assessed for pSer-2808 hRyR2 expression (left image), before membrane stripping and the assessment of GFP-
hRyR2 expression (right image). Molecular weight of bands was estimated against the prestained Kaleidoscope ladder (Biorad, lane marked L). 
CONT refers to 100 µg of a mouse cardiac homogenate preparation. Densitometric analysis in Figure 4.4 was of 100 µg loads only.
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Appendix IX Western blotting of the basal phosphorylation at the S2031 hRyR2 site. Following SDS PAGE of cell homogenate preparations, 
blots A-D were assessed for pS2031-hRyR2 expression (left image), before membrane stripping and the assessment of eGFP-hRyR2 expression 
(right image). Molecular weight of bands was estimated against the prestained Kaleidoscope ladder (Biorad, lane marked L). CONT refers to 100 
µg of a mouse cardiac homogenate preparation. Densitometric analysis in Figure 4.5 was of 100 µg loads only. 
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Appendix X Western blotting of WT hRyR2-transfected HEK293 cells treated with dioctanoyl-cAMP, investigating phosphorylation at the 
S2808 site. Transfected HEK293 cells were treated with various concentrations of dioctanoyl-cAMP in DMSO, as described in Section 4.2.2.2. 
Following SDS PAGE of cell homogenate preparations, blots A-C were assessed for pS2808-hRyR2 expression (top image), and reprobed for 
vinculin expression (lower image) as a loading control, at loads of 100 µg. No strip was necessary since antibodies were raised in different animals 
and proteins were far apart on the blot. Where ladder was visible, molecular weight of bands was estimated against the prestained Kaleidoscope 
ladder (Biorad, marked L). CONT refers to 100 µg of a mouse cardiac homogenate preparation – this was only included in one blot since a control 
for strip was not necessary. Where ladder was not visible, blots were using GBOX system to match equivalent bands. HEK refers to 100 µg of a 
preparation of untransfected HEK293 cells. WT PKA refers to a PKA-treated sample which should indicate total phosphorylation levels.
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Appendix XI Western blotting of S2246L hRyR2-transfected HEK293 cells treated with dioctanoyl-cAMP, investigating the 
phosphorylation at the S2808 site. Transfected HEK293 cells were treated with various concentrations of dioctanoyl-cAMP in DMSO, as 
described in Section 4.2.2.2. Following SDS PAGE of cell homogenate preparations, A-C were assessed for pS2808-hRyR2 expression (top 
image), and reprobed for vinculin expression (lower image) as a loading control, at loads of 100 µg. No strip was necessary since antibodies were 
raised in different animals and proteins were far apart on the blot. Where ladder was visible, molecular weight of bands was estimated against the 
prestained Kaleidoscope ladder (Biorad, marked L). Where ladder was not visible, blots were using GBOX system to match equivalent bands. 
HEK refers to 100 µg of a preparation of untransfected HEK293 cells. WT PKA refers to a PKA-treated sample which should indicate total 
phosphorylation levels.
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Appendix XII Western blotting of N4104K hRyR2-transfected HEK293 cells treated with dioctanoyl-AMP, investigating phosphorylation 
at the S2808 site. Transfected HEK293 cells were treated with various concentrations of dioctanoyl-cAMP in DMSO, as described in Section 
4.2.2.2. Following SDS PAGE of cell homogenate preparations, blots A-C were assessed for pS2808-hRyR2 expression (top image), and 
reprobed for vinculin expression (lower image) as a loading control, at loads of 100 µg. No strip was necessary since antibodies were raised in 
different animals and proteins were far apart on the blot. Molecular weight of bands was estimated against the prestained Kaleidoscope ladder 
(Biorad, marked L). HEK refers to 100 µg of a preparation of untransfected HEK293 cells. 
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Appendix XIII Scatter plots of baseline fluorescence of WT and mutant hRyR2-transfected HEK293 
cells, before and after treatment with dioctanoyl-cAMP.  Corresponding graphs can be found in Figure 
4.15.  DcAMP refers to treatment with 100 µM DcAMP in methanol.  
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Appendix XIV Normality testing of WT and mutant hRyR2-transfected HEK293 cells reveals data is 
not normally distributed. Equivalent bar graphs are displayed in Figure 4.15, 4.16 and 4.17. Analyzed 
by D’Agnosti-Pearson omnibus for normality test in GraphPad Prism, with red font indicating data is not 
normal. Gaussian distribution cannot be assumed at p<0.05
Ca2+ oscillation 
event parameters 
WT WT + DcAMP 
Amplitude 0.0080 0.0001 
Duration 0.0023 0.0007 
Inter-event duration <0.0001 <0.0001 
Frequency <0.0001 0.0062 
Rate up <0.0001 0.0314 
Rate down 0.0005 <0.0001 
Ca2+ oscillation 
event parameters 
SL SL + DcAMP 
Amplitude 0.0012 0.0002 
Duration <0.0001 0.0022 
Inter-event duration <0.0001 <0.0001 
Frequency 0.2262 0.0273 
Rate up 0.0165 0.0002 
Rate down 0.0790 <0.0001 
Ca2+ oscillation 
event parameters 
NK NK + DcAMP 
Amplitude <0.0001 <0.0001 
Duration 0.1458 0.0012 
Inter-event duration 0.0002 0.0021 
Frequency 0.0176 0.3318 
Rate up 0.1396 0.0216 
Rate down 0.1196 0.0019 
298 
 
 
Appendix XV Posthoc power analysis of imaging data indicates that data is highly-powered for 
experiments with dioctanoyl-cAMP in Ca2+ imaging analysis. DcAMP refers to treatment with 100 μM 
dioctanoyl-cAMP in methanol. All experimental groups have power of >80% are in black font calculated 
with G*Power*3.19.2 software (Faul et al. 2009). n WT=164, WT+ DcAMP=49, S2246L=109, S2246L+ 
DcAMP=51, N4104K=97, N4104K+ DcAMP=38.
Ca2+ oscillation 
event 
parameters 
WT+ 100µM 
DcAMP vs WT 
 S2246L+ 100 µM 
DcAMP vs SL 
 N4104K+ 100 μM 
DcAMP vs NK 
Amplitude 98%  >99%  >99% 
Duration >99%  >99%  >99% 
Inter-event 
duration 
>99%  >99%  >99% 
Frequency 82%  99%  >99% 
Rate up >99%  >99%  >99% 
Rate down 99%  99%  99% 
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Appendix XVI Scatter plots of ER Ca2+ store load of WT and mutant hRyR2-transfected HEK293 
cells, before and after treatment with dioctanoyl-cAMP. DcAMP refers to the addition of 100 μM 
dioctanoyl-cAMP in methanol.  Equivalent bar graphs are found in Figure 4.12. 
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Appendix XVII Scatter plots of Ca2+ release kinetics of WT hRyR2-transfected HEK293 cells, before 
and after treatment with dioctanoyl-cAMP. DcAMP refers to treatment with 100 μM dioctanoyl-cAMP in 
methanol. Equivalent bar graphs and statistics are found in Figure 4.15. 
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Appendix XVIII Scatter plots of Ca2+ release kinetics of S2246L hRyR2-transfected HEK293 cells, 
before and after treatment with dioctanoyl-cAMP. DcAMP refers to treatment with 100 μM dioctanoyl-
cAMP in methanol. Equivalent bar graphs and statistics are found in Figure 4.16. 
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Appendix XIX Scatter plots of Ca2+ release kinetics of N4104K hRyR2-transfected HEK293 cells, 
before and after treatment with dioctanoyl-cAMP. DcAMP refers to treatment with 100 μM dioctanoyl-
cAMP in methanol. Equivalent bar graphs and statistics are found in Figure 4.17. 
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Appendix XX Western blotting of WT and mutant hRyR2-transfected HEK293 cells, treated with 1 
mM dioctanoyl-cAMP, for SERCa expression. Transfected HEK293 cells were treated with 1 mM 
dioctanoyl-cAMP in DMSO (+DcAMP), as described in Section 4.2.2.2. Following SDS PAGE of cell 
homogenate preparations, blots A and B were assessed for SERCa signal (higher band) and for β-tubulin 
signal (lower band) as a loading control. Molecular weight of bands was estimated against the prestained 
Kaleidoscope ladder (Biorad, marked L). Where ladder was not visible, blots were overlaid using GBOX 
system to match equivalent bands.
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Appendix XXI Expression of recombinant 
eGFP-tagged WT phosphomimetic hRyR2 in 
HEK293 cells following Effectene-mediated 
transfection. A. Left images were taken in 
phase, right images were taken under 
fluorescence. B. Transfection efficiencies of each 
hRyR2 construct were not comparable, with 
phosphomimetic WT31 hRyR2 transfection 
efficiencies significantly increased in comparison 
to WT (Kruskal-Wallis with Dunn’s posthoc, 
p<0.05 indicated by *. The total number of 
transfections for each hRyR2 construct n WT=8, 
WT08=2 WT31=2. The implications of this data 
are discussed in Section 5.3.4.  
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Appendix XXII Expression of recombinant 
eGFP-tagged S2246L phosphomimetic hRyR2 
in HEK293 cells following Effectene-mediated 
transfection. A. Left images were taken in 
phase, right images were taken under 
fluorescence. B. Transfection efficiencies of each 
hRyR2 construct were not comparable, with 
phosphomimetic SL08 hRyR2 transfection 
efficiencies significantly reduced in comparison to 
S2246L (Kruskal-Wallis with Dunn’s posthoc, 
p<0.001 by ***. The total number of transfections 
for each hRyR2 construct n SL=7, SL08=2, 
SL31=2. The implications of this data are 
discussed in Section 5.3.4.  
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Appendix XXIII Expression of recombinant 
eGFP-tagged N4104K phosphomimetic hRyR2 
in HEK293 cells following Effectene-mediated 
transfection. A. Left images were taken in 
phase, right images were taken under 
fluorescence. B. Transfection efficiencies of each 
hRyR2 construct were not comparable, with 
phosphomimetic N4104K hRyR2 transfection 
efficiencies significantly reduced in comparison to 
N4104K (Kruskal-Wallis with Dunn’s posthoc, 
p<0.001 indicated by ***. The total number of 
transfections for each hRyR2 construct n NK=6, 
NK08=3 NK31=3. The implications of this data 
are discussed in Section 5.3.4.  
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Appendix XXIV Scatter plots of ER Ca2+ store load of WT, mutant and phosphomimetic hRyR2-
transfected HEK293 cells. Equivalent bar graphs are found in Figure 5.13. 
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Appendix XXV Western blotting of WT and mutant phosphomimetic eGFP-hRyR2 expression in 
HEK293 cells. Following SDS PAGE of cell homogenate preparations, blots A-C were assessed for GFP-
hRyR2 expression (top image), and reprobed for vinculin expression (lower image) as a loading control, 
at loads of 100 µg. Where protein ladder was not visible, blots were overlaid using the GBOX system to 
Where ladder was not visible, blots were using GBOX system to match equivalent bands. For clarity, WT, 
SL and NK data was also combined with expression data in Appendix I for analysis in Figure 3.11 and 
5.14. 
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Appendix XXVI Normality testing of WT and mutant phosphomimetic hRyR2-transfected HEK293 
cells reveals data is not normally distributed. Equivalent bar graphs are displayed in Figure 5.17, 5.18 
and 5.19. Analysed by D’Agnosti-Pearson omnibus for normality test in GraphPad Prism, with red font 
indicating data is not normal. Gaussian distribution cannot be assumed at p<0.05. 
Ca2+ oscillation 
event parameters 
WT WT08 WT31 
Amplitude 0.0015 0.4289 0.0401 
Duration <0.0001 <0.0001 0.1638 
Inter-event duration <0.0001 <0.0001 <0.0001 
Frequency 0.0002  0.0240  0.0005 
Rate up <0.0001 0.0103 0.0380 
Rate down <0.0001 0.3063 0.0004 
Ca2+ oscillation 
event parameters 
SL SL08 SL31 
Amplitude 0.0086 0.2449 0.4181 
Duration <0.0001 0.7199 0.0395 
Inter-event duration <0.0001 0.0651 0.0038 
Frequency 0.0267 <0.0001 0.0721 
Rate up <0.0001 0.2487 0.0003 
Rate down <0.0001 0.1653 0.1647 
Ca2+ oscillation 
event parameters 
NK NK08 NK31 
Amplitude 0.0015 0.0086 <0.0001 
Duration <0.0001 <0.0001 0.0001 
Inter-event duration <0.0001 <0.0001 <0.0001 
Frequency 0.0002 0.0267 0.0113 
Rate up <0.0001 <0.0001 <0.0001 
Rate down <0.0001 <0.0001 0.0063 
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Appendix XXVII Posthoc power analysis of imaging data indicates that some phosphomimetic hRyR2-transfected HEK293 cell data is 
low powered in some parameters of Ca2+ imaging analysis. All experimental groups have power of >80% are in black font, those with power 
<80% are highlighted in red font, calculated with G*Power*3.19.2 software (Faul et al. 2009). n WT=164, WT-S2808D=49, WT-S2031D=73, 
S2246L=109, S2246L-S2808D=51, S2246L-S2031D=120, N4104K=97, N4104K-S2808D=38, N4104K-S2031D=12. Although SL08, SL31, NK08 
and NK31 appear to have low power in some parameters, they are very highly powered in others. 
 
 
 
Ca2+ oscillation 
event parameters 
WT-
S2808D 
vs WT 
WT-
S2031D 
vs WT 
 S2246L-
S2808D 
vs SL 
S2246L-
S2031D 
vs SL 
 N4104K-
S2808D vs 
NK 
N4104K-
S2031D vs 
NK 
Amplitude 99% 90%  >99% 91%  95% 31% 
Duration >99% >99%  >99% >99%  >99% 83% 
Inter-event 
duration 
>99% >99%  >99% >99%  >99% >99% 
Frequency >99% >99%  40% 30%  >99% 25% 
Rate up >99% >99%  >99% >99%  >99% >99% 
Rate down >99% 98%  71% >99%  15% 95% 
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Appendix XXVIII Scatter plots of Ca2+ release kinetics of WT and phosphomimetic WT hRyR2-
transfected HEK293 cells. Equivalent bar graphs and statistics are found in Figure 5.17.  
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Appendix XXIX Scatter plots of Ca2+ release kinetics of S2246L and phosphomimetic S2246L 
hRyR2-transfected HEK293 cells. Equivalent bar graphs and statistics are found in Figure 5.18. 
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Appendix XXX Scatter plots of Ca2+ release kinetic of N4104K and phosphomimetic hRyR2-
transfected HEK293 cells. Equivalent bar graphs and statistics are found in Figure 5.19. 
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Appendix XXXI Western blotting of WT and mutant and phosphomimetic hRyR2-transfected 
HEK293 cells, for SERCa expression. Following SDS PAGE of cell homogenate preparations, blots A 
and B were assessed for SERCa signal (higher band) and for β-tubulin signal (lower band) as a loading 
control. Molecular weight of bands was estimated against the prestained Kaleidoscope ladder (Biorad, 
marked L). 
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Appendix XXXII A comparison of changes in hRyR2 and SERCa expression in transfected HEK293 
cells. Data are protein expression level of interest, normalized to a loading control, presented as mean ± 
SEM. hRyR2 protein expression was normalized to vinculin expression, while SERCa protein expression 
was normalized to β-tubulin expression. See Chapter 5 for blots and discussion pertaining to this data 
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